# ESC Guidelines: Chronic Coronary Syndromes (2024)

**Source**: `2024_Chronic_Coronary_Syndromes.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 123

---

## Table of Contents

- [2024 ESC Guidelines for the management of chronic coronary syndromes](#2024-esc-guidelines-for-the-management-of-chronic-) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 8)*
  - [2. Introduction](#2-introduction) *(p. 9)*
    - [2.1. Evolving pathophysiological concepts of chronic coronary syndromes](#21-evolving-pathophysiological-concepts-of-chronic) *(p. 9)*
    - [2.2. Chronic coronary syndromes: clinical presentations (Figure 1)](#22-chronic-coronary-syndromes:-clinical-presentati) *(p. 10)*
    - [2.3. Changing epidemiology and management strategies](#23-changing-epidemiology-and-management-strategies) *(p. 10)*
    - [2.4. What is new](#24-what-is-new) *(p. 12)*
  - [3. Stepwise approach to the initial management of individuals with suspected chronic coronary syndrome](#3-stepwise-approach-to-the-initial-management-of-i) *(p. 19)*
    - [3.1. STEP 1: General clinical examination](#31-step-1:-general-clinical-examination) *(p. 19)*
      - [3.1.1. History, differential diagnosis, and physical examination](#311-history,-differential-diagnosis,-and-physical-) *(p. 19)*
      - [3.1.2. Basic testing: 12-lead electrocardiogram and biochemistry](#312-basic-testing:-12-lead-electrocardiogram-and-b) *(p. 22)*
        - [3.1.2.1. Electrocardiogram](#3121-electrocardiogram) *(p. 22)*
        - [3.1.2.2. Biochemical tests](#3122-biochemical-tests) *(p. 23)*
    - [3.2. STEP 2: Further evaluation](#32-step-2:-further-evaluation) *(p. 23)*
      - [3.2.1. Pre-test clinical likelihood of obstructive atherosclerotic coronary artery disease](#321-pre-test-clinical-likelihood-of-obstructive-at) *(p. 23)*
      - [3.2.2. Transthoracic echocardiography and cardiac magnetic resonance at rest](#322-transthoracic-echocardiography-and-cardiac-mag) *(p. 26)*
      - [3.2.3. Exercise electrocardiogram testing](#323-exercise-electrocardiogram-testing) *(p. 26)*
      - [3.2.4. Chest X-ray](#324-chest-x-ray) *(p. 27)*
      - [3.2.5. Ambulatory electrocardiogram monitoring](#325-ambulatory-electrocardiogram-monitoring) *(p. 27)*
    - [3.3. STEP 3: Confirming the diagnosis](#33-step-3:-confirming-the-diagnosis) *(p. 27)*
      - [3.3.1. Anatomical imaging: coronary computed tomography angiography](#331-anatomical-imaging:-coronary-computed-tomograp) *(p. 27)*
        - [3.3.1.1. Computed tomography perfusion imaging](#3311-computed-tomography-perfusion-imaging) *(p. 27)*
        - [3.3.1.2. Prognosis, plaque features, and opportunity to improve outcomes](#3312-prognosis,-plaque-features,-and-opportunity-t) *(p. 28)*
        - [3.3.1.3. Recognized pre-requisites for coronary computed tomography angiography](#3313-recognized-pre-requisites-for-coronary-comput) *(p. 28)*
      - [3.3.2. Functional imaging](#332-functional-imaging) *(p. 28)*
        - [3.3.2.1. Stress echocardiography](#3321-stress-echocardiography) *(p. 28)*
        - [3.3.2.2. Myocardial perfusion scintigraphy—single-photon emission computed tomography](#3322-myocardial-perfusion-scintigraphy—single-phot) *(p. 29)*
        - [3.3.2.3. Positron emission tomography-computed tomography](#3323-positron-emission-tomography-computed-tomogra) *(p. 30)*
        - [3.3.2.4. Cardiac magnetic resonance imaging](#3324-cardiac-magnetic-resonance-imaging) *(p. 30)*
        - [3.3.2.5. Non-invasive testing for microvascular dysfunction](#3325-non-invasive-testing-for-microvascular-dysfun) *(p. 31)*
      - [3.3.3. Invasive tests](#333-invasive-tests) *(p. 31)*
        - [3.3.3.1. Invasive coronary angiography](#3331-invasive-coronary-angiography) *(p. 31)*
        - [3.3.3.2. Functional assessment of epicardial stenosis severity to guide coronary revascularization](#3332-functional-assessment-of-epicardial-stenosis-) *(p. 32)*
        - [3.3.3.3. Assessment of microvascular dysfunction](#3333-assessment-of-microvascular-dysfunction) *(p. 33)*
        - [3.3.3.4. Testing for coronary vasospasm](#3334-testing-for-coronary-vasospasm) *(p. 33)*
      - [3.3.4. Diagnostic algorithm and selection of appropriate tests](#334-diagnostic-algorithm-and-selection-of-appropri) *(p. 34)*
      - [3.3.5. Adverse-event risk assessment](#335-adverse-event-risk-assessment) *(p. 39)*
    - [3.4. STEP 4: Initial therapy](#34-step-4:-initial-therapy) *(p. 40)*
  - [4. Guideline-directed therapy](#4-guideline-directed-therapy) *(p. 41)*
    - [4.1. Patient education, lifestyle optimization for risk-factor control, and exercise therapy](#41-patient-education,-lifestyle-optimization-for-r) *(p. 41)*
      - [4.1.1. Patient education](#411-patient-education) *(p. 41)*
      - [4.1.2. Key lifestyle interventions for risk-factor control](#412-key-lifestyle-interventions-for-risk-factor-co) *(p. 41)*
        - [4.1.2.1. Smoking and substance abuse](#4121-smoking-and-substance-abuse) *(p. 42)*
        - [4.1.2.2. Weight management](#4122-weight-management) *(p. 42)*
        - [4.1.2.3. Diet and alcohol](#4123-diet-and-alcohol) *(p. 42)*
        - [4.1.2.4. Mental health](#4124-mental-health) *(p. 42)*
        - [4.1.2.5. Physical activity and sedentary behaviour](#4125-physical-activity-and-sedentary-behaviour) *(p. 42)*
      - [4.1.3. Exercise therapy](#413-exercise-therapy) *(p. 43)*
    - [4.2. Antianginal/anti-ischaemic medication](#42-antianginal/anti-ischaemic-medication) *(p. 43)*
      - [4.2.1. General strategy](#421-general-strategy) *(p. 43)*
      - [4.2.2. Beta blockers](#422-beta-blockers) *(p. 44)*
      - [4.2.3. Combination therapy](#423-combination-therapy) *(p. 45)*
    - [4.3. Medical therapy for event prevention](#43-medical-therapy-for-event-prevention) *(p. 46)*
      - [4.3.1. Antithrombotic drugs](#431-antithrombotic-drugs) *(p. 46)*
        - [4.3.1.1. Antiplatelet drugs](#4311-antiplatelet-drugs) *(p. 46)*
          - [4.3.1.1.1. Aspirin monotherapy](#43111-aspirin-monotherapy) *(p. 46)*
          - [4.3.1.1.2. Oral P2Y12 inhibitor monotherapy](#43112-oral-p2y12-inhibitor-monotherapy) *(p. 46)*
          - [4.3.1.1.2.1. Clopidogrel monotherapy](#431121-clopidogrel-monotherapy) *(p. 46)*
          - [4.3.1.1.2.2. Ticagrelor monotherapy](#431122-ticagrelor-monotherapy) *(p. 46)*
          - [4.3.1.1.3. Dual antiplatelet therapy post-percutaneous coronary intervention](#43113-dual-antiplatelet-therapy-post-percutaneous-) *(p. 48)*
          - [4.3.1.1.4. Extended intensified antithrombotic therapy](#43114-extended-intensified-antithrombotic-therapy) *(p. 48)*
          - [4.3.1.1.5. Genotype- and phenotype-guided dual antiplatelet therapy](#43115-genotype--and-phenotype-guided-dual-antiplat) *(p. 49)*
        - [4.3.1.2. Anticoagulant therapy](#4312-anticoagulant-therapy) *(p. 50)*
          - [4.3.1.2.1. Monotherapy with oral anticoagulant](#43121-monotherapy-with-oral-anticoagulant) *(p. 50)*
          - [4.3.1.2.2. Combination of anticoagulant and antiplatelet therapy after percutaneous coronary intervention in chronic coronary syndrome patients with AF or other indication for oral anticoagulant](#43122-combination-of-anticoagulant-and-antiplatele) *(p. 50)*
        - [4.3.1.3. Coronary artery bypass grafting and antithrombotic therapy](#4313-coronary-artery-bypass-grafting-and-antithrom) *(p. 51)*
        - [4.3.1.4. Proton pump inhibitors](#4314-proton-pump-inhibitors) *(p. 51)*
      - [4.3.2. Lipid-lowering drugs](#432-lipid-lowering-drugs) *(p. 53)*
      - [4.3.3. Renin–angiotensin–aldosterone blockers/angiotensin receptor neprilysin inhibitor](#433-renin–angiotensin–aldosterone-blockers/angiote) *(p. 53)*
      - [4.3.4. Sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists](#434-sodium–glucose-cotransporter-2-inhibitors-and-) *(p. 54)*
      - [4.3.5. Anti-inflammatory agents for event prevention](#435-anti-inflammatory-agents-for-event-prevention) *(p. 54)*
    - [4.4. Revascularization for chronic coronary syndromes](#44-revascularization-for-chronic-coronary-syndrome) *(p. 55)*
      - [4.4.1. Appropriate indication for myocardial revascularization](#441-appropriate-indication-for-myocardial-revascul) *(p. 55)*
      - [4.4.2. Additional considerations on reduced systolic left ventricular function: myocardial viability, revascularization, and its modality](#442-additional-considerations-on-reduced-systolic-) *(p. 56)*
      - [4.4.3. Additional considerations—complete vs. partial revascularization](#443-additional-considerations—complete-vs-partial-) *(p. 57)*
      - [4.4.4. Assessment of clinical risk and anatomical complexity](#444-assessment-of-clinical-risk-and-anatomical-com) *(p. 57)*
      - [4.4.5. Choice of myocardial revascularization modality](#445-choice-of-myocardial-revascularization-modalit) *(p. 58)*
        - [4.4.5.1. Patients with single- or two-vessel coronary artery disease](#4451-patients-with-single--or-two-vessel-coronary-) *(p. 58)*
        - [4.4.5.2. Patients with unprotected left main coronary artery disease](#4452-patients-with-unprotected-left-main-coronary-) *(p. 58)*
        - [4.4.5.3. Patients with multivessel coronary artery disease](#4453-patients-with-multivessel-coronary-artery-dis) *(p. 60)*
        - [4.4.5.4. Impact of coronary pressure guidance on multivessel coronary artery disease patients undergoing percutaneous coronary intervention](#4454-impact-of-coronary-pressure-guidance-on-multi) *(p. 60)*
        - [4.4.5.5. Virtual percutaneous coronary intervention: combination of coronary pressure mapping with coronary anatomy for percutaneous coronary intervention planning](#4455-virtual-percutaneous-coronary-intervention:-c) *(p. 60)*
        - [4.4.5.6. Impact of intracoronary imaging guidance on multivessel coronary artery disease patients undergoing percutaneous coronary intervention](#4456-impact-of-intracoronary-imaging-guidance-on-m) *(p. 60)*
        - [4.4.5.7. Hybrid revascularization in multivessel coronary artery disease patients](#4457-hybrid-revascularization-in-multivessel-coron) *(p. 61)*
      - [4.4.6. Patient–physician shared decision-making to perform and select revascularization modality](#446-patient–physician-shared-decision-making-to-pe) *(p. 61)*
      - [4.4.7. Institutional protocols, clinical pathways, and quality of care](#447-institutional-protocols,-clinical-pathways,-an) *(p. 61)*
  - [5. Optimal assessment and treatment of specific groups](#5-optimal-assessment-and-treatment-of-specific-gro) *(p. 64)*
    - [5.1. Coronary artery disease and heart failure](#51-coronary-artery-disease-and-heart-failure) *(p. 64)*
    - [5.2. Angina/ischaemia with non-obstructive coronary arteries](#52-angina/ischaemia-with-non-obstructive-coronary-) *(p. 65)*
      - [5.2.1. Definition](#521-definition) *(p. 65)*
      - [5.2.2. Angina/ischaemia with non-obstructive coronary arteries endotypes](#522-angina/ischaemia-with-non-obstructive-coronary) *(p. 65)*
        - [5.2.2.1. Microvascular angina](#5221-microvascular-angina) *(p. 66)*
        - [5.2.2.2. Epicardial vasospastic angina](#5222-epicardial-vasospastic-angina) *(p. 67)*
      - [5.2.3. Clinical presentations](#523-clinical-presentations) *(p. 67)*
      - [5.2.4. Short- and long-term prognosis](#524-short--and-long-term-prognosis) *(p. 67)*
      - [5.2.5. Diagnosis](#525-diagnosis) *(p. 67)*
        - [5.2.5.1. Non-invasive diagnosis](#5251-non-invasive-diagnosis) *(p. 67)*
        - [5.2.5.2. Invasive coronary functional testing](#5252-invasive-coronary-functional-testing) *(p. 67)*
          - [5.2.5.2.1. Basic coronary functional testing](#52521-basic-coronary-functional-testing) *(p. 67)*
          - [5.2.5.2.2. Coronary vasomotor testing](#52522-coronary-vasomotor-testing) *(p. 67)*
      - [5.2.6. Management of angina/ischaemia with non-obstructive coronary arteries](#526-management-of-angina/ischaemia-with-non-obstru) *(p. 69)*
    - [5.3. Other specific patient groups](#53-other-specific-patient-groups) *(p. 71)*
      - [5.3.1. Older adults](#531-older-adults) *(p. 71)*
      - [5.3.2. Sex differences in chronic coronary syndromes](#532-sex-differences-in-chronic-coronary-syndromes) *(p. 71)*
      - [5.3.3. High bleeding-risk patients](#533-high-bleeding-risk-patients) *(p. 72)*
      - [5.3.4. Inflammatory rheumatic diseases](#534-inflammatory-rheumatic-diseases) *(p. 72)*
      - [5.3.5. Hypertension](#535-hypertension) *(p. 72)*
      - [5.3.6. Atrial fibrillation](#536-atrial-fibrillation) *(p. 72)*
      - [5.3.7. Valvular heart disease](#537-valvular-heart-disease) *(p. 72)*
      - [5.3.8. Chronic kidney disease](#538-chronic-kidney-disease) *(p. 73)*
      - [5.3.9. Cancer](#539-cancer) *(p. 73)*
      - [5.3.10. Optimal treatment of patients with human immunodeficiency virus](#5310-optimal-treatment-of-patients-with-human-immu) *(p. 73)*
      - [5.3.11. Socially and geographically diverse groups](#5311-socially-and-geographically-diverse-groups) *(p. 73)*
    - [5.4. Screening for coronary artery disease in asymptomatic individuals](#54-screening-for-coronary-artery-disease-in-asympt) *(p. 74)*
  - [6. Long-term follow-up and care](#6-long-term-follow-up-and-care) *(p. 75)*
    - [6.1. Voice of the patient](#61-voice-of-the-patient) *(p. 75)*
      - [6.1.1. Communication](#611-communication) *(p. 75)*
      - [6.1.2. Depression and anxiety](#612-depression-and-anxiety) *(p. 75)*
    - [6.2. Adherence and persistence](#62-adherence-and-persistence) *(p. 75)*
      - [6.2.1. Adherence to healthy lifestyle behaviours](#621-adherence-to-healthy-lifestyle-behaviours) *(p. 75)*
        - [6.2.1.1. Why behavioural changes are difficult](#6211-why-behavioural-changes-are-difficult) *(p. 75)*
        - [6.2.1.2. How to change behaviour and support healthy lifestyles](#6212-how-to-change-behaviour-and-support-healthy-l) *(p. 76)*
        - [6.2.1.3. Digital and mHealth](#6213-digital-and-mhealth) *(p. 77)*
        - [6.2.1.4. How to assess adherence](#6214-how-to-assess-adherence) *(p. 78)*
      - [6.2.2. Adherence to medical therapy](#622-adherence-to-medical-therapy) *(p. 78)*
        - [6.2.2.1. Strategies to improve medication adherence](#6221-strategies-to-improve-medication-adherence) *(p. 78)*
        - [6.2.2.2. mHealth strategies for medication adherence](#6222-mhealth-strategies-for-medication-adherence) *(p. 78)*
    - [6.3. Diagnosis of disease progression](#63-diagnosis-of-disease-progression) *(p. 78)*
      - [6.3.1. Risk factors for recurrent coronary artery disease events](#631-risk-factors-for-recurrent-coronary-artery-dis) *(p. 79)*
      - [6.3.2. Organization of long-term follow-up](#632-organization-of-long-term-follow-up) *(p. 79)*
      - [6.3.3. Non-invasive diagnostic testing](#633-non-invasive-diagnostic-testing) *(p. 80)*
    - [6.4. Treatment of myocardial revascularization failure](#64-treatment-of-myocardial-revascularization-failu) *(p. 81)*
      - [6.4.1. Percutaneous coronary intervention failure](#641-percutaneous-coronary-intervention-failure) *(p. 81)*
      - [6.4.2. Managing graft failure after coronary artery bypass grafting](#642-managing-graft-failure-after-coronary-artery-b) *(p. 81)*
    - [6.5. Recurrent or refractory angina/ischaemia](#65-recurrent-or-refractory-angina/ischaemia) *(p. 82)*
    - [6.6. Treatment of disease complications](#66-treatment-of-disease-complications) *(p. 83)*
  - [7. Key messages](#7-key-messages) *(p. 83)*
  - [8. Gaps in evidence](#8-gaps-in-evidence) *(p. 84)*
  - [9. ‘What to do’ and ‘What not to do’ messages from the guidelines](#9-‘what-to-do’-and-‘what-not-to-do’-messages-from-) *(p. 85)*
  - [10. Evidence tables](#10-evidence-tables) *(p. 91)*
  - [11. Data availability statement](#11-data-availability-statement) *(p. 91)*
  - [12. Author information](#12-author-information) *(p. 91)*
  - [Appendix](#appendix) *(p. 92)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2024 ESC Guidelines for the management 
of chronic coronary syndromes
Developed by the task force for the management of chronic 
coronary syndromes of the European Society of Cardiology (ESC)
Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)
Authors/Task Force Members: Christiaan Vrints  *†, (Chairperson) (Belgium), 
Felicita Andreotti  *†, (Chairperson) (Italy), Konstantinos C. Koskinas‡, 
(Task Force Co-ordinator) (Switzerland), Xavier Rossello  
‡, (Task Force 
Co-ordinator) (Spain), Marianna Adamo  
(Italy), James Ainslie (United Kingdom), 
Adrian Paul Banning  
(United Kingdom), Andrzej Budaj  
(Poland), 
Ronny R. Buechel  
(Switzerland), Giovanni Alfonso Chiariello  
(Italy), 
Alaide Chieffo  
(Italy), Ruxandra Maria Christodorescu  
(Romania), 
Christi Deaton  
(United Kingdom), Torsten Doenst  
1 (Germany), 
Hywel W. Jones (United Kingdom), Vijay Kunadian  
(United Kingdom), 
Julinda Mehilli  
(Germany), Milan Milojevic  
1 (Serbia), Jan J. Piek  
(Netherlands), Francesca Pugliese  
(United Kingdom), Andrea Rubboli  
(Italy), 
Anne Grete Semb  
(Norway), Roxy Senior  
(United Kingdom), 
Jurrien M. ten Berg  
(Netherlands), Eric Van Belle  
(France), 
Emeline M. Van Craenenbroeck  
(Belgium), Rafael Vidal-Perez  
(Spain), 
Simon Winther  
(Denmark), and ESC Scientific Document Group      
© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com.
* Corresponding authors: Christiaan Vrints, Department of Cardiology, Antwerp University Hospital, Edegem, Belgium, and Research Group Cardiovascular Diseases, GENCOR, University 
of Antwerp, Antwerp, Belgium. Tel: +32 3 8213571, E-mail: christiaan.vrints@uantwerpen.be; and Felicita Andreotti, Cardiovascular Science Department, Fondazione Policlinico Universitario 
Gemelli IRCCS, Rome, Italy, and Cardio-Thoracic Department, Catholic University Medical School, Rome, Italy. Tel: +39-06-30154187, E-mail: felicita.andreotti@unicatt.it.  
† The two Chairpersons contributed equally to the document and are joint first authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the Association European Association for Cardio-Thoracic Surgery (EACTS).
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice.
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Coronary Pathophysiology and Microcirculation, Thrombosis.
Patient Forum  
https://doi.org/10.1093/eurheartj/ehae177
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Michael Borger, (CPG Review Co-ordinator) (Germany), Ingibjörg J. Gudmundsdóttir, 
(CPG Review Co-ordinator) (Iceland), Juhani Knuuti, (CPG Review Co-ordinator) (Finland), Ingo Ahrens 
(Germany), Michael Böhm (Germany), Sergio Buccheri (Italy), Davide Capodanno (Italy), Evald Høj Christiansen 
(Denmark), Jean-Philippe Collet¶ (France), Kenneth Dickstein (Norway), Christian Eek (Norway), Volkmar Falk 
(Germany), Peter A. Henriksen (United Kingdom), Borja Ibanez (Spain), Stefan James (Sweden), Sasko Kedev 
(Macedonia), Lars Køber (Denmark), Martha Kyriakou (Cyprus), Emma F. Magavern (United Kingdom), 
Angela McInerney (Ireland), John William McEvoy (United Kingdom), Caius Ovidiu Mersha (Romania), 
Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), 
Franz-Josef Neumann (Germany), Jens Cosedis Nielsen (Denmark), Pasquale Paolisso (Italy), Valeria Paradies 
(Netherlands), Agnes A. Pasquet (Belgium), Massimo Piepoli (Italy), Eva Prescott (Denmark), Amina Rakisheva 
(Kazakhstan), Bianca Rocca (Italy), Marc Ruel (Canada), Sigrid Sandner (Austria), Antti Saraste (Finland), 
Karolina Szummer (Sweden), Ilonca Vaartjes (Netherlands), William Wijns (Ireland), Stephan Windecker 
(Switzerland), Adam Witkowsky (Poland), Marija Zdrakovic (Serbia), and Katja Zeppenfeld (Netherlands)
¶ Professor Jean-Philippe Collet sadly passed away during the development of these guidelines. Professor Collet’s 
contribution to these guidelines was, as always, highly valued.
All experts involved in the development of these guidelines have submitted declarations of interest, which are 
reported in a supplementary document to the guidelines. See the European Heart Journal online or https://www. 
escardio.org/Guidelines for supplementary documents as well as evidence tables.
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and 
medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, 
discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant 
public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged 
to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the 
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way 
whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do 
the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated 
recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the 
scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s 
responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC 
warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational 
use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written 
permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of 
the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords 
Guidelines • Antianginal therapy • Antithrombotic therapy • Atherosclerosis • Clinical likelihood • Chronic 
coronary syndromes • Coronary artery disease • Diagnostic testing/algorithm • Heart team • Lipid-lowering therapy 
• Microvascular disease • Myocardial ischaemia • Myocardial revascularization • Outcomes • PROMS/PREMS • 
Shared decision-making • Stable angina • Vasospasm


<!-- PAGE 3 -->

### Page 3

Table of contents
1. Preamble .............................................................................................................. 3422
2. Introduction ....................................................................................................... 3423
2.1. Evolving pathophysiological concepts of chronic coronary 
syndromes ..........................................................................................................
3423
2.2. Chronic coronary syndromes: clinical presentations 
(Figure 1) .............................................................................................................
3424
2.3. Changing epidemiology and management strategies ..............
3424
2.4. What is new .............................................................................................
3426
3. Stepwise approach to the initial management of individuals with 
suspected chronic coronary syndrome ....................................................... 3433
3.1. STEP 1: General clinical examination .............................................
3433
3.1.1. History, differential diagnosis, and physical examination
3433
3.1.2. Basic testing: 12-lead electrocardiogram and 
biochemistry .................................................................................................. 3436
3.1.2.1. Electrocardiogram .................................................................
3436
3.1.2.2. Biochemical tests ....................................................................
3437
3.2. STEP 2: Further evaluation .................................................................
3437
3.2.1. Pre-test clinical likelihood of obstructive atherosclerotic 
coronary artery disease ............................................................................ 3437
3.2.2. Transthoracic echocardiography and cardiac magnetic 
resonance at rest ........................................................................................ 3440
3.2.3. Exercise electrocardiogram testing ......................................... 3440
3.2.4. Chest X-ray ....................................................................................... 3441
3.2.5. Ambulatory electrocardiogram monitoring ........................ 3441
3.3. STEP 3: Confirming the diagnosis ...................................................
3441
3.3.1. Anatomical imaging: coronary computed tomography 
angiography .................................................................................................... 3441
3.3.1.1. Computed tomography perfusion imaging .................
3441
3.3.1.2. Prognosis, plaque features, and opportunity to 
improve outcomes ................................................................................
3442
3.3.1.3. Recognized pre-requisites for coronary computed 
tomography angiography ....................................................................
3442
3.3.2. Functional imaging .......................................................................... 3442
3.3.2.1. Stress echocardiography .....................................................
3442
3.3.2.2. Myocardial perfusion scintigraphy—single-photon 
emission computed tomography ....................................................
3443
3.3.2.3. Positron emission tomography-computed 
tomography ..............................................................................................
3444
3.3.2.4. Cardiac magnetic resonance imaging .............................
3444
3.3.2.5. Non-invasive testing for microvascular dysfunction
3445
3.3.3. Invasive tests ..................................................................................... 3445
3.3.3.1. Invasive coronary angiography .........................................
3445
3.3.3.2. Functional assessment of epicardial stenosis severity 
to guide coronary revascularization ...............................................
3446
3.3.3.3. Assessment of microvascular dysfunction ...................
3447
3.3.3.4. Testing for coronary vasospasm .....................................
3447
3.3.4. Diagnostic algorithm and selection of appropriate tests
3448
3.3.5. Adverse-event risk assessment ................................................. 3453
3.4. STEP 4: Initial therapy ..........................................................................
3454
4. Guideline-directed therapy .......................................................................... 3455
4.1. Patient education, lifestyle optimization for risk-factor 
control, and exercise therapy ....................................................................
3455
4.1.1. Patient education ............................................................................ 3455
4.1.2. Key lifestyle interventions for risk-factor control ............ 3455
4.1.2.1. Smoking and substance abuse ..........................................
3456
4.1.2.2. Weight management ............................................................
3456
4.1.2.3. Diet and alcohol .....................................................................
3456
4.1.2.4. Mental health ...........................................................................
3456
4.1.2.5. Physical activity and sedentary behaviour ....................
3456
4.1.3. Exercise therapy .............................................................................. 3457
4.2. Antianginal/anti-ischaemic medication ...........................................
3457
4.2.1. General strategy .............................................................................. 3457
4.2.2. Beta blockers .................................................................................... 3458
4.2.3. Combination therapy .................................................................... 3459
4.3. Medical therapy for event prevention ...........................................
3460
4.3.1. Antithrombotic drugs ................................................................... 3460
4.3.1.1. Antiplatelet drugs ...................................................................
3460
4.3.1.1.1. Aspirin monotherapy ...................................................
3460
4.3.1.1.2. Oral P2Y12 inhibitor monotherapy .......................
3460
4.3.1.1.2.1. Clopidogrel monotherapy .................................
3460
4.3.1.1.2.2. Ticagrelor monotherapy ....................................
3460
4.3.1.1.3. Dual antiplatelet therapy post-percutaneous 
coronary intervention .....................................................................
3462
4.3.1.1.4. Extended intensified antithrombotic therapy ...
3462
4.3.1.1.5. Genotype- and phenotype-guided dual 
antiplatelet therapy ..........................................................................
3463
4.3.1.2. Anticoagulant therapy ..........................................................
3464
4.3.1.2.1. Monotherapy with oral anticoagulant ..................
3464
4.3.1.2.2. Combination of anticoagulant and antiplatelet 
therapy after percutaneous coronary intervention in 
chronic coronary syndrome patients with AF or other 
indication for oral anticoagulant .................................................
3464
4.3.1.3. Coronary artery bypass grafting and antithrombotic 
therapy ........................................................................................................
3465
4.3.1.4. Proton pump inhibitors .......................................................
3465
4.3.2. Lipid-lowering drugs ...................................................................... 3467
4.3.3. Renin–angiotensin–aldosterone blockers/angiotensin 
receptor neprilysin inhibitor .................................................................. 3467
4.3.4. Sodium–glucose cotransporter 2 inhibitors and glucagon- 
like peptide-1 receptor agonists ........................................................... 3468
4.3.5. Anti-inflammatory agents for event prevention ................ 3468
4.4. Revascularization for chronic coronary syndromes ................
3469
4.4.1. Appropriate indication for myocardial revascularization
3469
4.4.2. Additional considerations on reduced systolic left 
ventricular function: myocardial viability, revascularization, and 
its modality .................................................................................................... 3470
4.4.3. Additional considerations—complete vs. partial 
revascularization .......................................................................................... 3471
4.4.4. Assessment of clinical risk and anatomical complexity .. 3471
4.4.5. Choice of myocardial revascularization modality ............. 3472
4.4.5.1. Patients with single- or two-vessel coronary artery 
disease .........................................................................................................
3472
4.4.5.2. Patients with unprotected left main coronary artery 
disease .........................................................................................................
3472
4.4.5.3. Patients with multivessel coronary artery disease ...
3474
4.4.5.4. Impact of coronary pressure guidance on multivessel 
coronary artery disease patients undergoing percutaneous 
coronary intervention ..........................................................................
3474
4.4.5.5. Virtual percutaneous coronary intervention: 
combination of coronary pressure mapping with coronary 
anatomy for percutaneous coronary intervention planning
3474
4.4.5.6. Impact of intracoronary imaging guidance on 
multivessel coronary artery disease patients undergoing 
percutaneous coronary intervention .............................................
3474
4.4.5.7. Hybrid revascularization in multivessel coronary 
artery disease patients .........................................................................


<!-- PAGE 4 -->

### Page 4

4.4.6. Patient–physician shared decision-making to perform and 
select revascularization modality .......................................................... 3475
4.4.7. Institutional protocols, clinical pathways, and quality of 
care .................................................................................................................... 3475
5. Optimal assessment and treatment of specific groups ................... 3478
5.1. Coronary artery disease and heart failure ..................................
3478
5.2. Angina/ischaemia with non-obstructive coronary arteries ...
3479
5.2.1. Definition ........................................................................................... 3479
5.2.2. Angina/ischaemia with non-obstructive coronary arteries 
endotypes ....................................................................................................... 3479
5.2.2.1. Microvascular angina .............................................................
3480
5.2.2.2. Epicardial vasospastic angina .............................................
3481
5.2.3. Clinical presentations .................................................................... 3481
5.2.4. Short- and long-term prognosis ............................................... 3481
5.2.5. Diagnosis ............................................................................................ 3481
5.2.5.1. Non-invasive diagnosis .........................................................
3481
5.2.5.2. Invasive coronary functional testing ...............................
3481
5.2.5.2.1. Basic coronary functional testing ............................
3481
5.2.5.2.2. Coronary vasomotor testing ....................................
3481
5.2.6. Management of angina/ischaemia with non-obstructive 
coronary arteries ........................................................................................ 3483
5.3. Other specific patient groups ...........................................................
3485
5.3.1. Older adults ...................................................................................... 3485
5.3.2. Sex differences in chronic coronary syndromes ............... 3485
5.3.3. High bleeding-risk patients ......................................................... 3486
5.3.4. Inflammatory rheumatic diseases ............................................. 3486
5.3.5. Hypertension .................................................................................... 3486
5.3.6. Atrial fibrillation ............................................................................... 3486
5.3.7. Valvular heart disease ................................................................... 3486
5.3.8. Chronic kidney disease ................................................................. 3487
5.3.9. Cancer ................................................................................................. 3487
5.3.10. Optimal treatment of patients with human 
immunodeficiency virus ............................................................................ 3487
5.3.11. Socially and geographically diverse groups ........................ 3487
5.4. Screening for coronary artery disease in asymptomatic 
individuals ...........................................................................................................
3488
6. Long-term follow-up and care ................................................................... 3489
6.1. Voice of the patient ..............................................................................
3489
6.1.1. Communication ............................................................................... 3489
6.1.2. Depression and anxiety ............................................................... 3489
6.2. Adherence and persistence ...............................................................
3489
6.2.1. Adherence to healthy lifestyle behaviours ........................... 3489
6.2.1.1. Why behavioural changes are difficult ..........................
3489
6.2.1.2. How to change behaviour and support healthy 
lifestyles ......................................................................................................
3490
6.2.1.3. Digital and mHealth ..............................................................
3491
6.2.1.4. How to assess adherence ..................................................
3492
6.2.2. Adherence to medical therapy ................................................. 3492
6.2.2.1. Strategies to improve medication adherence ............
3492
6.2.2.2. mHealth strategies for medication adherence ..........
3492
6.3. Diagnosis of disease progression .....................................................
3492
6.3.1. Risk factors for recurrent coronary artery disease 
events ............................................................................................................... 3493
6.3.2. Organization of long-term follow-up ..................................... 3493
6.3.3. Non-invasive diagnostic testing ................................................. 3494
6.4. Treatment of myocardial revascularization failure ...................
3495
6.4.1. Percutaneous coronary intervention failure ....................... 3495
6.4.2. Managing graft failure after coronary artery bypass 
grafting ............................................................................................................. 3495
6.5. Recurrent or refractory angina/ischaemia ...................................
3496
6.6. Treatment of disease complications ..............................................
3497
7. Key messages ..................................................................................................... 3497
8. Gaps in evidence .............................................................................................. 3498
9. ‘What to do’ and ‘What not to do’ messages from the guidelines
3499
10. Evidence tables ............................................................................................... 3505
11. Data availability statement ......................................................................... 3505
12. Author information ...................................................................................... 3505
13. Appendix ........................................................................................................... 3506
Tables of Recommendations
Recommendation Table 1 — Recommendations for history taking, 
risk factor assessment, and resting electrocardiogram in individuals 
with suspected chronic coronary syndrome (see also Evidence 
Table 1) ...............................................................................................................................
3436
Recommendation Table 2 — Recommendations for basic 
biochemistry in the initial diagnostic management of individuals 
with suspected chronic coronary syndrome (see also Evidence 
Table 2) ...............................................................................................................................
3437
Recommendation Table 3 — Recommendations for estimating, 
adjusting and reclassifying the likelihood of obstructive 
atherosclerotic coronary artery disease in the initial diagnostic 
management of individuals with suspected chronic coronary 
syndrome (see also Evidence Table 3) ......................................................... 3438
Recommendation Table 4 — Recommendations for resting 
transthoracic ultrasound and cardiac magnetic resonance imaging in 
the initial diagnostic management of individuals with suspected 
chronic coronary syndrome (see also Evidence Table 4) ................... 3440
Recommendation Table 5 — Recommendations for exercise ECG 
in the initial diagnostic management of individuals with suspected 
chronic coronary syndrome (see also Evidence Table 5) ................... 3441
Recommendation Table 6 — Recommendations for chest X-ray in 
the initial diagnostic management of individuals with suspected 
chronic coronary syndrome (see also Evidence Table 6) ................... 3441
Recommendation Table 7 — Recommendations for ambulatory ECG 
monitoring in the initial diagnostic management of individuals with 
suspected chronic coronary syndrome (see also Evidence Table 7) .
3441
Recommendation Table 8 — Recommendations for non-invasive 
anatomical imaging tests in the initial diagnostic management of 
individuals with suspected chronic coronary syndrome—coronary 
computed tomography angiography, if available, and supported by 
local expertise (see also Evidence Table 8) ............................................... 3442
Recommendation Table 9 — Recommendations for non-invasive 
tests in the initial diagnostic management of individuals with suspected 
chronic coronary syndrome—stress echocardiography, if available, 
and supported by local expertise (see also Evidence Table 9) ..............
3443
Recommendation Table 10 — Recommendations for non-invasive 
functional myocardial imaging tests in the initial diagnostic 
management of individuals with suspected chronic coronary 
syndrome—resting and stress single-photon emission computed 
tomography/positron emission tomography—cardiac magnetic 
resonance imaging, if available, and supported by local expertise (see 
also Evidence Table 10) ...................................................................................... 3444
Recommendation Table 11 — Recommendations for invasive 
coronary angiography in the diagnostic management of individuals 
with suspected chronic coronary syndrome (see also Evidence 
Table 11) ................................................................................................................... 3446
Recommendation Table 12 — Recommendations for functional 
assessment of epicardial artery stenosis severity during invasive


<!-- PAGE 5 -->

### Page 5

coronary angiography to guide revascularization (see also Evidence 
Table 12) ................................................................................................................... 3447
Recommendation Table 13 — Recommendations for selection of 
initial diagnostic tests in individuals with suspected chronic coronary 
syndrome (see also Evidence Table 13) ...................................................... 3453
Recommendation Table 14 — Recommendations for definition of 
high risk of adverse events (see also Evidence Table 14) .................... 3454
Recommendation Table 15 — Recommendations for cardiovascular 
risk reduction, lifestyle changes, and exercise interventions in 
patients with established chronic coronary syndrome (see also 
Evidence Table 15) ............................................................................................... 3457
Recommendation Table 16 — Recommendations for antianginal 
drugs in patients with chronic coronary syndrome (see also Evidence 
Table 16) ................................................................................................................... 3459
Recommendation Table 17 — Recommendations for 
antithrombotic therapy in patients with chronic coronary syndrome 
(see also Evidence Table 17) ............................................................................ 3465
Recommendation Table 18 — Recommendations for lipid-lowering 
drugs in patients with chronic coronary syndrome (see also Evidence 
Table 18) ................................................................................................................... 3467
Recommendation Table 19 — Recommendations for sodium– 
glucose cotransporter 2 inhibitors and/or glucagon-like peptide-1 
receptor agonists in patients with chronic coronary syndrome (see 
also Evidence Table 19) ...................................................................................... 3468
Recommendation Table 20 — Recommendations for 
anti-inflammatory drugs in patients with chronic coronary syndrome 
(see also Evidence Table 20) ............................................................................ 3469
Recommendation Table 21 — Recommendations for 
angiotensin-converting enzyme inhibitors in patients with chronic 
coronary syndrome (see also Evidence Table 21) ................................. 3469
Recommendation Table 22 — Recommendations for 
revascularization in patients with chronic coronary syndrome (see 
also Evidence Table 22) ...................................................................................... 3476
Recommendation Table 23 — Recommendations for mode of 
revascularization in patients with chronic coronary syndrome (see 
also Evidence Table 23) ...................................................................................... 3477
Recommendation Table 24 — Recommendations for management 
of chronic coronary syndrome patients with chronic heart failure 
(see also Evidence Table 24) ............................................................................ 3478
Recommendation Table 25 — Recommendations for diagnosis and 
management of patients with angina/ischaemia with non-obstructive 
coronary arteries (see also Evidence Table 25) ........................................ 3485
Recommendation Table 26 — Recommendations for older, female, 
high bleeding risk, comorbid, and socially/geographically diverse 
patients (see also Evidence Table 26) ........................................................... 3488
Recommendation Table 27 — Recommendations for screening for 
coronary artery disease in asymptomatic individuals (see also 
Evidence Table 27) ............................................................................................... 3488
Recommendation Table 28 — Recommendations for adherence to 
medical therapy and lifestyle changes (see also Evidence Table 28)
3492
Recommendation Table 29 — Recommendations for diagnosis of 
disease progression in patients with established chronic coronary 
syndrome (see also Evidence Table 29) ...................................................... 3495
Recommendation Table 30 — Recommendations for treatment of 
revascularization failure (see also Evidence Table 30) .......................... 3496
Recommendation Table 31 — Recommendations for recurrent or 
refractory angina/ischaemia (see also Evidence Table 31) .................. 3496
List of tables
Table 1 Classes of recommendations .......................................................... 3422
Table 2 Levels of evidence ................................................................................ 3423
Table 3 New major recommendations in 2024 ...................................... 3426
Table 4 Revised recommendations ............................................................... 3430
Table 5 Grading of effort angina severity according to the Canadian 
Cardiovascular Society ........................................................................................ 3436
Table 6 Overview of non-invasive tests used for first-line testing in 
individuals with suspected chronic coronary syndrome ...................... 3451
Table 7 Practical advice on lifestyle counselling and interventions . 3455
Table 8 Options for extended intensified antithrombotic therapy
3464
Table 9 Summary of trial-based evidence for the comparison of 
percutaneous coronary intervention and coronary artery bypass 
grafting in patients with left main coronary artery disease ................ 3473
Table 10 ‘What to do’ and ‘What not to do’ .......................................... 3499
List of figures
Figure 1 (Central Illustration) Clinical presentations of chronic 
coronary syndrome and mechanisms of myocardial ischaemia ........ 3425
Figure 2 Stepwise approach to the initial management of individuals 
with suspected chronic coronary syndrome ............................................ 3434
Figure 3 Main CCS symptoms: angina and exertional dyspnoea ..... 3435
Figure 4 Estimation of the clinical likelihood of obstructive coronary 
artery disease .......................................................................................................... 3439
Figure 5 Adjustment and reclassification of the estimated clinical 
likelihood of obstructive coronary artery disease .................................. 3448
Figure 6 Appropriate first-line testing in symptomatic individuals 
with suspected chronic coronary syndrome ............................................ 3449
Figure 7 Initial management of symptomatic individuals with 
suspected chronic coronary syndrome ....................................................... 3450
Figure 8 Ruling in and ruling out functionally significant obstructive 
coronary artery disease by sequential anatomical (coronary 
computed tomography angiography) and functional (dobutamine 
stress echocardiography) testing.a ................................................................. 3452
Figure 9 Possible combinations of antianginal drugs .............................. 3458
Figure 10 Antithrombotic drugs for chronic coronary syndromes: 
pharmacological targets ...................................................................................... 3461
Figure 11 Antithrombotic treatment in chronic coronary syndrome 
patients undergoing percutaneous coronary intervention ................. 3463
Figure 12 Prevalence of disease characteristics in patients with 
ANOCA/INOCA referred for invasive coronary functional testing
3480
Figure 13 Diagnostic algorithm for patients with angina/ischaemia 
with non-obstructive coronary arteries ...................................................... 3482
Figure 14 Spasm provocation and functional testing protocol ......... 3483
Figure 15 Treatment of angina/ischaemia with non-obstructive 
coronary arteries .................................................................................................. 3484
Figure 16 Actions on the five dimensions of adherence to therapy
3490
Figure 17 Strategies for long-term adherence to a healthy lifestyle
3491
Figure 18 Approach for the follow-up of patients with established 
chronic coronary syndrome ............................................................................. 3494
Abbreviations and acronyms
99mTc
Technetium-99m
ACE-I
Angiotensin-converting enzyme inhibitor
Ach
Acetylcholine
ACS
Acute coronary syndrome(s)
AF
Atrial fibrillation
AKI
Acute kidney injury
ALPHEUS
Assessment of Loading with the P2Y12 Inhibitor 
Ticagrelor or Clopidogrel to Halt Ischemic 
Events in Patients Undergoing Elective Coronary 
Stenting
ANOCA
Angina with non-obstructive coronary arteries
ARB
Angiotensin receptor blocker
ESC Guidelines                                                                                                                                                                                          3419


<!-- PAGE 6 -->

### Page 6

ARC-HBR
Academic Research Consortium for High 
Bleeding Risk
ARNI
Angiotensin receptor neprilysin inhibitor
ART
Antiretroviral therapy
ASCVD
Atherosclerotic cardiovascular disease
ASE
American Society of Echocardiography
AUGUSTUS
Open-Label, 2 × 2 Factorial, Randomized 
Controlled, Clinical Trial to Evaluate the Safety of 
Apixaban versus Vitamin K Antagonist and 
Aspirin versus Aspirin Placebo in Patients with 
Atrial Fibrillation and Acute Coronary Syndrome 
or Percutaneous Coronary Intervention
BARC
Bleeding Academic Research Consortium b.i.d.
bis in die (twice daily)
BMI
Body mass index
BP
Blood pressure b.p.m.
Beats per minute
CABG
Coronary artery bypass grafting
CAC
Coronary artery calcification
CACS
Coronary artery calcium score
CACS-CL
CACS + risk-factor-weighted clinical likelihood 
(RF-CL) model
CAD
Coronary artery disease
CANTOS
Canakinumab Antiinflammatory Thrombosis 
Outcome Study
CAPRIE
Clopidogrel versus Aspirin in Patients at Risk of 
Ischaemic Events
CCB
Calcium channel blocker
CCS
Chronic coronary syndrome(s)
CCTA
Coronary computed tomography angiography
CFC
Coronary flow capacity
CFR
Coronary flow reserve
CFVR
Coronary flow velocity reserve
CHA2DS2-VASc
Congestive heart failure or left ventricular 
dysfunction, hypertension, age ≥75 (doubled), 
diabetes, stroke (doubled), vascular disease, age 
65–74, sex category (female)
CI
Confidence interval
CKD
Chronic kidney disease
CMD
Coronary microvascular dysfunction
CMR
Cardiac magnetic resonance
COLCOT
Colchicine Cardiovascular Outcomes Trial
COMPASS
Cardiovascular Outcomes for People Using 
Anticoagulation Strategies
COURAGE
Clinical Outcomes Utilizing Revascularization 
and Aggressive Drug Evaluation
CRT
Cardiac resynchronization therapy
CT
Computed tomography
CVD
Cardiovascular disease
CYP2C19
Cytochrome P450 2C19
CYP3A4
Cytochrome P450 3A4
CZT
Cadmium–zinc–telluride
DAPT
Dual antiplatelet therapy
DEFINE GPS
Distal Evaluation of Functional Performance with 
Intravascular Sensors to Assess the Narrowing 
Effect: Guided Physiologic Stenting
DES
Drug-eluting stent
DEFINE-FLAIR
Functional Lesion Assessment of Intermediate 
Stenosis to Guide Revascularisation
DHP
Dihydropyridine
DM
Diabetes mellitus
DOAC
Direct oral anticoagulant dPR
Diastolic pressure ratio
DSE
Dobutamine stress echocardiography
EACTS
European Association for Cardio-Thoracic Surgery
EACVI
European Association of Cardiovascular Imaging
ECG
Electrocardiogram
EF
Ejection fraction eGFR
Estimated glomerular filtration rate
EMA
European Medicines Agency
ESC
European Society of Cardiology
EXCEL
Evaluation of XIENCE versus Coronary Artery 
Bypass Surgery for Effectiveness of Left Main 
Revascularization
FAME
Fractional Flow Reserve versus Angiography for 
Multivessel Evaluation
FFR
Fractional flow reserve
FFR-CT
Coronary computed tomography 
angiography-derived fractional flow reserve
FREEDOM
Strategies for Multivessel Revascularization in 
Patients with Diabetes
GDMT
Guideline-directed medical therapy
GI
Gastrointestinal
GIP
Glucose-dependent insulinotropic polypeptide
GLOBAL 
LEADERS
Ticagrelor plus aspirin for 1 month, followed by 
ticagrelor monotherapy for 23 months vs. aspirin 
plus clopidogrel or ticagrelor for 12 months, 
followed by aspirin monotherapy for 12 months 
after implantation of a drug-eluting stent (DES): 
a multicentre, open-label, randomized 
superiority trial
GLP-1
Glucagon-like peptide-1
GUSTO
Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Arteries
HbA1c
Glycated haemoglobin
HBR
High bleeding risk
HDL-C
High-density lipoprotein cholesterol
HF
Heart failure
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HIV
Human immunodeficiency virus
HMR
Hyperaemic myocardial velocity resistance
HOST-EXAM
Harmonizing Optimal Strategy for Treatment of 
Coronary Artery Stenosis-EXtended 
Antiplatelet Monotherapy
HR
Hazard ratio hs-CRP
High-sensitivity C-reactive protein
HSR
Hyperaemic stenosis resistance i.c.
Intracoronary i.v.
Intravenous
ICA
Invasive coronary angiography
ICD
Implantable cardioverter defibrillator
ICFT
Invasive coronary functional testing iFR
Instantaneous wave-free ratio iFR- 
SWEDEHEART
Instantaneous Wave-free Ratio versus Fractional 
Flow Reserve in Patients with Stable Angina 
Pectoris or Acute Coronary Syndrome
ILIAS
Inclusive Invasive Physiological Assessment in 
Angina Syndromes
IMR
Index of microcirculatory resistance
INOCA
Ischaemia with non-obstructive coronary arteries
INR
International normalized ratio
IQR
Interquartile range


<!-- PAGE 7 -->

### Page 7

ISCHEMIA
Initial Invasive or Conservative Strategy for 
Stable Coronary Disease (trial)
ISR
In-stent restenosis
ISTH
International Society on Thrombosis and 
Haemostasis
IVUS
Intravascular ultrasound
LAD
Left anterior descending
LBBB
Left bundle branch block
LDL-C
Low-density lipoprotein cholesterol
LGE
Late gadolinium enhancement
LIMA
Left internal mammary artery
LITA
Left internal thoracic artery
LMCA
Left main coronary artery
LMCAD
Left main coronary artery disease
LODOCO2
LOw-DOse COlchicine 2
LOE
Level of evidence
LV
Left ventricular
LVEF
Left ventricular ejection fraction
MACCE
Major adverse cardiac or cerebrovascular events
MACE
Major adverse cardiovascular events
MASTER-DAPT
Management of High Bleeding Risk Patients Post 
Bioresorbable Polymer Coated Stent Implantation 
with an Abbreviated versus Standard DAPT Regimen
MBF
Myocardial blood flow
MCE
Myocardial contrast echocardiography
MCS
Mechanical circulatory support
MFR
Myocardial flow reserve mHealth
Mobile device-based healthcare
MI
Myocardial infarction
MIDCAB
Minimally invasive direct coronary artery bypass
MRA
Mineralocorticoid receptor antagonist
MRI
Magnetic resonance imaging
MRR
Microvascular resistance reserve
MVA
Microvascular angina
MVD
Multivessel disease
NNH
Number needed to harm
NNT
Number needed to treat to prevent an adverse event
NOBLE
Nordic–Baltic–British Left Main 
Revascularisation Study
NSTEMI
Non-ST-segment elevation myocardial infarction
NTG
Nitroglycerine
NYHA
New York Heart Association
OAC
Oral anticoagulant
OCT
Optical coherence tomography
OR
Odds ratio
ORBITA
Objective Randomised Blinded Investigation with 
optimal medical Therapy of Angioplasty in stable 
angina
ORBITA-COSMIC
Coronary Sinus Reducer Objective Impact on 
Symptoms, MRI Ischaemia and Microvascular 
Resistance
PAD
Peripheral artery disease
PAR
Protease-activated receptor
PARR-2
F-18-Fluorodeoxyglucose Positron Emission 
Tomography Imaging-Assisted Management of 
Patients with Severe Left Ventricular 
Dysfunction and Suspected Coronary Disease: a 
Randomized, Controlled Trial
PCI
Percutaneous coronary intervention
PCSK9
Proprotein convertase subtilisin/kexin type 9
Pd/Pa
Distal coronary pressure to aortic pressure ratio
PDE-5
Phosphodiesterase-5
PEGASUS-TIMI 
54
Prevention of Cardiovascular Events in Patients 
with Prior Heart Attack Using Ticagrelor 
Compared to Placebo on a Background of 
Aspirin Thrombolysis In Myocardial Infarction
PESA
Progression of Early Subclinical Atherosclerosis
PET
Positron emission tomography
PRECISE-DAPT
PREdicting bleeding Complications In 
patients undergoing Stent implantation 
and subsEquent Dual AntiPlatelet Therapy
PRECOMBAT
Randomized Trial of Stents versus Bypass 
Surgery for Left Main Coronary Artery Disease 
(trial)
PRIZE
Precision Medicine with Zibotentan in 
Microvascular Angina
PROM
Patient-reported outcome measure
PROMISE
Prospective Multicenter Imaging Study for 
Evaluation of Chest Pain
PTP
Pre-test probability
QFR
Quantitative flow ratio
QoL
Quality of life
R3F
French FFR Registry
RAAS
Renin–angiotensin–aldosterone system
RCT
Randomized controlled trial
REVIVED-BCIS2
Percutaneous Revascularization for Ischemic Left 
Ventricular Dysfunction
RF-CL
Risk-factor-weighted clinical likelihood
RFR
Relative flow reserve
RIPCORD
Routine Pressure Wire Assessment Influence 
Management Strategy at Coronary Angiography 
for Diagnosis of Chest Pain trial
RR
Relative risk
RWTA
Regional systolic wall-thickening abnormalities
SAPT
Single antiplatelet therapy
SCORE2
Systematic Coronary Risk Estimation 2
SCORE2-OP
Systematic Coronary Risk Estimation 2–Older 
Persons
SCOT-HEART
Scottish Computed Tomography of the Heart
SELECT
Semaglutide Effects on Cardiovascular 
Outcomes in People With Overweight or 
Obesity
SGLT2
Sodium–glucose cotransporter 2
SLE
Systemic lupus erythematosus
SPECT
Single-photon emission computed  
tomography
STEMI
ST-segment elevation myocardial infarction
STICH
Surgical Treatment for Ischemic Heart Failure
STS-PROM
Society of Thoracic Surgeons Predicted Risk of 
Mortality
SURMOUNT
Efficacy and Safety of Tirzepatide Once Weekly 
in Participants Without Type 2 Diabetes Who 
Have Obesity or Are Overweight With Weight- 
Related Comorbidities: A Randomized, Double- 
Blind, Placebo-Controlled Trial
SYNTAX
SYNergy between PCI with TAXUS and Cardiac 
Surgery
THEMIS
The Effect of Ticagrelor on Health Outcomes  
in diabEtes Mellitus patients Intervention Study
TID
Transient ischaemic dilatation
TIMI
Thrombolysis In Myocardial Infarction
Tx
Thromboxane
ESC Guidelines                                                                                                                                                                                          3421


<!-- PAGE 8 -->

### Page 8

TWILIGHT
Ticagrelor with Aspirin or Alone in High-Risk 
Patients after Coronary Intervention vFFR
Vessel fractional flow reserve
VKA
Vitamin K antagonist
VSA
Vasospastic angina
VTE
Venous thrombo-embolism
WARRIOR
Women’s IschemiA Trial to Reduce Events 
in Non-ObstRuctIve CORonary Artery Disease
WOMEN
What is the Optimal Method for Ischemia 
Evaluation of Women
X-ECG
Exercise ECG testing
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeut­
ic approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals, and the European Society of 
Cardiology (ESC) makes its guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription and to respect the ethical rules of their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated when warranted by new evidence. ESC 
Policies and Procedures for formulating and issuing ESC Guidelines can 
be found on the ESC website (https://www.escardio.org/Guidelines/ 
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Gui 
delines). These guidelines update and replace the previous version from 
2019 and partly replace the myocardial revascularization guidelines 
from 2018.
The Members of this task force were selected by the ESC to include 
professionals involved in the medical care of patients with this path­
ology, as well as patient representatives and methodologists. The selec­
tion procedure included an open call for authors and aimed to include 
members from across the whole of the ESC region and from relevant 
ESC Subspecialty Communities. Consideration was given to diversity 
and inclusion, notably with respect to gender and country of origin. 
The task force performed a critical review and evaluation of the pub­
lished literature on diagnostic and therapeutic approaches including as­
sessment of the risk–benefit ratio. The strength of every 
recommendation and the level of evidence supporting them were 
weighed and scored according to predefined scales as outlined in 
Tables 1 and 2 below. Patient-reported outcome measures (PROMs) 
and patient-reported experience measures (PREMs) were also evalu­
ated as the basis for recommendations and/or discussion in these guide­
lines. The task force followed ESC voting procedures and all approved 
recommendations were subject to a vote and achieved at least 75% 
agreement among voting members. Members of the task force with de­
clared interests on specific topics were asked to abstain from voting on 
related recommendations.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules, 
which can be found on the ESC website (http://www.escardio.org/ 
guidelines) and have been compiled in a report published in a supple­
mentary document with the guidelines. Funding for the development 
of ESC Guidelines is derived entirely from the ESC with no involvement 
of the healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises 
and co-ordinates the preparation of new guidelines and is responsible 
Table 1 Classes of recommendations
©ESC 2024
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2024


<!-- PAGE 9 -->

### Page 9

for the approval process. In addition to review by the CPG Committee, 
ESC Guidelines undergo multiple rounds of double-blind peer review 
by external experts, including members from across the whole of the 
ESC region, all National Cardiac Societies of the ESC and from relevant 
ESC Subspecialty Communities. After appropriate revisions, the 
guidelines are signed off by all the experts in the task force. The finalized 
document is signed off by the CPG Committee for publication in the 
ESC Guidelines are based on analyses of published evidence, chiefly 
on clinical trials and meta-analyses of trials, but potentially including 
other types of studies. Evidence tables summarizing key information 
from relevant studies are generated early in the guideline development 
process to facilitate the formulation of recommendations, to enhance 
comprehension of recommendations after publication, and reinforce 
transparency in the guideline development process. The tables are pub­
lished in their own section of the ESC Guidelines and are specifically 
related to the recommendation tables.
Off-label use of medication may be presented in these guidelines if a 
sufficient level of evidence shows that it can be considered medically ap­
propriate for a given condition. However, the final decisions concerning 
an individual patient must be made by the responsible health profes­
sional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
The 2019 ESC (European Society of Cardiology) Guidelines for the 
diagnosis and management of chronic coronary syndromes introduced 
the term chronic coronary syndromes (CCS)1 to describe the clinical 
presentations of coronary artery disease (CAD) during stable periods, 
particularly those preceding or following an acute coronary syndrome 
(ACS). CAD was defined as the pathological process characterized by 
atherosclerotic plaque accumulation in the epicardial arteries, whether 
obstructive or non-obstructive. Based on expanded pathophysiological 
concepts, a new, more comprehensive definition of CCS is introduced: 
‘CCS are a range of clinical presentations or syndromes that 
arise due to structural and/or functional alterations related to 
chronic diseases of the coronary arteries and/or microcircula­
tion. These alterations can lead to transient, reversible, myocar­
dial demand vs. blood supply mismatch resulting in 
hypoperfusion (ischaemia), usually (but not always) provoked 
by exertion, emotion or other stress, and may manifest as angina, 
other chest discomfort, or dyspnoea, or be asymptomatic. 
Although stable for long periods, chronic coronary diseases 
are frequently progressive and may destabilize at any moment 
with the development of an ACS.’
Of note, ‘disease’ refers to the underlying coronary pathology, and ‘syn­
drome’ refers to the clinical presentation.
2.1. Evolving pathophysiological concepts 
of chronic coronary syndromes
Our understanding of the pathophysiology of CCS is transitioning from 
a simple to a more complex and dynamic model. Older concepts 
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2024
© ESC 2024
ESC Guidelines                                                                                                                                                                                          3423


<!-- PAGE 10 -->

### Page 10

considered a fixed, focal, flow-limiting atherosclerotic stenosis of a large 
or medium coronary artery as a sine qua non for inducible myocardial 
ischaemia and ischaemic chest pain (angina pectoris). Current concepts 
have broadened to embrace structural and functional abnormalities in 
both the macro- and microvascular compartments of the coronary tree 
that may lead to transient myocardial ischaemia. At the macrovascular 
level, not only fixed, flow-limiting stenoses but also diffuse atheroscler­
otic lesions without identifiable luminal narrowing may cause ischaemia 
under stress;2,3 structural abnormalities such as myocardial bridging4
and congenital arterial anomalies5 or dynamic epicardial vasospasm 
may be responsible for transient ischaemia. At the microvascular level, 
coronary microvascular dysfunction (CMD) is increasingly acknowl­
edged as a prevalent factor characterizing the entire spectrum of 
CCS;6 functional and structural microcirculatory abnormalities may 
cause angina and ischaemia even in patients with non-obstructive 
disease of the large or medium coronary arteries [angina with 
non-obstructive coronary arteries (ANOCA); ischaemia with non- 
obstructive coronary arteries (INOCA)].6 Finally, systemic or extracor­
onary conditions, such as anaemia, tachycardia, blood pressure (BP) 
changes, myocardial hypertrophy, and fibrosis, may contribute to the 
complex pathophysiology of non-acute myocardial ischaemia.7
The risk factors that predispose to the development of epicardial 
coronary atherosclerosis also promote endothelial dysfunction and ab­
normal vasomotion in the entire coronary tree, including the arterioles 
that regulate coronary flow and resistance,8–10 and adversely affect 
myocardial capillaries,6,11–14 leading to their rarefaction. Potential con­
sequences include a lack of flow-mediated vasodilation in the epicardial 
conductive arteries9 and macro- and microcirculatory vasoconstric­
tion.15
Of note, different mechanisms of ischaemia may act 
concomitantly.
2.2. Chronic coronary syndromes: clinical 
presentations (Figure 1)
In clinical practice, the following, not entirely exclusive, CCS patients 
seek outpatient medical attention: (i) the symptomatic patient with re­
producible stress-induced angina or ischaemia with epicardial obstruct­
ive CAD; (ii) the patient with angina or ischaemia caused by epicardial 
vasomotor abnormalities or functional/structural microvascular altera­
tions in the absence of epicardial obstructive CAD (ANOCA/INOCA); 
(iii) the non-acute patient post-ACS or after a revascularization; 
(iv) the non-acute patient with heart failure (HF) of ischaemic or 
cardiometabolic origin. A further growing category (v) are the 
asymptomatic individuals in whom epicardial CAD is detected during 
an imaging test for refining cardiovascular risk assessment,16 screening 
for personal or professional purposes, or as an incidental finding for an­
other indication.17 Patients may experience a variable and unpredict­
able course, transitioning between different types of CCS and ACS 
presentations throughout their lifetime.
The clinical presentations of CCS are not always specific for the 
mechanism causing myocardial ischaemia; thus, symptoms of 
dysfunctional microvascular angina (MVA) may overlap with those of 
vasospastic or even obstructive large–medium artery angina. 
Furthermore, it is important to note that CCS doesn’t always present 
as classical angina pectoris and symptoms may vary depending on age 
and sex. Sex-stratified analyses indicate that women with suspected 
angina are usually older and have a heavier cardiovascular risk 
factor burden, more frequent comorbidities, non-anginal symptoms 
such as dyspnoea and fatigue, and greater prevalence of MVA than 
men.18–21
2.3. Changing epidemiology and 
management strategies
Contemporary primary prevention,16 including lifestyle changes and 
guideline-directed medical therapy (GDMT), has led to a decline of 
the age-standardized prevalence22,23 of obstructive epicardial coronary 
atherosclerosis in patients with suspected CCS.24–28 As a consequence, 
the diagnostic and prognostic risk prediction models applied in the past 
to identify obstructive epicardial CAD in patients with suspected angina 
pectoris have required updating and refinement.27,29,30 Initial use of 
coronary computed tomography angiography (CCTA)31,32 for detect­
ing and assessing epicardial coronary atherosclerosis is increasingly 
being adopted since it has shown similar performance to non-invasive 
stress testing for detecting segmental myocardial ischaemia.33–35
Invasive coronary angiography (ICA), classically used to detect anatom­
ically significant stenoses, has expanded to become a functional test36
that includes refined haemodynamic assessment of epicardial stenoses, 
provocative testing for the detection of epicardial or microvascular 
spasm,37–40 and a functional assessment of CMD.41–43 Moreover, there 
is a growing interest in non-invasive imaging methods such as stress 
positron emission tomography (PET)44,45 or stress magnetic resonance 
imaging (MRI),46 which allow accurate assessment of the coronary 
microcirculation in a quantitative manner.
Medical therapy for CCS patients, including antithrombotic strat­
egies, anti-inflammatory drugs, statins and new lipid-lowering, meta­
bolic, and anti-obesity agents, has significantly improved survival 
after conservative treatment, making it harder to demonstrate the 
benefits of early invasive therapy.47 However, revascularization can 
still benefit patients with obstructive CAD at high risk of adverse 
events, not only for symptom relief48–52 but also to prevent spontan­
eous myocardial infarction (MI) and cardiac death and, in some 
groups, to improve overall survival53–56 during long-term follow-up. 
Recently, revascularization through percutaneous coronary interven­
tion (PCI) was shown to provide more angina relief than a placebo 
procedure in patients with stable angina and evidence of ischaemia, 
on minimal or no antianginal therapy, confirming the beneficial effects 
of revascularization.52
The present guidelines deal with the assessment and diagnostic algo­
rithm in patients with symptoms suspected of CCS (Section 3) and their 
treatment (Section 4), special subgroups of CCS patients (Section 5) and 
finally, long-term follow-up and care (Section 6).


<!-- PAGE 11 -->

### Page 11

Asymptomatic with abnormal coronary anatomical or functional test
Angina or equivalent with no obstructive CAD
(ANOCA/INOCA)
Stabilized phase after ACS, PCI, or CABG
Stress-induced angina, or equivalent, 
with obstructive CAD
A
B
LV dysfunction or heart failure of ischaemic origin
Structural
Epicardial
Microvascular
Main mechanisms of myocardial ischaemia in chronic coronary syndromes 
Functional
Structural
Functional
Atherosclerosis
(focal or diffuse)
Stabilized intramural haematoma
Myocardial 
bridge
Coronary aneurysm
Impaired vasodilation
Increased vasoconstriction
Epicardial vasospasm
Inward arteriolar remodelling
Capillary rarefaction
Intravascular plugging
Perivascular fibrosis or infiltration
Extramural compression
(myocardial hypertrophy,
increased LVEDP)
Clinical spectrum 
of suspected, or 
confirmed, 
chronic coronary 
syndromes 
Autonomic dysregulation
Endothelial dysfunction and/or
VSMC hyperreactivity
Autonomic dysregulation
Endothelial dysfunction and/or
VSMC hyperreactivity
Figure 1 (Central Illustration) Clinical presentations of chronic coronary syndrome and mechanisms of myocardial ischaemia. ACS, acute coronary 
syndrome; ANOCA, angina with non-obstructive coronary arteries; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, 
chronic coronary syndrome; INOCA, ischaemia with non-obstructive coronary arteries; LV, left ventricular; LVEDP, left ventricular end-diastolic pres­
sure; PCI, percutaneous coronary intervention; VSMC, vascular smooth muscle cell.
ESC Guidelines                                                                                                                                                                                          3425


<!-- PAGE 12 -->

### Page 12

2.4. What is new
The 2024 Guidelines contain a number of new and revised recommendations, which are summarized in Tables 3 and 4, respectively.
Table 3 New major recommendations in 2024
Recommendations
Classa
Levelb
History taking and risk factor assessment and resting electrocardiogram in individuals with suspected chronic coronary syndrome— 
Section 3
In individuals reporting symptoms of suspected myocardial ischaemic origin, a detailed assessment of cardiovascular risk factors, medical 
history, and symptom characteristics (including onset, duration, type, location, triggers, relieving factors, time of day) is recommended.
I
C
Symptoms like chest pain triggered by emotional stress; dyspnoea or dizziness on exertion; pain in the arms, jaw, neck, or upper back; or 
fatigue should be considered as potential angina equivalents.
IIa
B
Basic biochemistry in the initial diagnostic management of individuals with suspected chronic coronary syndrome—Section 3
• Additionally, high-sensitivity C-reactive protein and/or fibrinogen plasma levels should be considered.
IIa
B
Likelihood of obstructive atherosclerotic coronary artery disease in the initial diagnostic management of individuals with suspected 
chronic coronary syndrome—Section 3
It is recommended to estimate the pre-test likelihood of obstructive epicardial CAD using the Risk Factor-weighted Clinical Likelihood 
model.
I
B
It is recommended to use additional clinical data (e.g. examination of peripheral arteries, resting ECG, resting echocardiography, presence of 
vascular calcifications on previously performed imaging tests) to adjust the estimate yielded by the Risk Factor-weighted Clinical Likelihood 
model.
I
C
In individuals with a very low (≤5%) pre-test likelihood of obstructive CAD, deferral of further diagnostic tests should be considered.
IIa
B
In individuals with a low (>5%–15%) pre-test likelihood of obstructive CAD, CACS should be considered to reclassify subjects and to 
identify more individuals with very low (≤5%) CACS-weighted clinical likelihood.
IIa
B
In individuals with an initially low (>5%–15%) likelihood of obstructive CAD, exercise ECG and detection of atherosclerotic disease in 
non-coronary arteries may be considered to adjust the pre-test likelihood estimate.
IIb
C
Ambulatory electrocardiogram in the initial diagnostic management of individuals with suspected chronic coronary syndrome—Section 3
Ambulatory ECG monitoring should be considered in subjects with suspected vasospastic angina.
IIa
B
Non-invasive anatomical imaging tests in the initial diagnostic management of individuals with suspected obstructive coronary artery 
disease—coronary computed tomography angiography, if available and supported by local expertise—Section 3
In individuals with suspected CCS and low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA is recommended to 
diagnose obstructive CAD and to estimate the risk of MACE.
I
A
Non-invasive tests in the initial diagnostic management of individuals with suspected chronic coronary syndrome—stress 
echocardiography, if available and supported by local expertise—Section 3
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, stress echocardiography is 
recommended to diagnose myocardial ischaemia and to estimate the risk of MACE.
I
B
During stress echocardiography, when two or more contiguous myocardial segments are not visualized, it is recommended to use 
commercially available intravenous ultrasound contrast agents (microbubbles) to improve diagnostic accuracy.
I
B
During stress echocardiography, myocardial perfusion using commercially available intravenous ultrasound contrast agents (microbubbles) 
is recommended to improve diagnostic accuracy and to refine risk stratification beyond wall motion.
I
B
During stress echocardiography, Doppler left anterior descending coronary artery flow reserve may be considered to improve risk 
stratification beyond wall motion and to assess microvascular function.
IIb
B
Non-invasive functional myocardial imaging tests in the initial diagnostic management of individuals with suspected chronic coronary 
syndrome—resting and stress single-photon emission computed tomography/positron emission tomography—cardiac magnetic 
resonance imaging, if available and supported by local expertise—Section 3
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, SPECT or, preferably, PET 
myocardial perfusion imaging is recommended to:  
• diagnose and quantify myocardial ischaemia and/or scar;
• estimate the risk of MACE;
• quantify myocardial blood flow (PET).
I
B
In patients selected for PET or SPECT myocardial perfusion imaging, it is recommended to measure CACS from unenhanced chest CT 
imaging (used for attenuation correction) to improve detection of both non-obstructive and obstructive CAD.
I
B
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, CMR perfusion imaging is 
recommended to diagnose and quantify myocardial ischaemia and/or scar and estimate the risk of MACE.
I
B
Continued


<!-- PAGE 13 -->

### Page 13

Indications for invasive coronary angiography in individuals with suspected obstructive coronary artery disease—Section 3
When ICA is indicated, radial artery access is recommended as the preferred access site.
I
A
When ICA is indicated, it is recommended to have coronary pressure assessment available and to use it to evaluate the functional severity of 
intermediate non-left main stem stenoses prior to revascularization.
I
A
In individuals with de novo symptoms highly suggestive of obstructive CAD that occur at a low level of exercise, ICA with a view towards 
revascularization is recommended as first diagnostic test after clinical assessment by a cardiologist.
I
C
Functional assessment of epicardial artery stenosis severity during invasive coronary angiography—Section 3
During ICA, selective assessment of functional severity of intermediate diameter stenoses is recommended to guide the decision to revascularize, using the 
following techniques:
• FFR/iFR (significant ≤0.8 or ≤0.89, respectively);
I
A
• QFR (significant ≤0.8).
I
B
In addition:
• CFR/HSR/CFC should be considered as a complementary investigation;
IIa
B
• resting invasive measurement of Pd/Pa, dPR, RFR, or angiography-derived vessel FFR may be considered as alternative parameters.
IIb
C
Systematic and routine wire-based coronary pressure assessment of all coronary vessels is not recommended.
III
A
Selection of individual diagnostic tests in individuals with suspected chronic coronary syndrome—Section 3
To rule out obstructive CAD in individuals with low or moderate (>5%–50%) pre-test likelihood, CCTA is recommended as the preferred 
diagnostic modality.
I
B
CCTA is recommended in individuals with low or moderate (>5%–50%) pre-test likelihood of obstructive CAD if functional imaging for 
myocardial ischaemia is not diagnostic.
I
B
Invasive coronary angiography with the availability of invasive functional assessments is recommended to confirm or exclude the diagnosis of 
obstructive CAD or ANOCA/INOCA in individuals with an uncertain diagnosis on non-invasive testing.
I
B
In patients with a known intermediate coronary artery stenosis in a proximal or mid coronary segment on CCTA, CT-based FFR may be 
considered.
IIb
B
Definition of high risk of adverse events
An initial stratification of risk of adverse events is recommended based on basic clinical assessment (e.g. age, ECG, anginal threshold, 
diabetes, CKD, LVEF).
I
B
The use of one or more of the following test results is recommended to identify individuals at high risk of adverse events: 
• exercise ECG: 
⚬Duke Treadmill Score < −10;
• stress SPECT or PET perfusion imaging: 
⚬area of ischaemia ≥10% of the LV myocardium;
• stress echocardiography: 
⚬≥3 of 16 segments with stress-induced hypokinesia or akinesia;
• stress CMR: 
⚬≥2 of 16 segments with stress perfusion defects or
⚬≥3 dobutamine-induced dysfunctional segments;
• CCTA: 
⚬left main disease with ≥50% stenosis,
⚬three-vessel disease with ≥70 stenosis, or
⚬two-vessel disease with ≥70% stenosis, including the proximal LAD or
⚬one-vessel disease of the proximal LAD with ≥70% stenosis and FFR-CT ≤0.8
I
B
Cardiovascular risk, lifestyle changes, and exercise interventions in patients with established chronic coronary syndrome—Section 4
An informed discussion on CVD risk and treatment benefits tailored to individual patient needs is recommended.
I
C
Multidisciplinary behavioural approaches to help patients achieve healthy lifestyles, in addition to appropriate pharmacological management, 
are recommended.
I
A
Aerobic physical activity of at least 150–300 min per week of moderate intensity or 75–150 min per week of vigorous intensity and 
reduction in sedentary time are recommended.
I
B
Home-based cardiac rehabilitation and mobile health interventions should be considered to increase patients’ long-term adherence to 
healthy behaviours, and to reduce hospitalizations or cardiac events.
IIa
B
Antianginal drugs in patients with chronic coronary syndrome—Section 4
It is recommended to tailor the selection of antianginal drugs to the patient’s characteristics, comorbidities, concomitant medications, 
treatment tolerability, and underlying pathophysiology of angina, also considering local drug availability and cost.
I
C
Ivabradine should be considered as add-on antianginal therapy in patients with left ventricular systolic dysfunction (LVEF <40%) and 
inadequate control of symptoms, or as part of initial treatment in properly selected patients.
IIa
B
Continued 
ESC Guidelines                                                                                                                                                                                          3427


<!-- PAGE 14 -->

### Page 14

Ivabradine is not recommended as add-on therapy in patients with CCS, LVEF >40%, and no clinical heart failure.
III
B
Combination of ivabradine with non-DHP-CCB or other strong CYP3A4 inhibitors is not recommended.
III
B
Antithrombotic therapy in patients with chronic coronary syndrome—Section 4
Long-term antithrombotic therapy in patients with chronic coronary syndrome and no clear indication for oral anticoagulation
In CCS patients with a prior MI or PCI, clopidogrel 75 mg daily is recommended as a safe and effective alternative to aspirin monotherapy.
I
A
After CABG, aspirin 75–100 mg daily is recommended lifelong.
I
A
In CCS patients without prior MI or revascularization but with evidence of significant obstructive CAD, aspirin 75–100 mg daily is 
recommended lifelong.
I
B
Lipid-lowering drugs in patients with chronic coronary syndrome—Section 4
Lipid-lowering treatment with an LDL-C goal of <1.4 mmol/L (55 mg/dL) and a ≥50% reduction in LDL-C vs. baseline is recommended.
I
A
For patients who are statin intolerant and do not achieve their goal on ezetimibe, combination with bempedoic acid is recommended.
I
B
For patients who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, combination with bempedoic acid should 
be considered.
IIa
C
Sodium–glucose cotransporter 2 inhibitors and/or glucagon-like peptide-1 receptor agonists in patients with chronic coronary 
syndrome—Section 4
SGLT2 inhibitors with proven CV benefit are recommended in patients with T2DM and CCS to reduce CV events, independent of baseline 
or target HbA1c and independent of concomitant glucose-lowering medication.
I
A
The GLP-1 receptor agonist semaglutide should be considered in CCS patients without diabetes, but with overweight or obesity 
(BMI ≥27 kg/m2), to reduce CV mortality, MI, or stroke.
IIa
B
Anti-inflammatory drugs in patients with chronic coronary syndrome—Section 4
In CCS patients with atherosclerotic CAD, low-dose colchicine (0.5 mg daily) should be considered to reduce myocardial infarction, stroke, 
and need for revascularization.
IIa
A
Revascularization in patients with chronic coronary syndrome—Section 4
Informed and shared decisions
For complex clinical cases, to define the optimal treatment strategy, in particular when CABG and PCI hold the same level of 
recommendation, a Heart Team discussion is recommended, including representatives from interventional cardiology, cardiac surgery, 
non-interventional cardiology, and other specialties if indicated, aimed at selecting the most appropriate treatment to improve patient 
outcomes and quality of life.
I
C
It is recommended that the decision for revascularization and its modality be patient-centred, considering when possible patient 
preferences, health literacy, cultural circumstances, and social support.
I
C
Revascularization to improve outcomes
In CCS patients with LVEF ≤35%, it is recommended to choose between revascularization or medical therapy alone, after careful evaluation, 
preferably by the Heart Team, of coronary anatomy, correlation between coronary artery disease and LV dysfunction, comorbidities, life 
expectancy, individual risk-to-benefit ratio, and patient perspectives.
I
C
Assessment of procedural risks and post-procedural outcomes
Intracoronary imaging guidance by IVUS or OCT is recommended for performing PCI on anatomically complex lesions, in particular left 
main stem, true bifurcations and long lesions.
I
A
Intracoronary pressure measurement (FFR or iFR) or computation (QFR):
• is recommended to guide lesion selection for intervention in patients with multivessel disease;
I
A
• should be considered at the end of the procedure to identify patients at high risk of persistent angina and subsequent clinical events;
IIa
B
• may be considered at the end of the procedure to identify lesions potentially amenable to treatment with additional PCI.
IIb
B
Choice of revascularization modality
It is recommended that physicians select the most appropriate revascularization modality based on patient profile, coronary anatomy, 
procedural factors, LVEF, patient preferences and outcome expectations.
I
C
Mode of revascularization in patients with chronic coronary syndrome
Left main disease
In CCS patients at low surgical risk with significant left main coronary stenosis, CABG:
• is recommended over medical therapy alone to improve survival;
I
A
• is recommended as the overall preferred revascularization mode over PCI, given the lower risk of spontaneous myocardial infarction and 
repeat revascularization.
I
A
In CCS patients with significant left main coronary stenosis of low complexity (SYNTAX score ≤22), in whom PCI can provide equivalent 
completeness of revascularization to that of CABG, PCI is recommended as an alternative to CABG, given its lower invasiveness and non- 
inferior survival.
I
A
Continued


<!-- PAGE 15 -->

### Page 15

Management of chronic coronary syndrome patients with chronic heart failure—Section 5
In HF patients with LVEF ≤35% in whom obstructive CAD is suspected, ICA is recommended with a view towards improving prognosis by 
CABG, taking into account the risk-to-benefit ratio of the procedures.
I
B
In HF patients with LVEF >35% and suspected CCS with low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA or 
functional imaging is recommended.
I
C
In patients with HFpEF with angina or equivalent symptoms and normal or non-obstructive epicardial coronary arteries, PET or CMR 
perfusion or invasive functional coronary testing should be considered to detect or rule out coronary microvascular dysfunction.
IIa
B
In selected patients with HFrEF undergoing high-risk PCI for complex CAD, the use of a microaxial flow pump may be considered in 
experienced centres.
IIb
C
It is recommended that CCS patients with heart failure be enrolled in a multidisciplinary heart failure management programme to reduce 
the risk of heart failure hospitalization and to improve survival.
I
A
Sacubitril/valsartan is recommended as a replacement for an ACE-I or ARB in CCS patients with HFrEF to reduce the risk of heart failure 
hospitalization and death.
I
B
Diagnosis and management of patients with angina/ischaemia with non-obstructive coronary arteries—Section 5
Management of ANOCA/INOCA
In symptomatic patients with ANOCA/INOCA, medical therapy based on coronary functional test results should be considered to improve 
symptoms and quality of life.
IIa
A
For the management of endothelial dysfunction, ACE-I should be considered for symptom control.
IIa
B
For the management of microvascular angina associated with reduced coronary/myocardial blood flow reserve, beta-blockers should be 
considered for symptom control.
IIa
B
For the treatment of isolated vasospastic angina: 
• calcium channel blockers are recommended to control symptoms and to prevent ischaemia and potentially fatal complications;
I
A
• nitrates should be considered to prevent recurrent episodes.
IIa
B
In patients with evidence of overlapping endotypes, combination therapy with nitrates, calcium channel blockers, and other vasodilators may 
be considered.
IIb
B
Older, female, high bleeding risk, comorbid, and socially/geographically diverse patients—Section 5
Similar guideline-directed cardiovascular preventive therapy is recommended in women and men.
I
C
Bleeding risk assessment is recommended using the PRECISE-DAPT score, the qualitative ARC-HBR tool or other, validated methods.
I
B
Attention to interaction between antiretroviral treatment and statins is recommended in patients with HIV.
I
B
Socioeconomic, geographical, and under-investigated groups
Continued targeted efforts are recommended: 
• to increase delivery of safe and effective cardiac care to all CCS patients, especially those of lower socioeconomic classes, and
• to enhance inclusion in future clinical trials of geographical, social, or other groups that are currently underrepresented.
I
C
Screening for coronary artery disease in asymptomatic individuals—Section 5
When coronary artery calcification findings are available from previous chest CT scans, using these findings to enhance risk stratification and 
guide treatment of modifiable risk factors should be considered.
IIa
C
Coronary artery calcium scoring (CACS) may be considered to improve risk classification around treatment decision thresholds.
IIb
C
Adherence to medical therapy and lifestyle changes—Section 6
Mobile health interventions (e.g. using text messages, apps, wearable devices) are recommended to improve patient adherence to healthy 
lifestyles and medical therapy.
I
A
Behavioural interventions are recommended to improve adherence.
I
B
Simplifying medication regimens (e.g. using fixed-dose drug combinations) is recommended to increase patient adherence to medications.
I
B
Multiprofessional and family involvement is recommended to promote adherence, in addition to patient education and involvement.
I
C
Recurrent or refractory angina/ischaemia
In patients with refractory angina leading to poor quality of life and with documented or suspected ANOCA/INOCA, invasive coronary functional 
testing is recommended to define ANOCA/INOCA endotypes and appropriate treatment, considering patient choices and preferences.
I
B
© ESC 2024
ACE-I, angiotensin-converting enzyme inhibitor; ANOCA, angina with non-obstructive coronary arteries; ARB, angiotensin receptor blocker; ARC-HBR, Academic Research Consortium for High 
Bleeding Risk; BMI, body mass index; CABG, coronary artery bypass grafting; CACS, coronary artery calcium score; CAD, coronary artery disease; CCB, calcium channel blocker; CCS, chronic 
coronary syndrome; CCTA, coronary computed tomography angiography; CFC, coronary flow capacity; CFR, coronary flow reserve; CKD, chronic kidney disease; CMR, cardiac magnetic 
resonance; CT, computed tomography; CV, cardiovascular; CVD, cardiovascular disease; CYP3A4, cytochrome P450 3A4; DHP, dihydropyridine; dPR, diastolic pressure ratio; ECG, 
electrocardiogram; FFR, fractional flow reserve; FFR-CT, coronary computed tomography angiography-derived fractional flow reserve; GLP-1, glucagon-like peptide-1; HbA1c, glycated 
haemoglobin; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HIV, human immunodeficiency virus; HSR, hyperaemic 
stenosis resistance; ICA, invasive coronary angiography; iFR, instantaneous wave-free ratio; INOCA, ischaemia with non-obstructive coronary arteries; IVUS, intravascular ultrasound; LAD, left 
anterior descending; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; MCS, mechanical 
circulatory support; MI, myocardial infarction; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; Pd/Pa, distal coronary pressure to aortic pressure ratio; PET, 
positron emission tomography; PRECISE-DAPT, PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual AntiPlatelet Therapy; QFR, quantitative 
flow ratio; RFR, relative flow reserve; SGLT2, sodium–glucose cotransporter 2; SPECT, single-photon emission computed tomography; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3429


<!-- PAGE 16 -->

### Page 16

Table 4 Revised recommendations
Recommendations in 2019 version
Classa
Levelb
Recommendations in 2024 version
Classa
Levelb
Recommendations for antianginal drugs in patients with chronic coronary syndrome—Section 4
Nicorandil, ranolazine, ivabradine, or trimetazidine 
should be considered as a second-line treatment to 
reduce angina frequency and improve exercise 
tolerance in subjects who cannot tolerate, have 
contraindications to, or whose symptoms are not 
adequately controlled by beta-blockers, CCBs, and 
long-acting nitrates.
IIa
B
Long-acting nitrates or ranolazine should be considered 
as add-on therapy in patients with inadequate control of 
symptoms while on treatment with beta-blockers and/ 
or CCBs, or as part of initial treatment in properly 
selected patients.
IIa
B
In selected patients, the combination of a beta-blocker 
or a CCB with second-line drugs (ranolazine, nicorandil, 
ivabradine, and trimetazidine) may be considered for 
first-line treatment according to heart rate, blood 
pressure, and tolerance.
IIb
B
Nicorandil or trimetazidine may be considered as 
add-on therapy in patients with inadequate control of 
symptoms while on treatment with beta-blockers and/ 
or CCBs, or as part of initial treatment in properly 
selected patients.
IIb
B
Antithrombotic therapy in patients with chronic coronary syndrome—Section 4
Aspirin 75–100 mg daily is recommended in patients 
with a previous MI or revascularization.
I
A
In CCS patients with a prior MI or remote PCI, aspirin 
75–100 mg daily is recommended lifelong after an initial 
period of DAPT.
I
A
Clopidogrel 75 mg daily is recommended as an 
alternative to aspirin in patients with aspirin intolerance.
I
B
In CCS patients with a prior MI or remote PCI, 
clopidogrel 75 mg daily is recommended as a safe and 
effective alternative to aspirin monotherapy.
I
A
Clopidogrel 75 mg daily may be considered in 
preference to aspirin in symptomatic and asymptomatic 
patients with either PAD or a history of ischaemic 
stroke or transient ischaemic attack.
IIb
B
Aspirin 75–100 mg daily may be considered in patients 
without a history of MI or revascularization, but with 
definitive evidence of CAD on imaging.
IIb
C
In patients without prior MI or revascularization but with 
evidence of significant obstructive CAD, aspirin 75–100 
mg daily is recommended lifelong.
I
B
Antithrombotic therapy post-percutaneous coronary intervention in patients with chronic coronary syndrome and no indication for 
oral anticoagulation—Section 4
Aspirin 75–100 mg daily is recommended following 
stenting.
I
A
In CCS patients with no indication for oral 
anticoagulation, DAPT consisting of aspirin 75–100 mg 
and clopidogrel 75 mg daily for up to 6 months is 
recommended as the default antithrombotic strategy 
after PCI-stenting.
I
A
Clopidogrel 75 mg daily following appropriate loading 
(e.g. 600 mg or >5 days of maintenance therapy) is 
recommended, in addition to aspirin, for 6 months 
following coronary stenting, irrespective of stent type, 
unless a shorter durations (1–3 months) is indicated due 
to risk of occurrence of life-threatening bleeding.
I
A
Clopidogrel 75 mg daily following appropriate loading 
(e.g. 600 mg or >5 days of maintenance therapy) may be 
considered for 1 month in patients with very high risk of 
life-threatening bleeding.
IIb
C
In patients at high bleeding risk but not at high ischaemic 
risk, it is recommended to discontinue DAPT 1–3 
months after PCI and continue single antiplatelet 
therapy.
I
A
Clopidogrel 75 mg daily following appropriate loading 
(e.g. 600 mg or >5 days of maintenance therapy) should 
be considered for 3 months in patients with a higher risk 
of life-threatening bleeding.
IIa
A
Stopping DAPT after 1–3 months from PCI-stenting 
may be considered in patients who are not at high 
bleeding risk nor at high risk of ischaemic events.
IIb
B
Continued


<!-- PAGE 17 -->

### Page 17

Long-term antithrombotic therapy in patients with chronic coronary syndrome and an indication for oral anticoagulation—Section 4
When oral anticoagulation is initiated in a patient with 
AF who is eligible for a NOAC, a NOAC is 
recommended in preference to a VKA.
I
A
In CCS patients with a long-term indication for OAC, an 
AF-therapeutic-dose of VKA alone or, preferably, of 
DOAC alone (unless contraindicated) is recommended 
lifelong.
I
B
Long-term OAC therapy (NOAC or VKA with time in 
therapeutic range >70%) is recommended in patients 
with AF and a CHA2DS2-VASc score ≥2 in males and 
≥3 in females.
I
A
Long-term OAC therapy (NOAC or VKA with time in 
therapeutic range >70%) should be considered in 
patients with AF and a CHA2DS2-VASc score of 1 in 
males and 2 in females.
IIa
B
Aspirin 75–100 mg daily (or clopidogrel 75 mg daily) 
may be considered in addition to long-term OAC 
therapy in patients with AF, history of MI, and at high 
risk of recurrent ischaemic events who do not have a 
high bleeding risk.
IIb
B
Antithrombotic therapy post-percutaneous coronary intervention in chronic coronary syndrome patients and an indication for oral 
anticoagulation—Section 4
After uncomplicated PCI, early cessation (≤1 week) of 
aspirin and continuation of dual therapy with an OAC 
and clopidogrel should be considered if the risk of stent 
thrombosis is low, or if concerns about bleeding risk 
prevail over concerns about the risk of stent 
thrombosis, irrespective of the type of stent used.
IIa
B
After uncomplicated PCI in CCS patients with 
concomitant indication for OAC: 
• early cessation of aspirin (≤1 week);
• followed by continuation of OAC and clopidogrel: 
⚬up to 6 months in patients not at high ischaemic 
risk or
⚬up to 12 months in patients at high ischaemic risk;
• followed by OAC alone; is recommended.
I
A
Triple therapy with aspirin, clopidogrel, and an OAC for 
≥1 month should be considered when the risk of stent 
thrombosis outweighs the bleeding risk, with the total 
duration (≤6 months) decided according to assessment 
of these risks and clearly specified at hospital discharge.
IIa
C
Continuation of aspirin up to 1 month after PCI, in 
addition to OAC and clopidogrel, should be considered 
in patients at high thrombotic risk or with anatomical/ 
procedural characteristics judged to outweigh the 
bleeding risk.
IIa
B
Recommendations for lipid-lowering drugs in patients with chronic coronary syndrome—Section 4
Statins are recommended in all patients with CCS.
I
A
A high-intensity statin up to the highest tolerated dose 
to reach the LDL-C goals is recommended for all 
patients with CCS.
I
A
Diagnosis and management of patients with angina/ischaemia with non-obstructive coronary arteries—Section 5
Guidewire-based CFR and/or microcirculatory 
resistance measurements should be considered in 
patients with persistent symptoms, but coronary 
arteries that are either angiographically normal or have 
moderate stenoses with preserved iwFR/FFR.
IIa
B
In persistently symptomatic patients despite medical 
treatment with suspected ANOCA/INOCA (i.e. anginal 
symptoms with normal coronary arteries or 
non-obstructive lesions at non-invasive imaging, or 
intermediate stenoses with normal FFR/iFR at coronary 
arteriography) and poor quality of life, invasive coronary 
functional testing is recommended to identify 
potentially treatable endotypes and to improve 
symptoms and quality of life, considering patient choices 
and preferences.
I
B
Intracoronary acetylcholine with ECG monitoring may 
be considered during angiography, if coronary arteries 
are either angiographically normal or have moderate 
stenoses with preserved iwFR/FFR, to assess 
microvascular vasospasm.
IIb
B
Diagnostic tests for vasospastic angina—Section 5
Ambulatory ST-segment monitoring should be 
considered to identify ST-segment deviation in the 
absence of increased heart rate.
IIa
C
In individuals with suspected vasospastic angina and 
frequent symptoms, ambulatory ST-segment 
monitoring should be considered to identify 
ST-segment deviation during angina.
IIa
B
Continued 
ESC Guidelines                                                                                                                                                                                          3431


<!-- PAGE 18 -->

### Page 18

Screening for coronary artery disease in asymptomatic individuals—Section 5
Total risk estimation using a risk-estimation system such 
as SCORE is recommended for asymptomatic adults 
>40 years of age without evidence of CVD, diabetes, 
CKD, or familial hypercholesterolaemia.
I
C
Opportunistic screening of healthy individuals for 
cardiovascular risk factors and to estimate risk of future 
cardiovascular events using scoring systems, e.g. 
SCORE2 and SCORE2-OP, is recommended to detect 
individuals at high risk and guide treatment decisions.
I
C
Diagnosis of disease progression in patients with established chronic coronary syndrome—Section 6
Risk stratification is recommended in patients with new 
or worsening symptom levels, preferably using stress 
imaging or, alternatively, exercise stress ECG.
I
B
Risk stratification is recommended in patients with new 
or worsening symptoms, preferably using stress 
imaging.
I
C
2018 ESC/EACTS Guidelines on myocardial 
revascularization
Classa
Levelb
Recommendations in 2024 version
Classa
Levelb
Recommendations for revascularization in patients with chronic coronary syndrome—Section 4
Revascularization to improve outcomes
In CCS patients with LV ejection fraction ≤35%
In patients with one- or two-vessel disease, PCI should 
be considered as an alternative to CABG when 
complete revascularization can be achieved.
IIa
C
In selected CCS patients with functionally significant 
MVD and LVEF ≤35% who are at high surgical risk or 
not operable, PCI may be considered as an alternative 
to CABG.
IIb
B
In patients with three-vessel disease, PCI should be 
considered based on the evaluation by the Heart Team 
of the patient’s coronary anatomy, the expected 
completeness of revascularization, diabetes status, and 
comorbidities.
IIa
C
Anatomically and clinically based recommendations for revascularization in chronic coronary syndrome—Section 4
Left main disease
Left main disease with low SYNTAX score (0–22), PCI.
I
A
In CCS patients with significant left main coronary 
stenosis of low complexity (SYNTAX score ≤22), in 
whom PCI can provide equivalent completeness of 
revascularization to that of CABG, PCI is recommended 
as an alternative to CABG, given its lower invasiveness 
and non-inferior survival.
I
A
Left main disease with intermediate SYNTAX score 
(23–32), PCI.
IIa
A
In CCS patients with significant left main coronary 
stenosis of intermediate complexity (SYNTAX score 
23–32), in whom PCI can provide equivalent 
completeness of revascularization to that of CABG, PCI 
should be considered, given its lower invasiveness and 
non-inferior survival.
IIa
A
Left main with multivessel disease
For left main disease with high SYNTAX score (≥33), 
PCI.
III
B
In CCS patients at high surgical risk, PCI may be 
considered over medical therapy alone.
IIb
B
Multivessel disease and diabetes
For CCS patients with diabetes and three-vessel disease 
with low SYNTAX score 0–22, PCI.
IIb
A
In CCS patients at very high surgical risk, PCI should be 
considered over medical therapy alone to reduce 
symptoms and adverse outcomes.
IIa
B
For CCS patients with diabetes and three-vessel disease 
with intermediate or high SYNTAX score (>22), PCI.
III
A
Single- or double-vessel disease involving the proximal LAD
For one or two-vessel disease with proximal LAD 
stenosis, CABG, or PCI are recommended.
I
A
In CCS patients with significant single- or double-vessel 
disease involving the proximal LAD and insufficient 
response to guideline-directed medical therapy, CABG 
or PCI is recommended over medical therapy alone to 
improve symptoms and outcomes.
I
A
In CCS patients with complex significant single- or 
double-vessel disease involving the proximal LAD, less 
amenable to PCI, and insufficient response to 
guideline-directed medical therapy, CABG is 
recommended over PCI to improve symptoms and 
reduce revascularization rates.
I
B
Continued


<!-- PAGE 19 -->

### Page 19

### 3 Stepwise approach to the initial

management of individuals with 
suspected chronic coronary 
syndrome
Managing individuals with suspected CCS involves four steps (Figure 2): 
STEP 1. The first step is a general clinical evaluation that focuses on as­
sessing symptoms and signs of CCS, differentiating non-cardiac 
causes of chest pain and ruling out ACS. This initial clinical evaluation 
requires recording a 12-lead resting electrocardiogram (ECG), basic 
blood tests, and in selected individuals, chest X-ray imaging and pul­
monary function testing. This evaluation can be done by the general 
practitioner.
STEP 2. The second step is a further cardiac examination, including 
echocardiography at rest to rule out left ventricular (LV) dysfunc­
tion and valvular heart disease. After that, it is recommended to es­
timate the clinical likelihood of obstructive CAD to guide deferral or 
referral to further non-invasive and invasive testing.
STEP 3. The third step involves diagnostic testing to establish the diag­
nosis of CCS and determine the patient’s risk of future events.
STEP 4. The final step includes lifestyle and risk-factor modification 
combined with disease-modifying medications. A combination of 
antianginal medications is frequently needed, and coronary revascu­
larization is considered if symptoms are refractory to medical treat­
ment or if high-risk CAD is present. If symptoms persist after 
obstructive CAD is ruled out, coronary microvascular disease and 
vasospasm should be considered.
3.1. STEP 1: General clinical examination
3.1.1. History, differential diagnosis, and physical 
examination
Careful and detailed history taking is the initial step in diagnostic man­
agement for all clinical scenarios within the spectrum of CCS. Although 
chest pain or discomfort (Figure 3) is the most cardinal symptom of 
CCS, it must be emphasized that many patients do not present with 
characteristic anginal symptoms and that the symptomatology may 
vary with age, sex, race, socioeconomic class, and geographical location. 
In contemporary studies, only 10% to 25% of patients with suspected 
CCS present with angina with classic aggravating and relieving factors, 
while 57% to 78% have symptoms less characteristic of angina and 
10% to 15% have dyspnoea on exertion.33,57
While older studies suggested that women were more likely to ex­
perience less characteristic chest pain symptoms,58 recent data show 
that anginal chest pain is equally prevalent in both men and women, al­
beit with slightly different characteristics.59 Symptoms were classified as 
non-characteristic angina in over two-thirds of the patients of both 
sexes.21,60 Of note, the absence of anginal symptoms does not preclude 
CCS, as it may be absent in patients with diabetes with autonomic neur­
opathy or in elderly patients with a very sedentary lifestyle despite very 
severe obstructive CAD. Of course, chest pain is not always angina (i.e. 
of ischaemic origin), since it can be related to non-coronary (e.g. peri­
carditis) or non-cardiovascular conditions.61,62
Anginal pain symptoms have been traditionally classified as “typical, 
atypical, or non-anginal/non-cardiac” based on the location of the 
pain, as well as precipitating and relieving factors. Although angina 
that meets all three characteristics, with retrosternal chest discomfort 
provoked by exertion or emotional stress and relieved by rest or nitro­
glycerine, is highly suggestive of ischaemia caused by obstructive CAD, 
these characteristics are rarely all present when ischaemia is caused by 
microvascular dysfunction and vasospasm. Furthermore, patients with 
“typical” vs. “atypical” angina included in the PRECISE study had similar 
1-year outcomes,57 highlighting the limited prognostic value of symp­
tom classification on typicality of angina used in obstructive CAD pre­
diction models. Because this terminology to describe anginal symptoms 
no longer aligns with current concepts of CCS, it should be replaced 
by a detailed description of symptoms (Figure 3). It is important to 
thoroughly evaluate chest pain, including an objective exclusion of myo­
cardial ischaemia caused by obstructive CAD, microvascular disease, 
and/or coronary vasospasm, before classifying it as non-cardiac.
Single- or double-vessel disease not involving the proximal LAD
For one or two-vessel disease without proximal LAD 
stenosis PCI is recommended.
I
C
In symptomatic CCS patients with single- or 
double-vessel disease not involving the proximal LAD 
and with insufficient response to guideline-directed 
medical therapy, PCI is recommended to improve 
symptoms.
I
B
For one or two-vessel disease without proximal LAD 
stenosis, CABG may be considered.
IIb
C
In symptomatic CCS patients with single- or 
double-vessel disease not involving the proximal LAD 
and with insufficient response to guideline-directed 
medical therapy, not amenable to revascularization by 
PCI, CABG may be considered to improve symptoms.
IIb
C
© ESC 2024
AF, atrial fibrillation; ANOCA, angina with non-obstructive coronary arteries; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel blocker; CCS, 
chronic coronary syndrome; CFR, coronary flow reserve; CHA2DS2-VASc, congestive heart failure or left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke 
(doubled), vascular disease, age 65–74, sex category (female); CKD, chronic kidney disease; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DOAC, direct oral 
anticoagulant; EACTS, European Association for Cardio-Thoracic Surgery; ECG, electrocardiogram; ESC, European Society of Cardiology; FFR, fractional flow reserve; iFR(iwFR), 
instantaneous wave-free ratio; INOCA, ischaemia with non-obstructive coronary arteries; LAD, left anterior descending; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; 
LVEF, left ventricular ejection fraction; MI, myocardial infarction; MVD, multivessel disease; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; PAD, 
peripheral artery disease; PCI, percutaneous coronary intervention; SCORE2, Systematic Coronary Risk Estimation 2; SCORE-OP, Systematic Coronary Risk Estimation 2–Older 
Persons; SYNTAX, SYNergy Between PCI with TAXUS and Cardiac Surgery; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3433


<!-- PAGE 20 -->

### Page 20

Step 1
Step 2
Step 3
Step 4
History, 
symptoms,
physical examination
Resting ECG. Biochemistry
Pulmonary function testa
Chest X-raya
Initial evaluation
Non-cardiac reason for symptoms identified:
treat underlying cause
Unstable cardiac symptoms with angina,
heart failure or arrhythmia: 
acute assessment by the ED
Assess clinical likelihood of obstructive CAD
Echocardiography at rest
Exercise ECGa
Further evaluation
Very low clinical likelihood of obstructive CAD (≤5%):
consider deferring further testingb
Severe comorbidities or low quality of life: consider no further testing and treat medically
Further non-invasive 
testing recommended 
based on clinical likelihood, 
availability,
local expertise, patient 
characteristics and 
preferenceb
Confirming diagnosis and estimating event-risk
CCTA: obstructive CAD?
Revascularization if:
high risk of adverse events
GDMT fails to relieve 
symptoms
Treatment
Invasive angiography if:
Very high clinical likelihood (>85%)
Suspicion of high-risk obstructive CAD
Severe myocardial ischaemia
Revascularization
To reduce symptoms
To improve prognosis in patients with obstructive CAD who are at high risk of adverse events
Antianginal medical treatment
Lifestyle and risk factor 
modification
To improve prognosis
Disease-modifying medical treatment
To improve prognosis
Functional imaging: myocardial ischaemia?
Selective second-line imaging to increase post-test likelihood
To reduce symptoms
In individuals with low and moderate (>5–50%)
clinical likelihood
In individuals with moderate and high (>15–85%) 
clinical likelihood
Consider ANOCA/INOCA
Figure 2 Stepwise approach to the initial management of individuals with suspected chronic coronary syndrome. ANOCA, angina with non- 
obstructive coronary arteries; CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; 
ECG, electrocardiogram; ED, emergency department; GDMT, guideline-directed medical therapy; INOCA, ischaemia with non-obstructive coronary 
arteries. aIn selected patients. bConsider also coronary spasm or microvascular dysfunction.


<!-- PAGE 21 -->

### Page 21

The Canadian Cardiovascular Society classification is still widely used 
as a grading system for effort-induced angina to quantify the threshold 
at which symptoms occur with physical activities (Table 5). Importantly, 
the severity of symptoms is not well associated with the severity of ob­
structive CAD and appears to differ by sex. Women have more fre­
quent angina, independent of less extensive epicardial CAD, and less 
severe myocardial ischaemia than men.63 Angina at rest is not always 
indicative of severe, fixed obstructive CAD, as it may also occur in pa­
tients with transient epicardial or microvascular coronary vasospasm.
It is essential to document coronary risk factors during history taking, 
as they may be modifiable and will be used for the pre-test likelihood 
estimation of obstructive CAD. Smoking cessation counselling starts 
with a quantitative assessment of prior and current tobacco use to 
make the risk factor more evident to the patient. In addition, detailed 
family history looking for premature cardiovascular disease (CVD) or 
sudden cardiac death should always be obtained. If available, cholesterol 
levels help define familial hypercholesterolaemia.64 It is also essential 
to assess the presence of comorbidities that affect the likelihood of 
CAD and overall survival. Because of their high prevalence in CCS 
patients, diabetes, chronic obstructive pulmonary disease, kidney dis­
ease, and peripheral and cerebral vascular disease are particularly 
relevant.
Quality
Chest discomfort
Dyspnoea
Location and size
Decreasing likelihood of CCS
Increasing likelihood of CCS
Strangling
Constricting
Squeezing
Pressure
Heaviness
Retrosternal
Extending to left arm, or to jugular or intrascapular region
“Fist”-size
Burning
Sharp
Tearing - Ripping
Pleuritic
Aching
Right
Shifting
Large area or fine spot
Duration
Short: up to 5–10 min if triggered by physical exertion or emotion
Lasting
Trigger
On effort
More frequent in cold weather, strong winds or after a heavy meal
Emotional distress (anxiety, anger,
excitation or nightmare)
On deep inspiration or when coughing
When pressing on ribs or sternum
Relief
Subsiding within 1–5 min after effort discontinuation
Relief accelerated by sublingual nitroglycerin
Quality
Difficulty catching breath
Difficulty to exhale
With wheezing
Trigger
On effort
Both at rest and on effort
While coughing
Slowly subsiding at rest or after inhalation of bronchodilators
Relief
Rapidly subsiding after effort discontinuation
Symptom characteristics
At rest
By antacids, drinking milk
Figure 3 Main CCS symptoms: angina and exertional dyspnoea. CCS, chronic coronary syndrome.
ESC Guidelines                                                                                                                                                                                          3435


<!-- PAGE 22 -->

### Page 22

Recent-onset anginal symptoms with changing frequency or intensity 
should raise the suspicion that a coronary atherosclerotic plaque may 
be destabilizing. In these patients, the diagnostic algorithm recom­
mended by the 2023 ESC Guidelines for the management of patients 
with acute coronary syndromes should be used to rule out an acute 
event.65
When investigating suspected CCS, it is important to perform a 
thorough physical examination that includes BP measurement and 
body mass index (BMI) calculation, to assess the presence of anaemia, 
hypertension, valvular heart disease, LV hypertrophy, or arrhythmias. It 
is also recommended to search for evidence of non-coronary vascular 
disease, which may be asymptomatic (palpation of peripheral pulses; 
auscultation of carotid and femoral arteries), and signs of other co­
morbid conditions, such as thyroid disease, renal disease, or diabetes. 
This should be used in the context of other clinical information, such 
as the presence of cough or stinging pain, making CCS less likely. 
One should also try to reproduce the symptoms by palpation and 
test the effect of sublingual nitroglycerine to classify the symptoms.
3.1.2. Basic testing: 12-lead electrocardiogram and 
biochemistry
Basic testing in individuals with suspected CCS includes a 12-lead ECG, 
standard laboratory tests, resting echocardiography, and, in selected 
patients, a chest X-ray, and a pulmonary function test if dyspnoea is 
the main symptom. Such tests can be done on an outpatient basis.
3.1.2.1. Electrocardiogram
The paradigm of diagnosing myocardial ischaemia has, for almost a cen­
tury, been based on detecting repolarization abnormalities, mainly in 
the form of ST-segment depressions or T wave abnormalities. Thus, 
the resting 12-lead ECG remains an indispensable component of the ini­
tial evaluation of a patient with chest pain.67
A normal resting ECG is frequently recorded after an anginal attack. 
However, even in the absence of repolarization abnormalities, the ECG 
at rest may suggest CCS indirectly, through signs of previous MI (patho­
logical Q or R waves) or conduction abnormalities [mainly left bundle 
branch block (LBBB) and impaired atrioventricular conduction]. Atrial 
fibrillation (AF) is not rarely associated with CCS.68 ST-segment de­
pression during supraventricular tachyarrhythmias, however, is not a 
strong predictor of obstructive CAD.69–72
The ECG can be crucial for diagnosing transient myocardial ischae­
mia by recording dynamic ST-segment changes during ongoing angina. 
Vasospastic angina (VSA) should be suspected when observing typical 
transient ST-segment elevations or depressions with U-wave changes 
during an angina attack at rest.73
Long-term ambulatory ECG monitoring can be considered in se­
lected patients to detect ischaemia during anginal episodes unrelated 
to physical activities. ECG changes suggesting ischaemia on ambulatory 
ECG monitoring are frequent in women but do not correlate with find­
ings during stress testing.74 Ambulatory ECG monitoring may also re­
veal ‘silent’ ischaemia in patients with CCS, but therapeutic strategies 
targeting it have not demonstrated clear survival benefits.75,76
Table 5 Grading of effort angina severity according to 
the Canadian Cardiovascular Society
Grade
Description of angina severity66
I
Angina only with 
strenuous exertion
Presence of angina during strenuous, 
rapid, or prolonged ordinary activity 
(walking or climbing the stairs)
II
Angina with 
moderate exertion
Slight limitation of ordinary activities 
when they are performed rapidly, after 
meals, in the cold, in the wind, under 
emotional stress, or during the first 
few hours after waking up, but also 
walking uphill, climbing more than one 
flight of ordinary stairs at a normal 
pace, and in normal conditions
III
Angina with mild 
exertion
Having difficulties walking one or two 
blocks or climbing one flight of stairs at 
a normal pace and conditions
IV
Angina at rest
No exertion is needed to trigger angina
© ESC 2024
Recommendation Table 1 — Recommendations for his­
tory taking, risk factor assessment, and resting electro­
cardiogram in individuals with suspected chronic 
coronary syndrome (see also Evidence Table 1)
Recommendations
Classa
Levelb
History taking and risk factor assessment
In individuals reporting symptoms of suspected 
myocardial ischaemic origin, a detailed assessment of 
cardiovascular risk factors, medical history, and 
symptom characteristics (including onset, duration, 
type, location, triggers, relieving factors, time of day) 
is recommended.
I
C
Symptoms like chest pain triggered by emotional 
stress; dyspnoea or dizziness on exertion; pain in the 
arms, jaw, neck, or upper back; or fatigue should be 
considered as potential angina 
equivalents.18,33,57,59,77
IIa
B
Resting ECG
If clinical or ECG assessment suggests ACS rather 
than CCS, immediate referral to the emergency 
department and/or repeated measurement of blood 
troponin, preferably using high-sensitivity or 
ultrasensitive assays, to rule out acute myocardial 
injury, is recommended.78,79
I
B
A resting 12-lead ECG is recommended in all 
individuals reporting chest pain (unless an obvious 
non-cardiac cause is identified), particularly during, or 
immediately after, an episode suggestive of 
myocardial ischaemia.
I
C
Using ST-segment deviations during supraventricular 
tachyarrhythmias, particularly during re-entrant 
atrioventricular tachycardias, per se, as reliable 
evidence of obstructive CAD, is not 
recommended.80–84
III
B
© ESC 2024
ACS, acute coronary syndrome; CAD, coronary artery disease; CCS, chronic coronary 
syndrome; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 23 -->

### Page 23

3.1.2.2. Biochemical tests
Laboratory blood tests identify potential causes of ischaemia (e.g. se­
vere anaemia, hyperthyroidism), cardiovascular risk factors (e.g. lipids, 
fasting glucose), and yield prognostic information (e.g. renal disease, in­
flammation). When fasting plasma glucose and glycated haemoglobin 
(HbA1c) are both inconclusive, an additional oral glucose tolerance 
test is useful.85,86
A lipid profile, including total cholesterol, high-density lipoprotein 
cholesterol (HDL-C), and triglycerides, allowing calculation of low- 
density lipoprotein cholesterol (LDL-C), is necessary in every person 
with suspected CCS to refine his/her risk profile and guide treat­
ment.16,64 Fasting values are needed to characterize severe dyslipidae­
mia or follow-up hypertriglyceridaemia,64
but not in other 
situations.87 Elevated lipoprotein(a) is a marker of cardiovascular risk, 
particularly early-onset atherosclerotic disease;88
lipoprotein(a)- 
lowering strategies are currently being investigated in phase 3 cardiovas­
cular outcomes trials.89–91 Given that circulating lipoprotein(a) levels are 
genetically determined and do not fluctuate substantially over a life­
time,89,91 a single measure is sufficient in persons with suspected CCS.92
Renal dysfunction increases the likelihood of CAD and has a negative 
impact on prognosis.93–95 Glomerular filtration rate (GFR) also impacts 
renally cleared drugs. It is reasonable to also measure uric acid levels, as 
hyperuricaemia is frequent, and may affect renal function.
If there is a clinical suspicion of CAD instability, biochemical markers 
of myocardial injury—such as troponin T or troponin I—should be 
measured, preferably using high-sensitivity assays, and management 
should follow the 2023 ESC Guidelines for the management of patients 
with acute coronary syndromes.65 If high-sensitivity assays are em­
ployed, low troponin levels can be detected in many patients with stable 
angina. Increased troponin levels are associated with adverse out­
comes,96–100 and small studies have indicated a possible incremental va­
lue in diagnosing obstructive CAD,101–104 but larger trials are needed to 
verify the utility of systematic assessment in individuals suspected of 
CCS. While multiple biomarkers may be useful for prognostication, 
they do not yet have a role in diagnosing obstructive CAD, but some 
promising results have been published.105–108 Measuring NT-proBNP 
helps confirm or exclude suspected HF.
Markers of inflammation such as C-reactive protein109–113 and 
fibrinogen114–118 are predictors of an individual’s risk of CAD and can 
predict cardiovascular event risk in CCS patients,99,111 but their value 
is limited beyond traditional risk factors.111 However, in patients taking 
contemporary statins, high-sensitivity C-reactive protein (hs-CRP) was 
a stronger predictor for future cardiovascular events and death than 
LDL-C.119,120 These patients may benefit from additional LDL-C reduc­
tion through adjunctive lipid-lowering therapies, such as ezetimibe, 
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition,121
inclisiran, and bempedoic acid.122–124 Elevated hs-CRP levels in patients 
taking statins and PCSK9 inhibitors may indicate residual inflammatory 
risk that could be further reduced through inflammation modula­
tion.119,125,126 Experimental inhibition of interleukin-6, a pivotal factor 
in atherothrombosis, resulted in a marked parallel reduction of 
C-reactive protein and fibrinogen in patients with chronic kidney dis­
ease (CKD) and high cardiovascular risk.127
3.2. STEP 2: Further evaluation
3.2.1. Pre-test clinical likelihood of obstructive 
atherosclerotic coronary artery disease
The diagnosis of CCS is based on interpreting the individual’s symp­
toms, balancing the impact of age, sex, risk factors, and comorbidities 
on the likelihood that CCS is present, and choosing the most appropri­
ate diagnostic test to confirm the clinically suspected diagnosis. To aid 
diagnosis, prediction tables for obstructive CAD can be used that inte­
grate these clinical factors and provide guidance on selecting diagnostic 
tests based on their capacities to rule in and rule out obstructive 
atherosclerotic CAD. Importantly, these models do not include the prob­
ability of ANOCA/INOCA, which always needs to be considered if 
symptoms persist after deferral of further testing or diagnostic testing 
that excludes obstructive CAD.
The tables used to estimate the likelihood of obstructive CAD as 
confirmed by ICA were initially based on the Diamond–Forrester ap­
proach, which considered sex, age, and angina symptoms.25
However, these tables have had to be updated several times owing 
to the declining prevalence of obstructive CAD at invasive angiography 
in contemporary Western cohorts.26,29 The overestimation of ob­
structive CAD prevalence has limited the utility of these tables in clinical 
routine and in accurately estimating the post-test likelihood of ob­
structive CAD by diagnostic imaging methods.1,29,30
The 2019 ESC Guidelines for the diagnosis and management of CCS 
introduced the concept of clinical likelihood as a more comprehensive 
and individualized assessment of the probability of obstructive CAD.1
Compared with a basic pre-test probability model, incorporation of 
risk factors in the basic pre-test likelihood model (based on age, sex, and 
Recommendation Table 2 — Recommendations for ba­
sic biochemistry in the initial diagnostic management of in­
dividuals with suspected chronic coronary syndrome (see 
also Evidence Table 2)
Recommendations
Classa
Levelb
The following blood tests are recommended in all 
individuals to refine risk stratification, diagnose 
comorbidities, and guide treatment:
• lipid profile including LDL-C;64,128
I
A
• full blood count (including haemoglobin);129–133
I
B
• creatinine with estimation of renal function;134
I
B
• glycaemic status with HbA1c and/or fasting plasma 
glucose.16,86,135,136
I
B
In patients with suspected CCS, it is recommended 
to assess thyroid function at least once.137,138
I
B
Additionally, hs-CRP and/or fibrinogen plasma levels 
should be considered.109–118,121,125
IIa
B
© ESC 2024
CCS, chronic coronary syndrome; HbA1c, glycated haemoglobin; hs-CRP, high-sensitivity 
C-reactive protein; LDL-C, low-density lipoprotein cholesterol. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3437


<!-- PAGE 24 -->

### Page 24

symptoms) leads to improved prediction of obstructive CAD, down- 
classifies more individuals to very low and low likelihood of disease, 
and maintains high calibration.30,139,140 The Risk-Factor-weighted 
Clinical Likelihood (RF-CL) model includes sex, age, angina symptoms, 
and number of risk factors without losing diagnostic accuracy com­
pared with more advanced models requiring computed calculation 
(Figure 4).139,141,142 The RF-CL model increases three-fold the number 
of subjects categorized as at very low (≤5%) likelihood of obstructive 
CAD compared with the ESC pretest probability (ESC-PTP) model 
(38% vs. 12%),139 while predicting annualized event rates of MI and 
death of 0.5%, 1.1%, and 2.1% for individuals having very low, low, 
and moderate likelihood of obstructive CAD, respectively.143
Individual adjustment of the likelihood may be necessary for indivi­
duals with severe single risk factors or comorbidities associated with 
an increased prevalence of obstructive CAD, which are not reflected 
in the RF-CL model, e.g. familial hypercholesterolaemia, severe kidney 
dysfunction, rheumatic/inflammatory diseases, and peripheral artery 
disease (PAD).
Exercise ECG testing may modify the likelihood of obstructive CAD 
and can be used in patients with low (>5%–15%) clinical likelihood, in 
whom a negative test allows reclassification to the very low (≤5%) clin­
ical likelihood group with a favourable prognosis.144 However, CCTA 
as a first-line diagnostic test can give more accurate information and 
has been associated with fewer angina symptoms during follow-up 
than a strategy with exercise ECG as the first investigation.145–148 In 
addition, more adverse events were observed in randomized trials 
with an exercise ECG than with a CCTA-based diagnostic strat­
egy.34,146 However, exercise ECG remains clinically useful for reprodu­
cing anginal symptoms, which have a prognostic value.149,150
In contrast to exercise ECG, visualization of calcified atherosclerotic 
plaque in the coronary artery significantly impacts the clinical likelihood 
of atherosclerotic obstructive CAD. Coronary artery calcification 
(CAC) can be measured using the coronary artery calcium score 
(CACS), which is derived from an ECG-gated non-contrast-enhanced 
computed tomography (CT) scan. Alternatively, the presence of 
CAC can be evaluated qualitatively by visually inspecting the coronary 
arteries on a previous non-cardiac chest CT scan, if available. The ab­
sence of CAC (CACS = 0) has a very high negative predictive value 
(>95%) for obstructive CAD.151 Of note, in younger patients, obstruct­
ive CAD is rare, but when present, a higher percentage (58% of those 
younger than 40 years) have a CACS of 0 compared with older patients 
with obstructive CAD (9% among those aged 60 to 69 years).152
Small, randomized studies have shown that further testing can safely 
be deferred in patients without CAC, without increased event rates 
during follow-up.146,153 Finally, in a larger prospective observational 
study, absence of CAC alone was sufficient to define a low-risk 
group with no need for further testing with improved accuracy com­
pared with basic clinical prediction models.154 The combination of 
CACS with the RF-CL model [CACS + RF-CL (the Coronary Artery 
Calcium Score-Weighted Clinical Likelihood—CACS-CL)] showed 
the strongest potential to effectively defer cardiac testing compared 
with other clinical prediction models or CACS alone (adjustment of 
the estimation of the clinical likelihood of obstructive CAD).139,154
With the CACS-CL model, substantially more individuals (54%) com­
pared with the RF-CL model (38%) were categorized as having a very 
low clinical likelihood of obstructive CAD in the external validation co­
horts.139 Finally, the CACS-CL model was superior to other clinical 
prediction models in predicting MI and death during follow-up.143
Detection of atherosclerotic disease in non-coronary arteries with 
ultrasound or CT scans of, e.g. the aorta, and the carotid or femoral ar­
teries, may increase the clinical likelihood of obstructive CAD,155–158
and the risk for future CVD events.159,160 However, how accurately 
the detection of non-coronary atherosclerotic disease impacts the like­
lihood estimation of obstructive CAD needs further investigation.
In general, individuals with a very low (≤5%) likelihood of obstructive 
CAD do not require further diagnostic testing unless symptoms persist 
and non-cardiac causes have been excluded. In patients with a low 
(>5%–15%) likelihood of obstructive CAD, the benefit of diagnostic 
testing is uncertain but may be performed if symptoms are limiting 
and require clarification. Patients with moderate (>15%–50%), high 
(>50%–85%), and very high (>85%) likelihood of obstructive CAD 
are encouraged to undergo further diagnostic testing.
By using pre-test likelihood estimates and diagnostic imaging-test 
positive and negative likelihood ratios, it is possible to calculate the 
post-test probability of obstructive CAD. Hence, pre-test likelihood es­
timation is useful to guide non-invasive diagnostic test strategies for de­
tecting obstructive CAD (Section 3.3.4).
Recommendation Table 3 — Recommendations for 
estimating, adjusting and reclassifying the likelihood of 
obstructive atherosclerotic coronary artery disease in 
the initial diagnostic management of individuals with sus­
pected chronic coronary syndrome (see also Evidence 
Table 3)
Recommendations
Classa
Levelb
It is recommended to estimate the pre-test 
likelihood of obstructive epicardial CAD using the 
Risk Factor-weighted Clinical Likelihood 
model.139,140,142,143,161,162
I
B
It is recommended to use additional clinical data (e.g. 
examination of peripheral arteries, resting ECG, 
resting echocardiography, presence of vascular 
calcifications on previously performed imaging tests) 
to adjust the estimate yielded by the Risk 
Factor-weighted Clinical Likelihood model.163
I
C
In individuals with a very low (≤5%) pre-test likelihood 
of obstructive CAD, deferral of further diagnostic 
tests should be considered.139,164
IIa
B
In individuals with a low (>5%–15%) pre-test 
likelihood of obstructive CAD, CACS should be 
considered to reclassify subjects and to identify more 
individuals with very low (≤5%) CACS-weighted 
clinical likelihood.139,143,165
IIa
B
In individuals with an initially low (>5%–15%) 
likelihood of obstructive CAD, exercise ECG and 
detection of atherosclerotic disease in non-coronary 
arteries may be considered to adjust the pre-test 
likelihood estimate.144,166
IIb
C
© ESC 2024
CACS, coronary artery calcium score; CAD, coronary artery disease; ECG, 
electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 25 -->

### Page 25

1
2
3
Chest pain characteristics
Type and location
Constricting discomfort located retrosternally or in neck, jaw, shoulder or arm (I point)
Aggravated by
Physical or emotional stress (1 point)
Main symptom either:
Relieved by
Rest or nitrates within 5 min (1 point)
Symptom score
Shortness of breath and/or trouble catching breath aggravated by physical exertion (2 points)
Dyspnoea characteristics
Symptom score
Symptom score (0–3 points)
Estimate the Risk Factor-weighted Clinical Likelihood (RF-CL)
of obstructive CAD 
Number of risk factors for CAD (0–5): 
Family history, smoking, dyslipidaemia, hypertension and diabetes
Age 30–39
Very low
Low
Moderate
Age 40–49
Age 50–59
Age 60–69
Age 70–80
Clinical likelihood:
0–1 point
2 points
3 points
Number of risk factors
4
7
11
0
1
2
2
4
7
1
2
5
1
1
3
0–1 2–3 4–5
Women
15 19 24
1
2
5
8
12 17
4
7
12
2
4
8
0–1 2–3 4–5
Men
6
10 16
0
1
3
3
6
11
2
3
7
1
2
5
0–1 2–3 4–5
Women
22 27 34
2
4
8
12 17 25
6
11 17
3
6
12
0–1 2–3 4–5
Men
16 19 23
2
5
10
10 14 19
6
10 15
4
7
12
0–1 2–3 4–5
Women
44 44 45
9
14 22
32 35 39
21 27 33
14 20 27
0–1 2–3 4–5
Men
Chest pain
(0–3 points)
Dyspnoea
(2 points)
or
Figure 4 Estimation of the clinical likelihood of obstructive coronary artery disease. CAD, coronary artery disease; RF-CL, risk factor-weighted clinical 
likelihood. Data derived from Winther et al.139 The symptom score replaces the previous, potentially misleading terminology, that defined presence of 
three chest pain characteristics as ‘typical’ angina (here = 3 points), two of three characteristics as ‘atypical’ angina (here = 2 points), and no or one 
characteristic as ‘non-cardiac/non-anginal’ (here = 0–1 point). Family history of CAD is defined as 1 or more first-degree relatives with early signs 
of CAD (men <55 and women <65 years of age); smoking, as current or past smoker; dyslipidaemia, hypertension, and diabetes, as present at the 
time of diagnosis. Values in the lower panel are the clinical likelihood estimates expressed as %.
ESC Guidelines                                                                                                                                                                                          3439


<!-- PAGE 26 -->

### Page 26

3.2.2. Transthoracic echocardiography and cardiac 
magnetic resonance at rest
An echocardiographic study will provide important information about car­
diac function and anatomy. Patients with CCS have often preserved left 
ventricular ejection fraction (LVEF).167 A decreased LV function and/or 
regional wall motion abnormalities may increase the suspicion of ischaemic 
myocardial damage,167 and a pattern of LV dysfunction following the 
anatomical perfusion territory of the coronary arteries is typical in patients 
who have already had an MI.168,169 The detection of regional wall motion 
abnormalities can be challenging by visual assessment, and detection of 
early systolic lengthening, decreased systolic shortening, or post-systolic 
shortening by strain imaging techniques,170–172 or new parameters such 
as global myocardial work,173 may be helpful in individuals with apparently 
normal LV function but with clinical suspicion of CCS. Diastolic LV dysfunc­
tion has been reported to be an early sign of ischaemic myocardial dysfunc­
tion and may also be indicative of microvascular dysfunction.174,175
Echocardiography can help in detecting alternative causes of chest 
pain (e.g. pericarditis) and in diagnosing valvular heart diseases, ischae­
mic HF, and most cardiomyopathies,176 though these diseases may co- 
exist with obstructive CAD. The use of an echocardiographic contrast 
agent can be helpful in patients with poor acoustic windows.177
Cardiac magnetic resonance (CMR) is an alternative in patients with 
suspected CAD when the echocardiogram (having used ultrasound 
contrast agent) is inconclusive.178 Cardiac magnetic resonance can as­
sess global and regional function,179 and the use of late gadolinium en­
hancement (LGE) CMR can reveal a typical pattern of scarred 
myocardium in patients who have already experienced an MI.180
Moreover, CMR provides information on myocardial ischaemia 
through the evaluation of stress-induced perfusion defects.181
The strongest predictor of long-term survival is systolic LV function. 
Hence, risk stratification through the assessment of systolic LV function 
is useful in all symptomatic individuals with suspected CCS. Mortality 
increases as LVEF declines.182 Management of patients with either an­
gina or HF symptoms, with reduced LVEF ≤40% or mildly reduced 
LVEF 41%–49%, is described in Section 4.
3.2.3. Exercise electrocardiogram testing
Exercise ECG testing is low cost, does not use ionizing radiation, is 
widely accessible, and remains an alternative for diagnostic testing de­
pending on local resources and individual characteristics.
The classical exercise ECG, involving graded exercise until the occur­
rence of fatigue, limiting chest pain or discomfort, significant ischaemic 
ECG changes, arrhythmias, excessive hypertension, a BP drop or after 
reaching 85% of the maximal predicted heart rate, has been the main­
stay of the examination techniques used in clinical cardiology for asses­
sing individuals with suspected CCS. Exercise ECG testing has a lower 
diagnostic performance of obstructive CAD compared with modern 
functional imaging and CCTA,148 which, therefore, should be preferred 
as a first-line test in subjects with suspected CCS. Several clinical trials 
have confirmed that a strategy based on anatomical34,146,187,188 or func­
tional imaging189 simplifies the diagnosis, enables the targeting of pre­
ventive therapies and interventions, and potentially reduces the risk 
of MI compared with usual care based on exercise ECG. In addition, 
two randomized trials showed that patients reported fewer anginal 
complaints during follow-up when randomized to CCTA as an index 
investigation for stable chest pain compared with exercise ECG.145,146
Although the Scottish Computed Tomography of the Heart 
(SCOT-HEART) trial favoured CCTA as first-line test in CCS, a post 
hoc analysis suggested that abnormal results of exercise ECG remain 
a specific indicator of obstructive CAD, and are associated with future 
coronary revascularization and risk of MI.188 Exercise ECG testing with 
clearly abnormal results was most predictive for these outcomes; how­
ever, in a large proportion of individuals who underwent exercise ECG, 
particularly those with normal or inconclusive results, there was still a 
significant amount of unrecognized non-obstructive and obstructive 
CAD, which can be detected by additional CCTA imaging.188 In the 
WOMEN trial (What is the Optimal Method for Ischemia Evaluation 
of Women), including low-risk symptomatic women, exercise ECG 
was equally effective compared with exercise myocardial perfusion 
scintigraphy, with a similar 2-year incidence of major adverse cardiovas­
cular events (MACE), defined as CAD death, or hospitalization for an 
ACS or HF, while providing significant diagnostic cost savings.190
Individuals exercising >10 metabolic equivalents with a negative exer­
cise ECG and a low-risk Duke Treadmill Score have a good prognosis 
with limited need for downstream testing and revascularization.166,191
Patients with marked ischaemia at a low workload and a high-risk 
Duke Treadmill Score may benefit from further anatomical or function­
al testing. In regions with limited access to functional imaging or CCTA, 
or in individuals with a low (>5%–15%) pre-test likelihood of obstruct­
ive CAD,144 exercise ECG remains, therefore, useful for risk stratifica­
tion and prognostication.144 Particularly, in subjects with a low (>5%– 
15%) likelihood of obstructive CAD, a negative exercise ECG may help 
to down-classify patients into the very low likelihood (<5%) class, in 
whom further testing can be deferred.144
An exercise ECG is of no diagnostic value in patients with ECG ab­
normalities at rest that prevent interpretation of the ST-segment 
changes during stress (i.e. LBBB, paced rhythm, Wolff−Parkinson 
−White syndrome, ≥0.1 mV ST-segment depression on resting ECG, 
or treatment with digitalis). In patients with known CAD, exercise 
ECG may be considered in selected patients to complement their clin­
ical evaluation for assessing symptoms, ST-segment changes, exercise 
tolerance, arrhythmias, BP response, and event risk.
In summary, due to its low sensitivity (58%) and specificity (62%), ex­
ercise ECG testing has low diagnostic performance for the diagnosis of 
obstructive CAD148 and should mainly be used for risk stratification.
Recommendation Table 4 — Recommendations for 
resting transthoracic ultrasound and cardiac magnetic 
resonance imaging in the initial diagnostic management 
of individuals with suspected chronic coronary syn­
drome (see also Evidence Table 4)
Recommendations
Classa
Levelb
A resting transthoracic echocardiogram is 
recommended: 
to measure LVEF, volumes and diastolic function; 
• identify regional wall motion abnormalities;
• identify non-coronary cardiac disease (e.g. 
hypertrophy, cardiomyopathy, valve disease, 
pericardial effusion);
• assess right ventricular function and estimate 
systolic pulmonary artery pressure;
to refine risk stratification and guide 
treatment.167,183,184
I
B
CMR, if available, may be considered as an alternative 
imaging test in individuals with inconclusive 
echocardiographic evaluation.185,186
IIb
C
© ESC 2024
CMR, cardiac magnetic resonance; LVEF, left ventricular ejection fraction. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 27 -->

### Page 27

3.2.4. Chest X-ray
Chest X-ray is commonly utilized in the evaluation of patients experi­
encing chest pain. However, in the context of CCS, it does not yield 
specific information for accurate diagnosis or risk stratification. The 
test may provide assistance in assessing patients with suspected HF. 
Additionally, chest X-ray may prove beneficial in diagnosing pulmonary 
conditions that often co-exist with CAD, or in ruling out other poten­
tial causes of chest pain.
3.2.5. Ambulatory electrocardiogram monitoring
Ambulatory ECG monitoring can assist in evaluating patients with chest 
pain and palpitations. It can also help in detecting and evaluating silent 
myocardial ischaemia, as well as suspected VSA.192–194
3.3. STEP 3: Confirming the diagnosis
3.3.1. Anatomical imaging: coronary computed 
tomography angiography
Through the intravenous (i.v.) injection of contrast agent, CCTA allows 
direct anatomical visualization of the coronary artery lumen and wall. 
CCTA offers a practical, non-invasive test, with proven diagnostic per­
formance in detecting obstructive coronary artery stenoses when com­
pared with ICA.32,148
Obstructive coronary stenoses have typically been defined using 
visual thresholds of either 50% or 70% diameter reduction. It is 
accepted that not all anatomical stenoses above such thresholds, es­
pecially those of moderate (50%–69%) stenosis severity, are haemo­
dynamically or functionally significant195 or induce myocardial 
ischaemia.196 Depending on the clinical context, it may be necessary 
to complement CCTA with functional data either from non-invasive 
imaging techniques or from invasive angiography with fractional 
flow reserve (FFR) (see Section 3.3.3.2), when the haemodynamic con­
sequence of a stenosis is deemed questionable for management 
options.
While several earlier trials (publication date during or before 2016) 
reported a higher rate of downstream ICA in patients receiving CCTA 
compared with functional imaging,197 this was no longer observed in 
more recent trials (publication date after 2016). Moreover, increased 
downstream use of invasive procedures was linked to non-adherence 
to guideline recommendations as these procedures were used signifi­
cantly less when the guidelines were adopted.198
Coronary computed tomography angiography-derived fractional 
flow reserve (FFR-CT) can complement CCTA by providing values 
of model-based computational FFR along the coronary tree. 
FFR-CT has shown good agreement with invasive FFR,199 and has clin­
ical utility by reducing the number of unnecessary ICA procedures.200
However, in patients with severe disease at CCTA, FFR-CT has less 
impact on patient management.201 FFR-CT does not require pharma­
cological stress, additional contrast agent injection, or radiation ex­
posure. FFR-CT, however, is not ubiquitous and depends on image 
quality. Nevertheless, the rejection rate is reported to be quite low 
in real-world data with newest-generation scanners.202–204
3.3.1.1. Computed tomography perfusion imaging
Computed tomography perfusion imaging, performed under pharma­
cological stress, has been validated against several reference stan­
dards, including single-photon computed tomography (SPECT) and 
Recommendation Table 5 — Recommendations for 
exercise ECG in the initial diagnostic management of in­
dividuals with suspected chronic coronary syndrome 
(see also Evidence Table 5)
Recommendations
Classa
Levelb
Exercise ECG is recommended in selected patientsc 
for the assessment of exercise tolerance, symptoms, 
arrhythmias, BP response, and event risk.
I
C
Exercise ECG may be considered as an alternative 
test to rule in and rule out CAD when non-invasive 
imaging tests are unavailable.148,166,188,190,191
IIb
B
An exercise ECG may be considered to refine risk 
stratification and treatment.188
IIb
B
In individuals with a low (>5%–15%) pre-test 
likelihood of obstructive CAD, an exercise ECG may 
be considered to identify patients in whom further 
testing can be deferred.144
IIb
C
Exercise ECG is not recommended for diagnostic 
purposes in patients with ≥0.1 mV ST-segment 
depression on resting ECG, left bundle branch block 
or who are being treated with digitalis.
III
C
In individuals with a low or moderate (>5%–50%) 
pre-test likelihood of obstructive CAD, an exercise 
ECG is not recommended to rule out CAD if CCTA 
or functional imaging tests are available.148
III
C
© ESC 2024
BP, blood pressure; CAD, coronary artery disease; CCTA, coronary computed 
tomography angiography; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence. 
cWhen this information will have an impact on diagnostic strategy or management.
Recommendation Table 6 — Recommendations for 
chest X-ray in the initial diagnostic management of indi­
viduals with suspected chronic coronary syndrome (see 
also Evidence Table 6)
Recommendations
Classa
Levelb
A chest X-ray should be considered for individuals with: 
• signs and symptoms suggestive of heart failure;
• suspected acute pulmonary disease;
• suspected aortic, non-coronary cardiac, or other 
thoracic causes of chest pain.
IIa
C
© ESC 2024
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 7 — Recommendations for am­
bulatory ECG monitoring in the initial diagnostic manage­
ment of individuals with suspected chronic coronary 
syndrome (see also Evidence Table 7)
Recommendations
Classa
Levelb
Ambulatory ECG monitoring is recommended in 
subjects with chest pain and suspected arrhythmias.
I
C
Ambulatory ECG monitoring should be considered 
in subjects with suspected vasospastic angina.192–194
IIa
B
© ESC 2024
ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3441


<!-- PAGE 28 -->

### Page 28

invasive FFR. It has shown adequate diagnostic performance in se­
lected cohorts,205,206 and a potential to reduce the number of un­
necessary downstream invasive angiography procedures, when 
compared with functional tests (mostly symptom-limited exercise 
ECG).153 While CT perfusion imaging could complement CCTA dur­
ing the same visit, this technique requires the administration of a 
pharmacological stressor, contrast agent, and further patient irradi­
ation. Imaging techniques and analysis methods are not yet widely 
standardized (e.g. static and dynamic imaging techniques, visual and 
quantitative assessment).207–209
3.3.1.2. Prognosis, plaque features, and opportunity to improve 
outcomes
The SCOT-HEART trial demonstrated a small but significant decrease 
of the combined endpoint of cardiovascular death or non-fatal MI 
(from 3.9% to 2.3% during 5-year follow-up) in patients in whom 
CCTA was performed in addition to routine testing (exercise 
ECG).34 In a post hoc analysis of this trial, CCTA features (low- 
attenuation plaque, positive remodelling, spotty calcifications, and 
napkin-ring sign) conferred an increased risk of death or non-fatal 
MI, although these plaque features were not independent of 
CACS.210 Systematically evaluating adverse plaque features by 
CCTA can be challenging due to technical limitations (spatial reso­
lution) and patient characteristics (calcifications).
A network meta-analysis of randomized trials suggested that diag­
nostic testing with CCTA was associated with clinical outcomes similar 
to those with functional imaging in patients with suspected stable 
CAD.197 In another pairwise meta-analysis, CCTA showed a lower 
rate of MI compared with functional testing, but the absolute per 
cent risk difference was small (0.4%).211
In the available randomized trials comparing CCTA and functional 
testing (all testing a diagnostic strategy),33,210,212 test reporting and pa­
tient management variability could in part help explain the improved 
outcomes observed in the CCTA arm of SCOT-HEART. In this trial, 
CCTA findings, including non-obstructive atherosclerosis, emphasized 
the need to trigger the start or intensification of medical treatment. 
Increased standardization in reporting CCTA to encompass key plaque 
features (accepting inherent limitations) will be warranted to systemat­
ically harvest prognostic information and help fine-tune risk manage­
ment strategies.213
3.3.1.3. Recognized pre-requisites for coronary computed 
tomography angiography
Generally, a slow and regular heart rate, and compliance with breath- 
holding instructions are necessary to achieve good image quality. 
This includes suitability to receive pre-medication (typically oral or 
i.v. beta-blockers) when needed. Kidney function and allergy to con­
trast agents should be assessed prior to referral. Temporal and spatial 
resolution remain technical limitations and can hinder precision in 
adjudicating coronary stenosis severity. This is most problematic in 
older patients with heavily calcified coronary arteries, in whom func­
tional testing may be more appropriate than CCTA. Contemporary 
CT technology (64-slice technology or above) and a well-trained 
imaging team can help mitigate these limitations and must be consid­
ered a pre-requisite for CCTA.
3.3.2. Functional imaging
3.3.2.1. Stress echocardiography
Stress echocardiography is used to detect myocardial ischaemia by 
assessing regional systolic wall-thickening abnormalities (RWTA) 
during stress. It relies on inducing myocardial ischaemia by increasing 
myocardial oxygen demand beyond the myocardial blood supply. 
Because ischaemia starts in the subendocardium, which contributes 
to more than 50% of systolic myocardial wall thickening, stress testing 
will precipitate wall-thickening abnormalities in the perfusion territory 
of narrowed coronary arteries. Stress modalities used to increase myo­
cardial oxygen demand are exercise (treadmill or bicycle), or i.v. admin­
istration of dobutamine, or vasodilators (adenosine, dipyridamole, 
regadenoson) combined with atropine (to increase heart rate ad­
equately—a major determinant of oxygen demand). Stress echocardi­
ography using demand stress has provided diagnostic accuracy and 
risk-stratification capabilities similar to those obtained with other con­
temporary functional imaging testing modalities.148,223 The advantages 
of stress echocardiography are that it is widely available, low-cost, can 
be performed and interpreted at the bedside, rapid, free of ionizing ra­
diation, and can be repeated without safety concerns.224–227 Although 
stress echocardiography is operator-dependent, which may comprom­
ise reproducibility, the technique is within reach of every cardiology 
department or office. Compromised image quality, especially in obese 
and chronic obstructive pulmonary disease subjects, is a significant 
Recommendation Table 8 — Recommendations for 
non-invasive anatomical imaging tests in the initial 
diagnostic management of individuals with suspected 
chronic coronary syndrome—coronary computed tom­
ography angiography, if available, and supported by local 
expertise (see also Evidence Table 8)
Recommendations
Classa
Levelb
In individuals with suspected CCS and low or 
moderate (>5%–50%) pre-test likelihood of 
obstructive CAD, CCTA is recommended to 
diagnose obstructive CAD and to estimate the risk of 
MACE.33,34,145,212,214–221
I
A
CCTA is recommended in individuals with low or 
moderate (>5%–50%) pre-test likelihood of 
obstructive CAD to refine diagnosis if another 
non-invasive test is non-diagnostic.222
I
B
CCTA is not recommended in patients with severe 
renal failure (eGFR <30 mL/min/1.73 m2), 
decompensated heart failure, extensive coronary 
calcification, fast irregular heart rate, severe obesity, 
inability to cooperate with breath-hold commands, 
or any other conditions that can make obtaining 
good imaging quality unlikely.
III
C
© ESC 2024
CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary 
computed tomography angiography; eGFR, estimated glomerular filtration rate; MACE, 
major adverse cardiovascular events. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 29 -->

### Page 29

limitation. RWTA may not occur if the myocardial oxygen demand in­
crease is inadequate or if the induced perfusion abnormalities are not 
large enough (<10% of the myocardium), such as in mild atherosclerot­
ic CAD or single-vessel obstructive CAD.228 As stress echocardiog­
raphy relies on RWTA as a marker of ischaemia, it may 
under-estimate ischaemia in patients with microvascular disease not af­
fecting the subendocardium as in ANOCA/INOCA.36
Ultrasound contrast agents considerably enhance the quality of diag­
nostic images obtained during stress echocardiography. These micro­
bubbles, consisting of stable gas and shells about the size and 
rheology of red blood cells, can pass through the pulmonary microcir­
culation and induce a dense opacification of the left heart chambers. 
The enhanced image quality and endocardial border definition by using 
ultrasound contrast agents markedly improve the accuracy of stress 
echocardiography.229,230 Ultrasound contrast agents may be required 
in individuals with obesity and chronic obstructive pulmonary disease 
and must be used in all cases if it is evident at baseline that all segments 
may not be visible during stress. Passage of ultrasound contrast agents 
through the myocardium allows assessment of myocardial perfusion 
simultaneously with regional wall motion, improving the sensitivity of 
stress echocardiography (better detection of single-vessel and micro­
vascular disease) and risk stratification beyond RWTA.231–235 The 
use of ultrasound contrast agents during stress echocardiography for 
assessing regional and global LV function is strongly recommended by 
the European Association of Cardiovascular Imaging (EACVI) and the 
American Society of Echocardiography (ASE) guidelines—both class I 
indications. Similarly, myocardial perfusion assessment has received a 
class I recommendation by the EACVI and a class IIa recommendation 
by the ASE.177,236 Ultrasound contrast agents are generally safe, but 
rare cases of anaphylactic reactions have been reported.237
Measurement of the coronary flow velocity reserve (CFVR) based 
on Doppler flow velocity recordings at rest and during stress in the 
left anterior descending (LAD) artery, and assessment of lung conges­
tion through the visualization of B-lines on lung ultrasound, can easily be 
added to routine stress echocardiography procedures. In a prospective 
observational multicentre study, a reduced CFVR was often accompan­
ied by RWTA, abnormal LV contractile reserve, and pulmonary conges­
tion during stress, and showed independent value over RWTA in 
predicting an adverse outcome.238 The inclusion of these additional 
parameters in routine stress echocardiography procedures provides in­
sights on coronary microcirculatory dysfunction.
Finally, carotid ultrasound may be performed in the same session with 
stress echocardiography to assess extracoronary atherosclerosis; while 
this does not add value for confirming a CCS diagnosis per se, it provides 
incremental prognostic value beyond myocardial ischaemia.239,240
3.3.2.2. Myocardial perfusion scintigraphy—single-photon emission 
computed tomography
Myocardial perfusion SPECT imaging relies on the myocardial uptake and 
retention of a radiopharmaceutical. Technetium-99m (99mTc)-based 
tracers are the most commonly used radiopharmaceuticals, whereas 
Thallium 201 (201Tl) should be avoided as it is associated with higher ra­
diation exposure. Myocardial perfusion SPECT produces images of re­
gional myocardial tracer retention, which reflects relative regional 
myocardial blood flow (MBF). Myocardial hypoperfusion is characterized 
by relative reduced radionuclide tracer uptake and retention during vaso­
dilatation or stress, compared with the uptake and retention at rest. The 
inherent need for a normally perfused myocardial reference territory al­
lowing for visualization of the myocardium with relative hypoperfusion 
constitutes the main limitation of SPECT (and stress CMR), particularly 
in multivessel CAD. Coronary calcium scoring from non-contrast- 
enhanced CT, acquired for attenuation correction, as well as transient 
ischaemic dilatation (TID) and reduced post-stress ejection fraction 
(EF) are important non-perfusion predictors of severe obstructive CAD.
Ischaemia can be demonstrated by physical exercise or through the 
administration of pharmacological stressors (e.g. dobutamine) or 
vasodilators 
(e.g. 
dipyridamole, 
adenosine, 
or 
regadenoson). 
Pharmacological agents are indicated in patients who cannot exercise ad­
equately or may be used as an alternative or an adjunct to exercise stress. 
The possibility to use physical exercise and/or different pharmacological 
stressors in combination with the wide-spread availability of the technique 
and the lack of absolute contraindications contributes to the high versa­
tility and applicability of myocardial perfusion SPECT in clinical routine.
SPECT myocardial perfusion imaging is associated with good accur­
acy for the detection of flow-limiting coronary lesions,148,256–258 and 
has been shown to provide prognostic information223,259 and to im­
prove patient management in a randomized controlled trial (RCT).178
Newer-generation SPECT cameras based on cadmium–zinc–telluride 
(CZT) semiconductor detector technology enable a substantial reduction 
in radiation dose exposure and acquisition time, as well as an increased 
diagnostic accuracy260 and absolute quantification of MBF. Hence, its diag­
nostic performance for multivessel CAD has improved substantially.261
Recommendation Table 9 — Recommendations for 
non-invasive tests in the initial diagnostic management 
of individuals with suspected chronic coronary syndrome 
—stress echocardiography, if available, and supported by 
local expertise (see also Evidence Table 9)
Recommendations
Classa
Levelb
In individuals with suspected CCS and moderate or 
high (>15%–85%) pre-test likelihood of obstructive 
CAD, stress echocardiography is recommended to 
diagnose myocardial ischaemia and to estimate the 
risk of MACE.33,241–246
I
B
Continued 
During stress echocardiography, when two or more 
contiguous myocardial segments are not visualized, it 
is recommended to use commercially available 
intravenous ultrasound contrast agents 
(microbubbles) to improve diagnostic 
accuracy.177,229,236,247,248
I
B
During stress echocardiography, myocardial 
perfusion using commercially available intravenous 
ultrasound contrast agents (microbubbles) is 
recommended to improve diagnostic accuracy and 
to refine risk stratification beyond wall 
motion.177,230,232,236,249–254
I
B
During stress echocardiography, Doppler left 
anterior descending coronary artery flow reserve 
may be considered to improve risk stratification 
beyond wall motion and to assess microvascular 
function.177,238,255
IIb
B
© ESC 2024
CAD, coronary artery disease; CCS, chronic coronary syndrome; MACE, major adverse 
cardiovascular events. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3443


<!-- PAGE 30 -->

### Page 30

However, non-obstructive coronary atherosclerosis not linked with is­
chaemia remains undetected by functional testing in general.
If available, assessment of myocardial perfusion using SPECT is recom­
mended in patients with suspected CCS with moderate or high pre-test 
likelihood of obstructive CAD (15%–85%) or known CCS. Importantly, if 
non-contrast-enhanced CT for attenuation correction is acquired, this al­
lows for additional CAC scoring, providing important information for risk 
stratification even in the absence of flow-limiting coronary lesions.
3.3.2.3. Positron emission tomography-computed tomography
Similarly to myocardial perfusion SPECT imaging, PET also relies on 
radiopharmaceuticals. Contrary to SPECT, however, the radionuclides 
commonly used (i.e. 13N-ammonia, 15O-water, and 82Rubidium) are 
short-lived, with half-lives in the range of minutes, requiring production 
of these radionuclides ad hoc for every investigation. As attenuation 
correction is mandatory, PET is routinely performed in combination 
with non-contrast-enhanced CT. Scans are performed during both 
rest and infusion of pharmacological stressors (e.g. dobutamine) or va­
sodilators (e.g. dipyridamole, adenosine, or regadenoson).
While myocardial perfusion PET-CT produces retention images de­
picting relative differences in regional MBF similar to those from SPECT 
—albeit with superior image quality and at much lower radiation dose 
exposure—the unique strength of PET-CT imaging is its ability to pro­
vide robust absolute quantitative measures of MBF. Measuring MBF 
with cardiac PET does not increase radiation or imaging time. Several 
measurements of MBF can be routinely obtained, including MBF during 
hyperaemia, MBF at rest, the MBF reserve, and the relative MBF reserve, 
and confer added diagnostic and prognostic value beyond relative per­
fusion assessment.262,263
Quantitative measures of MBF offer the ability to assess individuals 
with known or suspected diffusely impaired MBF, e.g. with multivessel 
CAD, or microvascular dysfunction.45,264 In general, PET-CT myocar­
dial perfusion imaging is associated with high accuracy for detecting 
flow-limiting coronary lesions,148,258,265 and has been shown to provide 
prognostic information.223,262,263 In several head-to-head comparisons, 
PET-CT myocardial perfusion imaging outperformed other functional 
imaging modalities.257,266–269 However, whether the superiority in diag­
nostic accuracy leads to improved clinical effectiveness and post-test 
management remains to be elucidated.270 In a large retrospective study, 
a low MBF reserve measured by PET independently predicted mortality 
and helped identify patients with a survival benefit from early revascu­
larization with PCI or coronary artery bypass grafting (CABG) beyond 
the extent of myocardial ischaemia.271
Limitations of PET-CT arise from its limited availability compared with 
other imaging modalities. Furthermore, methodological heterogeneity 
exists, particularly regarding thresholds for abnormality of quantitative 
measurements. Finally, physical exercise is challenging to perform.
If available, assessment of myocardial perfusion using PET-CT is par­
ticularly recommended in obese patients (due to the high photon en­
ergy), in young patients (due to the low radiation dose exposure), 
and in those with known or suspected diffusely impaired MBF, e.g. those 
with multivessel CAD or microvascular dysfunction.264 Notably, the 
mandatory non-contrast-enhanced CT for attenuation correction al­
lows for additional CAC scoring, providing essential information for 
risk stratification even in the absence of flow-limiting coronary lesions.
3.3.2.4. Cardiac magnetic resonance imaging
Aside from providing highly accurate and reproducible assessments of 
overall cardiac anatomy, cardiac volumes, function, and tissue charac­
terization, CMR also offers the ability to assess myocardial perfusion, 
which relies on the first-pass myocardial perfusion of gadolinium-based 
contrast agents.
Recently, CMR methods using various parameters for quantitative MBF 
assessment have been introduced. However, the diagnostic performance 
of these parameters varies extensively among studies, and standardized 
protocols and software are lacking.272 Therefore, visual assessment of 
perfusion defects is currently used in clinical practice. Myocardial 
perfusion imaging by stress CMR combines high spatial resolution with 
the absence of ionizing radiation. This has been shown to provide high 
diagnostic accuracy in detecting flow-limiting coronary lesions,148,257,258
prognostic value,223,273–275 and improving patient management.178,276
Pharmacological vasodilators (e.g. adenosine or regadenoson) or stres­
sors (e.g. dobutamine) are commonly applied, as physical exercise is chal­
lenging to perform. In conjunction with a dobutamine infusion, wall 
motion abnormalities induced by ischaemia can also be detected.277 Of 
note, and as for all non-invasive imaging modalities used for assessing myo­
cardial perfusion, incorporating all available imaging and non-imaging in­
formation as part of an integrative approach is mandatory. For CMR, a 
multiparametric protocol, including LV function and assessment of LGE 
along with myocardial perfusion, increases the ability to rule in or rule 
out obstructive CAD in suspected CCS.278
Coronary magnetic resonance angiography allows non-invasive visu­
alization of the coronary arteries.279 However, CMR angiography re­
mains primarily a research tool due to limitations arising from long 
imaging times, low spatial resolution, and operator dependency. 
General limitations of CMR for myocardial perfusion arise from its lim­
ited availability, the claustrophobia experienced by patients, duration of 
image acquisition,280 and possible contraindications to CMR [e.g. non- 
conditional pacemakers and implantable cardioverter defibrillators 
(ICDs)] or to gadolinium-based contrast agents (e.g. renal failure due 
to the potential risk of nephrogenic systemic fibrosis). Finally, and con­
trary to SPECT/CT or PET-CT, stress CMR does not currently provide 
information on presence or absence of coronary calcifications.
If available, and if no contraindications are met, stress CMR is recom­
mended as an option in patients with suspected CCS with moderate or 
high (>15%–85%) pre-test likelihood of obstructive CAD or known 
CCS, particularly if additional information on cardiac function and tissue 
characterization is warranted.
Recommendation Table 10 — Recommendations for 
non-invasive functional myocardial imaging tests in the 
initial diagnostic management of individuals with 
suspected chronic coronary syndrome—resting and 
stress single-photon emission computed tomography/ 
positron 
emission 
tomography—cardiac 
magnetic 
resonance imaging, if available, and supported by local 
expertise (see also Evidence Table 10)
Recommendations
Classa
Levelb
In individuals with suspected CCS and moderate or 
high (>15%–85%) pre-test likelihood of obstructive 
CAD, stress SPECT or, preferably, PET myocardial 
perfusion imaging is recommended to: 
• diagnose and quantify myocardial ischaemia and/or 
scar;
• estimate the risk of MACE;
• quantify myocardial blood flow 
(PET).33,44,223,257,263,268,270,271,281–288
I
B
Continued


<!-- PAGE 31 -->

### Page 31

3.3.2.5. Non-invasive testing for microvascular dysfunction
Angina/ischaemia with non-obstructive coronary arteries (ANOCA/ 
INOCA) may be caused by transient and/or sustained impairments in 
the supply–demand of myocardial perfusion. Functional disorders leading 
to ANOCA/INOCA (e.g. MVA and VSA) are more common in women 
than in men.298,299 A recent meta-analysis reported an overall prevalence 
of MVA of 41% and VSA of 40% in selected patients without obstructive 
CAD.299 However, the true prevalence in unselected patient populations 
with suspected CCS remains unclear. Patients with ANOCA/INOCA 
have increased morbility/mortality,300,301 impaired quality of life (QoL), 
and weigh on health resource utilization. Early, accurate, and preferably 
non-invasive diagnosis is, therefore, of importance.
The possibility of a microcirculatory origin of angina should be con­
sidered in individuals with symptoms suggestive of myocardial ischaemia 
and coronary arteries that are either normal or with non-obstructive 
lesions on CCTA or ICA. Several measurements that rely on quantify­
ing blood flow through the coronary circulation are used to describe 
the function of the microvasculature to identify cases of MVA. 
Among the non-invasive imaging modalities, transthoracic Doppler 
echocardiography has been used as a non-invasive means to measure 
coronary blood flow but is limited to the assessment of the LAD artery 
and is affected by high inter- and intra-operator variability.302,303
Furthermore, this modality cannot distinguish between impairment of 
coronary flow caused by epicardial CAD or coronary microcirculatory 
dysfunction.
A more direct and accurate microvascular function assessment is 
based on MBF measurement. This is commonly achieved by PET-CT 
myocardial perfusion imaging.299 PET allows for the quantification of 
MBF (expressed as millilitres per minute per gram of myocardium) 
and myocardial flow reserve (MFR). The latter reflects the magnitude 
of the increase in MBF that can be achieved by maximal coronary vaso­
dilation conferred by vasodilators, such as adenosine or regadenoson. 
Since the microvasculature primarily determines vascular resistance, 
MFR measures the ability of the microvasculature to respond to a 
stimulus and therefore represents small vessel function. An MFR of 
less than 2.0 (2.5 for non-obstructive CAD) is often considered abnor­
mal for PET.304 Of note, however, no definitive references are available 
across imaging modalities due to the moderate correlation among dif­
ferent MBF estimates.264
Recently, quantitative CMR has been proposed as an emerging tech­
nique for the assessment of microvascular dysfunction through MBF 
quantification but is currently limited to experienced centres.275
Quantitative myocardial perfusion can also be achieved by myocardial 
contrast echocardiography (MCE) through destruction–reperfusion 
imaging and analysis of the time–intensity curves from different regions 
of interest in the myocardium.231,233–235 Of note, MCE assesses capil­
lary blood flow, and capillaries comprise 90% of the microvasculature. 
Measuring MBF at rest and during hyperaemia allows calculation of MBF 
reserve, which is associated with severity of coronary stenoses in pa­
tients with stable angina. In a meta-analysis, MBF reserve had high accur­
acy for predicting flow-limiting CAD.231 However, in the absence of 
obstructive CAD, reduced MBF reserve by MCE depicts microcircula­
tory abnormalities. Transthoracic Doppler evaluation of the LAD ar­
tery is also used to assess coronary flow reserve (CFR) during stress 
hyperaemia and has prognostic value.238,255,305,306
In contrast, the diagnosis of VSA ideally relies on the results of provo­
cation tests in the catheterization laboratory through selective intracor­
onary acetylcholine (Ach) infusion (see Section 5.2.5.2).
It is important to note that there is only a modest correlation be­
tween the values of MBF reserve measured by different techniques 
and modalities.269,305,307
3.3.3. Invasive tests
Invasive coronary angiography has undergone significant advancements 
over time. It is no longer just an angiographic technique that provides ana­
tomical information about the presence of coronary atherosclerosis and 
luminal obstructions of the epicardial coronary arteries. It can also deter­
mine the functional consequences of these obstructions on coronary 
blood flow [FFR and instantaneous wave-free ratio (iFR)] by direct meas­
urement of the coronary BP49,308–311 or by calculating the coronary 
pressure drop across a stenosis based on two or more angiographic 
projections.312 Furthermore, new technologies allow measurement of 
CFR and microvascular resistance, and protocols have been introduced 
for testing the presence of coronary vasospasm.36,39
3.3.3.1. Invasive coronary angiography
Invasive coronary angiography with available coronary pressure 
assessment49,308–311,313 is indicated in patients with a very high 
(>85%) clinical likelihood of obstructive CAD,1 in particular those 
with severe symptoms refractory to antianginal treatment, or charac­
teristic angina or dyspnoea at a low level of exercise1,47 or left ventricle 
dysfunction suggesting extensive obstructive CAD.47,182,314,315
Invasive coronary angiography/coronary pressure assessment is also 
indicated if non-invasive assessment suggests high event risk—e.g. 
CCTA shows ≥50% left main stenosis, or ≥70% proximal LAD stenosis 
with single or two-vessel CAD, or ≥70% proximal three-vessel 
CAD56,182,316,317—or when any stress test shows moderate to severe 
inducible ischaemia316 or when symptoms are highly suggestive for ob­
structive CAD. In all the above situations, ICA/coronary pressure as­
sessment is performed for additional risk stratification318–320 and to 
determine a potential revascularization approach (see Section 
4.4).49,308,309,313
Invasive coronary angiography/coronary pressure assessment may 
also be indicated to confirm or exclude the diagnosis of obstructive 
CAD in patients with uncertain results on non-invasive testing.316
Given the frequent mismatch between the angiographic and haemo­
dynamic severities of coronary stenoses, coronary pressure assessment 
should be readily available to complement ICA investigation for clinical 
decision-making.321–326
In patients selected for PET or SPECT myocardial 
perfusion imaging, it is recommended to measure 
CACS from unenhanced chest CT imaging (used for 
attenuation correction) to improve detection of 
both non-obstructive and obstructive CAD.289–293
I
B
In individuals with suspected CCS and moderate 
or high (>15%–85%) pre-test likelihood of 
obstructive CAD, stress CMR perfusion imaging is 
recommended to diagnose and quantify myocardial 
ischaemia and/or scar and estimate the risk of 
MACE.148,273,276,278,294–297
I
B
© ESC 2024
CACS, coronary artery calcium score; CAD, coronary artery disease; CCS, chronic 
coronary syndrome; CMR, cardiac magnetic resonance; CT, computed tomography; 
MACE, major adverse cardiovascular events; PET, positron emission tomography; 
SPECT, single-photon emission computed tomography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3445


<!-- PAGE 32 -->

### Page 32

In patients with suspected ANOCA/INOCA and an ICA/coronary 
pressure assessment disclosing no significant epicardial CAD, additional 
invasive investigations including index of microcirculatory resistance 
(IMR), CFR and, if necessary, invasive vasoreactivity testing using Ach 
(or ergonovine)36 as part of a complete ‘invasive coronary functional 
testing’ (ICFT) can be performed.
Performing ICA is not exempt from potential complications. Given 
that femoral diagnostic catheterization has been associated with a 
0.5%–2.0% composite rate of major complications, mainly bleeding re­
quiring blood transfusions,327 radial access is now the standard access 
when possible. Radial access has been associated with reduced mortal­
ity and reduced major bleeding while allowing rapid ambulation.327 Still, 
the composite ICA rate of death, MI, or stroke through radial access is 
of the order of 0.1%–0.2%.327 The decision to perform ICA should bal­
ance benefits and risks, as well as potential therapeutic consequences, 
of the investigation that should be part of the process of shared clinical 
decision-making. Patients should be adequately informed of these as­
pects ahead of the procedure.
3.3.3.2. Functional assessment of epicardial stenosis severity to 
guide coronary revascularization
When non-invasive stress tests are inconclusive or not performed, identi­
fying the artery responsible for ischaemia during ICA can be challenging, 
especially in cases with multivessel CAD or coronary stenoses of inter­
mediate severity (typically around 40%–90% for non-left main stem sten­
oses or 40%–70% for left main stem stenoses by visual estimate). In such 
cases, recording wire-based intracoronary pressure during maximal hyper­
aemia to calculate FFR or at rest to measure iFR is recommended to im­
prove risk assessment and clinical decision-making and to reduce clinical 
events.318–320 This has been confirmed by large clinical outcome studies 
such as FAME 1,308 FAME 2,49 DEFINE-FLAIR (Functional Lesion 
Assessment of Intermediate Stenosis to Guide Revascularisation),310
iFR-SWEDEHEART (Instantaneous Wave-free Ratio versus Fractional 
Flow Reserve in Patients with Stable Angina Pectoris or Acute Coronary 
Syndrome),311 R3F (French FFR Registry),313 and RIPCORD (Routine 
Pressure Wire Assessment Influence Management Strategy at Coronary 
Angiography for Diagnosis of Chest Pain trial).309 Haemodynamic rele­
vance, as defined by FFR of ≤0.80, or iFR of ≤0.89, correlates poorly 
with diameter stenosis by visual assessment. In the PRIME-FFR [Insights 
From the POST-IT (Portuguese Study on the Evaluation of FFR-Guided 
Treatment of Coronary Disease) and R3F Integrated Multicenter 
Registries—Implementation of FFR (Fractional Flow Reserve) in Routine 
Practice]322 and FAME (Fractional Flow Reserve versus Angiography for 
Multivessel Evaluation) study,195 31% of the 40%–49% stenoses were 
haemodynamically significant while only 35% of the 50%–70% stenoses 
were haemodynamically relevant, and of the 71%–90% stenoses, 20% 
were not. Only an estimated diameter stenosis of >90% predicted haemo­
dynamic relevance with high accuracy (96% correct classification). The 
discordance between angiographical and functional assessment of cor­
onary stenosis severity varies with age, presence of CMD and lesion- 
specific factors.338,339 Lesions in the left main or proximal LAD are 
more likely to result in a significant FFR, as they supply a larger myocar­
dial mass than those in smaller arteries. As a result, the optimal angio­
graphic cut-off value for functionally non-significant stenosis is 43% for 
the left main and 55% for small vessels.339 This implies that the thresh­
old for functional assessment for larger arteries should be set at 40% 
diameter stenosis.
Large management studies showed that integration of FFR to ICA is 
associated with treatment reclassification in 30%–50% of cases in the 
R3F, POST-IT, RIPCORD, and DEFINE-REAL studies.309,313,340,341
Subsequently, many other non-hyperaemic pressure parameters 
were introduced [distal coronary pressure to aortic pressure ratio 
(Pd/Pa), diastolic pressure ratio (dPR), relative flow reserve (RFR)], 
with good correlation with FFR or iFR, but without available clinical out­
come data. It is interesting to note that both separate and pooled ana­
lyses of the patients included in those studies reveal that ‘FFR/iFR-based 
reclassification’ does not have any significant effect on the number of 
patients recommended for revascularization.342
Meta-analyses of the 5-year outcome of patients managed with iFR 
and FFR as part of the randomized DEFINE-FLAIR and DEFINE- 
SWEDEHEART studies have reported a 2% absolute increase in all-cause 
mortality in those managed with iFR.343,344 This was not associated with 
any unplanned revascularization or non-fatal MI rate increase.343,344
Although it was initially hypothesized that this mortality excess could be 
related to a higher proportion of ‘inappropriate’ revascularization deferral 
with iFR compared with FFR (50% vs. 45%),343 it is reassuring that 
iFR-based deferral is as safe as FFR-based deferral up to 5 years.345
In patients with multivessel CAD, systematic FFR measurement of all 
epicardial vessels has been proposed to select appropriate therapy, but 
Recommendation Table 11 — Recommendations for 
invasive coronary angiography in the diagnostic manage­
ment of individuals with suspected chronic coronary 
syndrome (see also Evidence Table 11)
Recommendations
Classa
Levelb
When ICA is indicated, radial artery access is 
recommended as the preferred access site.327–330
I
A
When ICA is indicated, it is recommended to have 
coronary pressure assessment available and to use it 
to evaluate the functional severity of intermediate 
non-left main stem stenosesc prior to 
revascularization.49,195,308,313,321,322,325,331–333
I
A
Invasive coronary angiography is recommended to 
diagnose obstructive CAD in individuals with a very 
high (>85%) clinical likelihood of disease, severe 
symptoms refractory to guideline-directed medical 
therapy, angina at a low level of exercise, and/or high 
event risk.
I
C
In individuals with de novo symptoms highly 
suggestive of obstructive CAD that occur at a low 
level of exercise, ICA with a view towards 
revascularization is recommended as first diagnostic 
test after clinical assessment by a cardiologist.
I
C
When ICA is indicated, measurement of FFR/iFR 
should be considered to evaluate the functional 
severity of intermediate left main stem stenosesc 
prior to revascularization.331,334,335
IIa
A
When ICA is indicated, IVUS should be considered to 
evaluate the severity of intermediate stenoses of left 
main stemc prior to revascularization.336,337
IIa
B
© ESC 2024
CAD, coronary artery disease; FFR, fractional flow reserve; ICA, invasive coronary 
angiography; iFR, instantaneous wave-free ratio; IVUS, intravascular ultrasound. 
aClass of recommendation. 
bLevel of evidence. 
cTypically 40%–90% for non–left main stem stenoses and 40%–70% for left main stem 
stenoses by visual estimate. For ICA in the diagnostic management of individuals with 
suspected ANOCA/INOCA, see Section 5.3. (Specific groups).


<!-- PAGE 33 -->

### Page 33

recent studies (RIPCORD2 and FUTURE) did not demonstrate any clinical 
outcome improvement compared with angiography alone.346,347
Therefore, intracoronary pressure measurement in patients with multi­
vessel CAD should only be performed on intermediate lesions.
Several recent studies using either FFR or iFR suggest that the pattern 
of pressure drop along the coronary artery (focal vs. progressive) re­
corded during a pullback is important to select patients who will benefit 
more from PCI.2,348–352 Longitudinal functional vessel interrogation can 
therefore be helpful in patients with serial lesions or diffuse CAD.
New 3D angiographically derived wireless coronary pressure para­
meters, such as quantitative flow ratio (QFR) or vessel fractional flow 
reserve (vFFR), are at different stages of clinical investigation325,353,354
(NCT03729739) and have important features that may help to increase 
the use of coronary pressure measurement during ICA significantly. 
These technologies have indeed the unique advantage of providing 
both distal coronary pressure measures and a coronary pressure 
map along the coronary vessel without requiring the use of any pres­
sure wire. The lack of benefits shown in some recent FFR trials demon­
strates that it is not sufficient to validate such new coronary pressure 
indexes against FFR alone to demonstrate their clinical value, and it is 
important to also show benefit in a direct comparative trial vs. angiog­
raphy. In that context, the results of the FAVOR III China study355 are 
important, demonstrating an improved clinical outcome in the 
QFR-guided group compared with the angiography-guided group, 
driven by fewer MIs and ischaemia-driven revascularizations.
The combined measurements of pressure and flow (measured by 
Doppler or thermodilution) may further reduce the number of inter­
ventions. Patients with lesions and concordant normal FFR and CFR 
have an excellent prognosis. Patients with lesions and discordant results 
between FFR and CFR have a similar prognosis to that of patients with 
lesions and concordant abnormal FFR and CFR, treated with PCI. 
Lesions with an abnormal FFR but normal CFR pertain to a good clinical 
outcome up to 5 years of follow-up if left untreated.356–358 Moreover, 
hyperaemic stenosis resistance (HSR), by measuring the pressure gra­
dient across a lesion divided by flow, is an excellent index for both 
diagnostic and prognostic purposes.359,360 The recently introduced 
continuous thermodilution technique for measuring absolute coronary 
flow presents an alternative method for determining CFR. Additionally, 
this method allows for evaluation of the microvascular resistance 
reserve (MRR), a novel index for assessing coronary microvascular 
function.361–364
Coronary flow capacity (CFC) integrates hyperaemic flow and CFR 
and is useful for both diagnostic purposes as well as the evaluation of 
the result after PCI.365–368
Intravascular imaging techniques [e.g. intravascular ultrasound (IVUS) 
or optical coherence tomography (OCT)] have demonstrated good 
diagnostic accuracy in predicting FFR, especially in stenoses located in 
the left main stem.369,370 They are reasonable options to assess left 
main stenosis severity and prognosis; increasing left main plaque burden 
was associated with long-term all-cause and cardiac mortality in pa­
tients not undergoing revascularization.371
While coronary pressure thresholds, specifically 0.80 for FFR and 
0.89 for iFR, are crucial in aiding clinical decision-making, particularly 
in the case of deferring revascularization when FFR/iFR exceeds the is­
chaemic threshold,310,372 they must be considered alongside other 
parameters. These include a careful assessment of the patient’s symp­
toms and the results of non-invasive stress testing to determine the 
need for revascularization.
3.3.3.3. Assessment of microvascular dysfunction
Detailed discussion of microvascular dysfunction by invasive coronary 
functional testing is provided in Section 5.2.5.2. After nitroglycerine, ad­
enosine is administered to assess endothelium-independent vasodila­
tion [CFR, IMR, and hyperaemic myocardial velocity resistance 
(HMR)]. Coronary flow reserve can be calculated using bolus thermo­
dilution (as baseline transit time divided by hyperaemic transit time) or 
continuous thermodilution (as the ratio of hyperaemic and resting abso­
lute coronary flow), or Doppler flow velocity (hyperaemic flow velocity 
divided by baseline flow velocity).307,378,379 The IMR is calculated as the 
product of distal coronary pressure at maximal hyperaemia multiplied 
by the hyperaemic mean transit time. Increased IMR (≥25 U) indicates 
microvascular dysfunction.380,381 It is important to note that continuous 
thermodilution-derived measurements have shown higher reproducibil­
ity than similar measurements derived from bolus thermodilution.382
Angiography-derived index of coronary microcirculatory resistance 
(angio-IMR) allows microcirculation assessment without using intracor­
onary wires.383
3.3.3.4. Testing for coronary vasospasm
Vasoreactivity testing explores endothelium-dependent mechanisms of 
CMD and epicardial and microvascular vasomotor tone disorders.36,73,384
The most established approach for coronary vasoreactivity testing 
is by intracoronary infusion of Ach, although other substances like 
ergonovine have been proposed.384,385 The methodology is described 
in detail in Section 5.2.5.2.2.
Recommendation Table 12 — Recommendations for 
functional assessment of epicardial artery stenosis 
severity during invasive coronary angiography to guide 
revascularization (see also Evidence Table 12)
Recommendations
Classa
Levelb
During ICA, selective assessment of functional severity of intermediatec 
diameter stenoses is recommended to guide the decision to revascularize, 
using the following techniques:
• FFR/iFR (significant ≤0.8 or ≤0.89, 
respectively);49,308,310,311,313,321–323,332,373
I
A
• QFR (significant ≤0.8).325,355,374,375
I
B
In addition:
• CFR/HSR/CFC should be considered as a 
complementary investigation;359,360,366–368,376
IIa
B
• resting invasive measurement of Pd/Pa, dPR, RFR, 
or angiography-derived vessel FFR may be 
considered as alternative parameters.353,377
IIb
C
Systematic and routine wire-based coronary 
pressure assessment of all coronary vessels is not 
recommended.346,347
III
A
© ESC 2024
CFC, coronary flow capacity; CFR, coronary flow reserve; dPR, diastolic pressure ratio; 
FFR, fractional flow reserve; HSR, hyperaemic stenosis resistance; ICA, invasive coronary 
angiography; iFR, instantaneous wave-free ratio; Pd/Pa, distal coronary pressure to aortic 
pressure ratio; QFR, quantitative flow ratio; RFR, relative flow reserve. 
aClass of recommendation. 
bLevel of evidence. 
cTypically around 40%–90% for non-left main stem or 40%–70% for left main stem by visual 
estimate.
ESC Guidelines                                                                                                                                                                                          3447


<!-- PAGE 34 -->

### Page 34

3.3.4. Diagnostic algorithm and selection of 
appropriate tests
After estimation of the pre-test likelihood of obstructive epicardial 
CAD based on the RF-CL model (Figure 4 and Figure 5),139 further diag­
nostic testing is dependent on the clinical scenario, general condition, 
QoL, presence of comorbidities, local availability and expertise for dif­
ferent diagnostic techniques, and importantly patient expectations and 
preferences (Figure 6; Table 6).
In patients with severe comorbidities or severe frailty or very low 
QoL that all contribute to a limited life expectancy, in whom revascu­
larization is judged to be futile, the diagnosis of CCS can be made clin­
ically, and managed with medical therapy and lifestyle changes alone. If 
CCS diagnosis is uncertain in such patients, establishing a diagnosis using 
non-invasive functional imaging for myocardial ischaemia before treat­
ment is reasonable.
Individual adjustment of the clinical likelihood should always be con­
sidered based on the clinical CCS scenario including ECG and echocar­
diography findings (Figure 5, Section 2). Further diagnostic testing can be 
deferred in patients with a very low (≤5%) likelihood of obstructive 
CAD. Based on the CACS-CL model, in patients with a low 
(>5%–15%) likelihood of obstructive CAD, CACS can be considered 
to re-estimate the likelihood of obstructive CAD.139,165,141,154
Further diagnostic testing can also be deferred in patients reclassified 
based on CACS from a low to a very low (<5%) likelihood of 
Risk Factor-weighted Clinical Likelihood  (RF-CL)
Symptom score
Age 30–39
Very low
Low
Moderate
Age 40–49
Age 50–59
Age 60–69
Age 70–80
Clinical likelihood:
0–1 point
2 points
3 points
Number of risk factors
4
7
11
0
1
2
2
4
7
1
2
5
1
1
3
0–1 2–3 4–5
Women
15 19 24
1
2
5
8
12 17
4
7
12
2
4
8
0–1 2–3 4–5
Men
6
10 16
0
1
3
3
6
11
2
3
7
1
2
5
0–1 2–3 4–5
Women
22 27 34
2
4
8
12 17 25
6
11 17
3
6
12
0–1 2–3 4–5
Men
16 19 23
2
5
10
10 14 19
6
10 15
4
7
12
0–1 2–3 4–5
Women
44 44 45
9
14 22
32 35 39
21 27 33
14 20 27
0–1 2–3 4–5
Men
Resting ECG changes (Q-wave or ST-segment/T-wave changes)
LV dysfunction (severe or segmental)
Exercise ECG with abnormal findings
Ventricular arrhythmia
Coronary calcification on pre-existing chest CT
Peripheral artery disease
0
0
1
5
10
15
20
30
50
70
85
100
CACS 1000
CACS 400–999
CACS 100–399
CACS 10–99
CACS 1–9
CACS 0
Coronary artery calcium score (CACS)-weighted clinical likelihood of obstructive CAD (%)
Risk Factor-Weighted Clinical Likelihood of obstructive CAD (%)
10
20
30
40
50
60
70
80
1
2
3
Consider reclassification of low RF-CL (>5–15%) using
CACS to identify very low (5%) CACS-CL
(Class I)
(Class IIa)
Adjust clinical likelihood based on abnormal clinical findings
(Class I)
Figure 5 Adjustment and reclassification of the estimated clinical likelihood of obstructive coronary artery disease. CACS, coronary artery calcium 
score; CACS-CL, coronary artery calcium score + RF-CL model; CAD, coronary artery disease; CT, computed tomography; ECG, electrocardiogram; 
LV, left ventricular; RF-CL, risk factor-weighted clinical likelihood.


<!-- PAGE 35 -->

### Page 35

obstructive CAD (Figure 5).143 Conversely, if CACS is high and there 
are clinical findings indicating that the RF-CL model may be under- 
estimating the likelihood of obstructive CAD, further diagnostic testing 
should be selected based on the adjusted clinical likelihood and coron­
ary calcium burden. It is important to note that patients with a very low 
and low (≤15%) likelihood of obstructive CAD constitute approxi­
mately 85% of individuals with de novo symptoms suspected of 
CCS.27,30,139 Most can be treated conservatively without the need 
for further testing as they have no stenoses or non-obstructive CAD 
with a very low incidence of events during long-term follow-up.27,139,143
Individuals with a moderate or high (>15%–85%) likelihood of 
obstructive CAD should be referred for non-invasive anatomical or 
functional imaging to establish the diagnosis and assess the risk for 
future cardiac events. There is growing support for using CCTA as a 
first-line test in the group with a low or moderate (15%–50%) likeli­
hood.27,31,32,139,386 Given the low prevalence of CAD in this group of 
patients and its high negative predictive value, CCTA is the most effect­
ive diagnostic method to rule out obstructive CAD. Moreover, besides 
its strength in ruling out CAD, CCTA offers direct visualization of 
non-obstructive CAD, which may trigger intensification of preventive 
measures. The use of CCTA as a first-line test is supported by large, 
randomized trials showing equivalence in health outcomes with func­
tional testing33 and even superiority compared with usual care using ex­
ercise ECG.34
In patients with a very high (≥85%) clinical likelihood of obstructive 
CAD, symptoms unresponsive to medical therapy, or angina at a low 
level of exercise, and an initial clinical evaluation (including echocardio­
gram and, in selected patients, exercise ECG) that indicates a high event 
risk, proceeding directly to ICA without further diagnostic testing is a 
reasonable option. Under such circumstances, the indication for revas­
cularization of stenoses with a diameter reduction of <90% should be 
guided by coronary pressure assessment (Figure 6; Table 6).
Clinical likelihood of 
obstructive CADa
Very high
Appropriate first-line test for suspected CCS
>85%
High
>50–85%
Moderate
>15–50%
Low
>5–15%
Very low
Invasive coronary angiography
Functional imaging
PET/SPECT
CMR
Stress ECHO
OR
Functional imaging
CCTA
CCTA
Adjust the clinical likelihood
OR
Defer further testing
5%
PET/SPECT
CMR
Stress ECHO
Figure 6 Appropriate first-line testing in symptomatic individuals with suspected chronic coronary syndrome. CAD, coronary artery disease; CACS- 
CL, coronary artery calcium score + RF-CL model; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac 
magnetic resonance; ECHO, echocardiography; PET, positron emission tomography; RF-CL, risk factor-weighted clinical likelihood; SPECT, single-photon 
emission computed tomography. aThe clinical likelihood of obstructive CAD should be estimated based on the RF-CL model (Figure 4). Individual adjust­
ment of the RF-CL values is in some cases needed based on abnormal clinical finding (Figure 5) or highly suspicious symptoms. Beyond the CACS-CL no 
methods are validated to give accurate adjusted values to the RF-CL and the adjusted values is therefore based on clinical judgment.
ESC Guidelines                                                                                                                                                                                          3449


<!-- PAGE 36 -->

### Page 36

Functional imaging should be selected as a first line test if information 
on myocardial ischaemia, viability, or microvascular disease is desired. 
Tests for detecting ischaemia have better rule-in power compared 
with CCTA and therefore should be selected if there is a moderate- 
high (>15-85%) likelihood of obstructive CAD. Moreover, functional 
imaging tests overcome the limitations of CCTA in certain groups (old­
er patients with more extensive coronary calcifications, AF, and other 
situations with an irregular or fast heart rate, renal insufficiency, or io­
dinated contrast allergy), and avoid exposure to ionizing radiation in 
young individuals and in those suspected of ANOCA/INOCA (Figure 7).
Anatomical imaging by CCTA
preferable if:
Low or moderate pre-test likelihood of obstructive CAD
Information on CAD (also non-obstructive) desired
Individual characteristics suggest high image quality
Invasive coronary angiography with FFR/iFR preferable if:
Very high pre-test likelihood of obstructive CAD
Low-threshold angina or equivalent
Findings suggestive of poor prognosis: e.g. severe
LV dysfunction, ventricular arrhythmia, or hypotension during exercise
Functional imaging by stress echo,
SPECT, PET or CMR preferable if:
Moderate or high pre-test likelihood of obstructive CAD
Information on myocardial ischaemia,
viability or microvascular disease desired
Individual with suspected CCS: pre-test likelihood of obstructive CAD?
CCTA
Functional imaging
Lifestyle and risk factor modification
Disease-modifying and antianginal treatment
Selective sequential testing
Severe ischaemia
High-risk
CADa
Refractory symptoms
Obstructive epicardial CAD
Consider revascularization
No obstructive CAD
Consider ICFT: ANOCA/INOCA?
Invasive investigation
Figure 7 Initial management of symptomatic individuals with suspected chronic coronary syndrome. ANOCA, angina with non-obstructive coronary 
arteries; CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac mag­
netic resonance; Echo, echocardiography; FFR, fractional flow reserve; ICFT, invasive coronary functional testing; iFR, instantaneous wave-free ratio; 
INOCA, ischaemia with non-obstructed coronary arteries; LV, left ventricular; PET, positron emission tomography; SPECT, single-photon emission 
computed tomography. Consider local availability and expertise, and individual characteristics when choosing non-invasive testing. Table 6 offers 
tips for selecting the first-line test in people with suspected CCS. aHigh–risk CAD: obstructive CAD at high risk of adverse events by CCTA: ≥50% 
stenosis of the left main stem; three–vessel disease with severe stenoses (≥70% diameter stenosis); single- or two–vessel disease including the proximal 
LAD with severe stenoses. Consider functional imaging or invasive investigation.


<!-- PAGE 37 -->

### Page 37

The discussion about which modality to use as a first-line test has 
been heavily focused on the detection of obstructive epicardial sten­
oses, neglecting the relatively high prevalence of non-obstructive cor­
onary disease and ANOCA/INOCA, especially in female patients. 
The current rationale behind choosing a first-line test should be to as­
sess the anatomical severity and functional consequences of coronary 
disease, whether obstructive or not. In this regard, PET-CT should 
be more frequently considered and its availability increased as it 
combines calcium scoring with accurate operator-independent 
detection of myocardial ischaemia and CMD with a low irradiation 
dose.45
Individuals in the moderate likelihood group, except older men with all 
three CCS symptom characteristics, will have a likelihood of obstructive 
CAD around 20%. In these, anatomical and functional testing will each re­
sult in an intermediate positive predictive value with eventually many false 
positives, especially with CCTA  easily overestimating stenosis severity. 
Sequential testing (i.e. functional testing after CCTA, or vice versa) will 
therefore be needed in many individuals to establish an accurate diagnosis 
of obstructive, ischaemia-inducing CAD  (Figure 8). Sequential or combined 
anatomical and functional testing is also useful for the non-invasive diagnosis 
of ANOCA/INOCA.41 Moreover, combined testing, e.g. combining CCTA 
and PET, may result in improved prognostication of CCS patients.387
Table 6 Overview of non-invasive tests used for first-line testing in individuals with suspected chronic coronary 
syndrome
Main imaging target(s) in 
CCS
Requirements
Limitations
Anatomical imaging
CCTA
Atherosclerosis (obstructive and 
non-obstructive) in epicardial 
coronary arteries
Iodinated contrast 
Radiation 
Premedication: 
• Beta-blockers or ivabradine for heart rate control
• Nitroglycerine for adequate vasodilation
Severely impaired kidney functiona 
Documented allergy to iodinated contrast 
Tachyarrhythmia refractory to 
beta-blockade 
Irradiation (especially young women)
SPECT/CT 
PET/CT
Atherosclerosis coronary artery 
calcium score
Radiation
Irradiation (especially young women)
Functional imaging
Stress Echo
LVEF and volumes
Poor Echo windows
Wall motion abnormalities 
Myocardial perfusion 
Coronary velocity flow reserve
Performed with exercise, dobutamine and vasodilators 
Echo contrast to improve image quality and assess 
perfusion
Poor Echo windows 
Contraindications to stressor
CMR
LVEF and volumes
Non-CMR-compatible metal devices 
Severe claustrophobia
MI (scar)
Paramagnetic contrast
Non-CMR-compatible metal devices 
Severe claustrophobia 
Haemodialysis
Ischaemia/blood flow
Vasodilator stress + paramagnetic contrast
Non-CMR-compatible metal devices 
Severe claustrophobia 
Contraindications to stressor 
Haemodialysis
Wall motion abnormalities
Inotropic stress (dobutamine)
Non-CMR-compatible metal devices 
Severe claustrophobia 
Contraindication to stressor
SPECT
LVEF and volumes 
Ischaemia/viability
Vasodilator or exercise stress 
Radioactive tracer
Contraindication to stressor 
Irradiation (especially young women)
PET
LVEF 
Ischaemia/blood flow 
Viability
Vasodilator stress 
Radioactive tracer (13N-ammonia, 15O-water, 82Rb)
Contraindication to stressor 
Irradiation (especially young women)
© ESC 2024
CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic resonance; CT, computed tomography; Echo, echocardiography; LVEF, left 
ventricular ejection fraction; MI, myocardial infarction; PET, positron emission tomography; SPECT, single-photon emission computed tomography. 
aPreventive measures are recommended for patients with eGFR <30 mL/min/1.73 m2.389
ESC Guidelines                                                                                                                                                                                          3451


<!-- PAGE 38 -->

### Page 38

100
80
60
40
20
0
0
20
40
60
80
100
Pre-test likelihood (%)
Post-test likelihood (%)
DSE +
CCTA +
CCTA -
DSE -
A
B
C
Figure 8 Ruling in and ruling out functionally significant obstructive coronary artery disease by sequential anatomical (coronary computed tomog­
raphy angiography) and functional (dobutamine stress echocardiography) testing.a CAD, coronary artery disease; CCTA, coronary computed tomog­
raphy angiography; DSE; dobutamine stress echocardiography; ECG, electrocardiogram; FFR, fractional flow reserve. The curves display the post-test 
likelihood of obstructive CAD for a positive (+) and a negative (−) test result for CCTA and DSE, as the pre-test likelihood of obstructive CAD in­
creases. The post-test likelihoods were calculated using the likelihood ratios taken from recent meta-analyses.148,388 aBased on invasive FFR measure­
ment or diameter stenosis of ≥70%.   
• A 70-year-old woman with four coronary risk factors and exertional dyspnoea has a pre-test likelihood of 16% (A). A normal CCTA almost com­
pletely rules out obstructive CAD with a very low negative post-test likelihood (2%).  
• A 55-year-old man with two coronary risk factors and all three anginal symptom characteristics has a pre-test likelihood of 27% (B). An abnormal 
CCTA brings the post-test likelihood to 40%, insufficient to rule in obstructive CAD. Sequential testing with DSE performed after CCTA brings the 
post-test likelihood to 82%. A normal CCTA effectively rules out obstructive CAD.  
• A 69-year-old man with four coronary risk factors and all three anginal symptom characteristics has an adjusted pre-test likelihood of 60% (C) (ad­
justment based on abnormalities on the resting ECG and on symptoms during exercise). A positive DSE alone has a high post-test likelihood 
(± 90%). A negative DSE is associated with a 32% post-test likelihood. Sequential testing by CCTA would allow ruling out obstructive CAD 
(<5% post-test likelihood).


<!-- PAGE 39 -->

### Page 39

After confirmation of diagnosis with the first line of testing, all patients 
should receive lifestyle and risk-factor modification recommendations, 
and disease-modifying and antianginal therapy should be prescribed. 
The ISCHEMIA trial (Initial Invasive or Conservative Strategy for Stable 
Coronary Disease)47 showed that an early revascularization strategy 
did not yield a short-term survival benefit in patients without left main 
disease nor reduced LVEF and with moderate-severe ischaemia at 
non-invasive testing, suggesting that most such patients should initially 
be treated conservatively with optimized GDMT. Patients can be re­
ferred for ICA if CCTA detects a ≥50% stenosis of the left main stem, 
three-vessel or two-vessel disease including the proximal LAD artery 
with ≥70% stenosis, or if functional imaging shows moderate or severe 
ischaemia encompassing an extensive perfusion territory.
For patients with obstructive CAD and refractory symptoms despite 
optimized GDMT, a referral for ICA may be considered to improve 
symptoms through revascularization. Optimization of medical therapy 
by combining two or more antianginal drugs can safely be obtained over 
6 weeks in almost all patients and should be awaited before referral to 
ICA.402,403 It is worth noting that in the Objective Randomised Blinded 
Investigation with optimal medical Therapy of Angioplasty in stable an­
gina (ORBITA) trial, PCI did not provide short-term advantages com­
pared with GDMT in terms of reducing anginal frequency or physical 
limitations.402 In the CLARIFY registry, anginal symptoms resolved in 
many CCS patients over time without requiring revascularization or 
changes in antianginal therapy.404
Combined anatomical and functional imaging before ICA facilitates 
its planning by orientating the invasive cardiologist to perform, in the 
same session, haemodynamic assessment of coronary stenoses and 
ICFT to detect microvascular disease or vasospasm in individuals sus­
pected of ANOCA/INOCA, performing these tests in a single session 
rather than in staged procedures.
3.3.5. Adverse-event risk assessment
Chronic coronary syndromes can be complicated by cardiovascular 
death, ischaemic and haemorrhagic events, HF, arrhythmic events, the 
development of valvular heart disease, and other comorbidities, which 
are further discussed in the Supplementary data, available at European 
Heart Journal online. It is recommended that all patients with newly diag­
nosed obstructive CAD or myocardial ischaemia undergo an adverse- 
risk event assessment to identify those at high risk of adverse outcomes 
who could benefit from revascularization beyond symptom relief. Based 
on large registries and historical RCTs, a high event risk has been defined 
as a cardiac mortality rate of >3% per year, intermediate event risk as 
between ≥1% and ≤3% per year, and low event risk as <1% per year.405
Adverse-event risk stratification is usually based on the same clinical, 
non-invasive and invasive investigations used to diagnose obstructive 
CAD (see Table 14).
Clinical history, physical examination, 12-lead ECG and laboratory 
tests can provide important prognostic information. Assessment of 
risk factors such as advanced age, diabetes mellitus (DM), or renal fail­
ure allows the identification of patients at high risk of events.406–408 Left 
ventricular function is the strongest predictor of long-term survival; a 
patient with an LVEF of <50% is already at high risk for all-cause and 
cardiovascular death.409,410
Although the diagnostic value of an exercise ECG is limited, the oc­
currence of ST-segment depression at a low workload combined with 
exertional symptoms (angina or dyspnoea), low exercise capacity, com­
plex ventricular ectopy, or other arrhythmias and abnormal BP re­
sponse are markers of a high risk of cardiac mortality.411–414
High plaque burden and coronary stenoses are well-known prognostic 
markers. The ISCHEMIA trial using a cut-off of 70% stenosis on CCTA317
confirms the very old observations of the Coronary Artery Surgery 
Study182 that the prognosis of obstructive CAD-related CCS is mainly 
determined by the number of >70% obstructed coronary arteries or 
by the presence of a left main stenosis (using for the latter a cut-off of 
>50% diameter stenosis on coronary angiography).317 More recently, 
the classical paradigm that the severity of stenoses and the number of dis­
eased vessels are the main determinants of prognosis has been challenged 
by post hoc analyses of the SCOT-HEART trial and other CCTA-based 
Recommendation Table 13 — Recommendations for 
selection of initial diagnostic tests in individuals with sus­
pected chronic coronary syndrome (see also Evidence 
Table 13)
Recommendations
Classa
Levelb
Selection of non-invasive testing
It is recommended to select the initial non-invasive 
diagnostic test based on pre-test likelihood of 
obstructive CAD, other patient characteristics that 
influence the performance of non-invasive tests,c and 
local expertise and availability.29,148
I
C
In symptomatic patients in whom the pre-test 
likelihood of obstructive CAD by clinical assessment 
is >5%, CCTA or non-invasive functional imaging for 
myocardial ischaemia is recommended as the initial 
diagnostic test.33,148,178,187,189,211,212,219,222,390
I
B
To rule out obstructive CAD in individuals with low 
or moderate (>5%–50%) pre-test likelihood, CCTA 
is recommended as the preferred diagnostic 
modality.29,148
I
B
CCTA is recommended in individuals with low or 
moderate (>5%–50%) pre-test likelihood of 
obstructive CAD if functional imaging for myocardial 
ischaemia is not diagnostic.391
I
B
Functional imaging for myocardial ischaemia is 
recommended if CCTA has shown CAD of 
uncertain functional significance or is not 
diagnostic.392–394
I
B
In patients with a known intermediate coronary 
artery stenosisd in a proximal or mid coronary 
segment on CCTA, CT-based FFR may be 
considered.395–401
IIb
B
Subsequent invasive testing
Invasive coronary angiography with the availability of 
invasive functional assessments is recommended to 
confirm or exclude the diagnosis of obstructive CAD 
or ANOCA/INOCA in individuals with an uncertain 
diagnosis on non-invasive testing.36,49,308,384
I
B
© ESC 2024
ANOCA, angina with non-obstructive coronary arteries; CAD, coronary artery disease; 
CCTA, coronary computed tomography angiography; CT, computed tomography; FFR, 
fractional flow reserve; INOCA, ischaemia with non-obstructive coronary arteries. 
aClass of recommendation. 
bLevel of evidence. 
cCharacteristics determining ability to exercise, likelihood of good image quality, expected 
radiation exposure, and risks or contraindications. 
dTypically around 40%–90% by visual estimate.
ESC Guidelines                                                                                                                                                                                          3453


<!-- PAGE 40 -->

### Page 40

registries showing that plaque burden and presence of adverse plaque 
characteristics, especially low-attenuation plaque, are the strongest pre­
dictors of fatal and non-fatal MI above the classical risk factors, including 
stenosis severity.210,415–417 These findings emphasize a major advantage 
of anatomical imaging by CCTA as an initial test in selected patients, al­
lowing the assessment of severity and extent of obstructive CAD as 
well as coronary plaque characteristics.
Regarding the prognostic impact of inducible myocardial ischaemia 
by functional stress imaging, the evidence remains conflicting. While 
there are extensive data from large observational studies315,418–425
consistently demonstrating a robust prognostic value conferred by 
the extent of inducible ischaemia as detected by functional imaging 
(e.g. ≥3/16 abnormal segments at stress echocardiography, ≥10% LV 
ischaemia at nuclear or magnetic resonance perfusion imaging, or de­
creased hyperaemic flow or flow reserve at quantitative PET imaging), 
post hoc analyses of the randomized COURAGE426,427
and 
ISCHEMIA317 trials showed that only CAD severity, but not ischaemia 
severity, was independently predictive of long-term mortality and MI 
risk. These discrepancies may be explained by selection and entry biases 
between registries and RCTs.428 Registries typically report on all- 
comer populations with suspected CCS referred for diagnostic testing 
and/or revascularization, representing the real-life scenario. RCTs usu­
ally include only a very selected group of patients, and the external ap­
plicability of their findings is always open for debate. As COURAGE and 
ISCHEMIA selectively included only patients with functionally moderate 
or severe myocardial ischaemia but without any information on CAD 
anatomical severity, it becomes harder to demonstrate a prognostic ef­
fect of myocardial ischaemia, and the anatomical burden becomes the 
prominent prognostic factor. The PROMISE (Prospective Multicenter 
Imaging Study for Evaluation of Chest Pain) trial, which included pa­
tients more representative of an all-comer population, demonstrated 
that CCTA, mainly by detecting non-obstructive CAD, outperformed 
functional testing in predicting outcomes, emphasizing the prognostic 
significance of imaging coronary atherosclerosis beyond myocardial is­
chaemia.208 However, adding the Framingham Risk Score to the func­
tional test result improved its prognostic value, making the difference 
with anatomical testing insignificant. Both modalities are thus equivalent 
for detecting CCS symptoms and predicting outcomes when consider­
ing risk factors.
Besides imaging coronary atherosclerosis, the additional benefit of ICA 
is the ability to perform intracoronary pressure measurements. While 
FFR of ≤0.8 and iFR of ≤0.89 have been associated with a higher risk of 
vessel-related cardiovascular events, it is important to remember that a 
lower FFR/iFR reflects more profound ischaemia in the vessel territory 
and is associated with a progressive and proportional increase in 
risk.318,319 A similar observation has been made with FFR-CT.401 It has 
also been shown that for any given FFR value, a more proximal lesion is 
associated with more extensive ischaemia and an increased risk of a clinical 
event.429In addition, global FFR, summing the coronary pressure collected 
in each of the three main coronary vessel territories as a single patient- 
related index (normal value of global FFR = 1 + 1 + 1 = 3), can appreciate 
overall cardiovascular risk; patients with a borderline FFR but with a global 
FFR of <2.72 showed a significantly increased risk compared with higher 
global-FFR patients.430,431 One of the main limitations of such a global in­
tegrative approach based on invasive coronary pressure is that it requires 
advancing a pressure wire in each of the three coronary arteries, which is 
not often performed341 and is not recommended as a routine, based on 
the RIPCORD2347 and FUTURE results.346 Recent methods using 3-di­
mensional image reconstruction and computational fluid dynamics enable 
FFR estimation with CCTA432 or with ’wire-less’ invasive coronary 
angiography.433,434 This allows a less invasive, easier and more accurate 
global FFR calculation, provided imaging is of sufficiently good 
quality.369–371
In summary, when assessing event risk, clinicians should choose an 
integrative approach, considering risk factors, comorbidities, LV dys­
function, the severity of myocardial ischaemia, the number of function­
ally significantly stenotic coronary arteries, and the coronary plaque 
burden and characteristics, as all of these are likely interrelated factors 
that affect overall prognosis.
3.4. STEP 4: Initial therapy
Initial therapy frequently starts during the diagnostic process. In indivi­
duals with a high suspicion of CCS, sublingual nitroglycerine is frequent­
ly prescribed to treat anginal pain symptoms. Rapid relief within 1 or 2 
Recommendation Table 14 — Recommendations for 
definition of high risk of adverse events (see also 
Evidence Table 14)
Recommendations
Classa
Levelb
An initial stratification of risk of adverse events is 
recommended based on basic clinical assessment 
(e.g. age, ECG, anginal threshold, diabetes, CKD, 
LVEF).406–408
I
B
The use of one or more of the following test results is 
recommended to identify individuals at high risk of 
adverse events:405
• exercise ECG: 
⚬Duke Treadmill Score < −10;191
• stress SPECT or PET perfusion imaging: 
⚬area of ischaemia ≥10% of the LV 
myocardium;287,315,422,423,435
• stress echocardiography: 
⚬≥3 of 16 segments with stress-induced 
hypokinesia or akinesia;435
• stress CMR: 
⚬≥2 of 16 segments with stress perfusion defects 
or ≥3 dobutamine-induced dysfunctional 
segments;435
• CCTA: 
⚬left main disease with ≥50% stenosis, three-vessel 
disease with ≥70 stenosis, or two-vessel disease 
with ≥70% stenosis, including the proximal LAD 
or317one-vessel disease of the proximal LAD with 
≥70% stenosis and FFR-CT ≤0.8.
I
B
In individuals at high risk of adverse events (regardless 
of symptoms), ICA—complemented by invasive 
coronary pressure (FFR/iFR) when appropriate—is 
recommended, with the aim of refining risk 
stratification and improving symptoms and 
cardiovascular outcomes by revascularization.318,319
I
A
© ESC 2024
CCTA, coronary computed tomography angiography; CKD, chronic kidney disease; CMR, 
cardiac magnetic resonance; CT, computed tomography; ECG, electrocardiogram; FFR, 
fractional flow reserve; FFR-CT, CCTA-derived FFR; ICA, invasive coronary angiography; 
iFR, instantaneous wave-free ratio; LAD, left anterior descending; LV, left ventricular; 
LVEF, left ventricular ejection fraction; PET, positron emission tomography; SPECT, 
single-photon emission computed tomography. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 41 -->

### Page 41

min of chest discomfort after sublingual nitroglycerine increases the 
likelihood of CCS. Patients may be advised to refrain from strenuous 
physical activities before the diagnostic process is completed and 
should be instructed what to do if prolonged anginal chest pain indica­
tive of acute MI arises.
Guideline-directed management and therapy are started during or 
after the diagnostic process is concluded. The main goals of treating 
CCS are to improve both QoL and life expectancy. This involves vari­
ous interventions to reduce the risk of (i) cardiac mortality, (ii) non-fatal 
ischaemic events, (iii) progression of epicardial and/or microvascular 
chronic coronary disease, and (iv) symptoms and limitations caused 
by CCS. When deciding on treatment options, it is important to con­
sider patient preferences, possible complications of procedures or 
medications, and healthcare costs. In shared decision-making with pa­
tients, clinicians should clearly explain that certain treatments can alle­
viate symptoms, while others can reduce the likelihood of ischaemic 
events.
4. Guideline-directed therapy
4.1. Patient education, lifestyle 
optimization for risk-factor control, 
and exercise therapy
4.1.1. Patient education
In CCS patients, education on risk factors and symptom management is 
associated with improvements in knowledge, self-care, and patient 
empowerment, and may improve health-related QoL.436 In addition, 
education can facilitate long-term adherence to lifestyle interven­
tions.437,438 Educational programmes—either alone or as a core compo­
nent of multidisciplinary care management programmes—promote 
patients’ awareness of their condition and the rationale for lifestyle inter­
ventions. However, awareness of CVD risk factors through education 
alone might be insufficient for adoption of healthy behaviour.439
Therefore, self-care programmes are needed to enable patients to have 
a major role in coping with their condition and accepting their prescribed 
treatment.440,441 Elements in patient education include (modifiable) risk 
factors in relation to individual cardiovascular risk, since risk perception 
is an integral part of many major health behaviour theories, ultimately 
leading to modification of human habits.441,442
Information on benefits of risk-factor control on recurrence risk, dis­
ease progression, complications, and overall survival should be dis­
cussed. The format, time horizon, and outcome used for risk 
estimation influence patient perceptions and should be considered 
when designing risk communication tools.443–445
Lifelong education for patient-centred information and problem- 
based learning is superior to home-sent information in improving risk- 
factor control in the long term.438,444 Refer to Section 6.2.1 for further 
guidance on patient education.
4.1.2. Key lifestyle interventions for risk-factor 
control
Reducing CVD risk at the individual level begins with effective informa­
tion on risk and anticipated risk reduction by treatment. Risk algorithms 
are available for use in clinical practice by means of interactive tools on­
line. The use of the Smart risk score (U-prevent.com) is suggested by 
the European Association of Preventive Cardiology for risk estimation 
in patients with previous CVD.446 Ideally, patients are made aware of 
their individual risks and the potential benefit of prevention treatments 
and then actively engaged in managing their disease. Treatment goals 
are communicated using a patient-centred approach (Table 7).
Table 7 Practical advice on lifestyle counselling and 
interventions
Topic
Recommendation and treatment goals in 
patients with established CCS
Lifestyle counselling
Immunization
• Vaccination against influenza, pneumococcal 
disease and other widespread infections, e.g. 
COVID-19
Sleep quality
• Treat sleep-related breathing disorders
Sexual activity
• Males and females: low risk for stable patients 
who are not symptomatic at low-to-moderate 
activity levels
• Males: PDE-5 inhibitors are generally safe, not 
to be taken in combination with nitrate 
medications because of risk of severe 
hypotension
Psychosocial aspects
• Avoid psychosocial stress
• Treat depression and anxiety by psychological 
or pharmacological interventions
Environment/pollution
• Avoid passive smoking
• Reduce environmental noise
• Avoid exposure to air pollution
Lifestyle interventions for risk-factor control
Smoking and 
substance abuse
• Use pharmacological and behavioural 
strategies to assist in smoking cessation
• Avoid e-cigarettes
• Abstain from substance abuse
Obesity and being 
overweight
• Obtain and maintain a healthy weight (BMI 
18.5–25 kg/m2)
• Reduce weight through recommended energy 
intake and increased physical activity and 
through pharmacological/surgical 
interventions in selected patients
Hyperlipidaemia
• Ultimate LDL-C goal of <1.4 mmol/L (55 mg/ 
dL) and a ≥50% reduction in LDL-C vs. 
baseline is recommended
Diabetes
• HbA1c < 7.0% (53 mmol/mol)
Arterial hypertension
• SBP 120–129 mmHg, provided the 
antihypertensive treatment is well tolerated
Diet and alcohol 
consumption
• Limit alcohol consumption to <100 g/week
• Diet high in vegetables, fruit, and wholegrains 
(Mediterranean diet)
• Limit saturated fat to <10% of total calorie 
intake
Physical activity and 
exercise
• 30–60 min moderate activity, >5 days/week
• Reduce sedentary time and engage in at least 
light activity throughout the day
© ESC 2024
BMI, body mass index; CCS, chronic coronary syndrome; COVID-19, coronavirus disease 
2019; HbA1c, glycated haemoglobin; LDL-C, low-density lipoprotein cholesterol; PDE-5, 
phosphodiesterase-5; SBP, systolic blood pressure.
ESC Guidelines                                                                                                                                                                                          3455


<!-- PAGE 42 -->

### Page 42

4.1.2.1. Smoking and substance abuse
Smoking cessation in CCS patients improves prognosis, with a reported 
36% risk reduction of premature death in those who quit compared 
with those who continue to smoke.447 Measures to promote smoking ces­
sation include brief advice, counselling and behavioural interventions, and 
pharmacological therapy.448,449 Patients should also avoid passive smoking.
Drug support to assist in smoking cessation should be considered in 
all smokers who are ready to undertake this action. Nicotine- 
replacement therapy, bupropion, or varenicline are effective,450,451
and are not linked to an increase in MACE.452
The use of electronic cigarettes (e-cigarettes), as an alternative to con­
ventional cigarettes, should be discouraged because they are not harm- 
free.453 Newer devices deliver higher nicotine contents, and e-cigarettes 
emit other constituents, such as carbonyls, and fine and ultrafine particu­
lates.454 Evidence from several studies indicates that acute inhalation of 
e-cigarettes leads to negative changes in vascular endothelial func­
tion.453,454 E-cigarettes should only be considered to aid tobacco cessa­
tion alongside a formal tobacco cessation programme.453,455,456
Various substances, including cocaine, opioids, and marihuana can 
have adverse effects on the cardiovascular system and have a potential 
for drug–drug interactions with cardiovascular medication.457–459
Single-question screening for unhealthy drug use has been validated 
in primary care and can identify individuals requiring counselling on ad­
verse cardiovascular effects.460
4.1.2.2. Weight management
In a population-based study, lifetime risk of incident CVD, and cardiovas­
cular morbidity and mortality, were higher in those who were overweight 
or obese compared with those with a normal BMI (18.5–24.9 kg/m2).461
Compared with normal BMI, among middle-aged men and women, 
competing hazard ratios (HR) for incident CVD were 1.21 [95% 
confidence interval (CI), 1.14–1.28] and 1.32 (95% CI, 1.24–1.40), respect­
ively, for overweight (BMI of 25.0–29.9 kg/m2), 1.67 (95% CI, 1.55–1.79) 
and 1.85 (95% CI, 1.72–1.99) for obesity (BMI of 30.0–39.9 kg/m2), 
and 3.14 (95% CI, 2.48–3.97) and 2.53 (95% CI, 2.20–2.91) for mor­
bid obesity (BMI of ≥40.0 kg/m2). Obesity was associated with a 
shorter overall lifespan, and being overweight was associated with 
developing CVD at an earlier age.461 In subjects with CAD, intention­
al weight loss is associated with a significantly lower risk of adverse 
clinical outcomes,462 and has beneficial effects on risk-factor control 
and QoL.463 Healthy diets with energy intake limited to the amount 
needed to obtain and maintain a healthy weight (BMI of 18.5–25 kg/m2), 
and combined with increasing physical activity, are recommended for 
weight management.16 If weight targets are not reached, pharmaco­
logical treatment with glucagon-like peptide-1 (GLP-1) receptor ago­
nists may be considered for further weight reduction (Section 4.3.4). 
In patients without diabetes, the STEP8 trial showed a significant reduc­
tion in weight after 68 weeks with either semaglutide (mean weight 
change of −15.8%; 95% CI, −17.6% to −13.9%) or liraglutide (mean 
weight change of −6.4%; 95% CI, −8.2% to −4.6%) compared with pla­
cebo (−1.9%; 95% CI, −4.0% to 0.2%).464 The double-blind, placebo- 
controlled Semaglutide Effects on Cardiovascular Outcomes in 
People with Overweight or Obesity (SELECT) trial showed a significant 
reduction in the incidence of cardiovascular death, MI, or stroke (HR 
0.80; 95% CI, 0.72–0.90) in patients with pre-existing CVD who 
were overweight or obese, but without diabetes, treated with weekly 
subcutaneous semaglutide.465
The SURMOUNT-1 (Efficacy and Safety of Tirzepatide Once Weekly 
in Participants Without Type 2 Diabetes Who Have Obesity or Are 
Overweight With Weight- Related Comorbidities: A Randomized, 
Double-Blind, Placebo-Controlled Trial) trial showed a dose-dependent 
weight-loss benefit (mean weight change of up to −20.9%; 95% CI, 
−21.8% to −19.9%) with tirzepatide, a combined glucose-dependent in­
sulinotropic polypeptide (GIP) and GLP-1 receptor agonist, compared 
with placebo in obese adults without diabetes over 72 weeks,466 a dose 
effect that was confirmed in the SURMOUNT-2 trial.467 Bariatric surgery 
in severe obesity appears to be a safe and effective intervention for further 
weight loss in CCS patients.468
Cardiac rehabilitation programmes should include weight-loss inter­
ventions to reach a healthy weight as a specific component. The incre­
mental value of telehealth interventions and pharmacological 
interventions need full consideration in secondary prevention.469
4.1.2.3. Diet and alcohol
Dietary habits influence cardiovascular risk, mainly through risk factors 
such as lipids, BP, body weight, and DM. It is recommended to adopt a 
Mediterranean or similar diet to lower the risk of CVD, as described in 
the 2021 ESC Guidelines on cardiovascular disease prevention in clinical 
practice.16 If alcohol is consumed, it should be limited to <100 g/week 
or 15 g/day, since alcohol intake of >100 g/week is associated with higher 
all-cause and other CVD mortality in large individual-data meta-analyses.470
A recent genetic analysis showed that the causal association between 
light-to-moderate levels of alcohol intake and lower cardiovascular risk is 
possibly mediated by confounding lifestyle factors, therefore questioning 
the previously observed cardioprotective role of light alcohol use.471
4.1.2.4. Mental health
Psychosocial stress, depression, and anxiety are associated with worse 
cardiovascular outcomes, and make it difficult for patients to make posi­
tive changes to their lifestyles or adhere to a therapeutic regimen. 
Therefore, assessment for psychosocial risk factors is recommended 
in secondary prevention.16 Clinical trials have shown that psychological 
(e.g. counselling and/or cognitive behavioural therapy) and pharmaco­
logical interventions have a beneficial effect on depression, anxiety, 
and stress, with some evidence of a reduction in cardiac mortality 
and events compared with placebo (see Section 6.1.2).472
4.1.2.5. Physical activity and sedentary behaviour
Physical activity reduces the risk of many adverse health outcomes and risk 
factors in all ages and both sexes. There is an inverse relationship between 
moderate-to-vigorous physical activity and all-cause mortality, cardiovascu­
lar mortality, and atherosclerotic cardiovascular disease (ASCVD).473 The 
reduction in risk continues across the full range of physical activity volumes, 
and the slope of risk decline is steepest for the least active individuals.474
Adults are recommended to perform at least 150–300 min per week of 
moderate-intensity physical activity, or 75–150 min of vigorous-intensity 
physical activity, or an equivalent combination of both, spread throughout 
the week.473 Additional benefits are gained with even more physical activ­
ity.475 Practising physical activity should still be encouraged in individuals un­
able to meet the minimum. In sedentary individuals, a gradual increase in 
activity level is recommended.476 Physical activity can be incorporated flex­
ibly, either daily or limited to specific days. Activity patterns limited to 1–2 
sessions per week but meeting recommended levels of physical activity 
have been shown to reduce all-cause mortality (HR 0.66; 95% CI, 0.62– 
0.72), CVD mortality (HR 0.60; 95% CI, 0.52–0.69), and cancer mortality 
(HR 0.83; 95% CI, 0.73–0.94) when compared with inactive partici­
pants.477 Physical activity accumulated in bouts of even <10 min is asso­
ciated with favourable outcomes, including mortality.478
High levels of time spent sedentary is associated with an increased 
risk for several major chronic diseases and mortality.479 For physically


<!-- PAGE 43 -->

### Page 43

inactive adults, light-intensity physical activity, even as little as 15 min a 
day, is likely to produce benefits.479
4.1.3. Exercise therapy
Exercise training, either alone or in the context of multidisciplinary, 
exercise-based cardiac rehabilitation, leads to reduction in hospitaliza­
tions, adverse cardiovascular events, mortality rates, and improved 
CVD risk profile in patients with ASCVD.480–483 Therefore, exercise 
is a therapy that should be offered to every CCS patient in the setting 
of secondary disease prevention.16
Exercise training should be individually prescribed according to the 
FITT (frequency, intensity, time, type) model for aerobic and resistance 
training.484
For aerobic training (walking, jogging, cycling, swimming, etc.), an ex­
ercise frequency of at least 3 days/week, preferably 6–7 days/week, at 
moderate or moderate-to-high intensity is recommended. Relative in­
tensity is determined based on an individual’s maximum (peak) effort, 
e.g. percentage of cardiorespiratory fitness (%VO2 max), percentage 
of maximum (peak) heart rate (%HRmax) or ventilatory thresholds 
(VT1 and VT2).485 To date, there is insufficient evidence to promote 
high-intensity interval training over moderate-intensity continuous 
training; nevertheless, optimizing total energy expenditure (either by 
increasing intensity or total exercise volume) is related to greater 
favourable changes in cardiovascular risk and physical fitness.486
Moderate-intensity continuous training is the most feasible and cost- 
effective aerobic training modality for patients with CCS. 
High-intensity interval training can be prescribed in selected patients 
for specific targets of intervention (e.g. to increase VO2 peak).485
Resistance exercise in addition to aerobic training is associated with 
lower risks of total cardiovascular events and all-cause mortality.16 The 
suggested prescription is one to three sets of 8–12 repetitions, at the 
intensity of 6%–80% of the individual’s one-repetition maximum, at a 
frequency of at least 2 days per week, using a variety of 8–10 different 
exercises involving each major muscle group.16,484
Exercise is contraindicated in patients with refractory/unstable angina 
and other high-risk cardiovascular conditions (e.g. high-grade arrhyth­
mias, decompensated HF, severe aortic dilatation, active thrombo- 
embolic disease). In non-cardiac unstable conditions (e.g. active infection, 
uncontrolled diabetes, end-stage cancer, chronic obstructive pulmonary 
disease exacerbation), exercise is contraindicated. Maintenance of the 
prescribed exercise regimen is crucial. According to a meta-regression 
analysis, no single exercise component predicts mortality outcomes, 
whereas the largest reductions in total and cardiovascular mortality 
were seen in post-cardiac rehabilitation patients with the highest adher­
ence rate.487 In addition, continuation of the exercise therapy (Phase III 
cardiac rehabilitation) is recommended as it will result in increased/main­
tained functional capacity, QoL, and physical activity levels.488
Sharing decision-making and offering a personalized prescription, 
based on the patient’s preferences (self-selected training) and abilities 
(age, concomitant diseases, leisure and working habits, logistical re­
straints), is recommended to increase long-term adherence.489 In add­
ition, smartphone applications490 and wearable activity trackers491 may 
assist in long-term adherence to physical activity goals and exercise 
therapy (see Section 6.2.1.3).492
Home-based cardiac rehabilitation with or without telemonitoring 
may increase participation and be as effective as centre-based cardiac 
rehabilitation.493 Telehealth interventions are more effective than no 
intervention and may also complement conventional cardiac rehabilita­
tion.494,495 Also, mobile device-based healthcare (mHealth) delivery 
through smartphones may be as effective as traditional centre-based 
cardiac 
rehabilitation, 
showing 
significant 
improvements 
in 
health-related QoL.496
Small, single-centre studies on exercise training in patients with 
INOCA show that it is feasible and improves cardiorespiratory function 
and QoL.497 Larger trials are needed to determine the optimal rehabili­
tation protocols and define its long-term benefits.
4.2. Antianginal/anti-ischaemic medication
4.2.1. General strategy
In patients with CCS, antianginal medical therapy aims to control symp­
toms while ensuring acceptable tolerability and patient adherence. 
Several factors should be considered for the selection of antianginal 
medical therapy. First, there is no robust evidence from direct compar­
isons that some antianginal drugs are more effective than others for im­
proving symptoms.504,505 There have been no large randomized trials 
comparing head-to-head the historically first approved antianginal 
medications [i.e. beta-blockers or calcium channel blockers (CCBs)] 
vs. newer anti-ischaemic drugs (ivabradine, nicorandil, ranolazine, 
trimetazidine);504,506 the latter have been tested in smaller trials assessing 
non-inferiority compared with beta-blockers507 or CCBs,508 or in a lar­
ger trial as add-on therapy with a background of beta-blockers and/or 
CCBs.508,509 Moreover, there is no evidence that any antianginal medi­
cation may improve long-term cardiovascular outcomes, except beta- 
blockers if administered within 1 year after an acute MI.510 Second, 
many patients require a combination of anti-ischaemic drugs to ad­
equately control symptoms.511 It remains unclear whether upfront 
combination therapy with two antianginal drugs is preferable to mono­
therapy, or which combinations of antianginal classes may be better 
Recommendation Table 15 — Recommendations for 
cardiovascular risk reduction, lifestyle changes, and ex­
ercise interventions in patients with established chronic 
coronary syndrome (see also Evidence Table 15)
Recommendations
Classa
Levelb
An informed discussion on CVD risk and treatment 
benefits tailored to individual patient needs is 
recommended.16
I
C
Multidisciplinary behavioural approaches to help 
patients achieve healthy lifestyles, in addition to 
appropriate pharmacological management, are 
recommended.484,498–503
I
A
A multidisciplinary exercise-based programme to 
improve cardiovascular risk profile and reduce 
cardiovascular mortality is recommended.480–482
I
A
Aerobic physical activity of at least 150–300 min per 
week of moderate intensity or 75–150 min per week 
of vigorous intensity and reduction in sedentary time 
are recommended.16,473,478,479
I
B
Home-based cardiac rehabilitation and mobile health 
interventions should be considered to increase 
patients’ long-term adherence to healthy behaviours, 
and to reduce hospitalizations or cardiac 
events.480,493,494
IIa
B
© ESC 2024
CVD, cardiovascular disease. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3457


<!-- PAGE 44 -->

### Page 44

than others for improving angina symptoms. Third, in any given patient, 
myocardial ischaemia and angina symptoms may be caused by various 
underlying pathophysiological mechanisms, alone or in combin­
ation;6,512 these may include obstruction of epicardial coronary arter­
ies, vasospasm, and endothelial/microvascular dysfunction. Based on 
their mechanisms of action, different classes of antianginal drugs may 
be preferable (as initial therapy or as part of combination therapy) 
for patients with myocardial ischaemia of predominantly obstructive, 
vasospastic, or microvascular origin.513
The current empirical paradigm for the selection of antianginal med­
ical therapy has consisted of a hierarchical, stepwise approach including 
first-line (beta-blockers, CCBs) and second-line drugs (long-acting ni­
trates, nicorandil, ranolazine, ivabradine, trimetazidine).1,514 This task 
force reinforces the concept that medical therapy for symptom control 
in CCS should be tailored to each patient’s haemodynamic profile (BP, 
heart rate), comorbidities (particularly presence of HF), concomitant 
medications with potential drug interactions, and preferences, also tak­
ing into account the pathophysiological basis of myocardial ischaemia in 
each patient, as well as local availability of different drugs.515,516 For 
many patients with CCS, initial drug therapy should include a beta- 
blocker and/or a CCB. Other antianginal drugs (long-acting nitrates, 
ivabradine, nicorandil, ranolazine, trimetazidine) can be added on top 
of a beta-blocker and/or a CCB, or as a part of initial combination ther­
apy in appropriately selected patients (Figure 9).
Regardless of the initial strategy, response to initial antianginal therapy 
should be reassessed, and treatment should be adapted if adequate an­
gina control is not achieved or if the initial treatment is poorly tolerated.
A review of the antianginal agents that can be used in the medical 
treatment of CCS can be found in the Supplementary data.
4.2.2. Beta blockers
Beta-blockers can be used for symptomatic relief of angina, or to im­
prove prognosis in some patients with CCS. If used for antianginal pur­
poses, the aim should be to lower resting heart rate to 55–60 beats per 
minute (b.p.m.).517,518
Beyond improving symptoms, the clinical benefit of beta-blockers in 
patients with CAD without prior MI and with normal LVEF is largely un­
known in the absence of evidence from RCTs. The main findings of 
some observational studies addressing this issue are summarized in 
the Supplementary data.
The clinical benefit of beta-blockers in post-ACS patients with reduced 
LVEF is supported by solid evidence.519–521 However, there are no large 
RCTs supporting the prescription of beta-blockers after uncomplicated 
ACS in patients with LVEF >40%.522 The evidence provided by 
Useful combinations 
Possible combinations 
Drugs with similar effects 
Not recommended 
Beta-blockers
DihydropyridineCCB
Diltiazem
Verapamil
Trimetazidine
Ranolazine
Ivabradine
Nitrates
Nicorandil
Obstructive CAD
Microvascular dysfunction
Arterial hypertension
Atrial fibrillation
HFrEF
Obstructive CAD
Vasospastic angina
Arterial hypertension
COPD
Peripheral arterial disease
Type I diabetes mellitus
Obstructive CAD
Vasospastic angina
Atrial fibrillation
Obstructive CAD
Microvascular dysfunction
Obstructive CAD
Microvascular dysfunction
Obstructive CAD
Vasospastic angina
May be indicated in 
specific situations
HCM
Sick sinus syndrome
Sick sinus syndrome
HFrEF
Sick sinus syndrome
HFrEF
HFrEF
HFrEF
Contraindicated
Indicated unless there are specific contraindications
Figure 9 Possible combinations of antianginal drugs. CAD, coronary artery disease; CCB, calcium channel blocker; COPD, chronic obstructive pul­
monary disease; HCM, hypertrophic cardiomyopathy; HFrEF, heart failure with reduced ejection fraction. The schematic shows useful combinations 
(green lines), combinations that are not recommended (red lines), possible combinations (solid blue lines), and drugs with similar effects (blue dashed 
lines), which can be combined in selected indications: HFrEF (ivabradine and beta-blocker), atrial fibrillation (diltiazem/verapamil and beta-blocker), 
vasospastic angina (dihydropyridine CCB and nitrates). Modified from Davies et al.555.


<!-- PAGE 45 -->

### Page 45

observational studies and meta-analyses is conflicting (some suggest an as­
sociation between beta-blockers and better clinical outcomes, whereas 
others show a lack of association).521,523–526 There have been only two 
open-label trials testing the efficacy of beta blockers in post-MI patients 
(NCT03278509 and NCT01155635), though both trials were under­
powered to yield solid conclusions.527 To further elucidate the benefit 
of beta-blockers in this clinical scenario, three European pragmatic, pro­
spective, large-scale RCTs recruiting post-ACS patients with preserved 
LVEF to receive beta-blockers or control treatment are currently under­
way.522,528–530
The duration of beta-blocker therapy, in the long run, is a matter of 
debate, particularly in patients with prior MI and preserved LVEF.531
Evidence from RCTs assessing beta-blockers rarely goes beyond a 
few years of follow-up, but patients are often given continuous treat­
ment up to old age.531 Observational data are also conflicting in this re­
gard. One study has suggested that the clinical benefit of beta-blockers 
might be restricted to the first year after the index event, showing that 
their discontinuation at 1 year was not associated with higher 5-year 
mortality.532 In contrast, a Swedish study starting the follow-up 1 
year after the ACS episode has shown a lack of association between 
the use of beta-blockers and a composite of all-cause mortality, MI, un­
scheduled revascularization, or hospitalization for HF.533 Another study 
has shown that the discontinuation of beta-blockers beyond 1 year 
after acute MI was associated with an increased risk of a composite 
of death or readmission for ACS, but not of all-cause mortality.534
The impact of beta-blocker withdrawal 6–12 months after uncompli­
cated ACS in patients with LVEF ≥40% is being tested in two large-scale 
RCTs (NCT03498066, NCT04769362.535
4.2.3. Combination therapy
The aim of antianginal medications is to ensure adequate relief of angina 
symptoms in patients with CCS, in part independently of their effect or 
lack of effect on MACE. Initiation of monotherapy, with subsequent es­
calation to a combination of antianginal drugs in the case of inadequate 
relief of symptoms, is a reasonable approach. In this context, the empir­
ical approach of starting with a beta-blocker can be recommended in 
many patients with CCS, unless there are contraindications or other 
drugs are more suitable instead of beta-blockers (e.g. patients with 
low heart rate and/or BP). If a combination of antianginal drugs is re­
quired, the selection of the most appropriate drugs should be individua­
lized and determined by the haemodynamic profile, comorbidities, and 
tolerability. The combination of a beta-blocker with a dihydropyridine 
CCB is appropriate for most patients, whereas the addition of other 
antianginal drugs (long-acting nitrates, ranolazine, nicorandil, trimetazi­
dine, or ivabradine in patients with LV systolic dysfunction) can be con­
sidered when treatment with a beta-blocker and/or CCB is 
contraindicated or poorly tolerated, or when angina symptoms are in­
adequately controlled.
The following points should additionally be kept in mind: (i) beta- 
blockers are not indicated in the presence of sick sinus syndrome or 
Recommendation Table 16 — Recommendations for 
antianginal drugs in patients with chronic coronary syn­
drome (see also Evidence Table 16)
Recommendations
Classa
Levelb
General strategy
It is recommended to tailor the selection of 
antianginal drugs to the patient’s characteristics, 
comorbidities, concomitant medications, treatment 
tolerability, and underlying pathophysiology of angina, 
also considering local drug availability and cost.
I
C
Selection of antianginal medication
Short-acting nitrates are recommended for 
immediate relief of angina.536,537
I
B
Initial treatment with beta-blockers and/or CCBs to 
control heart rate and symptoms is recommended 
for most patients with CCS.c 518,538
I
B
If anginal symptoms are not successfully controlled 
by initial treatment with a beta-blocker or a CCB 
alone, the combination of a beta-blocker and a 
DHP-CCB should be considered, unless 
contraindicated.505,538,539
IIa
B
Long-acting nitrates or ranolazine should be 
considered as add-on therapy in patients with 
inadequate control of symptoms while on treatment 
with beta-blockers and/or CCBs, or as part of initial 
treatment in properly selected patients.d 513,540
IIa
B
Continued 
When long-acting nitrates are prescribed, a 
nitrate-free or low-nitrate interval should be 
considered to reduce tolerance.540
IIa
B
Ivabradine should be considered as add-on 
antianginal therapy in patients with left ventricular 
systolic dysfunction (LVEF <40%) and inadequate 
control of symptoms, or as part of initial treatment in 
properly selected patients.541,542
IIa
B
Nicorandil or trimetazidine may be considered as 
add-on therapy in patients with inadequate control 
of symptoms while on treatment with beta-blockers 
and/or CCBs, or as part of initial treatment in 
properly selected patients.543–550
IIb
B
Ivabradine is not recommended as add-on therapy in 
patients with CCS, LVEF >40%, and no clinical heart 
failure.509
III
B
Combination of ivabradine with non-DHP-CCB or 
other strong CYP3A4 inhibitors is not 
recommended.551
III
B
Nitrates are not recommended in patients with 
hypertrophic cardiomyopathy or in 
co-administration with phosphodiesterase 
inhibitors.552,553
III
B
© ESC 2024
CCB, calcium channel blocker; CCS, chronic coronary syndrome; CYP3A4, cytochrome 
P450 3A4; DHP, dihydropyridine; DM, diabetes mellitus; LVEF, left ventricular ejection 
fraction. 
aClass of recommendation. 
bLevel of evidence. 
cThese drugs may require caution or may be contraindicated in certain patients with low BP 
(beta-blockers and DHP-CCB), DM (beta-blockers), atrioventricular conduction disorders 
(beta-blockers 
and 
non-DHP-CCB), 
chronic 
obstructive 
pulmonary 
disease 
(non-cardioselective beta-blockers). 
dConsideration for initial therapy: ivabradine, nicorandil, long-acting nitrates, ranolazine, or 
trimetazidine for patients with intolerance or contraindications to beta-blockers and/or 
CCBs; ranolazine and trimetazidine for patients with microvascular angina; nicorandil or 
nitrates for patients with coronary artery spasm. The drugs are listed in alphabetical order.
ESC Guidelines                                                                                                                                                                                          3459


<!-- PAGE 46 -->

### Page 46

atrioventricular conduction disorders,554 and should be used with 
caution in patients with PAD and chronic obstructive pulmonary dis­
ease; (ii) CCBs require caution in patients with heart failure with re­
duced ejection fraction (HFrEF);526 (iii) ivabradine should not be 
combined with non-dihydropyridine CCBs (verapamil or diltiazem); 
and (iv) ranolazine and trimetazidine are reasonable options as part 
of antianginal combination therapy in patients with low heart rate 
and/or BP.
4.3. Medical therapy for event prevention
Prevention of coronary ischaemic events is based on lowering the risk 
of coronary artery occlusion and consequent ACS. Medical event- 
preventing 
therapies 
include 
antithrombotic, 
lipid-lowering, 
anti-RAAS (renin–angiotensin–aldosterone system), anti-inflammatory, 
and metabolic-acting agents.
4.3.1. Antithrombotic drugs
The standard antithrombotic treatment of patients with epicardial ath­
erosclerotic CAD is single antiplatelet therapy (SAPT), typically with as­
pirin. In patients with ACS or post-PCI, standard treatment is dual 
antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 inhibitor, 
for a duration of 12 months after ACS (with or without PCI)65 or 
6 months after CCS-PCI.1,556 Thus, in ACS or CCS-PCI patients, 
DAPT is usually replaced by SAPT at some point. Several recent trials 
have investigated shortened DAPT durations and P2Y12 inhibitor 
monotherapy post-PCI to reduce the risk of bleeding. On the other 
hand, in CCS patients with persistently high ischaemic risk and low 
bleeding risk, extended intensified antithrombotic therapy should be 
considered. Ultimately, the choice and duration of antithrombotic regi­
mens largely depend on the delicate balance between each individual’s 
ischaemic and bleeding risks.
The mechanisms of action of the most commonly used antithrombo­
tic drugs in CCS patients are depicted in Figure 10.
4.3.1.1. Antiplatelet drugs
For details on antiplatelet drugs, please see Supplementary data, 
Table S1.
4.3.1.1.1. Aspirin monotherapy. Low-dose aspirin (75–100 mg once 
daily) is the traditional drug of choice in patients with CCS, with or 
without prior MI.557,558 In an individual-patient data meta-analysis of 
secondary prevention trials (43 000 patient-years), aspirin vs. no aspirin 
significantly reduced the combined risk of non-fatal MI, non-fatal ischae­
mic stroke, or death from vascular causes [from 8.2% to 6.7% per year 
(P < .0001), with relative risk (RR) reductions of 31%, 22%, and 9%, re­
spectively], translating into 15 fewer fatal and non-fatal serious vascular 
events for every 1000 patients treated for 1 year.558 Aspirin allocation 
increased major gastrointestinal (GI) and extracranial bleeds, from 
0.07% to 0.10% per year (P < .0001), with a non-significant increase 
in haemorrhagic stroke but reductions of about a fifth in total stroke 
(from 2.54% to 2.08% per year, P = .002) and in coronary events 
(from 5.3% to 4.3% per year, P < .0001).
Thus, for secondary prevention, the reduction of ischaemic events 
with aspirin outweighs serious bleeding events.557,558 There is no evi­
dence of different aspirin effects in women and men.558,559 Daily aspirin 
doses of 75–100 mg seem to be as effective as higher doses for long- 
term treatments.558–561
4.3.1.1.2. Oral P2Y12 inhibitor monotherapy.
4.3.1.1.2.1. 
Clopidogrel 
monotherapy. In 
addition 
to 
the 
cyclooxygenase-I pathway inhibited by aspirin, the platelet P2Y12 recep­
tor also plays a pivotal role in arterial thrombus formation and is the 
target for three oral platelet inhibitors: clopidogrel, prasugrel, and 
ticagrelor. The relative efficacy and safety of clopidogrel compared 
with aspirin for secondary prevention in CCS patients has been tested 
in multiple randomized trials that, taken together, have involved over 
29 000 patient-years.562,563
In an overall population of 19 185 patients with either previous MI 
(within 35 days), stroke (within 6 months), or PAD, followed for a 
mean of 1.9 years, the CAPRIE trial (Clopidogrel versus Aspirin in 
Patients at Risk of Ischaemic Events) demonstrated a small benefit in is­
chaemic events (RR reduction of 8.7%) with clopidogrel 75 mg/day vs. 
aspirin 325 mg/day.564
In the recent, open-label, South Korean, non-inferiority HOST-EXAM 
(Harmonizing Optimal Strategy for Treatment of Coronary Artery 
Stenosis-EXtended Antiplatelet Monotherapy) trial, clopidogrel was 
compared with low-dose aspirin in 5530 patients after 6–18 months of 
uneventful DAPT post-PCI (72% initial ACS, 28% initial CCS).565
Relative to aspirin, clopidogrel reduced the composite of all-cause death, 
non-fatal MI, readmission attributable to ACS, stroke, and BARC 
(Bleeding Academic Research Consortium) ≥3 bleeding from 7.7% to 
5.7% at the end of the 2-year follow-up; the results were maintained 
at 5.8 years, in a post hoc, per-protocol, post-trial analysis.566
A very recent individual patient-level meta-analysis examined seven 
trials involving 24 325 patients (including recent ACS, post-CABG, or 
initial CCS patients) randomized to either aspirin monotherapy 
(12 147 patients) or P2Y12 inhibitor monotherapy [clopidogrel in 7545 
(62.0%), ticagrelor in 4633 (38.0%)] and followed for 6–36 months.562
P2Y12 inhibitors reduced the combined ischaemic outcome of cardio­
vascular death, MI, and stroke compared with aspirin (in doses of 100 
or 325 mg daily), mainly through reduction of infarction. The risk of ma­
jor bleeding was similar, whereas GI bleeding and haemorrhagic stroke 
occurred less frequently with a P2Y12 inhibitor. The treatment effect 
was consistent across pre-specified subgroups (ACS or CCS) and 
type of P2Y12 inhibitor.562
The above overall evidence supports clopidogrel monotherapy as an 
effective and safe alternative to aspirin monotherapy for long-term sec­
ondary prevention in patients with CCS.
4.3.1.1.2.2. Ticagrelor monotherapy. Since ticagrelor compared with 
clopidogrel is more effective and displays less variable platelet inhib­
ition,567,568 although with greater bleeding potential,569 ticagrelor 
monotherapy has been compared with aspirin monotherapy for sec­
ondary prevention in CCS patients treated with PCI.
The RCT GLOBAL LEADERS trial [Ticagrelor plus aspirin for 
1 month, followed by ticagrelor monotherapy for 23 months vs. as­
pirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin 
monotherapy for 12 months after implantation of a drug-eluting stent 
(DES): a multicentre, open-label, randomized superiority trial]570 of 
15 968 patients (53% with initial CCS) did not show superiority of 
ticagrelor monotherapy vs. standard of care in terms of survival or 
new Q-wave MI.570 A pre-specified GLOBAL LEADERS ancillary ana­
lysis of independently adjudicated outcomes in 7585 patients reported 
non-inferiority for ischaemic events and no difference in BARC major 
bleeding between the two strategies.571 A post hoc landmark analysis 
of the GLOBAL LEADERS trial, conducted in 11 121 uneventful patients 
at 1 year (53% CCS from trial onset, 47% transitioning to CCS from


<!-- PAGE 47 -->

### Page 47

ACS), showed reduced ischaemic events, but increased BARC 3 and 5 
major bleeding, during ticagrelor monotherapy compared with aspirin 
monotherapy from 1 to 2 years after PCI.572
The double-blind, non-inferiority TWILIGHT trial, conducted in 7119 
patients [35% CCS, 65% NSTE (non-ST-segment elevation)-ACS] 
undergoing high-risk PCI (defined as multivessel, stenting of >30 mm, 
thrombotic, two-stent bifurcation, left main, proximal LAD, or 
atherectomy-treated calcified lesions) and uneventfully receiving 
3 months of ticagrelor-based DAPT after PCI, showed that ticagrelor 
monotherapy 90 mg b.i.d. (twice daily) compared with ticagrelor- 
based DAPT for an additional 12 months significantly reduced the 
primary endpoint of clinically relevant bleeds (BARC 2, 3, and 5, or 
BARC 3 and 5), with no significant increase in the composite of any 
death, MI, or stroke (3.9% in both groups).573
P
P
Clopidogrel
Aspirin
Vorapaxar
Ticagrelor
Prasugrel
Cangrelor
Rivaroxaban
Apixaban
Edoxaban
UFH
Enoxaparin
Eptifibatide
Tirofiban
Dabigatran
VKA
Bivalirudin
Argatroban
Fondaparinux
GP IIb/IIIa
GP IIb/IIIa
PAR I
PAR 4
TxA2
P2Y12 receptor
Thromboxane receptor
ADP
Plaque rupture or plaque erosion
TF:FVIIa coagulation
Platelet rolling and adhesion
Platelet activation
Platelet aggregation
Fibrinogen
Fibrinogen
Fibrin
FXa
Thrombin
Thrombin
Fibrin network
Platelet fibrin thrombus
Figure 10 Antithrombotic drugs for chronic coronary syndromes: pharmacological targets. ADP, adenosine diphosphate; FVIIa, activated factor VII; 
FXa, activated factor X; GP, glycoprotein; PAR, protease-activated receptor; TF, tissue factor; TxA2, thromboxane A2; UFH, unfractionated heparin; 
VKA, vitamin K antagonist. Orally administered drugs are shown on a blue background, parenterally administered ones on red. Aspirin prevents TxA2 
formation by acetylating platelet cyclooxygenase-1.
ESC Guidelines                                                                                                                                                                                          3461


<!-- PAGE 48 -->

### Page 48

The above trial data570–573 and meta-analytical data562,563,574 suggest 
that ticagrelor monotherapy may be an option for selected CCS or sta­
bilized post-ACS patients treated with PCI. However, the overall evi­
dence is weaker than for other recommended antithrombotic 
strategies. Moreover, the optimal timing and duration (longest tested 
duration 23 months) are unclear. Only the 90 mg b.i.d. regimen has 
been tested as monotherapy.573,575 Data on prasugrel monotherapy 
for CCS patients are limited to a single-armed, open-label study with 
3 months of follow-up.576
In summary, for long-term secondary prevention in CCS patients 
without an indication for oral anticoagulant (OAC), aspirin or, as an al­
ternative, clopidogrel monotherapy are generally recommended. In se­
lected patients at high ischaemic risk without high bleeding risk (HBR), 
ticagrelor monotherapy may be considered [at the time of writing 
not contemplated by the European Medicines Agency (EMA) (https:// 
www.ema.europa.eu/en/medicines/human/EPAR/brilique)] with a low­
er level of evidence than for aspirin or clopidogrel (Figure 11). Details 
on the pharmacology of antiplatelet drugs567,577–582 and on the rando­
mized evidence (including trial limitations) can be found in the 
Supplementary data, Table S1 and in the evidence tables.
4.3.1.1.3. Dual antiplatelet therapy post-percutaneous coronary 
intervention. After PCI for CCS, DAPT consisting of aspirin and clopido­
grel is recommended to reduce the risk of stent thrombosis and MI com­
pared with aspirin alone.556 With few exceptions, there is no reason to 
replace clopidogrel with ticagrelor, based on the ALPHEUS 
(Assessment of Loading with the P2Y12 Inhibitor Ticagrelor or 
Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective 
Coronary Stenting) trial results demonstrating, in 1883 patients followed 
for 30 days, that ticagrelor did not significantly reduce PCI-related MI or 
major myocardial injury, while minor bleeding was significantly increased 
compared with clopidogrel.583
In the THEMIS trial (The Effect of Ticagrelor on Health Outcomes in 
diabEtes Mellitus patients Intervention Study) of 19 220 CCS patients aged 
≥50 years, with type 2 DM and no previous MI or stroke (58% with prior 
PCI), ticagrelor plus low-dose aspirin marginally reduced ischaemic events 
compared with placebo plus aspirin at a median follow-up of 40 months, 
but increased major bleeding, including intracranial haemorrhage.584
A default DAPT duration of 6 months is recommended for CCS pa­
tients undergoing PCI.556 However, multiple RCTs have investigated 
shorter DAPT durations (1 or 3 months) to decrease the risk of 
bleeding.570,573,585–588 The combined evidence indeed shows a decrease 
in—mostly minor—bleeding, without an increase in ischaemic events, in­
dicating that a shorter duration of DAPT of 1–3 months post-PCI may 
benefit CCS patients who are not at high ischaemic risk or who are at HBR.
This concept was tested in the MASTER-DAPT trial (Management of 
High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent 
Implantation with an Abbreviated versus Standard DAPT Regimen), 
randomizing 4579 PCI patients (∼50% CCS) with HBR, after 1-month 
uneventful DAPT, to immediate DAPT discontinuation or to DAPT 
continuation for at least 2 additional months.587 After 335 days, the trial 
demonstrated that discontinuation was non-inferior for ischaemic 
events compared with standard duration of DAPT, but major and clin­
ically relevant non-major bleeding was reduced.587
A meta-analysis, including 11 RCTs and 9006 patients (42% CCS) at 
HBR [defined by a PREdicting bleeding Complications In patients 
undergoing Stent implantation and subsEquent Dual AntiPlatelet 
Therapy (PRECISE-DAPT) score of >25 or by Academic Research 
Consortium for High Bleeding Risk (ARC-HBR) criteria, listed in 
Supplementary data, Table S2]589–591 showed at 12 months of follow-up 
that an abbreviated DAPT of 1–3 months reduced both major bleeding 
and ischaemic events, as well as cardiovascular mortality, compared with 
standard DAPT, irrespective of CCS or ACS presentation.591
The overall data indicate that, in CCS patients with HBR, DAPT dis­
continuation 1–3 months after PCI is recommended, while in patients 
without HBR, DAPT duration may be reduced only in the absence of 
high ischaemic risk (Figure 11). For patients at high ischaemic risk with­
out HBR, see below.
4.3.1.1.4. Extended intensified antithrombotic therapy. In patients at 
high ischaemic risk without HBR, there are three options for intensifying 
antithrombotic therapy to prevent ischaemic events, albeit at the cost of 
increased bleeding: (i) continue DAPT, consisting of aspirin and clopido­
grel or of aspirin and prasugrel after PCI, based on the results of the 
DAPT Study;592 (ii) add ticagrelor to aspirin in post-MI patients, based 
on the PEGASUS-TIMI (Prevention of Cardiovascular Events in 
Patients with Prior Heart Attack Using Ticagrelor Compared to 
Placebo on a Background of Aspirin - Thrombolysis In Myocardial 
Infarction) 54 trial;593 or (iii) add very low-dose rivaroxaban to aspirin 
in CCS patients, based on the COMPASS trial (Cardiovascular 
Outcomes for People Using Anticoagulant Strategies).594
The randomized DAPT Study demonstrated, in patients at 1-year 
post-PCI, that an additional 18 months of DAPT reduced ischaemic 
events compared with aspirin alone, but moderate and severe GUSTO 
(Global Utilization of Streptokinase and Tissue Plasminogen Activator 
for Occluded Arteries) or BARC bleeding rates were higher, and all- 
cause death tended to be increased.592 Of note, in the DAPT Study, first- 
generation DES were used with an increased risk of stent thrombosis.
The PEGASUS-TIMI 54 trial showed that in aspirin-treated patients 
with a history of MI 1–3 years previously and at least one high-risk char­
acteristic (i.e. aged >65 years, DM, second MI, multivessel CAD, or 
CKD), ticagrelor (90 or 60 mg b.i.d.) vs. placebo reduced ischaemic 
events at 3 years, while it increased TIMI (Thrombolysis In Myocardial 
Infarction) major, but not fatal, bleeding.593 The 60 mg dose was safer 
and better tolerated than the 90 mg dose584,593 and therefore approved. 
The subgroups of patients with (compared with those without) DM, 
multivessel CAD, and PAD benefited more from ticagrelor.595–597
The COMPASS trial demonstrated that the combination of aspirin 
plus rivaroxaban 2.5 mg b.i.d., but not rivaroxaban 5.0 mg b.i.d. mono­
therapy, reduced ischaemic events, but increased modified-ISTH 
(International Society on Thrombosis and Haemostasis) major bleeding, 
compared with aspirin alone in patients with stable atherosclerotic 
disease (mostly CAD, with additional risk conditions if younger than 
65 years).594 There was no significant difference in intracranial or fatal 
bleeding between the two treatment arms, and death rates were lower 
in the aspirin plus rivaroxaban 2.5 mg b.i.d. group. Subgroups of patients 
with (compared with those without) DM, PAD, mild CKD, and active 
smoking habit benefited more from aspirin plus rivaroxaban.594,598
Patient eligibility for extended intensified antithrombotic therapy 
must be defined taking into account individual patient characteristics 
(see Supplementary data, Table S2), as well as study inclusion and exclu­
sion criteria. The different options are described in Table 8.
In summary, in high ischaemic risk CCS patients without HBR, either 
aspirin plus ticagrelor 60 mg b.i.d. or aspirin plus rivaroxaban 2.5 mg 
b.i.d. should be considered, based on patient characteristics 
(Figure 11). DAPT prolongation with clopidogrel or prasugrel may 
also be an option, although the evidence for this choice suffers limita­
tions. In patients with extended intensified antithrombotic therapy, re- 
evaluation of bleeding and ischaemic risk at regular intervals is essential. 
Randomized evidence beyond study follow-up times is unavailable.


<!-- PAGE 49 -->

### Page 49

4.3.1.1.5. Genotype- and phenotype-guided dual antiplatelet 
therapy. There is high laboratory interindividual variability in patients 
treated with clopidogrel, with patients who carry a cytochrome 
P450 2C19 (CYP2C19) loss-of-function allele having less platelet 
inhibition and a higher risk of ischaemic events post-PCI compared 
with non-carriers.599,600 In ST-segment elevation myocardial infarction 
(STEMI) patients, early de-escalation from aspirin plus ticagrelor or as­
pirin plus prasugrel to aspirin plus clopidogrel based on genotyping or 
platelet function testing was non-inferior for net adverse clinical events 
(ischaemic endpoints and bleeding combined) compared with routine 
Patients with CCS without indication for OAC undergoing PCI
Assess bleeding risk
Non-high bleeding risk
High bleeding risk
Default
Non-high ischaemic risk
High ischaemic risk
Default
1 month
3 months
6 months
Long term
A
A
C
C
A
C
A
C
A
R
A
A
P
A
C
T
T
P
A
C
6 mo. DAPT
(Class I)
A
C
1–3 mo. DAPT
(Class I)
(Class I)
1–3 mo. DAPT
(Class IIb)
OR
A
C
(Class I)
OR
A
C
(Class I)
OR
OR
OR
OR
1–6 mo. DAPTa
(Class IIb)
(Class IIa)
R
(Class IIb)
Aspirin 100 mg o.d.
T
Clopidogrel 75 mg o.d.
Ticagrelor 90 mg b.i.d.
Prasugrel 10 mg o.d.b
Rivaroxaban 2.5 mg b.i.d.
T
Ticagrelor 60 mg b.i.d.
A
T
A
P
OR
6 mo. DAPT
(Class I)
Figure 11 Antithrombotic treatment in chronic coronary syndrome patients undergoing percutaneous coronary intervention. ARC-HBR, Academic 
Research Consortium for High Bleeding Risk; b.i.d., bis in die (twice daily); CCS, chronic coronary syndrome; CYP2C19, cytochrome P450 2C19; DAPT, dual 
antiplatelet therapy; mo., months; OAC, oral anticoagulant; o.d., once daily; PCI, percutaneous coronary intervention; PRECISE-DAPT, PREdicting bleeding 
Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy.  aIn CCS patients undergoing high-thrombotic risk stent­
ing (e.g. complex left main stem, 2-stent bifurcation, suboptimal stenting result, prior stent thrombosis, previously known CYP2C19*2/*3 polymorphisms), 
prasugrel or ticagrelor (in addition to aspirin) may be considered instead of clopidogrel for the first month, and up to 3-6 months. bPrasugrel 5 mg o.d. for 
patients aged ≥75 years or with a body weight <60 kg. Bleeding risk criteria according to PRECISE-DAPT or ARC-HBR.
ESC Guidelines                                                                                                                                                                                          3463


<!-- PAGE 50 -->

### Page 50

treatment with ticagrelor or prasugrel.601,602 In patients with CCS, 
current evidence does not support the routine use of genotype or plate­
let function testing.602–607 However, in patients undergoing high-risk PCI 
who are known carriers of a CYP2C19 loss-of-function allele, replacing 
aspirin plus clopidogrel with aspirin plus ticagrelor or prasugrel is a rea­
sonable option.600,607,608
4.3.1.2. Anticoagulant therapy
4.3.1.2.1. Monotherapy with oral anticoagulant. Historical rando­
mized data from patients with recent MI not undergoing PCI, followed 
for up to 4 years, showed that OAC monotherapy with a vitamin K 
antagonist (VKA) targeted to an international normalized ratio (INR) 
of about 3.0–4.0 was at least as effective as low-dose aspirin in prevent­
ing MACE, but with a significant increase in major bleeding.609,610
Moreover, given the obsoletely high INR target and the cumbersome 
management, VKA has not gained popularity for secondary prevention 
in patients with CCS. Successful introduction of the direct oral 
anticoagulants (DOACs) for stroke prevention in AF and for preven­
tion and treatment of venous thrombo-embolism (VTE) has renewed 
the interest in OAC for patients with CAD. The COMPASS trial in 
CCS and/or PAD patients at high ischaemic risk, however, reported 
no significant ischaemic benefit of rivaroxaban monotherapy 5 mg twice 
daily over aspirin alone, with a significantly higher incidence of 
modified-ISTH major bleeding, although not of fatal bleeding.594
Thus, in CCS patients without a concomitant long-term indication 
for OAC, OAC monotherapy with either VKA or rivaroxaban (the 
only DOAC currently tested in this context) is not recommended. 
OAC may be considered, however, when antiplatelet agents are not 
tolerated, if the risk of bleeding is not high,594,611 or in CCS patients 
with a concomitant long-term indication for OAC (see below).
4.3.1.2.2. Combination of anticoagulant and antiplatelet therapy 
after percutaneous coronary intervention in chronic coronary 
syndrome patients with AF or other indication for oral anticoagu­
lant. Approximately one in five patients with AF need to undergo 
PCI, with a theoretical indication for both OAC for stroke prevention 
(for which DOACs are preferred to VKA) and DAPT for stent throm­
bosis and MI prevention, leading to triple antithrombotic therapy.612,613
The combination of an OAC plus DAPT, however, leads to an in­
creased bleeding risk, and major bleeding is associated with earlier mor­
tality and should therefore be avoided when possible.614 In this setting, 
the results of five RCTs have shown that double compared with triple 
antithrombotic therapy reduced major or clinically relevant non-major 
bleeding, without a significant increase of ischaemic events, leading to 
the recommended use of double antithrombotic therapy (OAC plus 
P2Y12 receptor inhibitor, mostly clopidogrel) after a 1–4 week 
period of triple antithrombotic therapy in CCS patients with AF under­
going PCI.615–620
The AUGUSTUS trial (Open-Label, 2 × 2 Factorial, Randomized 
Controlled, Clinical Trial to Evaluate the Safety of Apixaban versus 
Vitamin K Antagonist and Aspirin versus Aspirin Placebo in Patients 
with AF and Acute Coronary Syndrome or Percutaneous Coronary 
Intervention) additionally demonstrated that the DOAC apixaban re­
duced major or clinically relevant non-major bleeding compared with 
VKA, independently of a double or triple antithrombotic regimen.619
The AUGUSTUS trial and several meta-analyses demonstrated that as­
pirin compared with placebo reduced stent thrombosis events, which 
occurred mainly during the first 30 days after PCI and not thereafter, 
while increasing bleeding risk.620–622
Thus, based on the combined evidence, double antithrombotic ther­
apy with a DOAC and clopidogrel for up to 12 months should be stand­
ard care for CCS patients with AF undergoing PCI, with additional 
aspirin only for a limited initial period (from during PCI up to a max­
imum of 30 days in patients at high ischaemic risk). In patients with 
the highest bleeding risk, clopidogrel discontinuation at 6 (or even 3) 
months post-PCI and continuation of OAC alone may be considered 
when ischaemic risk is not high [Class IIb/level of evidence (LOE) C]. 
Ticagrelor or prasugrel should generally not be used as part of triple an­
tithrombotic therapy, while ticagrelor, and possibly prasugrel (although 
specific data are not available), may be considered as part of double 
Table 8 Options for extended intensified antithrombotic therapy
Drug
Dose
Clinical setting
NNT (ischaemic 
outcomes)
NNH (bleeding outcomes)
Co-administered with aspirin 100 mg o.d.
Rivaroxaban (COMPASS 
trial; vs. placebo)
2.5 mg b.i.d.
Patients with CAD or symptomatic 
PAD at high risk of ischaemic events
77
84 
(modified-ISTH major bleeding)
Co-administered with low-dose aspirin 75–162 mg o.d.
Clopidogrel, (6505/9961 of 
DAPT trial; vs. placebo)
75 mg/day
Post MI in patients who have 
tolerated DAPT for 1 year (25% ACS, 
22% previous MI)
63
105 
(moderate and severe GUSTO 
bleeds, or BARC 2, 3, and 5 
bleeds)
Prasugrel, (3456/9961 of 
DAPT trial; vs. placebo)
10 mg/day (5 mg/day if 
body weight <60 kg or 
age ≥75 years)
Post PCI for MI in patients who have 
tolerated DAPT for 1 year
63
105 
(as above)
Ticagrelor (PEGASUS-TIMI 
54; vs. placebo)
60/90 mg b.i.d.
Post-MI in patients who have 
tolerated DAPT for 1 year
84
81 
(TIMI major bleeds)
© ESC 2024
ACS, acute coronary syndrome; BARC, Bleeding Academic Research Consortium; b.i.d., bis in die (twice daily); CAD, coronary artery disease; DAPT, dual antiplatelet therapy; GUSTO, 
Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; ISTH, International Society on Thrombosis and Haemostasis; MI, myocardial infarction; 
NNH, number needed to cause a harmful event; NNT, number needed to treat to prevent an adverse event; o.d., once daily; PAD, peripheral artery disease; PCI, percutaneous 
coronary intervention; TIMI, Thrombolysis In Myocardial Infarction. Drugs (in addition to aspirin 75–100 mg/day) for extended DAPT options are listed in alphabetical order. For 
definitions of highly/moderately increased ischaemic and bleeding risk see Supplementary data, Tables S2 and S3. NNT refers to the primary ischaemic endpoints and NNH refers to the 
key safety endpoints of the respective trials. NNT and NNH from the DAPT trial are pooled numbers for clopidogrel and prasugrel.


<!-- PAGE 51 -->

### Page 51

antithrombotic therapy when there is a very high risk of stent throm­
bosis and a low bleeding risk.619,623,624
After a 6- to 12-month period of double antithrombotic therapy, in 
most AF-PCI CCS patients, OAC alone is preferred over continuation 
of double antithrombotic therapy.625,626 An open-label randomized trial, 
conducted in 2236 Japanese AF patients who had undergone PCI (71% of 
patients) or CABG (11% of patients) >1 year before or had known CAD 
not requiring revascularization, compared rivaroxaban monotherapy (15 
or 10 mg once daily based on creatinine clearance) with rivaroxaban plus 
SAPT (mostly aspirin).627 At a median follow-up of 23 months, the occur­
rence of ISTH major bleeding and of all-cause deaths were each signifi­
cantly lower with rivaroxaban monotherapy, whereas MACE 
occurrence did not differ significantly in the two treatment arms.627
Whether the above considerations remain valid when the indication 
for OAC is other than AF, e.g. mechanical heart valves (where 
DOACs are not indicated) or VTE, is uncertain given limited available evi­
dence. In the absence of data regarding the efficacy for MACE prevention 
of rivaroxaban 10 mg once daily and apixaban 2.5 mg twice daily, which 
should be used for extended OAC after the first 6 months of therapeutic 
anticoagulation in patients with VTE,628 it is recommended to resume full 
doses of these anticoagulants in case of concomitant CCS.
4.3.1.3. Coronary artery bypass grafting and antithrombotic therapy
Low-dose aspirin is recommended lifelong in patients undergoing 
CABG.629,630 Aspirin should be continued until the day of CABG and 
restarted as soon as there is no concern over bleeding, possibly within 
24 h of CABG.631,632 In general, other antithrombotic drugs should be 
stopped at intervals related to their duration of action (prasugrel 
stopped ≥7 days before; clopidogrel ≥5 days before; ticagrelor 
≥3 days before; and rivaroxaban, apixaban, edoxaban, and dabigatran 
1–2 days before, depending on drug and renal function).633,634
Although not consistent, there is evidence that DAPT with a P2Y12 re­
ceptor inhibitor compared with aspirin monotherapy provides higher 
graft patency rates after CABG.635,636,637 A meta-analysis of four 
RCTs, involving 1316 patients (with 3079 grafts) followed for 3 to 12 
months after CABG, reported superior vein graft patency with 
ticagrelor-based DAPT vs. aspirin alone, but with increased rates of 
BARC 2–5 (but not BARC 3–5) bleeds, and no significant differences 
in cardiovascular death, or the composite of cardiovascular death, 
MI, and stroke, or the composite of all-cause death, MI, stroke, and 
revascularization.635 Therefore, in patients undergoing CABG for CCS, 
DAPT is not routinely indicated; however, it may be considered in se­
lected cases at increased risk of graft occlusion who are not at high bleed­
ing risk (defined in Supplementary data, Tables S2 and S3).
Transient new-onset AF is common 2 to 3 days after CABG, occur­
ring in approximately one-third of patients.638 AF after CABG is asso­
ciated with a higher stroke risk,639 which is, however, lower than that 
with AF unrelated to surgery.640 The impact of early OAC initiation 
on patient outcomes remains unclear.641,642 In a Danish cohort study, 
early OAC initiation was associated with a lower risk of thrombo- 
embolic events,641 while in a Swedish cohort study, OAC was asso­
ciated with no reduction of thrombo-embolic complications but an 
increased risk of major bleeding.642
Decisions on OAC should consider thrombo-embolic and bleeding 
risks, timing, and duration of post-operative AF. Longer AF durations 
and delayed-onset post-CABG have higher risks. We refer to the 
dations for OAC in this context. It is unknown whether, in such pa­
tients, the combination of aspirin and OAC may be more effective 
compared with OAC alone in preventing ischaemic events post-CABG.
4.3.1.4. Proton pump inhibitors
Antithrombotic therapy may provoke GI bleeding, especially in patients at 
increased risk, such as the elderly, those with a history of GI bleeding or 
peptic disease, high alcohol consumption, chronic use of steroids or non- 
steroidal anti-inflammatory drugs (NSAIDs), or receiving a combination of 
antithrombotic drugs.643–645 In patients on various types of antithrombo­
tic therapy, proton pump inhibitors may be effective in reducing the risk of 
GI bleeding, in particular from gastroduodenal lesions.646–648 In general, 
gastric protection with proton pump inhibitors is recommended in pa­
tients at increased risk of GI bleeding for as long as any antithrombotic 
therapy is administered.65,86 Because the proton pump inhibitors omepra­
zole and esomeprazole inhibit CYP2C19, when administered with clopi­
dogrel, they reduce exposure to clopidogrel’s active metabolite; while 
their use is discouraged in combination with clopidogrel, univocal effects 
of these combinations on the risk of ischaemic events or stent thrombosis 
have not been demonstrated (https://www.ema.europa.eu/en/medicines/ 
human/EPAR/plavix).643,646 Of note, proton pump inhibitors do not in­
crease MACE vs. placebo in patients with CVD.646
Recommendation Table 17 — Recommendations for antithrombotic therapy in patients with chronic coronary syn­
drome (see also Evidence Table 17)
Recommendations
Classa
Levelb
Long-term antithrombotic therapy in patients with chronic coronary syndrome and no clear indication for oral anticoagulation
In CCS patients with a prior MI or remote PCI, aspirin 75–100 mg daily is recommended lifelong after an initial period of DAPT.558,559
I
A
In CCS patients with a prior MI or remote PCI, clopidogrel 75 mg daily is recommended as a safe and effective alternative to aspirin 
monotherapy.562,564–566,649
I
A
After CABG, aspirin 75–100 mg daily is recommended lifelong.558,559,629
I
A
In patients without prior MI or revascularization but with evidence of significant obstructive CAD, aspirin 75–100 mg daily is recommended 
lifelong.557–559
I
B
Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention should be considered in patients at enhanced 
ischaemic riskc and without high bleeding riskd (options and definitions in Table 8 and in the Supplementary data online, Tables S2 and S3).592–594
IIa
A
In CCS or stabilized post-ACS patients who underwent PCI and were initially treated with ticagrelor-based DAPT, who remain at high 
ischaemic risk and are not at high bleeding risk, ticagrelor monotherapy 90 mg b.i.d. may be considered as an alternative to dual or other 
single antiplatelet therapy.563,570–573
IIb
C
Continued 
ESC Guidelines                                                                                                                                                                                          3465


<!-- PAGE 52 -->

### Page 52

Antithrombotic therapy post-percutaneous coronary intervention in patients with chronic coronary syndrome and no indication for 
oral anticoagulation
In CCS patients with no indication for oral anticoagulation, DAPT consisting of aspirin 75–100 mg and clopidogrel 75 mg daily for up to 6 
months is recommended as the default antithrombotic strategy after PCI-stenting.650–654
I
A
In patients at high bleeding riskd but not at high ischaemic risk,c it is recommended to discontinue DAPT 1–3 months after PCI and to 
continue with single antiplatelet therapy.587,591
I
A
Stopping DAPT after 1–3 months from PCI-stenting may be considered in patients who are not at high bleeding risk nor at high risk of 
ischaemic events.588,655–657,c,d
IIb
B
In CCS patients undergoing high-thrombotic risk stenting (e.g. complex left main stem, 2-stent bifurcation, suboptimal stenting result, prior 
stent thrombosis, previously known CYP2C19 *2/*3 polymorphisms), prasugrel or ticagrelor (in addition to aspirin) may be considered 
instead of clopidogrel, for the first month, and up to 3–6 months.
IIb
C
Long-term antithrombotic therapy in patients with chronic coronary syndrome and an indication for oral anticoagulation
In CCS patients with a long-term indication for OAC, an AF therapeutic dose of VKA alone or, preferably, of DOAC alone (unless 
contraindicated) is recommended lifelong.609,627
I
B
Antithrombotic therapy post-percutaneous coronary intervention in chronic coronary syndrome patients with an indication for oral 
anticoagulation
In patients with an indication for OAC who undergo PCI, initial low-dose aspirin once daily is recommended (loading dose when not on 
maintenance dose) in addition to OAC and clopidogrel.
I
C
In patients who are eligible for OAC, DOAC (unless contraindicated) is recommended in preference to VKA.619,658
I
A
After uncomplicated PCI in CCS patients with concomitant indication for OAC: 
• early cessation of aspirin (≤1 week);
• followed by continuation of OAC and clopidogrel: 
⚬up to 6 months in patients not at high ischaemic risk;c or
⚬up to 12 months in patients at high ischaemic risk;c
• followed by OAC alone;
is recommended.616–619,622,627,659
I
A
Continuation of aspirin up to 1 month after PCI, in addition to OAC and clopidogrel, should be considered in patients at high ischaemic riskc 
or with anatomical/procedural characteristics judged to outweigh the bleeding risk.620–622,e
IIa
B
When concerns about high bleeding risk prevail over concerns about stent thrombosis or ischaemic stroke: 
rivaroxaban 15 mg daily should be considered in preference to rivaroxaban 20 mg daily for the duration of concomitant antiplatelet therapy;616
IIa
B
dabigatran 110 mg twice daily should be considered in preference to dabigatran 150 mg twice daily for the duration of concomitant 
antiplatelet therapy.617
IIa
B
In patients with an indication for VKA in combination with single or dual antiplatelet therapy, targeting VKA intensity to an INR in the lower 
part of the recommended range and to a time in therapeutic range >70% should be considered.615,660–663
IIa
B
The use of ticagrelor or prasugrel is generally not recommended as part of triple antithrombotic therapy with aspirin and an OAC.
III
C
Antithrombotic therapy post-coronary artery bypass grafting
It is recommended to initiate aspirin post-operatively as soon as there is no concern over bleeding.629,630
I
B
DAPT may be considered after CABG in selected patients at greater risk of graft occlusionf and at low risk of bleeding.635
IIb
B
Use of proton pump inhibitors
A proton pump inhibitor is recommended in patients at increased risk of gastrointestinal bleeding for the duration of combined 
antithrombotic therapy (antiplatelet therapy and/or OAC).646–648,664
I
A
A proton pump inhibitor should be considered when a single antithrombotic (antiplatelet or anticoagulant) drug is used, considering the 
gastrointestinal bleeding risk of the individual patient.646,665–668
IIa
A
© ESC 2024
ACS, acute coronary syndrome; AF, atrial fibrillation; ARC-HBR, Academic Research Consortium for High Bleeding Risk; b.i.d., bis in die (twice daily); CABG, coronary artery bypass grafting; 
CAD, coronary artery disease; CCS, chronic coronary syndrome; CKD, chronic kidney disease; CYP2C19, cytochrome P450 2C19; DAPT, dual antiplatelet therapy; DOAC, direct oral 
anticoagulant; INR, international normalized ratio; LAD, left anterior descending; MI, myocardial infarction; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; 
PRECISE-DAPT, PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual AntiPlatelet Therapy; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cEnhanced thrombotic/ischaemic risk criteria for extended treatment with a second antithrombotic agent (Supplementary data, Table S3). Thrombotic risk encompasses (i) the risk of 
thrombosis occurring, and (ii) the risk of death should a thrombotic event occur, both of which relate to anatomical, procedural, and clinical characteristics. Thrombotic/ischaemic risk 
factors for CCS (that may also apply to CABG) patients include stenting of left main stem, proximal LAD, or last remaining patent artery; suboptimal stent deployment; stent length of 
>60 mm; diabetes mellitus; CKD; bifurcation with two stents implanted; treatment of chronic total occlusion; and previous stent thrombosis on adequate antithrombotic therapy. 
dBleeding-risk criteria according to PRECISE-DAPT or ARC-HBR (Supplementary data, Table S2). 
eAnatomical/procedural thrombotic risk characteristics: stenting of left main, proximal LAD, or last remaining patent artery; suboptimal stent deployment; stent length of >60 mm; bifurcation 
with two stents implanted; treatment of chronic total occlusions. 
fFor example, stentectomy, endarterectomy, poor venous graft quality.


<!-- PAGE 53 -->

### Page 53

4.3.2. Lipid-lowering drugs
Evidence from genetic, epidemiological, and randomized clinical 
studies has established the key causal role of LDL-C and other 
apo-B-containing lipoproteins in the development of atherosclerotic 
disease.669 In patients with established ASCVD, lowering of LDL-C le­
vels reduces the risk of recurrent MACE.128,670,671 Elevated lipid levels 
should be managed according to the 2019 ESC/EAS Guidelines for the 
management of dyslipidaemias64 and the 2021 ESC Guidelines on car­
diovascular disease prevention in clinical practice.16
Because patients with CCS are considered at very high cardiovascular 
risk, the treatment goal is to lower LDL-C levels to <1.4 mmol/L 
(<55 mg/dL) and achieve a reduction by at least 50% from baseline. 
For patients who experience a second vascular event within 2 years 
while taking maximum tolerated statin-based therapy, an even lower 
LDL-C goal of <1.0 mmol/L (40 mg/dL) may be considered.
In addition to exercise, diet, and weight control, which favourably af­
fect blood lipid levels and are recommended for all patients with CCS 
(see Section 5.1), pharmacological treatment with a maximally tolerated 
dose of a potent statin is the first-line therapy recommended for all 
CCS patients.128,670,671 In a landmark meta-analysis involving patients 
with and without ASCVD, statin treatment was shown to reduce the 
risk of major vascular events by 22%, all-cause mortality by 10%, and 
mortality due to coronary heart disease by 20% per 1.0 mmol/L of 
achieved reduction in LDL-C levels.670 High-intensity statin treatment 
(i.e. atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily) reduces 
LDL-C levels by 45%–50% on average, although interindividual variabil­
ity exists.672 Statins should not be given when pregnancy is planned, 
during pregnancy, or during the breastfeeding period.64
In many patients with CCS, statin therapy alone will not suffice to 
achieve the recommended LDL-C goals;673 hence, a combination of 
lipid-lowering drug therapy is required. In a trial of patients with recent 
ACS, the combination of statin with ezetimibe resulted in additional re­
duction of LDL-C levels by 20%–25% compared with simvastatin 
monotherapy. This LDL-C reduction translated into a modest reduc­
tion of a composite endpoint involving fatal and non-fatal events 
(6.4% RR reduction, 2.0% absolute risk reduction).674 Ezetimibe should 
be used as second-line therapy when the treatment goal is not achieved 
with maximally tolerated statin therapy, or as first-line therapy in the 
case of intolerance to any statin regimen. Proprotein convertase subti­
lisin/kexin type 9 inhibitors (alirocumab or evolocumab), administered 
subcutaneously every 2 or 4 weeks, lower LDL-C levels by 60% when 
added to statin therapy.675 In cardiovascular outcomes trials, these 
monoclonal antibodies resulted in significant reduction of non-fatal car­
diovascular events, with no impact on cardiovascular mortality.675,676
Their favourable safety profile was recently confirmed for longer 
follow-up (median 5 years) in open-label extension studies of the out­
comes trials.677 The high cost of PCSK9 inhibitors is still a limitation for 
broader implementation.
Bempedoic acid is an oral cholesterol synthesis inhibitor that lowers 
LDL-C by approximately 18% in monotherapy and 38% when com­
bined with ezetimibe.678,679 In a recent cardiovascular outcomes trial 
including statin-intolerant patients, bempedoic acid significantly re­
duced MACE.680 Inclisiran, a small interfering ribonucleic acid molecule, 
is administered subcutaneously every 3–6 months and reduces LDL-C 
by approximately 50% either in combination with statin or without sta­
tin therapy.681 A cardiovascular outcomes trials for inclisiran is current­
ly underway (ClinicalTrials.gov identifier: NCT03705234).
In patients scheduled to undergo elective PCI, pre-treatment with a 
high-dose statin in statin-naïve patients or loading with high-dose statin 
in statin-treated patients has been shown to reduce the risk of 
periprocedural events.682 Routine pre-treatment or loading (in the 
context of pre-existing statin treatment) with a high-dose statin can 
be considered in patients with CCS undergoing PCI.
4.3.3. Renin–angiotensin–aldosterone blockers/ 
angiotensin receptor neprilysin inhibitor
Modulation of the RAAS and the neprilysin inhibitor sacubitril in com­
bination with a RAS blocker has proved beneficial in patients with HF 
post-MI and in patients with hypertension. In these clinical syndromes, 
RAAS inhibition has greatly improved morbidity and mortality. 
Angiotensin-converting enzyme inhibitors (ACE-Is) can reduce mortal­
ity, MI, stroke, and HF among patients with LV dysfunction,683–685 pre­
vious vascular disease,686–688 and high-risk DM.689 These data bring 
strong evidence to recommend ACE-Is [or angiotensin receptor block­
ers (ARBs) in cases of intolerance] for the treatment of patients with 
CCS with co-existing hypertension, LVEF ≤40%, DM, or CKD, unless 
contraindicated (e.g. severe renal impairment, hyperkalaemia, etc.). In 
trials that include patients with mildly reduced and preserved LV func­
tion >40%, the effect of ACE-Is to reduce all-cause death, cardiovascu­
lar death, non-fatal MI, stroke, or HF in patients with atherosclerosis is 
not uniform.686,687,690 A meta-analysis, including 24 trials and 61 961 
patients, documented that, in CCS patients without HF, RAAS inhibi­
tors reduced cardiovascular events and death only when compared 
Recommendation Table 18 — Recommendations for 
lipid-lowering drugs in patients with chronic coronary 
syndrome (see also Evidence Table 18)
Recommendations
Classa
Levelb
Lipid-lowering treatment with an LDL-C goal of <1.4 
mmol/L (55 mg/dL) and a ≥50% reduction in LDL-C 
vs. baseline is recommended.64,670,671
I
A
A high-intensity statin up to the highest tolerated 
dose to reach the LDL-C goals is recommended for 
all patients with CCS.670,671
I
A
If a patient’s goal is not achieved with the maximum 
tolerated dose of statin, combination with ezetimibe 
is recommended.674
I
B
For patients who are statin intolerant and do not 
achieve their goal on ezetimibe, combination with 
bempedoic acid is recommended.680
I
B
For patients who do not achieve their goal on a 
maximum tolerated dose of statin and ezetimibe, 
combination with a PCSK9 inhibitor is 
recommended.675,676
I
A
For patients who do not achieve their goal on a 
maximum tolerated dose of statin and ezetimibe, 
combination with bempedoic acid should be 
considered.
IIa
C
For patients with a recurrent atherothrombotic 
event (not necessarily of the same type as the first 
event) while taking maximally tolerated statin 
therapy, an LDL-C goal of <1.0 mmol/L (<40 mg/dL) 
may be considered.675,676
IIb
B
© ESC 2024
CCS, chronic coronary syndrome; LDL-C, low-density lipoprotein cholesterol; PCSK9, 
proprotein convertase subtilisin/kexin type 9. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3467


<!-- PAGE 54 -->

### Page 54

with placebo, but not when compared with active control treat­
ment.691 For this reason ACE-I therapy in CCS patients without HF 
or high cardiovascular risk is not generally recommended, unless re­
quired to meet BP targets. However, a new observational study 
showed that ACE-I/ARB therapy was associated with significant long- 
term survival benefit in patients post-PCI for STEMI/non-ST-segment 
elevation myocardial infarction (NSTEMI). This survival benefit is appar­
ent in patients with both preserved and reduced LV function. These 
findings provide contemporary evidence to support the use of these 
agents in coronary patients who underwent PCI for STEMI/NSTEMI, ir­
respective of their baseline LV function.692
Sacubitril/valsartan contains an ARB and a prodrug of neprilysin 
inhibitor, which inhibits the degradation of endogenous natriuretic pep­
tides. In patients with LVEF ≤35% (of ischaemic aetiology in 60%), 
sacubitril/valsartan proved to reduce HF hospitalization and cardiovas­
cular death compared with ACE-I.693 Moreover, sacubitril/valsartan 
may decrease myocardial ischaemia because of its effect in reducing 
LV wall stress and improving coronary circulation. The risk of coronary 
events using sacubitril/valsartan compared with ACE-I was also signifi­
cantly reduced on post-hoc analyses.694
4.3.4. Sodium–glucose cotransporter 2 inhibitors and 
glucagon-like peptide-1 receptor agonists
Sodium–glucose cotransporter 2 (SGLT2) inhibitors and GLP-1 recep­
tor agonists were initially intended as glucose-lowering medications for 
patients with type 2 DM; however, a growing body of evidence has es­
tablished that these drugs lower ASCVD risk and confer cardiovascular 
benefits beyond their glucose-lowering potential.688,695–697 Among pa­
tients with DM, SGLT2 inhibitor use was associated with a reduced risk 
of MACE, especially in patients with established ASCVD.698 The exact 
mechanism(s) by which SGLT2 inhibitors improve CVD outcomes re­
main largely unknown, but several hypotheses have been pro­
posed.695,696,699–702 The benefits of SGLT2 inhibitors may relate 
more to cardiorenal haemodynamic effects than to atherosclerosis16
The cardiovascular benefits of GLP-1 receptor agonists is driven by re­
duced risk of ASCVD-related events.703 Overall, the results of cardio­
vascular outcome trials of SGLT2 inhibitors and GLP-1 receptor 
agonists support their recommendation as first-line treatment for all 
patients with type 2 DM and ASCVD including CCS, independently 
of decisions about glycaemic management (Recommendation Table 19).
In patients with HF with reduced (HFrEF) or preserved EF (HFpEF), 
dapagliflozin and empagliflozin lowered the risk of worsening HF or car­
diovascular death in the presence or absence of type 2 DM.704–707
Recent results indicate benefits of SGLT2 inhibitors on hospitalization 
for HF and cardiovascular death in patients at high cardiovascular risk, ir­
respective of HF history.708 Recommendations for the use of SGLT2 in­
hibitors in patients with diabetes and patients with HF are detailed in the 
tients with diabetes86 and the 2021 ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure526 and its 2023 Focused 
Update. 709 Recommendations on the use of these medications in pa­
tients with HF are given in Section 4.3.4 and Recommendation Table 24.
In patients with pre-existing CVD, the SELECT trial assessed the ef­
fect of weekly subcutaneous administration of the GLP-1 receptor 
agonist semaglutide at a dose of 2.4 mg on MACE reduction in over­
weight or obese adults without type 2 DM. The trial involved 17 604 
patients with established CVD and a BMI ≥27 kg/m2. Patients lost a 
mean of 9.4% of body weight over the first 2 years with semaglutide 
vs. 0.88% with placebo. The primary cardiovascular endpoint—a 
composite of death from cardiovascular causes, non-fatal MI, or non- 
fatal stroke—was reduced significantly, with an HR of 0.80 (95% CI, 
0.72–0.90; P < .001).465
4.3.5. Anti-inflammatory agents for event prevention
Four large double-blind trials have compared the effects of anti- 
inflammatory agents vs. placebo in patients with atherothrombotic 
CAD. The Canakinumab Antiinflammatory Thrombosis Outcome 
Study (CANTOS) tested three doses of the anti-interleukin-1-beta 
monoclonal antibody canakinumab against placebo in over 10 000 pa­
tients with previous MI and plasma C-reactive protein ≥2 mg/L.712
The highest dose (300 mg every 3 months) reduced plasma 
interleukin-6 and C-reactive protein and the combined endpoint of car­
diovascular death, non-fatal MI, and non-fatal stroke over a mean of 
3.7 years: 3.90 vs. 4.50 events per 100 person-years (HR 0.86; 95% 
CI, 0.75–0.99; P = .031). The other doses did not provide favourable re­
sults. Despite efficacy, the drug was not developed further for this indi­
cation because of the risk of fatal infections and high costs.
Low-dose methotrexate (target dose 15–20 mg once weekly) did not 
reduce the composite of cardiovascular death, non-fatal MI, non-fatal 
stroke, or unstable angina-driven revascularization in 4786 patients 
with previous MI or multivessel coronary atherosclerosis and additional 
DM or metabolic syndrome.713 The trial was stopped early (median 
2.3 year follow-up) for futility.
The COLCOT (Colchicine Cardiovascular Outcomes Trial) tested 
low-dose colchicine (0.5 mg daily) vs. placebo in 4745 patients with re­
cent MI (<30 days) regardless of C-reactive protein values.714 During a 
median of 2.3 years, the composite of cardiovascular death, resuscitated 
Recommendation Table 19 — Recommendations for 
sodium–glucose cotransporter 2 inhibitors and/or 
glucagon-like peptide-1 receptor agonists in patients 
with chronic coronary syndrome (see also Evidence 
Table 19)
Recommendations
Classa
Levelb
CCS patients with type 2 diabetes
SGLT2 inhibitors with proven CV benefitc are 
recommended in patients with T2DM and CCS to 
reduce CV events, independent of baseline or target 
HbA1c and independent of concomitant 
glucose-lowering medication.86,688,695,697,700
I
A
GLP-1 receptor agonists with proven CV benefitd 
are recommended in patients with T2DM and CCS 
to reduce CV events, independent of baseline or 
target HbA1c and independent of concomitant 
glucose-lowering medication.710,711
I
A
CCS patients without type 2 diabetes
The GLP-1 receptor agonist semaglutide should be 
considered in overweight  (BMI ≥27 kg/m2) or obese 
CCS patients without diabetes to reduce CV 
mortality, MI, or stroke.465
IIa
B
© ESC 2024
BMI, body mass index; CCS, chronic coronary syndrome; CV, cardiovascular; GLP-1, 
glucagon-like peptide-1; HbA1c, glycated haemoglobin; MI, myocardial infarction; SGLT2, 
sodium–glucose cotransporter 2; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cCanaglifozin, dapagliflozin, empagliflozin, sotagliflozin (listed in alphabetical order). 
dDulaglutide, efpeglenatide, liraglutide, semaglutide (listed in alphabetical order).


<!-- PAGE 55 -->

### Page 55

cardiac arrest, non-fatal MI, non-fatal stroke, or unstable angina-driven 
revascularization occurred in 5.5% on colchicine vs. 7.1% on placebo 
(HR 0.77; 95% CI, 0.61–0.96; P = .02). Colchicine had favourable effects 
on each outcome component. All-cause mortality did not differ (43 vs. 44 
events). Diarrhoea was reported in 9.7% vs. 8.9% (statistically non- 
significant); pneumonia, although not frequent, was recorded more often 
with colchicine than placebo (0.9% vs. 0.4%; P = .03).
The LODOCO2 trial (Low-Dose Colchicine 2) randomized 5500 
patients with atherosclerotic CAD who had been stable for at least 
6 months to low-dose colchicine (0.5 mg daily) or placebo for a median 
of 2.4 years.715 The primary endpoint (cardiovascular death, spontan­
eous MI, ischaemic stroke, or ischaemia-driven revascularization) oc­
curred in 6.8% on colchicine vs. 9.6% on placebo (HR 0.69; 95% CI, 
0.57–0.83; P < .001). The main secondary endpoint (cardiovascular 
death, non-fatal MI, or non-fatal stroke) was reduced by 28% (4.2% 
on colchicine vs. 5.7% on placebo; HR 0.72; 95% CI, 0.57–0.92; 
P = .007). There were no significant differences in rates of pneumonia 
or GI disorders. The incidence of non-cardiovascular death was nomin­
ally higher, but not statistically significant (0.7 vs. 0.5 events per 100 
person-years; HR 1.51; 95% CI, 0.99–2.31).
A recent meta-analysis including over 12 000 patients with athero­
thrombotic CAD716 has estimated the treatment effects of colchicine 
vs. placebo for individual outcome components. Significantly lower risks 
were found for MI (RR, 0.76; 95% CI, 0.61–0.96), stroke (RR, 0.48; 95% 
CI, 0.30–0.77) and unstable angina-driven revascularization (RR, 0.61; 
95% CI, 0.42–0.89), with no significant difference for cardiovascular 
death (RR, 0.73; 95% CI, 0.45–1.21), all-cause death (RR, 1.01; 95% 
CI, 0.71–1.43), or GI events (provided colchicine daily dose did not ex­
ceed 0.5 mg; RR, 1.02; 95% CI, 0.92–1.14).
4.4. Revascularization for chronic coronary 
syndromes
Invasive treatment of CAD with either CABG or PCI is historically de­
scribed under the term revascularization. Although both procedures in­
crease CFC365,366 and prevent myocardial ischaemia during exercise or 
emotional stress, they do not heal coronary atherosclerosis. 
Revascularization by both modalities improves angina-related health 
status.50,52,717 Randomized and meta-analytical evidence supports a 
survival benefit above medical therapy for CABG in patients with left 
main disease,718–721 as well as three-vessel disease,722 particularly in pa­
tients with LV dysfunction.719,723,724 Most of this evidence was obtained 
prior to the introduction of disease-modifying therapies such as ACE-Is/ 
ARBs and statins. Meta-analytical evidence suggests a potential benefit 
of PCI on cardiovascular survival,55,725,726 which, similarly to CABG, ap­
pears to be related to the prevention of MI.55,727 In general, among sur­
gically eligible patients with multivessel disease, CABG is superior to 
PCI and to medical therapy, particularly in those with diabetes and high­
er coronary complexity.727,728 Recent evidence has generated contro­
versy on (i) the value of routine early revascularization compared with 
optimal medical therapy alone,47,56,314,729 (ii) the value of PCI vs. CABG 
for complex CAD,326,730 and (iii) the value of ischaemia testing for 
decision-making in revascularization.315,317,726 At the same time, ad­
vances in interventional technologies and medications have expanded 
the application of PCI to more complex forms of CAD.731
4.4.1. Appropriate indication for myocardial 
revascularization
In CAD patients with moderate or severe inducible ischaemia but no 
left main disease nor LVEF of <35%, the largest-to-date ISCHEMIA trial, 
up to 5 years, did not show significant benefit of an initial invasive strat­
egy over an initial conservative strategy for the primary endpoint of is­
chaemic cardiovascular events or death from any cause,47 triggering 
discussion about the role of initial angiography followed by revascular­
ization when feasible, in this type of CCS patients, once optimal medical 
therapy has been established. The CLARIFY registry found that many 
CCS patients with angina experience a resolution of symptoms over 
time, often without changes in treatment or revascularization, and ex­
perience good outcomes.404 While these findings suggest that this type 
of CCS patients should initially receive conservative medical manage­
ment, it is worth noting that patients who were randomly assigned 
to the invasive strategy in the ISCHEMIA trial experienced significantly 
lower rates of spontaneous MI and greater improvement in 
angina-related health status compared with those assigned to the con­
servative strategy.47,50 Furthermore, the ORBITA 2 trial demonstrated 
that patients with stable angina, who were receiving minimal or no anti­
anginal medication and had objective evidence of ischaemia, experi­
enced a lower angina symptom score following PCI treatment 
compared with a placebo procedure, indicating a better health status 
with respect to angina.52 Although initial conservative medical manage­
ment of CCS patients is generally preferred, symptom improvement by 
revascularization should therefore not be neglected if patients remain 
symptomatic despite antianginal treatment.
After publication of the ISCHEMIA trial results, several meta- 
analyses have reported similar overall survival and inevitably higher 
rates of procedural MI with routine revascularization, while confirming 
consistently greater freedom from spontaneous MI, unstable angina, 
and anginal symptoms after revascularization compared with GDMT 
alone.732–734 Of note, these meta-analyses showed some differences 
in methodology, in selected trials, and follow-up duration. 
Recommendation Table 20 — Recommendations for 
anti-inflammatory drugs in patients with chronic coron­
ary syndrome (see also Evidence Table 20)
Recommendation
Classa
Levelb
In CCS patients with atherosclerotic CAD, low-dose 
colchicine (0.5 mg daily) should be considered to 
reduce myocardial infarction, stroke, and need for 
revascularization.714–716
IIa
A
© ESC 2024
CAD, coronary artery disease; CCS, chronic coronary syndrome. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 21 — Recommendations for 
angiotensin-converting enzyme inhibitors in patients 
with chronic coronary syndrome (see also Evidence 
Table 21)
Recommendations
Classa
Levelb
In CCS patients, ACE-Is (or ARBs) are 
recommended in the presence of specific 
comorbidities, such as hypertension, diabetes, or 
heart failure.683–685
I
A
ACE-Is should be considered in CCS patients at very 
high risk of cardiovascular events.686,687,690,691
IIa
A
© ESC 2024
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCS, 
chronic coronary syndrome. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3469


<!-- PAGE 56 -->

### Page 56

Furthermore, the importance of ‘any myocardial infarction’ as an end­
point is complicated by a debate over the prognostic importance of 
procedural infarctions as well as how various MI definitions affect the 
prediction of long-term outcomes735,736 A more recent meta-analysis 
of RCTs that included the longest available follow-up showed that add­
ing revascularization to GDMT reduced cardiac mortality compared 
with GDMT alone. The cardiac survival benefit improved with the dur­
ation of follow-up and was linearly related to a lower rate of spontan­
eous MI.55
In ISCHEMIA, patients randomized to initial medical therapy alone had 
significantly more spontaneous MIs during the 5-year follow-up, which 
were associated with subsequent cardiovascular death.737 An early inva­
sive strategy was associated with lower long-term risks of cardiovascular 
events, mainly spontaneous MIs, compared with a conservative strategy, 
at the cost of a higher risk of procedural MIs.738
Extended follow-up of the ISCHEMIA trial population up to 7 years 
(ISCHEMIA-EXTEND) revealed a significant 2.2% absolute decrease in 
cardiovascular mortality (adjusted HR 0.78; 95% CI, 0.63–0.96) favour­
ing the initial invasive strategy.56 The benefit was most marked in pa­
tients with multivessel CAD (≥70% diameter stenosis on CCTA; 
adjusted HR 0.68; 95% CI, 0.48–0.97) but was offset by a significant 
1.2% absolute increase in non-cardiac mortality, without a significant 
difference (absolute decrease of −0.7%) in all-cause mortality.56 In a re­
cent meta-analysis of 18 trials, on the other hand, non-cardiac mortality 
did not differ significantly by initial invasive or conservative strategy in 
CCS patients with preserved or slightly impaired LVEF.739 In a post 
hoc analysis of the ISCHEMIA trial, CAD severity was associated with 
a higher risk of all-cause death, MI, and the primary endpoint of the 
trial.317 This effect appeared to be most noticeable in patients with mul­
tivessel disease and/or proximal LAD stenosis (≥70% diameter stenosis 
on CCTA).
4.4.2. Additional considerations on reduced systolic 
left ventricular function: myocardial viability, 
revascularization, and its modality
Ischaemic cardiomyopathy is the leading cause of HFrEF, and new ischae­
mic events are the main drivers of worsening LV function, strongly im­
pacting long-term survival.740 Ischaemic HFrEF is characterized by 
irreversibly damaged and scarred myocardium alternating with ‘viable’ 
myocardium that may be dysfunctional owing to repetitive ischaemic epi­
sodes (stunning) or chronic hypoperfusion (hibernation).741 According 
to classical concepts, revascularization combined with GDMT synergis­
tically improves systolic LV function and overall prognosis in patients 
with ischaemic HFrEF by restoring sufficient perfusion to dysfunctional 
yet viable myocardial segments and preventing new ischaemic events.742
However, it carries increased periprocedural risk, especially in patients 
with severe LV dysfunction (LVEF ≤ 35%). A meta-analysis of 26 obser­
vational studies, including 4119 patients, showed that CABG can be per­
formed with acceptable operative mortality (5.4%; 95% CI, 4.5%–6.4%) 
and 5-year actuarial survival (75%) in patients with severe LV dysfunction 
(mean pre-operative EF of 24.7%).743
In the 1990s, observational studies reported improved survival after 
revascularization in patients with severe CAD, significant LV dysfunc­
tion, and evidence of myocardial viability on imaging tests.744 The 
PARR-2 trial (PET and Recovery Following Revascularization) rando­
mized 430 patients with suspected ischaemic cardiomyopathy to an 
F-18-fluorodeoxyglucose PET-assisted strategy or standard care. 
While there was a non-significant trend towards lower risk of cardiac 
events at 1 year with PET assistance,745 the 5-year follow-up showed 
no overall reduction in cardiac events.746 However, significant benefits 
were observed when adhering to PET recommendations (after exclud­
ing 25% protocol violations).746 Post hoc analyses and substudies con­
firmed the positive outcomes of a PET-guided strategy.747,748
The Surgical Treatment for Ischemic Heart Failure (STICH) trial ran­
domized 1212 patients with CAD without left main diseases eligible 
for CABG and LVEF ≤35% to receive either CABG and GDMT, or 
GDMT alone. The trial failed to achieve its primary endpoint of all-cause 
mortality at a median follow-up of 4 years (HR with CABG, 0.86; 95% CI, 
0.72–1.04; P = .12).53 However, at a median follow-up of 9.8 years, both 
all-cause and cardiovascular mortality were significantly reduced with 
CABG compared with GDMT alone (from 66.1% to 58.9%; HR 0.84; 
95% CI, 0.73–0.97; P = .02; and from 49.3% to 40.5%; HR 0.79; 95% 
CI, 0.66–0.93; P = .006, respectively).54 The reduction of cardiovascular 
mortality by CABG was greater in patients with three-vessel disease54
and the reduction of all-cause mortality was greater in younger patients, 
in whom cardiovascular deaths accounted for a larger proportion of 
deaths vs. older patients (P = .004 for interaction).749 Viability was as­
sessed by SPECT, dobutamine echocardiography, or both in 50% of 
STICH patients (298 randomized to CABG and 303 randomized to 
GDMT alone).750 There were no significant interactions between pres­
ence or absence of myocardial viability and improved LV function or 
long-term survival benefit for CABG above GDMT.747,748,750
There have been no RCTs directly comparing CABG and PCI in pa­
tients with ischaemic HF. A meta-analysis of 21 studies, mostly obser­
vational except three including STICH, published between 1983 and 
2016, supported CABG and PCI on a background of GDMT in appro­
priate patients with multivessel disease and LV systolic dysfunction; re­
vascularization with either CABG or PCI improved long-term survival 
compared with GDMT, but compared with PCI, CABG provided a sur­
vival benefit and a lower risk of MI or repeat revascularization, with a 
slightly higher incidence of stroke.751
PCI is increasingly used over CABG for treating patients with ischaemic 
HF and multivessel disease, as shown by two large registries.752,753 While 
these registries suggest that CABG is associated with a lower risk of long- 
term all-cause and cardiovascular mortality and lower MACE compared 
with PCI in patients with CAD and LVEF ≤35%,752,753 it is important to 
interpret these observational studies with great caution, given significant 
differences in baseline characteristics, including age, history of previous MI, 
severity of CAD, and completeness of revascularization.754 For the com­
parison of CABG with PCI in managing ischaemic HF with severely im­
paired LV dysfunction and multivessel CAD, the results of ongoing trials 
(NCT05427370 and NCT05329285) are awaited.
The Percutaneous Revascularization for Ischemic Left Ventricular 
Dysfunction (REVIVED-BCIS2) trial randomized 700 patients with im­
paired LV function (EF ≤ 35%), extensive CAD amenable to PCI, and 
evidence of myocardial viability in at least four dysfunctional myocardial 
segments to a strategy of PCI plus GDMT or GDMT alone.729 After a 
3.4-year follow-up, PCI showed no significant reduction in the compos­
ite primary endpoint of all-cause death or HF rehospitalization (HR 
0.99; 95% CI, 0.78–1.27; P = .96). Patients treated by PCI showed slight 
and temporary improvements in their symptoms and no incremental 
improvement of overall LV function compared with GDMT.
A pre-specified secondary analysis of REVIVED-BCIS2, conducted in 
87% of patients, failed to establish significant correlations between via­
bility extent (assessed by CMR or dobutamine stress echocardiog­
raphy) and outcomes, thereby challenging the traditional concept of 
myocardial hibernation, which can be reversed by revascularization.755
However, the analysis did find that larger amounts of non-viable myo­
cardium were linked to an increased risk of the primary outcome,


<!-- PAGE 57 -->

### Page 57

regardless of whether PCI was performed, suggesting that viability as­
sessment may be useful for risk stratification.
The two main RCTs, STICH and REVIVED-BCIS2, differ in various 
aspects. The REVIVED-BCIS2 trial patients were, on average, 10 years 
older than those in the STICH trial, had a less frequent history of MI 
(50% vs. 78%) and were more likely to be angina-free at baseline 
(67% vs. 36%). REVIVED-BCIS2 included fewer patients with three- 
vessel disease (38% vs. 60%). Additionally, patients in REVIVED- 
BCIS2 received more modern HF therapy and were more commonly 
treated with an ICD/CRT (cardiac resynchronization therapy) 
(21%/53% vs. 2%/19%). Finally, the duration of follow-up was shorter 
compared with the STICH trials. All these factors may have contributed 
to the absence of any PCI effect on survival.
In conclusion, the heterogeneous designs of the above studies, the 
statistical underpower of subgroup analyses, the heterogeneous meth­
ods of viability assessments (e.g. based on metabolism, contractile re­
serve, or scar extent) and variable quantification (dichotomous vs. 
continuous) leave many open questions on how viability should be de­
fined,756 and when and why it should be assessed in ischaemic HFrEF 
patients. For instance, the classical binary definition of myocardial viabil­
ity may benefit from more contemporary paradigms and from greater 
focus on anatomic alignment between viable myocardial regions and 
feasible revascularization of corresponding perfusing arteries.741
Moreover, therapeutic aims should go beyond enhancing local and 
overall LV function to include safeguarding against new ischaemic 
events727 and their ensuing possibly lethal arrhythmias. Therefore, an 
integrative approach, including highly specialized imaging, HF, arrhyth­
mia, and revascularization specialists, is needed for optimal patient man­
agement and improved outcomes.
4.4.3. Additional considerations—complete vs. partial 
revascularization
Complete revascularization treating all vessels and lesions causing is­
chaemia is preferable to incomplete revascularization.757 However, 
various factors may influence the implementation of complete revascu­
larization, including clinical setting, comorbidities, anatomical and pro­
cedural features, advanced age, or frailty.758,759
Furthermore, 
whether the focus of complete revascularization should be anatomical 
or functional is still unclear. In the PCI group of the SYNTAX (SYNergy 
Between PCI with TAXUS and Cardiac Surgery) trial, a higher residual 
SYNTAX score, indicating incomplete anatomical revascularization, 
was associated with a higher mortality rate.760 However, the outcomes 
of anatomically incomplete but functionally complete revascularization 
by PCI were superior to those of anatomically complete revasculariza­
tion.49,308,761 Of note, recent studies suggest that significant levels of re­
sidual ischaemia can persist despite good angiographic results after 
complex coronary stenting.
Individual reports suggest that incomplete revascularization is asso­
ciated with increased mortality compared with complete revasculariza­
tion.762 In addition, unintended incomplete revascularization appears to 
be a surrogate marker of anatomic complexity and comorbidities, pre­
disposing to more rapid native CAD progression.760,763 An important 
predictor of anatomical incomplete revascularization by PCI is the pres­
ence of chronic total occlusion. Randomized trials have shown im­
provements of angina and QoL with PCI for chronic total occlusion 
lesions,764,765 but failed to show any reduction of mortality risk and 
MI rates.764–767
Among patients with high-risk multivessel CAD, incomplete anatom­
ical revascularization is reported more frequently among those treated 
with PCI compared with those treated with CABG. The rate ranges 
from 32% to 56% for PCI and 30% to 37% for CABG.759,762,768
However, interpreting these data is challenging due to several factors. 
Firstly, there is no uniform definition of complete revascularization.769,770
Secondly, although completeness of revascularization with PCI can be 
evaluated immediately after the procedure, many patients require staged 
procedures to achieve complete revascularization. Thirdly, within the 
first year after CABG, 20% to 40% of patients may experience asymp­
tomatic graft failure as determined by CCTA.771–773 Therefore, selecting 
a revascularization modality cannot be based solely on completeness of 
revascularization but rather should be determined through shared 
decision-making and a risk–benefit assessment.
4.4.4. Assessment of clinical risk and anatomical 
complexity
While both CABG and PCI have shown continuous technical improve­
ments and better clinical outcomes over time,774,775 the potential benefit 
of revascularization must be carefully evaluated against the procedural 
risk. The Society of Thoracic Surgeons Predicted Risk of Mortality 
(STS-PROM) risk model has proved to be more effective than the 
EuroSCORE II risk model in predicting peri-operative mortality and com­
plications in CABG patients due to its continuous calibration.776 It has 
also shown satisfactory discrimination for all-cause death at 30 days in pa­
tients undergoing CABG, allowing differentiation of high (>8%) and inter­
mediate (4% to 8%) from low (<4%) surgical mortality risk. Although 
primarily designed for surgical risk assessment, the STS-PROM score 
can also be used to evaluate the risk of revascularization through PCI 
in patients with multivessel disease, as recent studies326 have shown simi­
lar mortality rates between PCI and CABG. However, in patients with 
left main coronary artery disease (LMCAD) participating in the EXCEL 
trial (Evaluation of XIENCE versus Coronary Artery Bypass Surgery 
for Effectiveness of Left Main Revascularization), the STS risk models 
were effective in predicting outcomes for CABG but not for PCI regard­
ing peri-operative mortality and renal failure.777 Interestingly, the STS 
stroke risk model was more successful in predicting outcomes for PCI 
compared with CABG. More accurate risk prediction tools are needed 
to precisely estimate adverse events following LMCAD revascularization 
through both CABG and PCI. Other clinical factors, such as frailty or liver 
cirrhosis,778,779 have been found to increase post-operative mortality and 
should be taken into consideration during the decision-making 
process.780
The SYNTAX score was prospectively developed as an angiographic 
stratification tool to quantify the complexity of coronary lesions in pa­
tients with left main coronary artery (LMCA) or multivessel CAD and 
aid clinicians in deciding the most appropriate revascularization proced­
ure during Heart Team discussions.781 However, there are limitations 
to the SYNTAX score. Firstly, it is a time-consuming score requiring 
a detailed angiographic evaluation of each lesion. Secondly, there is con­
siderable inter-observer variability in its calculation, with a poor correl­
ation between core lab and operator-calculated SYNTAX score being 
reported.779 Thirdly, it is an anatomical score that quantifies obstruc­
tion but not plaque burden. Fourthly, it does not take physiological 
and clinical variables into account.782 Machine learning may streamline 
this process, generating prognostic information that is superior to clin­
ical risk scores783 and relevant to clinical decision-making.
The SYNTAX II score was developed by combining clinical and ana­
tomic features to better guide decision-making between CABG and PCI 
than the anatomical SYNTAX score.784,785 Although the usefulness of 
the SYNTAX II score was demonstrated in several studies,785–787 it 
ESC Guidelines                                                                                                                                                                                          3471


<!-- PAGE 58 -->

### Page 58

overestimated 4-year all-cause mortality in the EXCEL trial.788 The up­
dated version, SYNTAX score II 2020, using the SYNTAX Extended 
Survival (SYNTAXES) data and external validation in the population 
of the FREEDOM, BEST, and PRECOMBAT trials,789 showed modest 
discrimination for predicting 5-year MACE (c-index for PCI and 
CABG of 0.62 and 0.67, respectively) and acceptable discrimination 
for predicting 10-year mortality. Another validation study indicated 
that the score displayed acceptable discrimination for all-cause mortal­
ity at 5 years in a Japanese cohort with LMCAD and/or multivessel 
CAD,787 but external validation in a prospective setting is lacking.783
The British Cardiovascular Intervention Society myocardial jeopardy 
score (BCIS-JS) is an alternative to the SYNTAX score, enabling the as­
sessment of the severity and extent of CAD. It has been proven effect­
ive in predicting mortality after PCI and assessing the completeness of 
revascularization,790 but it is not as commonly used as the SYNTAX 
score.
4.4.5. Choice of myocardial revascularization 
modality
Both myocardial revascularization modalities—PCI and CABG—can 
achieve excellent outcomes, although through different mechanisms, 
in appropriately selected patients when GDMT alone fails.
4.4.5.1. Patients with single- or two-vessel coronary artery disease
Randomized evidence and subgroup analyses of trials enrolling a broad­
er spectrum of CAD patients showed similar performance of PCI and 
CABG in patients with one- or two-vessel CAD, with or without the 
involvement of the proximal LAD in terms of death, stroke, or 
MI.791–797 In patients with complex LAD lesions, the need for late re­
peat revascularization is higher after PCI than CABG,797 but CABG is 
a more invasive procedure with inherent risks, longer hospital stay 
and healing.758
4.4.5.2. Patients with unprotected left main coronary artery disease
Over the past two decades, several trials have compared PCI and 
CABG in patients with multivessel CAD, with or without unprotected 
LMCAD326,728,730,798–801 (Table 9). The patients who were included in 
these trials had to meet the eligibility criteria for both CABG or PCI at 
an acceptable risk level, and their coronary anatomy had to allow com­
plete revascularization through both procedures. However, due to the 
strict inclusion criteria, only a small percentage of eligible patients (ran­
ging from 6% to 40%) were enrolled in these trials.798,801 The strict in­
clusion criteria resulted in enrolling a relatively young population with a 
lower burden of comorbidities (mean age <66 years).728,730,798,801
Meta-analyses of RCTs have shown that the risk of death is similar for 
both CABG and PCI for LMCAD, even for patients with a high 
SYNTAX score, up to 5–10 years after the intervention. However, 
the risk of stroke is higher with CABG, while the risk of spontaneous 
MI is higher with PCI.728,730,800,802–804 In the individual-patient data 
meta-analysis of four randomized trials,730 mortality over 5 years was 
not statistically different between patients treated with PCI or with 
CABG [11.2% vs. 10.2%; HR 1.10 (95% CI, 0.91–1.32); P = .33; absolute 
risk difference of 0.9%]. A similar treatment effect was observed for 
10-year mortality [22.4% vs. 20.4%; HR 1.10 (95% CI, 0.93–1.29); 
P = .25; absolute risk difference 2.0%]. Spontaneous MI was lower in 
the CABG arm [6.2% vs. 2.6%; HR 2.35 (95% CI, 1.71–3.23); 
P < .0001; absolute risk difference 3.5%], while the results of periproce­
dural MI differed according to whether the analysis used the protocol 
definition or the universal definition of MI (available for only two 
studies). Stroke was not statistically different overall [2.7% vs. 3.1%; 
HR 0.84 (95% CI, 0.59–1.21); P = .36; absolute risk difference of 
−0.4%]. However, in a pre-specified analysis of the first 12 months of 
follow-up, stroke was lower after PCI than after CABG [0.6% vs. 
1.6%; HR 0.37 (95% CI, 0.19–0.69); P = .002; absolute risk difference 
of −1.0%].782 Subgroup analysis based on the SYNTAX score and 
the number of additionally involved coronary vessels revealed no differ­
ence in all-cause mortality between CABG and PCI for SYNTAX score 
≤32 or LMCA stenosis with 0/1 vessel disease. However, a trend for 
higher all-cause mortality was noted with PCI for SYNTAX score 
>32 (HR 1.30; 95% CI, 0.92–1.84) and/or LMCA stenosis with 2/3 ves­
sel disease (HR 1.25; 95% CI, 0.97–1.60).782 Of note, the LMCA sten­
osis involved distal bifurcation in 75% of the patients, and the absence of 
a bifurcation lesion had no impact on mortality.730 True bifurcation left 
main lesions (defined as Medina type 1,1,1 or 0,1,1 both main vessel and 
side vessel >50% narrowed with reference diameters ≥2.75 mm),805
which frequently require 2-stent techniques, have worse clinical out­
comes than non-bifurcation lesions.806–808 Despite excellent results 
after LMCA bifurcation stenting on angiography, 13% of patients still 
experience residual ischaemia in turn associated with higher long- 
term cardiovascular mortality.809 Using intracoronary imaging guidance 
to optimize stent expansion and prevent side-branch jailing may im­
prove outcomes after PCI of bifurcation LMCA lesions.810
Operator experience may significantly affect the outcomes after 
interventional procedures. A single-centre study from China found 
that operators with a higher volume of procedures performed 
(>15 per year) had better outcomes for unprotected LMCA PCI.811
An analysis of the outcome data from the British Cardiovascular 
Intervention Society’s national PCI database on 6724 patients who under­
went PCI for unprotected LMCA between 2012 and 2014 revealed that 
the volume of procedures performed by the operator plays a significant 
role in determining the outcome after PCI of unprotected LMCA.812
Although high-volume operators undertook PCIs on patients with greater 
comorbid burden and CAD complexity compared with low-volume op­
erators, 12-month survival was lower in high-volume operators [odds 
ratio (OR) 0.54; 95% CI, 0.39–0.73]. A close association between oper­
ator volume and superior 12-month survival was observed (P < .001).
A 2022 Joint ESC/EACTS (European Association for Cardio- 
Thoracic Surgery) task force recently reviewed the 2018 guideline 
recommendations on the revascularization of LMCAD in low-risk 
surgical patients with suitable anatomy for PCI or CABG.782 The 
review was mainly based on the recent individual-patient data 
meta-analysis730 of the long-term outcomes after CABG or PCI for 
LMCAD from four randomized clinical trials that included 4394 pa­
tients between March 2005 and January 2015. The review confirmed 
that for stable CCS patients with left main stem disease requiring re­
vascularization, both treatment options are clinically reasonable based 
on patient preference, expertise availability, and local operator vo­
lumes. It was proposed that revascularization with CABG be the re­
commended option, with suggested class I and LOE A, while PCI be 
overall recommended with a suggested class IIa and LOE A. The pre­
sent guidelines confirm that, among patients suitable for both revascu­
larization modalities, CABG is recommended as the overall preferred 
revascularization mode over PCI, given the lower risk of spontaneous 
MI and repeat revascularization.730,782 The present guidelines also ac­
knowledge that in patients with significant LMCA stenosis of low com­
plexity (SYNTAX score ≤22), in whom PCI can provide equivalent 
completeness of revascularization to that of CABG, PCI is recom­
mended as an alternative to CABG, given its lower invasiveness and 
non-inferior survival.718,728,730,802,813


<!-- PAGE 59 -->

### Page 59

Table 9 Summary of trial-based evidence for the comparison of percutaneous coronary intervention and coronary artery bypass grafting in patients with left 
main coronary artery disease
Study
Study population
Primary endpoint
Follow-up
Findings
PRECOMBAT 
(non-inferiority)814
600 patients with newly diagnosed LMCAD who 
had stable angina, unstable angina, silent ischaemia, 
or non-ST-segment elevation MI
All-cause death, MI, stroke, or 
ischaemia-driven target vessel 
revascularization
2 years
1-year follow-up: 
8.7% and 6.7% primary endpoints for PCI and CABG, respectively, 
absolute risk difference 2% (95% CI, –1.6% to 5.6%), P = .01 for 
non-inferiority 
2-year follow-up: 
12.2% and 8.1% primary endpoints for PCI and CABG, respectively, 
HR 1.50 (95% CI, 0.90–2.52), P = .12
PRECOMBAT 
(extended follow-up)815
5 years
17.5% and 14.3% primary endpoints for PCI and CABG, respectively, 
HR 1.27 (95% CI, 0.84–1.90), P = .26
PRECOMBAT 
(extended follow-up)816
11.3 years 
(median)
29.8% and 24.7% primary endpoints for PCI and CABG, respectively, 
HR 1.25 (95% CI, 0.93–1.69)
SYNTAX817
1800 patients with de novo three-vessel (n = 1095) 
and LMCAD (n = 795)
All-cause death, stroke, MI, and 
repeat revascularization
1 year
For the LMCAD group: 15.8% and 13.7% primary endpoints for PCI 
and CABG, respectively; P = .44
SYNTAX818
3 years
For the LMCAD group: 26.8% and 22.3%, primary endpoints for PCI 
and CABG, respectively; P = .20
SYNTAX813
5 years
For the LMCAD group: 36.9% and 31.0% primary endpoints for PCI 
and CABG, respectively, HR 1.25 (95% CI, 0.93–1.69), P = .12
SYNTAX (extended 
follow-up)795
All-cause death
10 years
For the LMCAD group: 27% and 28% primary endpoints for PCI and 
CABG, respectively, HR 0.92 (95% CI, 0.69–1.22)
NOBLE (non-inferiority 
hypothesis)819
1201 patients with LMCAD who had stable angina 
pectoris, unstable angina pectoris, or 
non-ST-segment elevation myocardial infarction
All-cause death, non-procedural MI, 
any repeat coronary 
revascularization, or stroke
3.1 years 
(mean)
28% and 18% primary endpoints for PCI and CABG, HR 1.51 (95% 
CI, 1.13–2.00), P = .004 for superiority
NOBLE (extended 
follow-up)820
4.9 years 
(median)
28% and 19% primary endpoints for PCI and CABG, HR 1.58 (95% 
CI, 1.24–2.01), P < .001 for superiority
EXCEL (non-inferiority 
hypothesis)821
1905 patients with LMCAD of low or intermediate 
anatomical complexity (SYNTAX score ≤ 32)
All-cause death, stroke, or MI
3 years 
(median)
15.4% and 14.7% primary endpoints for PCI and CABG, absolute risk 
difference 0.7% (upper 97.5% confidence limit: 4%), P = .02 for 
non-inferiority; HR 1.00 (95% CI, 0.79–1.26), P = .98 for superiority
EXCEL (extended 
follow-up)822
5 years
22.0% and 19.2% primary endpoints for PCI and CABG, absolute risk 
difference 2.8% (95% CI, −0.9 to 6.5), P = .13; OR 1.19 (95% CI, 
0.95–1.50)
© ESC 2024
CABG, coronary artery bypass grafting; CI, confidence interval; HR, hazard ratio; LMCAD, left main coronary artery disease; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.
ESC Guidelines                                                                                                                                                                                          3473


<!-- PAGE 60 -->

### Page 60

4.4.5.3. Patients with multivessel coronary artery disease
The SYNTAX and SYNTAXES randomized trials, comparing PCI and 
CABG for multivessel CAD with or without unprotected LMCAD, re­
ported differences in terms of survival and freedom from cardiovascular 
events dependent on SYNTAX score.795,798,823 The recently published 
10-year follow-up results of the SYNTAX trial (SYNTAXES trial) re­
ported similar all-cause death rates with both revascularization modal­
ities,795 while there was significantly higher mortality in patients with 
SYNTAX scores ≥33 who were randomized for PCI (HR 1.41; 95% 
CI, 1.05–1.89).795 A significant 5-year mortality gap between PCI and 
CABG has been reported among patients with complex multivessel 
CAD in the presence of DM (15.7% after PCI vs. 10.7% after CABG; 
HR 1.44; 95% CI, 1.20–1.77; P = .0001).728
In the FREEDOM trial (Strategies for Multivessel Revascularization in 
Patients with Diabetes), 1900 patients with diabetes and multivessel 
disease without LMCAD were randomized to CABG vs. PCI (using 
first-generation DES). Long-term results at a median follow-up dur­
ation of 3.8 years [interquartile range (IQR) 2.5–4.9 years] showed 
higher all-cause mortality in the PCI group vs. CABG group (24.3% 
vs. 18.3%; P = .01).801 Out of all the centres that participated in the 
study, only 25 agreed to participate in the FREEDOM extended follow- 
up, and therefore, only 49.6% of patients in the study were followed up 
for up to 8 years thus limiting statistical power. The all-cause mortality 
rate among the FREEDOM follow-up patients was not significantly dif­
ferent between those who underwent PCI and CABG procedures 
(23.7% vs. 18.7%; HR 1.32; 95% CI, 0.97–1.79; P = .076). In multivariable 
analysis, a significant interaction emerged between patient age and long- 
term survival benefit of CABG surgery. Patients younger than the 
median age at study entry (63.3 years) preferentially derived benefit 
from CABG; mortality among patients ≤63.3 years old was 20.7% 
(PCI) vs. 10.2% (CABG); mortality among patients >63.3 years old 
was 26.3% vs. 27.6% (P = .01 for interaction).824
4.4.5.4. Impact of coronary pressure guidance on multivessel coronary 
artery disease patients undergoing percutaneous coronary intervention
Consistently higher rates of repeat revascularizations following PCI 
compared with CABG have been shown in clinical trials involving multi­
vessel CAD patients, with significant impacts on outcomes.825 With the 
use of modern DESs, the rate of repeat revascularization after PCI has 
declined.725,795,802,820 FFR guidance during PCI leads to lower revascu­
larization rates compared with angiography-guided PCI, with fewer 
stents placed in the FFR group.826
In the FAME 3 trial, 1500 patients with three-vessel CAD not involv­
ing the LMCA were randomly assigned to PCI with second-generation 
DESs (durable polymer zotarolimus-eluting stents) guided by FFR, or to 
CABG.326 At 1-year follow-up, the incidence of the composite primary 
endpoint, MACCE [major adverse cardiac (death from any cause, MI, 
stroke, or repeat revascularization) or cerebrovascular events], was 
10.6% among patients assigned to FFR-guided PCI and 6.9% among 
patients assigned to CABG surgery (HR 1.5; 95% CI, 1.1–2.2), findings 
that were not consistent with non-inferiority (P = .35 for non- 
inferiority).326 At 3-year follow-up, there still was a significantly higher 
rate of MACCE for PCI than for CABG (18.6% vs. 12.5%; HR 1.5; 95% 
CI, 1.2–2.0; P = .002), consistent with the 1-year follow-up results. 
However, there was no difference in the incidence of the composite 
of death, MI, or stroke after FFR-guided PCI compared with CABG 
(12.0% vs. 9.2%; HR 1.3; 95% CI, 0.98–1.83; P = .07). The rates of death 
(4.1% vs. 3.9%; HR 1.0; 95% CI, 0.6–1.7; P = .88) and stroke (1.6% vs. 
2.0%; HR 0.8; 95% CI, 0.4–1.7; P = .56) were not different, while MI 
again occurred more frequently after PCI (7.0% vs. 4.2%; HR 1.7; 
95% CI, 1.1–2.7; P = .02).827 Repeat revascularization was also more 
frequent after PCI (11.1% vs. 5.9%; HR 1.9; 95% CI, 1.3–2.7; 
P = .001). Of note, after both PCI and CABG, event rates were lower 
(about half for mortality) than in the SYNTAX cohort of patients with 
three-vessel CAD. There was a narrower difference for MI rates be­
tween the two modalities, probably owing to procedural advances 
with PCI and CABG and improvements in GDMT. In patients with 
less complex CAD (SYNTAX score ≤22), outcomes were as favour­
able as after CABG.
4.4.5.5. Virtual percutaneous coronary intervention: combination of 
coronary pressure mapping with coronary anatomy for percutaneous 
coronary intervention planning
There is increasing evidence on the impact of post-PCI FFR/iFR/QFR on 
outcomes after PCI.828–833 A quarter of these patients have residual is­
chaemia (FFR < 0.80 or iFR ≤ 0.89) after angiographically successful 
PCI, with circa 80% of cases attributable to focal lesions not identified 
by angiography alone.830 One randomized trial reported that post-PCI 
iFR/FFR can be improved by additional intracoronary intervention, in­
cluding post-dilatation or additional stent implantation, but remains 
≤0.80 in 18% of cases.829 Preliminary results demonstrate that the 
combination of invasive coronary pressure mapping by iFR pullback 
or QFR mapping superimposed on the anatomical information of 
ICA accurately predict the post-PCI coronary pressure for any combin­
ation of stent location and stent length, as part of a ‘virtual PCI’ ap­
proach,348,834 and allows modification of the procedural planning in 
about 30% of cases.835 The AQVA (Angio-based Quantitative Flow 
Ratio Virtual PCI Versus Conventional Angio-guided PCI in the 
Achievement of an Optimal Post-PCI QFR) trial (n = 300) demonstrated 
that a strategy of QFR/ICA-based virtual PCI was associated with a higher 
rate of post-PCI QFR ≥0.90 compared with angiography-based PCI 
(93.4% vs. 84.9%, P = .009).836 The DEFINE GPS trial (NCT04451044) 
is currently investigating the clinical benefit of pre-procedural coronary 
pressure mapping with iFR pullback and ‘virtual PCI’ to clarify this issue 
further and improve post-PCI clinical outcomes.
Virtual PCI can be conducted by combining anatomical information 
from CCTA with that of FFR-CT. FFR-CT/CCTA-based virtual PCI has 
two theoretical advantages over ICA-based virtual PCI: (i) it does not re­
quire invasive investigation, and (ii) it provides information on vessel wall/ 
plaque composition.837 FFR-CT/CCTA-based virtual PCI has been 
shown to accurately predict post-PCI FFR838 and to modify PCI proced­
ural planning in 31% of lesions and 45% of patients.839 The Precise 
Procedural and PCI Plan (P4) trial (NCT05253677) is currently investi­
gating the clinical benefit of iFR-based virtual PCI to clarify this issue fur­
ther and improve post-PCI clinical outcomes.
4.4.5.6. Impact of intracoronary imaging guidance on multivessel 
coronary artery disease patients undergoing percutaneous coronary 
intervention
Three large randomized trials have recently investigated the clinical 
benefit of intracoronary imaging during ‘complex’ PCI. One trial, 
RENOVATE-COMPLEX PCI,840 mainly investigated the benefit of 
IVUS (74% IVUS, 26% OCT), while the two others, OCTOBER810
and ILUMIEN IV,841 investigated the benefit of OCT. Importantly, 
while OCTOBER (true bifurcation lesions) and RENOVATE- 
COMPLEX PCI (including true bifurcation lesions, long lesions,


<!-- PAGE 61 -->

### Page 61

chronic total occlusion lesions) focused on ‘anatomically’ complex le­
sions, ILUMIEN IV made the choice to define ‘complexity’ by the clin­
ical context (DM and STEMI/NSTEMI) and/or by the anatomical 
characteristics of the lesions.
In RENOVATE-COMPLEX PCI, intravascular imaging-guided PCI led 
to a lower risk of a composite of death from a cardiac cause, target 
vessel-related MI, or clinically driven target-vessel revascularization 
than angiography-guided PCI by 2 years (7.7% vs. 12.3%; HR 0.64; 
95% CI, 0.45–0.89; P = .008).840
In OCTOBER, OCT-guided PCI led to a lower risk of a composite of 
death from a cardiac cause, target-lesion MI, or ischaemia-driven 
target-lesion revascularization than angiography-guided PCI by 2 years 
(10.1% vs. 14.1%; HR 0.70; 95% CI, 0.50–0.98; P = .035).810 In ILUMIEN 
IV, OCT-guided PCI failed to decrease the rate of the primary efficacy 
endpoint of target-vessel failure, defined as death from cardiac causes, 
target-vessel MI, or ischaemia-driven target-vessel revascularization 
(7.4% vs. 8.2%; HR 0.90; 95% CI, 0.67–1.19; P = .45), while the incidence 
of definite/probable stent thrombosis was significantly reduced by OCT 
guidance vs. angiography guidance (0.5% vs. 1.4%; HR 0.36; 95% CI, 
0.14–0.91; P = .02).841
4.4.5.7. Hybrid revascularization in multivessel coronary artery 
disease patients
Arterial grafting with left internal mammary artery (LIMA) to the LAD 
system and multiple arterial grafting reduces the risk of graft occlusion, 
thus increasing the longevity of revascularization efficacy after 
CABG.842,843 Hybrid revascularization of multivessel CAD with minim­
ally invasive direct coronary artery bypass (MIDCAB)-LAD plus PCI of 
the remaining arteries may represent an alternative option. Hybrid off- 
pump revascularization seems a suitable option for patients at moder­
ate-to-high risk for surgery by avoiding the use of cardiopulmonary by­
pass. Despite this attractive concept, the frequency of hybrid 
revascularizations remains extremely modest, with about 0.1% of sur­
gical revascularizations.844 Few data are available comparing hybrid re­
vascularization vs. conventional CABG or PCI. Large registry data 
report higher rates of bleeding, renal failure, MI, and HF with hybrid re­
vascularization compared with PCI alone,844 while a very small rando­
mized trial reported similar clinical outcomes at long-term 
follow-up.845 It seems challenging to perform larger RCTs to investigate 
this question. The recent National Heart, Lung, and Blood 
Institute-funded Hybrid Trial (Hybrid Coronary Revascularization 
Trial; NCT03089398) was prematurely discontinued due to slow en­
rolment, with only 200 patients in 5 years.
4.4.6. Patient–physician shared decision-making to 
perform and select revascularization modality
Shared decision-making between patients and healthcare professionals, 
based on patient-centred care, is considered a paramount process in 
defining the appropriate therapeutic pathway. Essential aspects of 
shared decision-making are: a complete and accurate explanation of 
the disease; presentation and description of therapeutic options; dis­
cussion of potential risks, benefits, and impact on QoL for each proced­
ure; considering patient preferences and goals; and carefully explaining 
each step of the post-procedural course and follow-up. Poor shared 
decision-making is associated with worse physical and mental out­
comes, lower adherence to therapy, and an increased number of emer­
gency department visits.846–848 Shared decision-making and family 
meetings involving relatives increase patient trust in the physicians, 
with greater adherence to therapeutic decisions. Shared decision- 
making and patient medical education, considering the patient’s charac­
teristics, mental status, cultural beliefs, and educational level, are there­
fore associated with increased patient knowledge and better QoL and 
with lower levels of anxiety and depression.849–851
Using lay language and discussion with patients and relatives of short- 
term procedure-related and long-term risks and benefits—such as sur­
vival, relief of angina, QoL, the potential need for late reintervention, 
the need for prevention measures, and uncertainties associated with 
different treatment strategies—are of great importance. Although cur­
rent recommendations are primarily based on the ability of treatments 
to reduce adverse events, including improved survival, there is growing 
interest in PROMs.852 Patients are not only interested in knowing how 
recommended treatment impacts prognosis but also their QoL in the 
way they perceive it.853 The patient’s right to decline the treatment op­
tion recommended by the Heart Team must be respected. Patient re­
fusal of a recommended treatment should be acknowledged in a 
written document after the patient has received the necessary informa­
tion. In this case, the Heart Team may offer the patient an alternative 
treatment option.
The multidisciplinary Heart Team, on site or with partner institutions 
(Hub-Spoke institutions)—comprising clinical or non-invasive cardiolo­
gists, cardiac surgeons and interventional cardiologists, as well as anaes­
thetists or other specialists and healthcare professionals, if deemed 
necessary—should provide a balanced multidisciplinary decision- 
making process.
Transparency in informed consent is critical, particularly when treat­
ment options are debated. Complex cases, such as patients with CAD 
of high anatomic complexity and significant non-cardiac comorbidities, 
should be discussed in the Heart Team, taking into consideration other 
characteristics not always included in traditional databases, such as 
frailty. Heart Team/guideline discordance is common in complex 
CAD patients undergoing revascularization, especially in elderly pa­
tients, those with complex coronary disease, and those treated at cen­
tres without cardiac surgery service. These patients have a higher risk of 
mid-term mortality.854
In all cases, it is necessary to allow sufficient time to assess all available 
information and clearly explain and discuss the findings with each patient. 
The rationale for a decision and consensus on the optimal revasculariza­
tion treatment should be documented on the patient’s chart. While the 
Heart Team decision is mainly driven by long-term survival benefits with 
a certain modality of revascularization, patient’s preferences must be 
respected.853,855,856
4.4.7. Institutional protocols, clinical pathways, and 
quality of care
Institutional protocols, developed by the Heart Team and aligned with 
the current guidelines, should delineate specific anatomical and func­
tional criteria of disease complexity and specific clinical subsets of pa­
tient’ risk for cardiac surgery or intervention that may or may not be 
treated ad hoc. These protocols should be incorporated into clinical 
pathways, with regular meetings to assess the applied indications for 
myocardial revascularization and monitor the safety and effectiveness 
of the procedures, ensuring the quality of delivered patient care. 
Collaborative protocols are necessary when cardiac surgery isn’t avail­
able on site, and remote Heart Team meetings should be established.
ESC Guidelines                                                                                                                                                                                          3475


<!-- PAGE 62 -->

### Page 62

Recommendation Table 22 — Recommendations for revascularization in patients with chronic coronary syndrome (see 
also Evidence Table 22)
Recommendations
Classa
Levelb
Informed and shared decisions
It is recommended that patients scheduled for percutaneous or surgical revascularization receive complete information about the benefits, 
risks, therapeutic consequences, and alternatives to revascularization, as part of shared clinical decision-making.847,848,857
I
C
For complex clinical cases, to define the optimal treatment strategy, in particular when CABG and PCI hold the same level of 
recommendation, a Heart Team discussion is recommended, including representatives from interventional cardiology, cardiac surgery, 
non-interventional cardiology, and other specialties if indicated, aimed at selecting the most appropriate treatment to improve patient 
outcomes and quality of life.
I
C
It is recommended to communicate the proposal of the Heart Team in a balanced way using language that the patient can understand.
I
C
It is recommended that the decision for revascularization and its modality be patient-centred, considering patient preferences, health 
literacy, cultural circumstances, and social support.849–851
I
C
It is recommended that the Heart Team (on site or with a partner institution) develop institutional protocols to implement the appropriate 
revascularization strategy in accordance with current guidelines.855,856,858
I
C
Revascularization to improve outcomes
In chronic coronary syndrome patients with left ventricular ejection fraction >35%
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant left main stem stenosis to improve survival.718,719,859,860
I
A
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant three-vessel disease to improve long-term survival and to reduce long-term cardiovascular mortality 
and the risk of spontaneous myocardial infarction.55,56,317,732–734
I
A
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant single- or two-vessel disease involving the proximal LAD, to reduce long-term cardiovascular mortality 
and the risk of spontaneous myocardial infarction.55,56,317,719,732–734
I
B
In chronic coronary syndrome patients with left ventricular ejection fraction ≤35%
In CCS patients with LVEF ≤35%, it is recommended to choose between revascularization or medical therapy alone, after careful evaluation, 
preferably by the Heart Team, of coronary anatomy, correlation between coronary artery disease and LV dysfunction, comorbidities, life 
expectancy, individual risk-to-benefit ratio, and patient perspectives.
I
C
In surgically eligible CCS patients with multivessel CAD and LVEF ≤35%, myocardial revascularization with CABG is recommended over 
medical therapy alone to improve long-term survival.53,54,749,861
I
B
In selected CCS patients with functionally significant MVD and LVEF ≤35% who are at high surgical risk or not operable, PCI may be 
considered as an alternative to CABG.526,729
IIb
B
Revascularization to improve symptoms
In CCS patients with persistent angina or anginal equivalent, despite guideline-directed medical treatment, myocardial revascularization of 
functionally significant obstructive CAD is recommended to improve symptoms.50,321,402,732,734,757
I
A
Assessment of procedural risks and post-procedural outcomes
In patients with complex CAD in whom revascularization is being considered, it is recommended to assess procedural risks and 
post-procedural outcomes to guide shared clinical decision-making.
I
C
Calculation of the STS score is recommended to estimate in-hospital morbidity and 30-day mortality after CABG.777,862–864
I
B
In patients with multivessel obstructive CAD, calculation of the SYNTAX score is recommended to assess the anatomical complexity of 
disease.786,865
I
B
Intracoronary imaging guidance by IVUS or OCT is recommended when performing PCI on anatomically complex lesions, in particular left 
main stem, true bifurcations, and long lesions.866,337,810,840,841
I
A
Intracoronary pressure measurement (FFR or iFR) or computation (QFR) :
• is recommended to guide lesion selection for intervention in patients with multivessel disease; 308,826,866,867
I
A
• should be considered at the end of the procedure to identify patients at high risk of persistent angina and subsequent clinical 
events;828,830,831,868
IIa
B
• may be considered at the end of the procedure to identify lesions potentially amenable to treatment with additional PCI.350,829,831
IIb
B
Continued


<!-- PAGE 63 -->

### Page 63

Choice of revascularization modality
It is recommended that physicians select the most appropriate revascularization modality based on patient profile,c coronary anatomy,d 
procedural factors,e LVEF, preferences, and outcome expectations.719,725,728,792–795,801,816,820,822,859,869
I
C
© ESC 2024
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, chronic coronary syndrome; FFR, fractional flow reserve; iFR, instantaneous wave-free ratio; IVUS, intravascular 
ultrasound; LAD, left anterior descending; LV, left ventricular; LVEF, left ventricular ejection fraction; MVD, multivessel disease; OCT, optical coherence tomography; PCI, percutaneous 
coronary intervention; QFR, quantitative flow ratio; STS, Society of Thoracic Surgeons; SYNTAX, SYNergy Between PCI with TAXUS and Cardiac Surgery. 
aClass of recommendation. 
bLevel of evidence. 
cAge, frailty, cognitive status, diabetes, and any other comorbidities. 
dMultivessel disease with/out left main stem involvement, high anatomical complexity, and likelihood of revascularization completeness. 
eLocal expertise and outcomes, surgical and interventional risk.
Recommendation Table 23 — Recommendations for mode of revascularization in patients with chronic coronary syn­
drome (see also Evidence Table 23)
Anatomically and clinically based recommendations for revascularization in CCS
Classa
Levelb
Left main disease
In CCS patients at low surgical riskc with significant left main coronary stenosis, CABG:
• is recommended over medical therapy alone to improve survival;719
I
A
• is recommended as the overall preferred revascularization mode over PCI, given the lower risk of spontaneous myocardial infarction and 
repeat revascularization.728,730,782
I
A
In CCS patients with significant left main coronary stenosis of low complexity (SYNTAX score ≤22), in whom PCI can provide equivalent 
completeness of revascularization to that of CABG, PCI is recommended as an alternative to CABG, given its lower invasiveness and 
non-inferior survival. 718,728,730,802,813
I
A
In CCS patients with significant left main coronary stenosis of intermediate complexity (SYNTAX score 23–32), in whom PCI can provide 
equivalent completeness of revascularization to that of CABG, PCI should be considered, given its lower invasiveness and non-inferior 
survival.718,728,730,802,805,809,813,820,822
IIa
A
Left main with multivessel diseased
In CCS patients at low surgical risk with suitable anatomy, CABG is recommended over medical therapy alone to improve survival.718,719,870
I
A
In CCS patients at high surgical risk, PCI may be considered over medical therapy alone.728,813
IIb
B
Multivessel diseased and diabetes
In CCS patients with significant multivessel disease and diabetes, with insufficient response to guideline-directed medical therapy, CABG is 
recommended over medical therapy alone and over PCI to improve symptoms and outcomes.801,824,871–874
I
A
In CCS patients at very high surgical risk, PCI should be considered over medical therapy alone to reduce symptoms and adverse 
outcomes.55,874
IIa
B
Three-vessel disease, without diabetes
In CCS patients with significant three-vessel disease, preserved LVEF, no diabetes, and insufficient response to guideline-directed medical 
therapy, CABG is recommended over medical therapy alone to improve symptoms, survival, and other outcomes.719,722,875
I
A
In CCS patients with preserved LVEF, no diabetes, insufficient response to guideline-directed medical therapy, and significant three-vessel 
disease of low-to-intermediate anatomic complexity in whom PCI can provide similar completeness of revascularization to that of CABG, 
PCI is recommended, given its lower invasiveness, and generally non-inferior survival.326,728,795,798,876
I
A
Single- or double-vessel disease involving the proximal LAD
In CCS patients with significant single- or double-vessel disease involving the proximal LAD and insufficient response to guideline-directed 
medical therapy, CABG or PCI is recommended over medical therapy alone to improve symptoms and outcomes.52,321,719,791,792
I
A
In CCS patients with complex significant single- or double-vessel disease involving the proximal LAD, less amenable to PCI, and insufficient 
response to guideline-directed medical therapy, CABG is recommended to improve symptoms and reduce revascularization rates.877–879
I
B
Single- or double-vessel disease not involving the proximal LAD
In symptomatic CCS patients with significant single- or double-vessel disease not involving the proximal LAD and with insufficient response 
to guideline-directed medical therapy, PCI is recommended to improve symptoms.50,321,732
I
B
In symptomatic CCS patients with significant single- or double-vessel disease not involving the proximal LAD and with insufficient response 
to guideline-directed medical therapy, not amenable to revascularization by PCI, CABG may be considered to improve symptoms.
IIb
C
© ESC 2024
CABG, coronary artery bypass grafting; CCS, chronic coronary syndrome; LAD, left anterior descending; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; 
SYNTAX, SYNergy Between PCI with TAXUS and Cardiac Surgery. 
aClass of recommendation. 
bLevel of evidence. 
cFor example: absence of previous cardiac surgery, or severe morbidities, or frailty, or immobility precluding CABG. 
dMultivessel disease is defined as the involvement of at least two main coronary arteries.
ESC Guidelines                                                                                                                                                                                          3477


<!-- PAGE 64 -->

### Page 64

### 5 Optimal assessment and

treatment of specific groups
5.1. Coronary artery disease and heart 
failure
About half of acute and chronic HF patients have an ischaemic aeti­
ology.880,881 Over the last decades, the proportion of ischaemic 
HFrEF has decreased while that of HFpEF, defined according to the 
chronic heart failure,526 has increased.882 The evaluation of inducible is­
chaemia is important in patients with HF, given the high prevalence of 
CAD.883–885 Moreover, patients with HFpEF may present MVA due to 
CMD.886 Indeed, CMD was observed in up to 75% of patients with 
HFpEF and was associated with worse diastolic relaxation velocities, 
as well as higher filling pressures, and an increased risk of adverse 
events.883–885,887–890 Clinical assessment alone may under-estimate 
the proportion of patients with obstructive or non-obstructive CAD, 
which can be found in up to 81% of HFpEF patients.887
Under-estimation of obstructive CAD leads to failure in identifying 
those patients who may benefit from revascularization. Conversely, 
in ANOCA patients with preserved LV function, a CFR of <2 was in­
dependently associated with diastolic dysfunction and future MACE, es­
pecially HFpEF events.891 This suggests that CMD and myocardial 
stiffness may contribute to HFpEF pathophysiology.892 In HFpEF pa­
tients, functional imaging should, therefore, be considered to detect 
CMD and epicardial CAD.
Exercise or pharmacological stress echocardiography can be used 
for the assessment of inducible ischaemia and can also help in the dif­
ferential diagnosis of HFpEF.893,894 Stress SPECT or PET can also be 
used for the detection of inducible ischaemia. Non-invasive stress 
testing can be difficult in patients with HF because of possible exer­
cise intolerance. CCTA is recommended in patients with HF with a 
low-to-intermediate pre-test likelihood of obstructive CAD and 
those with equivocal non-invasive stress tests, provided there is no 
contraindication to contrast administration.894–898 In HFpEF pa­
tients, perfusion PET should be considered for the detection of 
CMD.891 In patients with HFrEF and moderate-to-severe inducible 
myocardial ischaemia, surgical revascularization improved long-term 
survival.54,315 The results of the REVIVED-BCIS2 trial seem to 
contradict these findings, as PCI did not reduce mortality or HF hos­
pitalization in patients with severe LV systolic dysfunction (LVEF ≤  
35%) receiving optimal medical therapy.729 The same trial also re­
vealed that viability testing did not offer any prognostic benefit.755
The role of myocardial revascularization and viability testing is further 
addressed in Section 4.4.2.
In HF patients with anginal (or equivalent) symptoms, despite opti­
mized GDMT, CCTA or ICA is recommended to confirm the diagnosis 
of obstructive CAD and its severity.
Over the past three decades, several landmark clinical trials have pro­
vided robust evidence on the prognostic benefit of pharmacological 
therapies in patients with HFrEF. In these patients, four drug classes 
[ACE-Is or angiotensin receptor neprilysin inhibitors (ARNIs),891 beta- 
blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 
inhibitors] are recommended for outcome improvement regardless 
of HF aetiology and comorbidities, including CAD.526
In patients with HFrEF, an ARB is recommended in patients who do 
not tolerate ACE-Is or ARNIs. Also, ivabradine should be considered in 
addition to the four pillars. It can be used as an alternative to beta- 
blockers, when contraindicated or not tolerated, or as additional 
antianginal therapy in patients with sinus rhythm and heart rate of 
>70 b.p.m.899 Other antianginal drugs (e.g. amlodipine, felodipine, ni­
corandil, trimetazidine, ranolazine, and nitrates) are effective for im­
proving symptoms in patients with HFrEF.546,900–902 Diltiazem and 
verapamil increase HF-related events in patients with HFrEF and are 
contraindicated.526 In patients with LVEF ≤35% of ischaemic aetiology, 
an ICD is strongly recommended for primary prevention; in those with 
LVEF ≤35% and QRS >130 ms, CRT needs to be considered.526
Further details regarding the management of patients with HFrEF are 
reported in the 2021 ESC Guidelines for the diagnosis and treatment 
of acute and chronic heart failure.526
In patients with HFpEF, in addition to diuretics for treating conges­
tion, SGLT2 inhibitors are now recommended for outcome improve­
ment.709 Additionally, beta-blockers, long-acting nitrates, CCBs, 
ivabradine, ranolazine, trimetazidine, nicorandil, and their combinations 
should be considered in patients with HFpEF and CAD for angina relief, 
but without foreseen benefits on HF and coronary endpoints. 
Low-dose rivaroxaban may be considered in patients with CAD and 
HF, LVEF of >40%, and sinus rhythm when at high risk of stroke and 
with low haemorrhagic risk.526,903,904
Evidence and recommendations for myocardial revascularization in 
patients with HF are reported in Section 4.4.2. Notably, patients with 
advanced HF may be candidates for LV assistance devices and/or heart 
transplantation.526
During of high-risk PCI for complex CAD905 in patients with HFrEF, 
mechanical cardiac support, such as the microaxial flow pump, may min­
imize the risk of severe complications and provide haemodynamic stabil­
ity, facilitating the achievement of complete revascularization.906,907
Recommendation Table 24 — Recommendations for management of chronic coronary syndrome patients with chronic 
heart failure (see also Evidence Table 24)
Recommendations
Classa
Levelb
Managing CCS in heart failure patients
In HF patients with LVEF ≤35% in whom obstructive CAD is suspected, ICA is recommended with a view towards improving prognosis by 
CABG, taking into account the risk-to-benefit ratio of the procedures.54,729,749,908
I
B
In HF patients with LVEF >35% and suspected CCS with low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA or 
functional imaging is recommended.887
I
C
In HF patients with LVEF >35% and suspected CCS with very high (>85%) pre-test likelihood of obstructive CAD, ICA (with FFR, iFR, or 
QFR when needed) is recommended.887
I
C
Continued


<!-- PAGE 65 -->

### Page 65

5.2. Angina/ischaemia with 
non-obstructive coronary arteries
5.2.1. Definition
A large proportion of patients undergoing coronary angiography be­
cause of angina do not have obstructive epicardial coronary arteries 
(ANOCA). In these patients, the prevalence of demonstrable ischaemia 
(INOCA) varies, depending on the stress test performed, between 10% 
and 30% (Figure 12).926–928 Angina/ischaemia with non-obstructive cor­
onary arteries is more frequent among women (approximately 50% to 
70%) than in men (30% to 50%) referred for ICA.7,929 The mismatch 
between blood supply and myocardial oxygen demands leading to an­
gina and ischaemia in ANOCA/INOCA may be caused by CMD and/ 
or epicardial coronary artery spasm.36 However, these conditions are 
rarely correctly diagnosed, and, therefore, no tailored therapy is pre­
scribed for these patients. As a consequence, these patients continue 
to experience recurrent angina with poor QoL, leading to repeated 
hospitalizations, unnecessary repeat coronary angiography, and adverse 
cardiovascular outcomes in the short and long term.36
5.2.2. Angina/ischaemia with non-obstructive 
coronary arteries endotypes
Invasive functional coronary testing using Ach and adenosine in indivi­
duals suspected of CCS and with non-obstructive coronary arteries en­
ables the differentiation of the following endotypes: (i) endothelial 
dysfunction; (ii) impaired vasodilation (low coronary flow reserve and/ 
or high microvascular resistance); (iii) epicardial vasospastic angina; 
(iv) microvascular vasospastic angina; (v) endotype combinations; (vi) 
equivocal response, i.e. angina without fulfilling any endotype criteria.37,38
The prevalence of ANOCA and INOCA in relation to the presence of 
the endotypes is shown in Figure 12. Angina with non-obstructive cor­
onary arteries occurs in up to 70% of the patients undergoing ICA, of 
whom 25% have documented ischaemia (INOCA). Among the patients 
who are tested with Ach, 80% show endothelial dysfunction, 60% have 
MVA/VSA, and 50% have an impaired CFR and/or high microvascular 
resistance.38,927,930,931 This emphasizes the importance of testing not 
only patients with INOCA but also all patients with ANOCA to deter­
mine the final endotype so that appropriate treatment can be initiated.
In patients with HFpEF with persistent angina or equivalent symptoms and normal or non-obstructive epicardial coronary arteries, PET 
or CMR perfusion or invasive coronary functional testing should be considered to detect or rule out coronary microvascular 
dysfunction.883–885,887–889
IIa
B
In selected patients with HFrEF undergoing high-risk PCI for complex CAD, the use of a microaxial flow pump may be considered in 
experienced centres.905–907
IIb
C
Managing heart failure in CCS patients
It is recommended that CCS patients with HF be enrolled in a multidisciplinary HF management programme to reduce the risk of HF 
hospitalization and to improve survival.526,909–911
I
A
An ACE-I, an MRA, an SGLT2 inhibitor (dapagliflozin or empagliflozin), and, in stable conditions, a beta-blocker are recommended for CCS 
patients with HFrEF to reduce the risk of HF hospitalization and death.526,704,705,912,913
I
A
An SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in patients with Heart Failure with mildly reduced Ejection Fraction 
(HFmrEF) or HFpEF to reduce the risk of HF hospitalization or cardiovascular death.706,707
I
A
An ARB is recommended in symptomatic patients with CCS and HFrEF unable to tolerate an ACE-I or ARNI to reduce the risk of HF 
hospitalization and cardiovascular death.914
I
B
Sacubitril/valsartan is recommended as a replacement for an ACE-I or ARB in CCS patients with HFrEF to reduce the risk of HF 
hospitalization and of cardiovascular and all-cause death.693
I
B
Diuretics are recommended in CCS patients with HF and signs and/or symptoms of congestion to alleviate symptoms, improve exercise 
capacity, and reduce HF hospitalizations.915
I
B
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class II–III) of 
ischaemic aetiology (unless they have had an MI in the prior 40 days), and an LVEF ≤35% despite ≥3 months of optimized medical treatment, 
provided they are expected to survive substantially longer than 1 year with good functional status.526,916
I
A
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular 
arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of 
reversible causes or unless the ventricular arrhythmia has occurred <48 h after an MI. 917–920
I
A
CRT is recommended for CCS patients with symptomatic HF, sinus rhythm, LVEF ≤35% despite GDMT, and a QRS duration ≥150 ms with 
an LBBB QRS morphology to improve symptoms and survival and to reduce morbidity.526,921,922
I
A
CRT rather than right ventricular pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an 
indication for ventricular pacing for high-degree AV block in order to reduce morbidity. This includes patients with AF. 923–925
I
A
© ESC 2024
ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; AV, atrioventricular; CABG, 
coronary artery bypass grafting; CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic 
resonance; CRT, cardiac resynchronization therapy; FFR, fractional flow reserve; GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved 
ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICA, invasive coronary angiography; ICD, implantable cardioverter defibrillator; iFR, instantaneous wave-free ratio; 
LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; PCI, 
percutaneous coronary intervention; PET, positron emission tomography; SGLT2, sodium–glucose cotransporter 2. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3479


<!-- PAGE 66 -->

### Page 66

5.2.2.1. Microvascular angina
Microvascular angina is the clinical manifestation of myocardial ischaemia 
caused by structural or functional changes in the coronary microvascula­
ture (leading to impaired CFR and/or reduced microcirculatory conduct­
ance) and/or abnormal vasoconstriction of coronary arterioles (causing 
dynamic arteriolar obstruction).932,933 Both vascular dysfunction me­
chanisms may co-exist and contribute to MVA.
The prevalence of MVA was 26% in a study of patients with 
non-obstructive CAD who had a CFVR below 2 when assessed by 
transthoracic Doppler echocardiography.934 Studies assessing CMD in­
vasively or by PET with different cut-offs have found that 39% to 54% 
had CMD.935,936 The threshold for CMD varies between studies and 
depending on the techniques used (PET, CMR, thermodilution, or 
Doppler); the threshold is a CFR of <2.0–2.5.36,39 A thermodilution 
CFR of <2.0 has low sensitivity for identifying CMD, but using the 
same threshold as for Doppler (<2.5) results in reasonable diagnostic 
accuracy.937
Smoking, age, diabetes, hypertension, and dyslipidaemia are associated 
with CMD.934,935,938 Other studies have shown that diabetes was un­
common among patients with angina and non-obstructive CAD, while 
hypertension and dyslipidaemia were relatively more prevalent.939,940
Inflammatory conditions such as systemic lupus erythematosus (SLE) 
and rheumatoid arthritis appear to be associated with MVA and are 
not infrequently encountered in patients with angina.941 Inflammatory 
diseases occur more often in women after menopause than in men, 
which may contribute to the sex differences in MVA.942–944 Last, but 
not least, there is increasing evidence that psychosocial stress is involved 
in coronary vasomotor disorders.945,946
Obstructive CAD
Coronary risk 
factors
Detectable demand ischaemia
INOCA
ANOCA
50–70%
30–50%
Ischaemiaª
Abnormal vasodilation
(CFR <2.5)
Vasospasm on Ach
Endothelial dysfunction
Non-obstructive or no apparent CAD
30–50%
50–70%
25%
50%
60%
80%
Figure 12 Prevalence of disease characteristics in patients with ANOCA/INOCA referred for invasive coronary functional testing. Ach, acetylcholine; 
ANOCA, angina with non-obstructive coronary arteries; CFR, coronary flow reserve; i.c., intracoronary; INOCA, ischaemia with non-obstructive cor­
onary arteries. In the ILIAS (Inclusive Invasive Physiological Assessment in Angina Syndromes) registry,927 ANOCA is present in up to 70% of patients 
referred for invasive coronary angiography and functional testing. Endothelial dysfunction is present in 80% and an acetylcholine test is positive in 60% of 
these patients. An impaired CFR (≤2.5), measured by i.c. Doppler guidewires, is present in 50%, while ischaemia (INOCA) is documented by non- 
invasive functional testing in only 25% of ANOCA patients. The prevalence of coronary vasospasm can vary in different studies depending on dose 
of acetylcholine and test protocol. aPrevalence of ischaemia by non-invasive functional testing increases from non-obstructive to obstructive CAD.


<!-- PAGE 67 -->

### Page 67

5.2.2.2. Epicardial vasospastic angina
Vasospastic angina is the clinical manifestation of myocardial ischaemia 
caused by abnormal vasoconstriction of one or more epicardial coron­
ary arteries leading to a dynamic coronary obstruction. Standardized 
diagnostic criteria for VSA have been defined.73 Microvascular angina 
and epicardial VSA can co-exist, which is associated with a worse prog­
nosis.947 Concomitant endothelial dysfunction is prevalent in most pa­
tients with INOCA with inducible coronary artery spasm and/or 
impaired adenosine-mediated vasodilation.38,948
The Japanese population has a higher prevalence of coronary vaso­
spasm than Western populations. In addition, the frequencies of mul­
tiple coronary spasms (≥2 spastic arteries) by provocative testing in 
Japanese (24.3%) and Taiwanese populations (19.3%) are markedly 
higher than those in Caucasians (7.5%).949–951
5.2.3. Clinical presentations
Angina/ischaemia with non-obstructive coronary arteries is associated 
with a wide variation in its clinical presentation, and symptom burden 
may vary over time. Failure to diagnose epicardial obstructive CAD in 
a patient with documented ischaemia should stimulate a subsequent 
search pathway to elucidate ANOCA/INOCA endotypes.
5.2.4. Short- and long-term prognosis
Symptoms of angina/ischaemia with non-obstructive coronary arteries 
are associated with adverse physical, mental, and social health.952
Angina/ischaemia with non-obstructive coronary arteries is associated 
with poor QoL, higher risk of disability, and a higher incidence of ad­
verse events, including mortality, morbidity, healthcare costs, recurrent 
hospital readmissions and repeat coronary angiograms.300,953–958 The 
incidence of all-cause death and non-fatal MI in patients with non- 
obstructive atherosclerosis was higher than in those with angiographi­
cally normal epicardial vessels.298,959–961 Proven myocardial ischaemia 
by stress echocardiography or nuclear imaging was associated with a 
higher incidence of events compared with ischaemia detected by exer­
cise electrocardiographic stress testing.958 There is a two- to four-fold 
higher risk of adverse cardiovascular outcomes in patients with MVA 
diagnosed by PET or transthoracic echocardiography and a two-fold 
higher risk in patients with epicardial endothelial-dependent dysfunc­
tion.300,962 Microvascular angina due to impaired CFR was associated 
with increased major adverse cardiac events and target-vessel failure 
rates over a 5-year follow-up period.931 Vasospastic angina is associated 
with major adverse events, including sudden cardiac death, acute MI, 
and syncope.963 In a group of ANOCA/INOCA patients, abnormal 
non-invasive testing did not allow the identification of patients with a 
higher risk of long-term cardiovascular events. However, adding intra­
coronary physiological assessment to non-invasive information allowed 
the identification of patient subgroups with up to a four-fold difference 
in long-term cardiovascular events.357
5.2.5. Diagnosis
The presence of myocardial ischaemia on functional imaging without 
obstructive CAD on CCTA or ICA should always raise the clinical sus­
picion of ANOCA/INOCA. The diagnosis of ANOCA/INOCA is exclu­
sively based on invasive functional evaluation of the coronary 
microcirculation, given that no technique allows direct visualization of 
the coronary microcirculation in vivo in humans. Several non-invasive 
and invasive tests have been established to assess the coronary micro­
vascular function (Figure 13).6,41,964,965
5.2.5.1. Non-invasive diagnosis
Non-invasive tests (stress echocardiography, PET, perfusion CCTA, and 
CMR) allow diagnosing ANOCA/INOCA by measuring the CFR.41
These techniques have an excellent negative predictive value, but the 
positive predictive value is an issue for most, as obstructive CAD needs 
to be ruled out before the diagnosis of CMD can be made. Only hybrid 
techniques such as CCTA with perfusion and PET-CT offer combined 
imaging of the epicardial coronary arteries and functional testing of the 
coronary microcirculation in a single test.6,964
5.2.5.2. Invasive coronary functional testing
Invasive coronary functional testing consists of a comprehensive 
evaluation of the coronary circulation in a single procedure by combin­
ing angiography, direct invasive assessment of the coronary haemo­
dynamics by intracoronary pressure and flow measurement either by 
thermodilution (bolus/continuous) or Doppler techniques, and 
pharmacological vasomotor testing. Recently, a standardized protocol 
has been proposed.36
5.2.5.2.1. Basic coronary functional testing. Intracoronary pressure 
and flow measurements allow assessment of the haemodynamic signifi­
cance of focal or diffuse coronary lesions by measuring FFR or iFR (see 
Section 3.3.3.2) and of microcirculatory function by measuring CFR and 
IMR, HMR, or MRR361,961 (see Section 3.3.3.3). Coronary microvascular 
dysfunction is characterized by decreased CFR and increased microvascu­
lar vascular resistance (IMR, HMR, MRR). Decreased CFR can be due to 
structural or functional microvascular dysfunction.926,966 Functional CMD 
is characterized by increased resting flow linked to enhanced nitric oxide 
synthase (NOS) activity, whereas patients with structural CMD have 
endothelial dysfunction, leading to a reduced increase of coronary blood 
flow during exercise.926,966
A Doppler-derived CFR of <2.5 in non-obstructive CAD indicates 
an abnormal microcirculatory response corresponding to a 
thermodilution-derived CFR of <2.5.361,926,937,961 Of note, in assessing 
coronary microvascular function, continuous thermodilution showed 
significantly less variability than bolus thermodilution on repeated mea­
surements.382 An increased IMR (≥25) indicates microvascular dysfunc­
tion.380,381 For the Doppler-derived HMR, a value of >2.5 mmHg/cm/s 
indicates augmented microvascular resistance.42 Recently, MRR has 
been considered abnormal for values <2.7.364,967 Doppler flow analysis 
allows assessment of the flow-recovery time after Ach administration 
as a sign of myocardial ischaemia, which is helpful in the diagnosis of pa­
tients with equivocal test results.968
5.2.5.2.2. Coronary vasomotor testing. Epicardial and microvascular 
endothelium-dependent vasodilation and vasospasm are tested by in­
tracoronary bolus administration or graded infusion of Ach, first at a 
low dose/grade to assess endothelial dysfunction at the microvascular 
or epicardial level, and after that at a higher dose/grade to eventually in­
duce microvascular or/and epicardial coronary vasospasm. The LAD ar­
tery is usually preferred as the pre-specified target vessel reflecting its 
subtended myocardial mass and coronary dominance. The left circum­
flex coronary artery is also tested if Ach is administered in the LMCA. 
Additional studies in the right coronary artery may be appropriate if the 
initial tests are negative and clinical suspicion is high. As Ach exerts a 
cholinergic effect on the atrioventricular node, significant bradycardia 
may ensue if infused especially in the right coronary artery or a domin­
ant left circumflex coronary artery. Bradycardia can be prevented by se­
lective infusion in the LAD, prophylactic ventricular pacing, or reduction 
of the concentration infused or of the injected dose. If necessary, the 
ESC Guidelines                                                                                                                                                                                          3481


<!-- PAGE 68 -->

### Page 68

bradycardia effect of Ach can be antagonized by atropine. The effect of 
Ach is short in contrast to the prolonged effect of ergonovine, which 
was previously used for the provocation of coronary vasospasm.969
The diagnosis of MVA and VSA due to microvascular or macrovascular 
vasospasm is made according to established criteria.41,73,932 The test is 
considered positive for macrovascular spasm if symptoms occur, 
accompanied by ischaemic ECG changes and an angiographic ≥90% re­
duction of the coronary lumen. If the lumen reduction is <90%, the diag­
nosis of microvascular spasm is made. The vasospastic effect of Ach is 
rapidly transient and can, if needed, be reversed by intracoronary admin­
istration of nitroglycerine, which also allows assessment of 
endothelium-independent epicardial coronary vasodilation. The safety 
CCS likely
ANOCA/INOCA
Initial clinical evaluation
History including risk factors
Exclude non-cardiac symptoms
Physical exam
ECG
Functional imaging 
(PET, MRI, stress echo, SPECT)
Coronary microvascular dysfunction and/or
Myocardial ischaemia and
Further cardiac evaluation
Treat for ANOCA-INOCA and evaluate symptoms
Invasive coronary functional testing if persisting symptoms
Sequential testing (in any order):
FFR, iFR: distal pressure drop ~ focal or diffuse epicardial atherosclerosis?
Anatomical imaging (CCTA)
Endotheliumindependent
Endotheliumdependent
Adenosine
CFR <2.5
IMR >25
HMR >2.5
Ach
Low dose
2–20 µg i.c.
Abnormal vasodilation?
Epicardial
Microvascular
Ach
High dose
100–200 µg i.c.
Ach
High dose
100–200 µg i.c.
Abnormal vasoconstriction?
No apparent or non-obstructive CAD
[Obstructive CAD    GDMT ± ICA]
Figure 13 Diagnostic algorithm for patients with angina/ischaemia with non-obstructive coronary arteries. Ach, acetylcholine; ANOCA, angina with 
non-obstructive coronary arteries; CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary computed tomography angiog­
raphy; CFR, coronary flow reserve; ECG, electrocardiogram; echo, echocardiography; FFR, fractional flow reserve; GDMT, guideline-directed medical 
therapy; HMR, hyperaemic myocardial velocity resistance; i.c., intracoronary; ICA, invasive coronary angiography; iFR, instantaneous-wave free ratio; 
IMR, index of microcirculatory resistance; INOCA, ischaemia with non-obstructive coronary arteries; MRI, magnetic resonance imaging; PET, positron 
emission tomography; SPECT, single-photon emission  computed tomography.


<!-- PAGE 69 -->

### Page 69

of coronary vasospasm provocation testing with increasing intracoronary 
Ach boluses of up to a maximum of 200 μg has been repeatedly re­
ported.37,970,971 In a small study, testing coronary vasospasm using this al­
gorithm was also safe in patients with a recent ACS.972
At the end of the procedure, microcirculatory vasomotor response 
to i.v. administration of the endothelium-independent vasodilator ad­
enosine973 is assessed and CFR, IMR, HMR, or MRR are measured. In 
patients with contraindications to the use of adenosine, papaverine 
can be used974 but precautionary measures need to be taken given 
the risk of inducing polymorphic ventricular tachycardia.975,976
Different protocols have been applied in clinical practice. Figure 14
shows an example of a standardized and stepwise algorithm for ICFT 
that may be adopted in the cardiac catheterization laboratory for diag­
nosing vasospasm. Informed consent should be obtained, mentioning 
unlicensed, parenteral use of Ach, and administration performed by 
an experienced interventional cardiologist.
5.2.6. Management of angina/ischaemia with 
non-obstructive coronary arteries
Management should be patient-centred with a patient-oriented multi­
disciplinary care approach.977 Figure 15 provides an algorithm for the 
therapeutic management of ANOCA/INOCA. In all patients with es­
tablished ANOCA/INOCA due to the frequent presence of coronary 
atherosclerosis and endothelial dysfunction, tailored counselling on life­
style factors is warranted to address risk factors, reduce symptoms, and 
improve QoL and prognosis. Management of traditional CVD risk fac­
tors, hypertension, dyslipidaemia, smoking, and diabetes should be as 
per clinical practice guidelines recommendations.
Treatment of anginal symptoms in patients with ANOCA/INOCA is 
challenging as the patients represent a heterogeneous group and rando­
mized trials are lacking. A small study showed that a stratified antianginal 
therapy algorithm based on coronary functional testing resulted in im­
proved angina symptoms and QoL compared with a control group 
treated with standard therapy.978 In patients with MVA and reduced 
CFR and/or increased IMR (which may reflect arteriolar remodelling), 
beta-blockers, CCBs, ranolazine, and ACE-Is are used.979 In these pa­
tients, anti-ischaemic therapy with amlodipine or ranolazine resulted 
in a significant improvement in exercise time.980 In patients with either 
epicardial or microvascular spasm following Ach testing, calcium an­
tagonists should be considered as first-line therapy. In patients with se­
vere VSA, it may be necessary to administer unusually high dosages of 
calcium antagonist (2 × 200 mg diltiazem daily or higher up to 960 mg 
daily) or even a combination of non-dihydropyridine (such as diltiazem) 
with dihydropyridine calcium blockers (such as amlodipine). Of note, a 
small study using either oral diltiazem or placebo up to 360 mg/day in 
CMD for 6 weeks did not substantially improve symptoms or QoL, 
but diltiazem therapy did reduce the prevalence of epicardial spasm.981
Nicorandil, a combinatorial vasodilator agent acting via nitrate- and 
potassium-channel activation, may be an effective alternative, although 
side effects are frequent.982 First-line therapy can also be combined 
Ach 2 µga i.c. 
over 60 s
Ach 20 µga i.c.
over 60 s
Ach 100 µga i.c.
over 60 s
Ach 200 µga i.c. 
over 60 s
Adenosine
200 µg i.c.b
Continuous Doppler flow monitoring,12-lead ECG and symptom monitoring
Ach testing performed after at least 24 hours of washout from CCB and nitrates
Repeat angiogram after each dose
NTG
200 µg i.c. 
Final angiogram
Baseline angiogram
CFR / MR
Ach- and adenosine-based vasoreactivity protocol 
Figure 14 Spasm provocation and functional testing protocol. Ach, acetylcholine; CCB, calcium channel blocker; CFR, coronary flow reserve; ECG, 
electrocardiogram; i.c., intracoronary; i.v., intravenous; MR, microvascular resistance; NTG, nitroglycerine. i.c. bolus injections of Ach over 60s to assess: 
(i) endothelial-dependent vasodilation using low-dose Ach (2–20 µg), and (ii) endothelial dysfunction and vasoconstriction using high-dose Ach 
(100–200 µg). This is followed by i.c. administration of nitroglycerine (200 µg) to revert vasospasm. Endothelial-independent vasodilation is assessed 
by i.c. adenosine (200 µg) or i.v. infusion to determine CFR and IMR. Coronary flow can be continuously monitored if i.c. Doppler guidewires are used. 
aThe incremental administration of Ach is stopped whenever a coronary vasospasm is induced. bi.v. adenosine can also be used.
ESC Guidelines                                                                                                                                                                                          3483


<!-- PAGE 70 -->

### Page 70

with ranolazine, an antianginal agent that improves myocyte relaxation 
and ventricular compliance by decreasing sodium and calcium over­
load.983 Spinal cord stimulation is an option for patients who remain re­
fractory after medical therapy.984
There are currently several studies evaluating therapies specific to 
ANOCA/INOCA. The Women’s IschemiA Trial to Reduce Events in 
Non-ObstRuctIve 
CORonary 
Artery 
Disease 
(WARRIOR, 
NCT03417388) is currently enrolling subjects in a multicentre, 
prospective, randomized, blinded outcome evaluation to assess inten­
sive statin and ACE-I/ARB therapy (ischaemia-intensive medical ther­
apy) vs. usual care on MACE in symptomatic women with ANOCA. 
The Precision Medicine with Zibotentan in Microvascular Angina 
(PRIZE) trial holds future promise (NCT04097314). Zibotentan is an 
oral, endothelin A receptor antagonist that may provide benefit by 
opposing the reported vasoconstrictor response of coronary micro­
vessels to endothelin.
Endothelial dysfunction and co-existing atherosclerosis
Nutrition
Exercise
Coping with stress
Hypertension
Dyslipidaemia
Diabetes mellitus
2
3
Weight management
Smoking cessation
Consider statins and ACEi
Abnormal vasodilation
Microvascular
Abnormal vasoconstriction
Microvascular
Epicardial
1
Medical treatment based on pathophysiological endotypes
Lifestyle
Risk factors
Treatment of ANOCA/INOCA
CCB
Nitrates
Nicorandil
CCB
2nd CCB
Nitrates
Beta-blocker
CCB
Ranolazine
Trimetazidine
Ivabradine
Figure 15 Treatment of angina/ischaemia with non-obstructive coronary arteries. ACE-I, angiotensin-converting enzyme inhibitor; ANOCA, angina 
with non-obstructive coronary arteries; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; INOCA, ischaemia with non-obstructive 
coronary arteries. Treatment of ANOCA/INOCA patients includes lifestyle modification, management of cardiovascular risk factors, and antianginal 
treatment according to underlying endotypes. Note: endotypes frequently overlap, requiring combined medical therapy.


<!-- PAGE 71 -->

### Page 71

5.3. Other specific patient groups
5.3.1. Older adults
Between 2015 and 2050, the proportion of the world’s population 
aged >60 years is set to nearly double to 22%. Ageing predisposes 
patients to a high incidence and prevalence of CAD, in both men 
and women. Typically, in the context of CVD, older patients are de­
fined as those ≥75 years of age;1 it should be noted, however, that 
such age cut-offs are relatively arbitrary, and biological age influences 
this threshold in clinical practice. Clinical characteristics of the older 
adult population are heterogeneous, with frailty, comorbidity, cogni­
tive function, and health-related QoL playing important roles in guid­
ing clinical care and as predictors of adverse outcomes.1001–1005
Older patients often present with symptoms other than angina, 
which may delay the diagnosis of CCS.1004
Ageing is often accompanied by both comorbidities and frailty, and 
consequently leads to potentially excessive polypharmacy.531 In mak­
ing treatment decisions, clinicians should take into account the lim­
ited external validity of RCTs for older adults.36 Older people are 
often underrepresented in RCTs as a consequence of exclusion cri­
teria and under-recruitment,531,1006,1007 though they have been 
shown to have a higher underlying risk for cardiovascular out­
comes.1008 The treatment of CCS in older adults is complicated by 
a higher vulnerability to complications for both conservative and in­
vasive strategies, such as bleeding, renal failure, and neurological im­
pairments, all of which require special attention. The use of DES, 
compared with bare-metal stents, in combination with a short dur­
ation of DAPT, is associated with significant safety and efficacy ben­
efits in older adults.1009 Frailty is of utmost importance in the clinical 
decision-making.1010
5.3.2. Sex differences in chronic coronary syndromes
Ischaemic heart disease is the leading cause of mortality for women, yet 
they have been historically underrepresented in RCTs.1011–1013
Differences in symptom presentation, in the accuracy of diagnostic tests 
for obstructive CAD, and other factors that lead to differential triage, 
evaluation, or early treatment of women with myocardial ischaemia 
Recommendation Table 25 — Recommendations for 
diagnosis and management of patients with angina/ 
ischaemia with non-obstructive coronary arteries (see 
also Evidence Table 25)
Recommendations
Classa
Levelb
Diagnosis of ANOCA/INOCA endotypes
In persistently symptomatic patients despite 
medical treatment with suspected ANOCA/ 
INOCA (i.e. anginal symptoms with normal 
coronary arteries or non-obstructive lesions at 
non-invasive imaging, or intermediate stenoses with 
normal FFR/iFR at coronary arteriography) and 
poor quality of life, invasive coronary functional 
testing is recommended to identify potentially 
treatable endotypes and to improve symptoms and 
quality of life, considering patient choices and 
preferences.36,37,298,930,939,985
I
B
In persistently symptomatic patients with 
documented or suspected ANOCA/INOCA, 
transthoracic Doppler of the LAD, stress 
echocardiography, CMR, and PET may be 
considered for the non-invasive assessment 
of coronary/myocardial flow reserve.44,231,233– 
235,300,986,987
IIb
B
Diagnostic tests for vasospastic angina
In individuals with suspected vasospastic angina, a 
resting 12-lead ECG recording during angina is 
recommended.
I
C
In patients with suspected vasospastic angina and 
repetitive episodes of rest angina associated with 
ST-segment changes that resolve with nitrates and/or 
calcium antagonists, invasive coronary functional 
testing is recommended to confirm the diagnosis and 
to determine the severity of underlying 
atherosclerotic disease.
I
C
In individuals with suspected vasospastic angina and 
frequent symptoms, ambulatory ST-segment 
monitoring should be considered to identify 
ST-segment deviation during angina.192–194
IIa
B
Management of ANOCA/INOCA
In symptomatic patients with ANOCA/INOCA, 
medical therapy based on coronary functional test 
results should be considered to improve symptoms 
and quality of life.298,977
IIa
A
For the management of endothelial dysfunction, 
ACE-I should be considered for symptom 
control.988
IIa
B
For the management of microvascular angina 
associated with reduced coronary/myocardial blood 
flow reserve, antianginal medications aiming at 
preventing demand myocardial ischaemia should be 
considered for symptom control.989,990
IIa
B
Continued 
For the treatment of isolated vasospastic angina
Calcium channel blockers are recommended to 
control symptoms and to prevent ischaemia and 
potentially fatal complications.991–996
I
A
Nitrates should be considered to prevent recurrent 
episodes.993,997,998
IIa
B
For the treatment of overlapping endotypes
In patients with evidence of overlapping endotypes, 
combination therapy with nitrates, calcium channel 
blockers, and other vasodilators may be 
considered.999,1000
IIb
B
© ESC 2024
ACE-I, angiotensin-converting enzyme inhibitor; ANOCA, angina with non-obstructive 
coronary arteries; CMR, cardiac magnetic resonance; ECG, electrocardiogram; FFR, 
fractional flow reserve; iFR, instantaneous wave-free ratio; INOCA, ischaemia with 
non-obstructive coronary arteries; LAD, left anterior descending; PET, positron emission 
tomography. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3485


<!-- PAGE 72 -->

### Page 72

compared with men could contribute to unfavourable outcomes. There 
are also risk factors that are unique to women.1014,1015 Not only prema­
ture menopause,1016 but also hypertensive disorders of pregnancy, 
pre-term delivery, gestational diabetes, small-for-gestational-age delivery, 
placental abruption, and pregnancy loss are predictors of subsequent 
CVD.1017 Also, the association between low socioeconomic status and 
increased cardiovascular risk seems stronger in women.1018 In addition, 
higher levels of residential segregation are associated with incident 
CVD and obesity among black women.1019
Women are less likely to be referred for diagnostic testing and are 
under-treated for essential secondary prevention therapies.1020
Compared with men, women have a shorter survival after PCI1021
and CABG.1022 In a large-scale, individual-patient data pooled analysis 
of contemporary PCI trials with early and new-generation DES, women 
had a higher risk of MACE and ischaemia-driven target-lesion revascu­
larization compared with men at 5 years following PCI.1021 However, 
the excess risk after PCI among women can be primarily explained 
by a greater burden of cardiovascular risk factors and comorbid condi­
tions.1023 Nevertheless, in a population undergoing contemporary PCI, 
women and men had similar risks of death or new Q-wave MI at 2 years, 
but women faced a higher risk of bleeding and haemorrhagic stroke 
compared with men.1024
Women with signs and symptoms suggestive of cardiac ischaemia 
should be investigated carefully. The same guideline-recommended car­
diovascular preventive therapy should be provided to women and 
men.1025 Hormone replacement therapy in post-menopausal women 
does not reduce the risk of ischaemic myocardial disease1015 and it 
may come at the cost of other health risks,1026 which should be dis­
cussed with the patient.
5.3.3. High bleeding-risk patients
An HBR is increasingly present in many CCS patients referred for cor­
onary revascularization. The ARC-HBR consortium provided a consist­
ent definition of HBR for patients undergoing PCI. Patients are 
considered at HBR if at least one major or two minor criteria are 
met.590 In the context of PCI in HBR patients, short duration of 
DAPT (1–3 months) and PCI with a DES was beneficial in many recent 
studies.1009,1027–1032
5.3.4. Inflammatory rheumatic diseases
Patients with inflammatory rheumatic diseases have an increased risk of 
CVD compared with the general population.1033,1034 Accumulating evi­
dence has shown elevated cardiovascular morbidity and mortality in 
other rheumatic and musculoskeletal diseases, including gout, vasculitis, 
systemic sclerosis, myositis, mixed connective tissue disease, Sjögren 
syndrome, SLE, and the antiphospholipid syndrome.1035–1044
Some of these patient categories have two- to three-fold higher pre­
valences of asymptomatic ASCVD compared with the general popula­
tion,1045–1051 which is linked to ASCVD outcomes.1049,1052–1054 Thus, 
identification of ASCVD such as carotid artery plaque(s) may be consid­
ered in ASCVD and CAD risk evaluation.1050,1055–1057
In patients with inflammatory rheumatic diseases and CCS, CVD 
preventive medications such as lipid-lowering medications and antihy­
pertensive treatment should be used as in the general popula­
tion.1058–1062
5.3.5. Hypertension
Blood pressure lowering has been associated with favourable cardio­
vascular outcomes in patients regardless of the presence of CAD.1063
Due to concerns of a possible J-curve relationship between achieved 
BP and cardiovascular outcomes in patients with CAD, previous guide­
lines did not recommend a target BP of <120/70 mmHg. In line with the 
2024 ESC Hypertension Guidelines1064, the present guidelines recom­
mend that treated systolic BP values in most CCS patients be targeted 
to 120–129 mmHg, provided the treatment is well tolerated. In cases 
where on-treatment systolic BP is at or below target (120–129 
mmHg) but diastolic BP is not at target (≥80 mmHg), intensifying 
BP-lowering treatment to achieve an on-treatment diastolic BP of 
70–79 mmHg may be considered to reduce CVD risk.1065 More leni­
ent targets (e.g. 140/90 mmHg) can be considered in older patients 
(≥85 years of age) or patients with pre-treatment symptomatic 
orthostatic hypotension. In hypertensive patients with a history of 
MI, beta-blockers and RAS blockers are first-line treatments. In 
patients with symptomatic angina, beta-blockers and/or CCBs can 
be useful.1065
5.3.6. Atrial fibrillation
Diagnostic assessment of CAD (CCTA and non-invasive tests) may be 
difficult in AF with a high ventricular rate. In patients with CAD and AF, 
rhythm or rate control strategies may help improve symptoms of myo­
cardial ischaemia. Amiodarone or dronedarone are drugs of choice for 
rhythm control, as an alternative to catheter ablation, in patients with 
CAD and AF. Sotalol may also be considered. Beta-blockers, diltiazem, 
verapamil, or digoxin can be used for rate control depending on the 
LVEF.613 After PCI, combined anticoagulant and antiplatelet therapies 
are needed. Recommendations on post-PCI antithrombotic therapy 
in patients with AF and indication for OAC are detailed in Section 
4.3.1.2.2 and Recommendation Table 17.613,621,659 Surgical ablation of 
AF during isolated CABG seems to be safe and effective in improving 
long-term outcomes.1066 Concomitant surgical closure of the left atrial 
appendage is recommended as an adjunct to oral anticoagulation in 
patients with AF undergoing cardiac surgery (e.g. CABG) to prevent is­
chaemic stroke and thrombo-embolism (see the ESC 2024 Guidelines 
for the management of Atrial Fibrillation).1067
5.3.7. Valvular heart disease
In patients with valvular heart disease with a risk for associated CAD 
who require surgery or in whom a decision of a percutaneous or sur­
gical approach is still pending, ICA or CCTA is recommended to deter­
mine the need for coronary revascularization.1068 Evidence of CAD in 
patients with valvular heart disease can drive to a surgical instead of a 
percutaneous treatment of valvular heart disease. Invasive coronary 
angiography is recommended in patients with secondary mitral regur­
gitation as this condition is frequently due to ischaemic LV dysfunc­
tion.1068 Routine stress testing to detect CAD associated with severe 
symptomatic valvular heart disease is not recommended because of 
low diagnostic value and potential risk. The usefulness of FFR or iFR 
in patients with valvular heart disease is not well established, and cau­
tion is warranted in interpreting these measurements, especially in 
the presence of aortic stenosis.1068 Beta-blockers need to be used 
with caution in patients with aortic valve disease. Coronary artery by­
pass grafting is recommended in patients with a primary indication for 
aortic/mitral/tricuspid valve surgery and significant coronary stenosis. 
Percutaneous coronary intervention should be considered in patients 
with a primary indication of transcatheter aortic valve implantation 
or transcatheter mitral valve intervention and coronary artery diameter 
stenosis of >70% in proximal segments.1068


<!-- PAGE 73 -->

### Page 73

5.3.8. Chronic kidney disease
Chronic kidney disease increases the risk of CAD progression and is as­
sociated with high mortality rates due to cardiovascular causes.1069,1070
Patients with CKD have a higher burden of atherosclerosis and more 
advanced plaque features.1070 Despite the higher prevalence of disease, 
non-invasive diagnostic testing is often less accurate, and guidance re­
lated to the use of pharmacological and interventional therapy is limited 
due to inconsistent definitions of CKD and underrepresentation of 
CKD patients in clinical trials.1070–1072
Careful assessment of the risk-to-benefit ratio is needed in patients 
with CKD before considering ICA, CCTA, or non-invasive tests requir­
ing nephrotoxic agents.1073 Pre-existing CKD is the primary patient- 
related risk factor for the development of acute kidney injury (AKI), 
whereas DM increases the susceptibility to develop AKI. The most im­
portant measures to prevent AKI are using the lowest necessary total 
dose of low-osmolality or iso-osmolality contrast medium and suffi­
cient pre- and post-hydration.1073
CKD raises the risks associated with both CABG and PCI.316 The 
ISCHEMIA-CKD trial included patients with advanced CKD [estimated 
glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 or dialysis] 
and CCS with moderate or severe myocardial ischaemia detected by 
stress test. An invasive strategy of ICA and PCI was not superior to con­
servative management in reducing the primary endpoint of death or 
non-fatal MI.1074
In a propensity score-matched analysis involving 5920 CKD patients 
(2960 pairs), PCI utilizing second-generation DES displayed a reduced 
risk of death, stroke, and repeat revascularization at 30 days when com­
pared with CABG.1075 However, PCI was associated with a higher risk 
of repeat revascularization over the long term. Conversely, among pa­
tients on dialysis, the findings favoured CABG over PCI. Additionally, a 
meta-analysis of 11 registries revealed lower rates of death, MI, and re­
peat revascularization with CABG in contrast to PCI among patients 
with eGFR of <60 mL/min/1.73 m².1076 Nevertheless, there is a notable 
absence of large RCTs comparing revascularization modalities among 
CKD patients.
5.3.9. Cancer
Several cancer treatments are associated with an increased risk of CCS. 
Spontaneous bleeding in ACS and CCS patients has been associated 
with subsequent cancer diagnosis.1077 A prompt evaluation of bleeding 
may be useful to enable an early detection of cancer. The management 
of CCS is similar in patients with and without cancer. However, deci­
sions regarding coronary revascularization should be undertaken by a 
multidisciplinary team. The approach should be individualized and based 
on life expectancy, additional comorbidities such as thrombocyto­
paenia, increased thrombosis, or bleeding risk, and potential interac­
tions between drugs used in CCS management and anticancer 
therapy.1078,1079
5.3.10. Optimal treatment of patients with human 
immunodeficiency virus
Patients with human immunodeficiency virus (HIV) have longer life expect­
ancy than before due to effective antiretroviral therapy (ART), but are 
twice as likely to develop CVD compared with the general population.1080
The long-term CVD outcomes in patients with HIV may change, given the 
relatively recent epidemiological transition of HIV to a chronic disease. 
Dyslipidaemia is a common condition in patients with HIV, whether trea­
ted or untreated with ART.1081 The treatment of dyslipidaemia in patients 
with HIV includes both non-pharmacological and pharmacological options. 
Special attention to the impact of polypharmacy, drug interactions be­
tween ART and lipid-lowering medications, and close monitoring for ad­
verse events is critical to successfully managing dyslipidaemia and risk of 
CVD in patients with HIV. Hepatic cytochrome P450 3A4 (CYP3A4) me­
tabolizes many statins; many ARTs are also metabolized by CYP3A4 and, 
thus, may have interactions with statins. Simvastatin and lovastatin are con­
traindicated with protease inhibitors; atorvastatin has less of a CYP3A4 
interaction; pravastatin, fluvastatin, pitavastatin and rosuvastatin are not 
or minimally metabolized through CYP3A4.1082,1083 Ezetimibe has no in­
teractions with CYP3A4 or ART.1081
A clinical trial investigating the impact of PCSK9 inhibitor therapy on 
lipids, inflammatory markers, and subclinical ASCVD (including non- 
calcified plaque and arterial inflammation) in HIV is currently being con­
ducted [EPIC-HIV study (Effect of PCSK9 Inhibition on Cardiovascular 
Risk in Treated HIV Infection), NCT03207945]. Future studies are 
needed to evaluate the impact of PCSK9 inhibition on clinical events 
in HIV.
5.3.11. Socially and geographically diverse groups
A lower socioeconomic status has implications of increased CVD mor­
tality1084 and poorer CVD risk factor profiles.1085 A multicohort study 
of 1.7 million adults followed up for any cause of death for an average of 
13 years found that low socioeconomic status was associated with a 
2.1-year reduction in life expectancy between the ages 40 and 85 
years.1086 Education level, occupation, household income, health, dis­
ability, and living conditions also contribute to socioeconomic status. 
There were different rates of decline in mortality from CVD in 
Europe between the most and the least deprived.1087 It has been pro­
posed that on this basis, CVD could become a disease prevalently of the 
lower socioeconomic groups by the mid-2020s.1088
Black patients with diabetes have a higher hospitalization burden 
with a concomitant disparity in comorbid presentation and outcome 
compared with other patients with diabetes.1089 South Asian ethnicity, 
even after adjustment for traditional risk factors, is associated with an 
increased risk of coronary heart disease outcomes. This risk was great­
er than other studied racial/ethnic groups and second only to diabetes 
in coronary heart disease risk prediction.1090
Within a large prospective study, South Asian individuals had a 
substantially higher risk of ASCVD than individuals of European 
ancestry.1091 South Asians have a more diffuse pattern with multives­
sel involvement. However, less is known about other morphological 
characteristics, such as atherosclerotic plaque composition and 
coronary diameter in South Asian populations. Despite a similar cor­
onary calcification burden, higher non-calcified plaque contribution, 
elevated thrombosis, and inflammatory markers likely contribute to 
the disease pattern. Although the current evidence on the role of cor­
onary vessel size remains inconsistent, smaller diameters in South 
Asians could play a potential role in the higher disease prevalence.1092
Individuals of South Asian descent have a high prevalence of CYP2C19 
loss-of-function alleles (poor metabolizers: 13% vs. 2.4% in European 
populations),1093 which are associated with reduced efficacy of 
clopidogrel.
ESC Guidelines                                                                                                                                                                                          3487


<!-- PAGE 74 -->

### Page 74

5.4. Screening for coronary artery disease 
in asymptomatic individuals
Presence of asymptomatic atherosclerotic CAD is common in the gen­
eral population.1097–1100 In the Swedish Cardiopulmonary Bioimage 
Study, CCTA was performed in randomly selected individuals from 
the general population.1097 In the 25 182 individuals without known 
CAD, atherosclerotic plaque was present in 42% of participants. 
Plaque was more common in older individuals and in males (males 
50–54 vs. 60–64 years old: 41% vs. 69%, and females 50–54 vs. 
60–64 years old: 19% vs. 40%). Obstructive coronary stenosis was pre­
sent in 5% of participants. In the PESA study (Progression of Early 
Subclinical Atherosclerosis), 63% of asymptomatic middle-aged partici­
pants had subclinical atherosclerosis,157 although most of them were 
categorized as low-risk individuals by several risk scores.142
The risk of adverse events in asymptomatic subjects can be estimated 
using the European risk-estimation system [Systematic Coronary Risk 
Estimation 2 (SCORE2)], described in the 2021 ESC Guidelines on car­
diovascular disease prevention in clinical practice.16,1101 Systematic 
screening of risk factors cannot be strongly recommended in the general 
population as it did not affect CVD outcomes.1102 However, when pa­
tients are seen for other reasons, opportunistic screening is effective at 
increasing detection rates of CVD risk factors, such as high BP or lipids. 
Hence, opportunistic screening is recommended, although its beneficial 
effect on clinical outcomes remains uncertain.1103
Information on CAC can be used to guide risk-factor management, and 
initiate lipid-lowering and antithrombotic treatment in patients with esti­
mated future risk around treatment decision thresholds.1104 To date, two 
randomized screening studies have indicated that statin therapy impacts 
outcomes when guided by CACS in younger patients with high 
CACS.1105,1106 Coronary artery calcium score could potentially guide 
not only risk-factor management but also primary prophylaxis with as­
pirin, but randomized studies are lacking.1107 Importantly, opportunistic 
screening of the burden of calcified atherosclerotic CAD can be accurate­
ly accessed with non-ECG-gated chest CT performed for other rea­
sons.17,1108 Reporting the visual interpretation of the coronary plaque 
burden according to a simple score with four categories (none, mild, 
moderate, severe) is recommended.1108–1110 However, there is no 
current evidence to support further diagnostic imaging in asymptomatic 
individuals on the basis of presence of calcified plaque alone.
Carotid ultrasound,1111 aortic pulse wave velocity, arterial augmen­
tation index, and ankle–brachial index are other modalities to improve 
the prediction of future CVD events. However, evidence is less exten­
sive for these modalities compared with CACS.
Recommendation Table 26 — Recommendations for 
older, female, high bleeding risk, comorbid, and socially/ 
geographically diverse patients (see also Evidence 
Table 26)
Recommendations
Classa
Levelb
Older adults
In older adults (≥75 years), particular attention to 
drug side effects, intolerance, drug–drug interactions, 
overdosing, and procedural complications is 
recommended.
I
C
In older, as in younger, individuals, diagnostic and 
revascularization decisions based on symptoms, 
extent of ischaemia, frailty, life expectancy, 
comorbidities, and patient preferences are 
recommended.
I
C
Sex
Similar guideline-directed cardiovascular preventive 
therapy is recommended in women and men.
I
C
Systemic post-menopausal hormone therapy is not 
recommended in women with CCS, given the lack of 
cardiovascular benefit and an increased risk of 
thrombo-embolic complications.1026,1094,1095
III
A
High bleeding risk
Bleeding risk assessment is recommended using the 
PRECISE-DAPT score, the qualitative ARC-HBR tool 
or other, validated methods.589,590
I
B
HIV
Attention to interaction between antiretroviral 
treatment and statins is recommended in patients 
with HIV.1096
I
B
Socioeconomic, geographical, and under-investigated groups
Continued targeted efforts are recommended: 
• to increase delivery of safe and effective cardiac 
care to all CCS patients, especially those of lower 
socioeconomic classes; and
• to enhance inclusion in future clinical trials of 
geographical, social, or other groups that are 
currently underrepresented.
I
C
© ESC 2024
ARC-HBR, Academic Research Consortium for High Bleeding Risk; CCS, chronic coronary 
syndrome; HIV, human immunodeficiency virus; PRECISE-DAPT, PREdicting bleeding 
Complications In patients undergoing Stent implantation and subsEquent Dual 
AntiPlatelet Therapy. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 27 — Recommendations for 
screening for coronary artery disease in asymptomatic 
individuals (see also Evidence Table 27)
Recommendations
Classa
Levelb
Opportunistic screening of healthy individuals for 
cardiovascular risk factors and to estimate the risk of 
future cardiovascular events using scoring systems, 
e.g. SCORE2 and SCORE-OP, is recommended to 
detect individuals at high risk and guide treatment 
decisions.16,1101,1112
I
C
When coronary artery calcification findings are 
available from previous chest CT scans, using these 
findings to enhance risk stratification and guide 
treatment of modifiable risk factors should be 
considered.17,1108–1110
IIa
C
CACS may be considered to improve risk classification 
around treatment decision thresholds.1104–1106
IIb
C
An ultrasound of the carotid arteries may be 
considered as an alternative when CACS is 
unavailable or not feasible to detect atherosclerotic 
disease and to improve risk classification around 
treatment decision thresholds.1111
IIb
B
© ESC 2024
CACS, coronary artery calcium scoring; CT, computed tomography; SCORE2, Systematic 
Coronary Risk Estimation 2; SCORE-OP, Systematic Coronary Risk Estimation 2–Older 
Persons. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 75 -->

### Page 75

### 6 Long-term follow-up and care

6.1. Voice of the patient
A diagnosis of CCS can have an impact on self-identity, lifestyle, employ­
ment, and cause anxiety, depression, and burdensome treatment. 
Patients are experts in their own conditions, and their voices and pre­
ferences are integral to decisions about treatment. Health outcomes 
improve with better patient involvement, and shared decision-making 
is central to future patient care.1113
6.1.1. Communication
Communication is essential to support patients’ understanding, adher­
ence, and engagement in decision-making.1114 Good communication 
requires providing information at an appropriate level, active listening, 
assessing patient understanding, and determining patient perspectives 
and priorities. A meta-analysis summarizing a total of 127 studies of 
communication training concluded that patients were 19% more likely 
to be non-adherent when physicians had poor communication, and 
12% more likely to be non-adherent when their physicians had not 
received communication training.1115 Communication and shared 
decision-making can be particularly challenging when patients have co­
morbidities, low health literacy, language differences, cognitive impair­
ment, depression, or anxiety, and when evidence for treatment is less 
robust.
Patient reported outcome measures can be useful to improve as­
sessment and communication of symptoms, function, and QoL, and 
can highlight problems that may not have been previously discussed. 
Under- and overestimation of symptoms can lead to a lack of or in­
appropriate treatment.1116,1117 The routine use of PROMs in clinical 
practice is hampered by the challenge of interpretation of scores and 
their integration into routine clinical processes.1116
Although quality of communication can be improved through train­
ing, meta-analyses have not found evidence of significant impact on out­
comes such as physical or mental health, satisfaction, QoL, or specific 
risk factors in patients with cancer, diabetes, and hyperten­
sion.1115,1118,1119 Structured tools and a flexible range of resources (in­
cluding videos, workbooks, and health-literacy materials) that provide 
individualized information and decision aids can be adjuncts to better 
communication and shared decision-making.443 A systematic review 
of 17 RCTs of tools to support decision-making in severe illness con­
cluded that they improved patient knowledge and readiness to make 
decisions.1120
Communicating the risk of future CVD events and how risk can be 
lowered through lifestyle and medications is best presented using visual 
or imaging approaches, natural frequencies rather than percentages, 
and positive framing (focusing on risk-reduction benefits).1121–1125
Relative risk reduction is more persuasive than either absolute risk re­
duction or the number needed to treat.1122 The use of risk prediction 
estimates may have an impact on individuals’ health when their informa­
tion (i.e. predicted risk stratification) changes individuals’ behaviour, 
self-management decisions, and even treatment decisions.446 This en­
ables patients to gain insights into their cardiovascular prognosis and 
to empower them to take part in the decision-making process.1126
This approach may increase self-motivation for therapy adherence 
and lifestyle changes, including changes in nutrition, physical activity, 
relaxation training, weight management, and participation in smoking 
cessation programmes for resistant smokers.446 Previous unsuccessful 
attempts to change to a healthy lifestyle or take guideline- 
recommended treatment can be addressed to set realistic goals.446
Communication should be clear regarding symptoms, even if not car­
diac. Patients with CCS experiencing non-cardiac chest pain experience 
uncertainty about the cause and actions to take. A multidisciplinary ap­
proach and evaluation of non-cardiac aetiology with an appropriate re­
ferral are advocated to ensure that appropriate treatment is 
initiated.1127,1128
6.1.2. Depression and anxiety
Depression is common (15%–20% prevalence) in CVD, and associated 
with poor adherence and worse outcomes, including MACE and pre­
mature death.1129 Coronary microvascular dysfunction (prevalent in 
INOCA) is linked with psychological stress and depression.946
Unfortunately, depression and psychological stress are often unrecog­
nized due to a lack of systematic screening using validated tools.1129 For 
anxiety, a recent meta-analysis involving 16 studies reported a preva­
lence in post-MI between 5.5% and 58%, and a 27% greater risk of 
poor clinical outcomes in anxious patients compared with those with­
out anxiety.1130 In contrast, in a 15-year follow-up of 1109 patients with 
CCS moderate anxiety did not increase the risk of cardiovascular 
events compared with low anxiety levels. Patients on a high but de­
creasing anxiety trajectory had an HR of 1.72 (95% CI, 1.11–2.68) for 
cardiovascular events.1131 Treatment of psychosocial factors, depres­
sion, and anxiety with pharmacotherapy, psychotherapy, and/or exer­
cise can improve symptoms and QoL in some patients, and there is 
some evidence for improvement in cardiac outcomes.472,1132–1134
Stepped care (initial therapy based on patient preferences) and a com­
bination of therapies may be more efficacious.1129,1135 First-line treat­
ment with selective serotonin reuptake inhibitors (recommended in 
CCS) or non-pharmacological interventions and a multidisciplinary col­
laborative approach are recommended.1129
6.2. Adherence and persistence
Earlier analyses reported that adherence to long-term therapies in 
chronic conditions in Western countries averaged 50% and was lower 
in developing countries.1136 Pooled prevalence of non-adherence from 
a recent meta-analysis of eight studies (n = 3904 patients with multimor­
bidity) was 42.63% (95% CI, 34%–51%).1137 Data from the ESC-EORP 
EUROASPIRE V registry indicate that many CCS patients still have un­
healthy lifestyles in terms of smoking, diet, and sedentary behaviour.1138
Poor adherence and persistence (duration of time in which medications 
and healthy behaviours are continued) have a profound effect on effect­
ive management, patient safety, and outcomes. The World Health 
Organization (WHO) advocates training in adherence for healthcare 
professionals, a multidisciplinary approach, support rather than blame, 
tailored interventions based on illness-related demands for each patient, 
and viewing adherence as a dynamic process.1136
The five dimensions of adherence are patient, disease, provider, ther­
apy, and healthcare system (Figure 16).1139 Therefore, identifying pa­
tients at risk of non-adherence, addressing all five dimensions, 
developing a multidisciplinary pathway to support sustained adherence, 
and a follow-up strategy are essential steps.1139
6.2.1. Adherence to healthy lifestyle behaviours
Different strategies may help improve long-term adherence to a 
healthy lifestyle (Figure 17).
6.2.1.1. Why behavioural changes are difficult
Making changes to unhealthy lifestyles and controlling risk factors can 
be a daunting task as these are usually longstanding habits and patterns 
ESC Guidelines                                                                                                                                                                                          3489


<!-- PAGE 76 -->

### Page 76

of behaviour. Habits and environmental cues primarily govern beha­
viours, so education and information alone are seldom enough.1140
Factors such as psychological state and low health literacy (associated 
with depression and worse behavioural risk factors) also impact the 
ability to make changes.1141,1142
6.2.1.2. How to change behaviour and support healthy lifestyles
A multidisciplinary approach and behavioural counselling can improve 
adherence. A systematic review and meta-analysis of 12 RCTs of 
nurse-led patient-centred interventions for secondary prevention 
found greater adherence to smoking cessation and physical activity, 
and better control of total cholesterol (with medication titration), 
but no improvements in dietary habits, BP, blood glucose, or sur­
vival.1143 A systematic review of behavioural counselling found that 
medium- to high-contact counselling resulted in 20% lower risk of 
CVD events, lower BP, and decreased LDL-C and adiposity in adults 
with CVD risk factors.1144 Incorporating cardiovascular visual images 
into risk-factor discussions is effective in reducing subsequent 10-year 
risk assessment and individual risk factors.445
Actions on the five dimensions of adherence to therapy
Disease
Be aware of low adherence predictors
Consider graded therapy in multimorbidity
Prevent frequent change in therapy
(especially in multimorbidity)
Health care provider
Provide correct,
timely and sufficient information
Improve communication skills
Optimize the patient’s perception of risk
Prevent clinical inertia
Patient
Provide additional psychosocial support in distress,
depression and anxiety
Optimize health literacy
Empower the 
patient. 
Increase the patient's self-efficacy
Therapy
Prefer poly-pill treatment
Intensify/increase use of mHealth and e-Health
Consider complexity and workload for 
patient
Healthcare system
Make access to care easy, rapid,
efficient and affordable
Implement community-based programs/
interventions
Encourage social media coverage to assist therapeutic adherence
Involve informal caregivers
Shared-decision making
Structured tools (PROMs and clinical processes)
Improved outcomes
Figure 16 Actions on the five dimensions of adherence to therapy. e-Health, healthcare services provided electronically; mHealth, mobile device- 
based healthcare; PROMs, patient-reported outcome measures. Adapted from Pedretti et al.1139.


<!-- PAGE 77 -->

### Page 77

Lifestyle changes also impact relatives, partners, and friends, so they 
should be involved in patient support.1139 Physical activity can be incor­
porated flexibly, either daily, or limited to specific days. Activity pat­
terns limited to 1–2 sessions per week but meeting recommended 
levels of physical activity have been shown to reduce or postpone 
all-cause, CVD, and cancer mortality risk.477 Importantly, maintaining 
changed behaviour over time is a challenge. Some trials have shown 
an impact of lifestyle intervention on cardiovascular health and behav­
ioural metrics, which became attenuated in the long term as the inten­
sity of the intervention declined.1145
6.2.1.3. Digital and mHealth
Behavioural change and habit formation can be facilitated through tech­
nology such as wearable devices, the internet, and smartphones. In 27 
studies including 5165 patients with CAD or cerebrovascular disease, 
text messaging and smartphone apps resulted in a greater ability to 
reach BP targets and exercise goals, less anxiety, and increased aware­
ness of diet and exercise compared with control.1146 Nevertheless, 
there was no significant difference in smoking cessation, LDL-C, and 
hospital readmissions.1146 Digital interventions mainly stimulate healthy 
behavioural factors but are less effective in reducing unhealthy behav­
ioural factors (smoking, alcohol intake, sedentary behaviour, and un­
healthy diet) and clinical outcomes.1146,1147
The use of wearable devices has significantly increased physical activ­
ity and decreased waist circumference, systolic BP, and LDL-C among 
individuals with chronic conditions including CVD.491 Younger age 
has been associated with a higher increase in physical activity, and 
CVD has been associated with a lower increase. Wearable activity 
trackers have shown effectiveness, but the effect was greater when 
ealthy diet
H
xercise
E
chieve normal weight
A
eave smoking
L
ake control of cholesterol and blood pressure
T
andle alcohol consumption
H
ield to stress management
Y
Supporting adherence
Good communication,
structured tools and visual images
Multidisciplinary behavioural interventions mHealth and telehealth
Fixed dose combination pills and simplified medication regimens
PROMs and feedback
Cardiovascular risk reduction
Figure 17 Strategies for long-term adherence to a healthy lifestyle. mHealth, mobile device-based healthcare; PROMs, patient-reported outcome 
measures.
ESC Guidelines                                                                                                                                                                                          3491


<!-- PAGE 78 -->

### Page 78

combined with other behaviour-change strategies.491 A systematic re­
view of CCS patients that used activity trackers combined with feed­
back by healthcare professionals (most also giving lifestyle education) 
showed a significant increase in peak VO2 in studies using an acceler­
ometer (but not a pedometer) compared with non-users. The overall 
effect across studies reduced MACE and improved QoL.1148 Similarly, 
smartphone and tablet computer apps have been shown to increase 
physical activity (minutes per week or steps per day) among people 
with CVD (1543 participants, most of them with CCS). This effect 
was largest in small studies focused on physical activity only, partici­
pants ≥60 years old, and duration of up to 3 months.1149
Adherence to the apps was 20% to 85% and tended to wane over 
time. Of note, the implementation of digital and mHealth should 
not be at odds with a less digital-oriented care for those unfamiliar 
with new technologies (e.g. elderly people).
6.2.1.4. How to assess adherence
Addressing lifestyle behaviour and medication adherence in a non- 
judgemental way at clinical encounters is important to identify barriers 
and offer tailored solutions to promote healthier actions. The encoun­
ter can be useful to review patient self-monitoring records (digital or 
written), accelerometer data, and diaries, or validated questionnaires 
on physical activity.
6.2.2. Adherence to medical therapy
Guideline-directed medications are key to the effective management of 
CCS and prevention of subsequent cardiovascular events, but depend­
ent on patient adherence and persistence with treatment. Despite ro­
bust evidence of benefits in terms of mortality and morbidity,1150
adherence remains suboptimal.1151 Although adherence is usually high­
er in RCTs, approximately 28% of CCS patients in the ISCHEMIA trial 
were non-adherent to prescribed medications at baseline.1152
Non-adherence was associated with significantly worse health status 
regardless of randomization to the conservative or invasive strat­
egy.1152 Medication adherence can be intentional or unintentional, 
and can be adversely affected by polypharmacy, complex drug regi­
mens, high cost, and side effects.
6.2.2.1. Strategies to improve medication adherence
Improving adherence to medications has proved challenging.1153 One 
systematic review and meta-analysis (771 studies to 2015) found that 
interventions that were behaviourally focused, e.g. linking medication- 
taking to existing habits, were more effective than those that were 
cognitively focused.1154 A systematic review of 17 trials of adherence 
for secondary CVD prevention found that a short message service, a 
fixed-dose combination pill, and a community health worker-based 
intervention (one trial each) increased adherence compared with 
usual care.1155 Behavioural and mixed behavioural/educational inter­
ventions improved adherence in older adults with multiple medica­
tions (low-quality evidence), with little evidence for educational-only 
interventions.1156 Drug reminder packaging—i.e. incorporating the 
date and time for the medication to be taken in a package (pre-filled 
containers)—can act as a prompt, with some evidence that it in­
creases pills taken and improves diastolic BP and HbA1c levels.1157
Treating depression is important, as depression was associated with 
reduced adequate and optimal adherence to recommended medica­
tions 12 months post-PCI in an analysis of 124 443 patients.1158
Simplifying medication regimens using fixed-dose polypills has been 
shown to increase adherence.1159–1162 The SECURE trial demon­
strated that patients 6 months post-MI randomized to a polypill con­
taining aspirin, ramipril, and atorvastatin had significantly lower MACE 
and were more likely to have high adherence at 6 and 24 months com­
pared with the usual care group.1163
6.2.2.2. mHealth strategies for medication adherence
A review of mobile phone text messaging found promising, if limited, 
evidence that such messaging could improve medication adherence 
up to 12 months after acute coronary events.1164 Similarly, another re­
view of 24 studies of text messages and/or apps found robust evidence 
for adherence to pharmacological therapy.1146 A pilot trial of 135 
non-adherent patients with hypertension and/or diabetes randomized 
patients to a highly tailored digital intervention (text messages and 
interactive voice response) or usual care for 12 weeks. Medication 
adherence was significantly improved in the intervention group, along 
with improvements in systolic BP and HbA1c, compared with the con­
trol group.1165
6.3. Diagnosis of disease progression
Long-term follow-up of patients with CCS who have either established 
CAD (prior acute MI, revascularization, known CAD) or non- 
obstructive CAD includes surveillance for disease progression. 
However, current literature is sparse regarding mode, frequency, and 
duration. Follow-up of patients is based on their clinical condition, 
which includes cardiovascular risk factors, residual symptoms, cardiac 
complications [such as post-infarction LV remodelling and dysfunction, 
associated mitral regurgitation (mostly functional), known HF, signifi­
cant arrhythmias], and non-cardiac comorbidities like PAD, stroke, 
and renal dysfunction.
The main goal of follow-up is to determine the patient’s risk of 
developing new cardiac events through risk stratification and to 
identify symptoms suggestive of CAD progression. A second goal is 
Recommendation Table 28 — Recommendations for 
adherence to medical therapy and lifestyle changes 
(see also Evidence Table 28)
Recommendations
Classa
Levelb
Mobile health interventions (e.g. using text messages, 
apps, wearable devices) are recommended to 
improve patient adherence to healthy lifestyles and 
medical therapy.491,1148,1149,1154,1156,1164
I
A
Behavioural interventions are recommended to 
improve adherence.491,1140,1144
I
B
Simplifying medication regimens (e.g. using 
fixed-dose drug combinations) is recommended to 
increase patient adherence to 
medications.1139,1163,1166
I
B
Multiprofessional and family involvement is 
recommended to promote adherence, in addition to 
patient education and involvement.1139
I
C
© ESC 2024
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 79 -->

### Page 79

to promptly diagnose and manage extracoronary complications, such as 
the onset of HF, arrhythmias, and valvular dysfunction. Additionally, 
during long-term follow-up, antianginal and disease-modifying medica­
tion should be optimized and adjusted based on the development of co­
morbidities. The potential benefits vs. bleeding risks of antithrombotic 
drugs should be considered and evaluated over time.
Although assessing the anginal status is traditionally considered the 
cornerstone of clinical follow-up, it is worth noting that angina resolves 
in 40% of CCS patients at 1 year with further annual decreases, most 
often without revascularization or adaptation of antianginal therapy.404
In contrast to patients with resolving symptoms, those with persistent 
or recurrent angina are at higher risk of cardiovascular death or MI.404
The worse prognosis of persisting angina, however, was only observed 
in patients with a previous MI.408
6.3.1. Risk factors for recurrent coronary artery 
disease events
Patients with established ASCVD are at high risk of recurrent events 
and different risk factors have been identified. The REACH registry de­
monstrated that, in addition to the traditional risk factors, the burden of 
disease, lack of treatment, and geographical location are all related to an 
increased risk of cardiovascular morbidity and mortality in CCS patients 
and validated a risk score that allows estimation of the risk for 
MACE.1167 Using data from stabilized CCS patients from 27 
European countries included in the EUROASPIRE IV and V surveys, a 
new risk model with an online risk calculator to predict recurrent 
CVD events in patients under the age of 75 years was developed and 
externally validated in the SWEDEHEART registry.1168,1169 This model 
indicated that the risk of recurrent MACE is mainly driven by comorbid­
ities including diabetes, renal insufficiency, and dyslipidaemia, but also 
symptoms of depression and anxiety. A study of patients with estab­
lished CAD from the UK Biobank confirmed the value of classical risk 
factors, lifestyle, and sociodemographic factors in predicting recurrent 
MACE.1170 In addition, it was found that high genetic predisposition to 
CAD, low HDL-C, and younger age at first ACS event most strongly 
predicted the recurrence risk. A polygenic risk score, when added to 
the Framingham score, improved predictions of events in a large popu­
lation in the USA.1171 Although the prediction of recurrent MACE has 
been refined, it must be emphasized that the predictive power of the 
different risk factors is weak and that a significant part of recurrent 
MACE in CCS patients remains unexplained. Furthermore, the models 
do not incorporate information on LV function, HF, concomitant valvu­
lar disease, atherosclerotic disease burden in other vascular beds, or the 
severity of existing CAD.1172 While risk factors for recurrent cardiac 
events have been established, no clinical studies have tested predefined 
clinical pathways for long-term follow-up of various types of CCS pa­
tients. As a result, the long-term clinical follow-up of CCS patients is 
primarily empirical, based on good clinical judgement, and on the 
same criteria used in the initial diagnostic process to define high risk 
of adverse events (Section 3.3.5 and Figure 18).
6.3.2. Organization of long-term follow-up
When scheduling long-term follow-up for CCS patients with recurring 
or worsening angina, it is important to consider factors such as patient 
type, the presence of risk factors, availability of diagnostic techniques, 
and cost-effectiveness following regional or national healthcare policies. 
Different CCS phenotypes may develop or recur during long-term 
follow-up, altering the follow-up needed over time. The intervals and 
examination methods during long-term follow-up may vary based on 
the CCS phenotype, coronary atherosclerotic burden, presence of 
CMD, and severity of ischaemic LV dysfunction.
A stepwise approach based on risk assessment can be followed, like 
that applied for diagnosing and treating individuals with suspected CCS.
Step 1: This involves an annual clinical evaluation, by a general prac­
titioner or a cardiologist, encompassing symptom evaluation, medica­
tion review, physical examination, a resting 12-lead ECG, and blood 
tests for lipid profile, renal function, glycaemic status, and full blood 
count. The ECG should be scrutinized for heart rate, rhythm, evidence 
of silent ischaemia/infarction, and evaluation of PR, QRS, and QT inter­
vals. Any new symptoms suggestive of ACS, especially with ECG 
changes, warrant adherence to the 2023 ESC Guidelines for the man­
agement of patients with acute coronary syndromes. 65 Current med­
ical therapy and lifestyle measures for risk-factor control can be 
maintained or optimized for asymptomatic patients.
Step 2: If CCS patients develop new or worsening angina or HF 
symptoms, arrhythmias or ECG changes, further cardiac evaluation is 
crucial, especially if symptoms persist despite optimized GDMT. 
Recurrent CAD event risk should be assessed based on symptoms, 
progression 
of 
risk 
factors, 
and 
resting 
ECG 
changes. 
Echocardiography may be performed to assess LV function, cardiac di­
mensions, and valvular abnormalities. Exercise ECG testing may be con­
sidered to confirm symptoms and evaluate functional capacity if it alters 
patient management. However, routine functional testing is not recom­
mended for asymptomatic post-PCI patients, as it has not been shown 
to improve outcomes compared with standard care after 2 years.1173
Step 3: CCS patients with persistent symptoms at low exercise levels 
despite optimized GDMT or unexpectedly reduced LV function, espe­
cially with regional contraction abnormalities, need further cardiac test­
ing to detect the progression of CAD and assess the event risk.
For patients with known non-obstructive CAD, CCTA can help 
detect new obstructive stenoses, evaluate atherosclerotic disease pro­
gression, and identify high-risk plaque features, while functional imaging 
is reasonable for detecting myocardial ischaemia and guiding further 
management. In patients with ANOCA/INOCA and stratified medical 
therapy, CCTA can be useful to detect new or progressing CAD.
For patients with obstructive CAD or previous cardiac events, non- 
invasive functional imaging is the preferred method to detect and quan­
tify myocardial ischaemia and/or scar. However, in patients with severe­
ly limiting angina and known severe ischaemia on functional testing or 
high-risk CAD on CCTA, direct referral to ICA for revascularization 
is preferred due to the very high risk of recurrent CAD events. 
Although CCTA can detect CABG graft patency and exclude in-stent 
restenosis (ISR) in broad lumen arteries, functional imaging is preferred 
for assessing patients with prior revascularization because of the high 
frequency of extensive CAD in these patients.1174–1176
Step 4: In all patients with recurrent or worsening anginal symptoms, 
lifestyle modifications, risk-factor management, and GDMT should be 
intensified before considering further interventions. For patients with 
significant inducible myocardial ischaemia or high-risk CAD, and persist­
ent anginal symptoms despite lifestyle modifications and intensified 
GDMT, repeat coronary revascularization may be necessary to alleviate 
symptoms and improve prognosis. For patients with prior CABG ex­
periencing stable symptoms, it’s important to optimize GDMT when­
ever possible. If frequent angina persists despite GDMT optimization, 
ICA or CCTA can assist in guiding treatment decisions.1177–1179
When symptoms are uncertain, functional testing may help clarify the 
presence and extent of myocardial ischaemia.
ESC Guidelines                                                                                                                                                                                          3493


<!-- PAGE 80 -->

### Page 80

6.3.3. Non-invasive diagnostic testing
All non-invasive diagnostic testing, including CCTA, stress SPECT, 
or PET myocardial perfusion imaging, stress echocardiography, 
and stress CMR have been shown to provide prognostic informa­
tion in patients with established CAD.296,1180,1181 Anatomical im­
aging with CCTA has the advantage of providing information on 
left main disease and graft patency. Stress imaging provides informa­
tion on the degree of ischaemia, which helps guide an appropriate 
management plan. For example, symptomatic patients with 
moderate-to-severe myocardial ischaemia despite GDMT will usu­
ally undergo additional revascularization. In patients with known 
ANOCA/INOCA, non-invasive imaging with stress SPECT or PET 
myocardial perfusion imaging, stress CMR, or stress echocardiog­
raphy remain first-line investigations, although the diagnostic yield 
may be low;927 however, the current standard remains invasive cor­
onary functional testing.
4
5
6
1
Symptom severity and frequency?
More frequent follow-up or new diagnostic or therapeutic action needed?
3
Extent and severity of known CAD?
Consider:
LV-function? Other heart diseases?
(e.g.  AF, valve disease, RV dysfunction)
Age and gender
Prior ACS, PCI or CABG
Risk factors for CAD
Comorbidities (e.g. CKD, PAD)
Recurrent or new CAD event?
Treatment compliance and lifestyle
Genetic predisposition
Inflammatory markers
Psychosocial factors
2
ECG changes?
Figure 18 Approach for the follow-up of patients with established chronic coronary syndrome. ACS, acute coronary syndrome; AF, atrial fibrillation; 
CABG, coronary aortic bypass grafting; CAD, coronary artery disease; CCS, chronic coronary syndrome; CKD, chronic kidney disease; ECG, electro­
cardiogram; LV, left ventricle; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; RV, right ventricle.


<!-- PAGE 81 -->

### Page 81

6.4. Treatment of myocardial 
revascularization failure
One in five revascularized patients needs a repeat revascularization 
within the first 5 years after myocardial revascularization, with higher 
risk after PCI compared with CABG.1182 Revascularization failure can 
manifest either shortly after the initial procedure (within 30 days) or la­
ter on, and recurring symptoms may result from either restenosis of 
the treated coronary segment or the failure of bypass grafts,772 along­
side the progression of underlying native CAD.1183,1184 Published evi­
dence 
regarding 
diagnosis 
and 
management 
of 
myocardial 
revascularization failure has been summarized in the 2020 EAPCI 
(European Association of Percutaneous Cardiovascular Interventions) 
Expert Consensus Paper.1182
6.4.1. Percutaneous coronary intervention failure
Stent thrombosis and ISR are the most frequent reasons for PCI failure. 
Stent thrombosis occurs infrequently and is multifactorial. Anatomical 
and mechanical factors, as well as lack of adherence or hyporesponsive­
ness to antiplatelet treatment, are frequently the reasons behind 
this.1182,1185 The majority of patients with stent thrombosis present 
with ACS and should be treated according to the 2023 ESC 
Guidelines for the management of patients with acute coronary syn­
dromes.65 Urgent ICA to confirm diagnosis and treatment is indicated. 
After restoration of coronary flow, intracoronary imaging to identify 
mechanical failure should be performed. Repeated DES implantation 
is indicated in case of stent fracture or collapse and residual edge dissec­
tions, while high-pressure non-compliant balloon dilation is indicated in 
case of stent under-expansion or malapposition.
In-stent restenosis results as a response to vessel wall injury 
(neointimal hyperplasia) or neoatherosclerosis in the stented segment 
of the coronary artery. Although significantly less frequent than after 
bare-metal stent implantation, the incidence of clinical in-DES restenosis 
is up to 10% within the first 10 years after DES implantation1182 and re­
mains the most frequent cause of PCI failure. The clinical presentation 
of ISR is mostly CCS, with 20% ACS, and the remaining asymptomatic. 
The indication to treat ISR is like that for native CAD. Radiological stent 
enhancement and intracoronary imaging are encouraged to determine 
the ISR mechanism. PCI treatment of ISR should be focused on the 
stenotic segment. Lesion preparation (ultra-high pressure balloon dila­
tion, intravascular lithotripsy, rotation atherectomy) and correction of 
mechanical issues are required.1182 Thereafter, drug-coated balloon 
angioplasty or DES implantation is necessary.1186,1187 Drug-eluting bal­
loon angioplasty and repeat stenting with DES were equally effective 
and safe in treating bare-metal ISR, but drug-coated balloon angioplasty 
was less effective than repeat paclitaxel DES implantation in treating 
DES ISR.1186 However, at 10-year follow-up there was no difference 
in clinical endpoints between drug-coated balloon angioplasty and 
DES implantation, whereas both were more effective than balloon 
angioplasty 
in 
preventing 
target-lesion 
revascularization.1187
Everolimus DES was associated with better long-term outcomes than 
drug-coated balloons.1188
6.4.2. Managing graft failure after coronary artery 
bypass grafting
A variety of reasons have the potential to adversely affect bypass graft 
patency.1189 These include technical (quality of graft material, surgical 
precision) and pathophysiological aspects (competitive flow, activity 
of the coagulation system, disease progression, etc.). Technical aspects 
and competitive flow are thought to influence early graft failure, while 
disease progression and graft degeneration affect long-term 
patency.1182,1189
The majority of graft occlusions are clinically silent.1189 If symptoms 
occur, prompt diagnostic workup (including ECG, assessment of bio­
markers, and possibly repeat coronary angiography) is warranted to 
limit or prevent potential damage from graft occlusion.316 Acute 
CABG graft failure (<1 month after surgery) is observed in approxi­
mately 12% of grafts mostly due to technical problems.1190 Late failure 
of saphenous vein grafts occurs in up to 50% at 10 years, with vein graft 
occlusion rates in up to 27% within 1 year after surgery. 771,1191
The decision for optimal treatment (conservative, CABG revision/ 
redo CABG or PCI of the native vessel or of the failed graft) should 
be made individually considering haemodynamic stability, technical 
Recommendation Table 29 — Recommendations for 
diagnosis of disease progression in patients with estab­
lished chronic coronary syndrome (see also Evidence 
Table 29)
Recommendations
Classa
Levelb
Asymptomatic patients with established chronic coronary 
syndromes
Regardless of symptoms, periodic visits (e.g. annual) 
to a general practitioner or cardiovascular healthcare 
professional are recommended to evaluate 
cardiovascular risk factor control and to assess 
changes in risk status, disease status, and 
comorbidities that may require lifestyle, medical, or 
procedural interventions.
I
C
Symptomatic patients with established chronic coronary 
syndromes
Reassessment of CAD status is recommended in 
patients with deteriorating LV systolic function that 
cannot be attributed to a reversible cause (e.g. 
longstanding tachycardia or myocarditis).
I
C
Risk stratification is recommended in patients with 
new or worsening symptoms, preferably using stress 
imaging.
I
C
In patients with symptoms refractory to medical 
treatment or at high risk of adverse events, invasive 
coronary angiography (with FFR/iFR when necessary) 
is recommended for risk stratification and for 
possible revascularization aimed at improving 
symptoms and prognosis.
I
C
In CCS patients with symptoms refractory to medical 
treatment, and who have had previous coronary 
revascularization, CCTA should be considered to 
evaluate bypass graft or stent patency (for stents ≥3 
mm).1174–1176
IIa
B
© ESC 2024
CAD, coronary artery disease; CCS, chronic coronary syndrome; CCTA, coronary 
computed tomography angiography; FFR, fractional flow reserve; iFR, instantaneous 
wave-free ratio; LV, left ventricular; QFR, quantitative flow ratio. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3495


<!-- PAGE 82 -->

### Page 82

reasons for graft failure, and ability to treat native CAD. PCI is the first 
choice over redo CABG for late graft failure, with PCI of the native ves­
sel rather than PCI of the graft. 772,1182,1192,1193
If re-operation is required, the surgical risk is generally in­
creased.1182,1192 If acute re-operation is required, acute ischaemia is 
generally present, and adhesions and the presence of patent grafts in­
crease the complexity of the procedure. It is, therefore, important to 
weigh this risk against the expected benefit. Since a patent left internal 
thoracic artery (LITA) to the LAD confers the largest part of CABG 
prognostic potential,1189,1194 redo CABG is primarily recommended 
in patients with indications for CABG and occluded LITA or if the 
LITA was not used during the first operation.772
6.5. Recurrent or refractory  
angina/ischaemia
An ageing population and an increased survival rate in patients with 
CAD due to improvements in anti-ischaemic medical therapy and cor­
onary revascularization have led to a growing number of patients with 
severe and diffuse CAD not amenable to further revascularization pro­
cedures. Despite the use of antianginal drugs and/or PCI or CABG, the 
proportion of patients with CAD who have daily or weekly angina 
ranges from 2% to 24%.555
Refractory angina is defined as long-lasting symptoms (for >3 months) 
due to established reversible ischaemia: (i) in the presence of ob­
structive CAD, which cannot be controlled by escalating medical ther­
apy with additional antianginal drugs, bypass grafting, or PCI including 
recanalization of chronic total coronary occlusion; or (ii) due to 
ANOCA/INOCA. In the case of ANOCA/INOCA, further investiga­
tions are required to define the different endotypes (Section 4.4.2) and 
appropriate treatment (Section 6.3) before diagnosing refractory 
angina.36
The QoL of patients with refractory angina is poor, with frequent 
hospitalization and a high level of resource utilization.555 Once conven­
tional anti-ischaemic targets have been exhausted, novel therapies can 
be ranked by mechanism of action, promotion of collateral growth, 
transmural redistribution of blood flow, and neuromodulation of the 
cardiac pain syndrome.
Considering the chronic nature of the disease and according to risk– 
benefit assessments, among the currently available options, the most 
promising and easily implementable in everyday clinical practice are en­
hanced external counterpulsation and the coronary sinus reducer de­
vice,555 after all medical therapy and mechanical revascularization 
options have been exhausted (see Sections 4.2 and 4.4). Enhanced ex­
ternal counterpulsation has been shown to ameliorate refractory an­
gina in several trials.1198
The coronary sinus reducer consists of controlled coronary sinus 
narrowing with the implantation of a large stainless-steel device to in­
crease coronary sinus pressure and improve perfusion in the LAD ter­
ritory.1199 In a recent meta-analysis including eight registries and one 
RCT, in a total of 846 patients with refractory angina, use of a coronary 
sinus reducer led to improvement of ≥1 CCS class in 76% (95% CI, 
73%–80%) of patients and an improvement of ≥2 CCS class in 40% 
(95% CI, 35%–46%) of patients.1200 The Coronary Sinus Reducer 
Objective Impact on Symptoms, MRI Ischaemia and Microvascular 
Resistance (ORBITA-COSMIC) trial, a small proof-of-concept RCT, 
found no evidence that implantation of a coronary sinus reducer im­
proved transmural myocardial perfusion, but it was associated with im­
proved angina symptoms compared with placebo. 1201
There are several ongoing RCTs evaluating the use of coronary 
sinus reducer in ANOCA/INOCA, such as COronary SInus Reducer 
for the Treatment of Refractory Microvascular Angina (COSIMA; 
NCT04606459), and the Efficacy of the COronary SInus Reducer in 
Patients with Refractory Angina II (COSIRA-II; NCT05102019).
A variety of new pharmacological approaches is becoming available 
and includes angiogenetic therapies with vascular endothelial growth 
factors and fibroblast growth factors, as well as stem cell therapy 
with intramyocardial delivery of CD34+ cells.1202,1203 However, further 
RCTs are needed to validate the feasibility of such therapeutic 
strategies.
To date, the main limitations of reported experiences with all novel 
therapeutic options regard the small number of treated patients and 
the duration of follow-up. Larger sham-controlled RCTs are required 
to define the role of each treatment modality for specific subgroups, 
and ultimately to aim at the best possible personalized treatment algo­
rithm, based on aetiology stratification, and escalation of available thera­
peutic modalities.
Recommendation Table 30 — Recommendations for 
treatment 
of 
revascularization 
failure 
(see 
also 
Evidence Table 30)
Recommendations
Classa
Levelb
DES is recommended over drug-coated balloons for 
treatment of in-DES restenosis.1186–1188
I
A
LIMA is indicated as the conduit of choice for redo 
CABG in patients in whom the LIMA was not used 
previously.1195
I
B
Redo CABG should be considered for patients 
without a patent LIMA graft to the LAD. 842,1192,1196
IIa
B
PCI of the bypassed native artery should be 
considered over PCI of the bypass graft.1197
IIa
B
© ESC 2024
CABG, coronary artery bypass grafting; DES, drug-eluting stent; LAD, left anterior 
descending; LIMA, left internal mammary artery; PCI, percutaneous coronary intervention. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 31 — Recommendations for 
recurrent or refractory angina/ischaemia (see also 
Evidence Table 31)
Recommendations
Classa
Levelb
In patients with refractory angina leading to poor 
quality of life and with documented or suspected 
ANOCA/INOCA, invasive coronary functional 
testing is recommended to define ANOCA/INOCA 
endotypes and appropriate treatment, considering 
patient choices and preferences.36,37,298,930,939,985
I
B
In patients with debilitating angina and obstructive 
CAD refractory to optimal medical and 
revascularization strategies, a reducer device for 
coronary sinus constriction may be considered to 
improve symptoms, in experienced centres.1199– 
1201,1204
IIb
B
© ESC 2024
ANOCA, angina with non-obstructive coronary arteries; CAD, coronary artery disease; 
INOCA, ischaemia with non-obstructive coronary arteries. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 83 -->

### Page 83

6.6. Treatment of disease complications
Patients with CCS who develop LV dysfunction may experience ad­
vanced HF, malignant arrhythmias and secondary valvular heart disease 
(i.e. mitral and tricuspid regurgitation).
Prior MI and ischaemic aetiology are negative prognostic markers in 
patients with advanced HF,1205 as well as in those with secondary mitral 
regurgitation.1206 Specific treatments need to be considered in these 
patients regardless of HF aetiology (i.e. ischaemic).526 Advanced HF 
treatments include: high diuretic doses; a combination of diuretics 
and renal replacement therapy to treat congestion; inotropic and vaso­
pressor agents to reduce hypoperfusion; and mechanical circulatory 
support in selected patients with severe symptoms or exercise intoler­
ance, despite optimal medical therapies, and without right ventricular 
dysfunction. Heart transplantation is recommended for patients with 
advanced HF, refractory to medical/device therapy, and who do not 
have absolute contraindications. Early evaluation for mechanical circu­
latory supports or heart transplantation is currently suggested also in 
patients with mild symptoms [i.e. New York Heart Association 
(NYHA) class II] and high-risk profile (i.e. LVEF of <20%, recurrent 
HF events, hypotension, intolerance to medical therapy, worsening or­
gan failure, ventricular arrhythmias/ICD shock).526
An ICD is recommended in patients with ischaemic cardiomyopathy 
and LVEF of <35% or who have recovered from ventricular arrhyth­
mias.526 Frequent, symptomatic ventricular arrhythmias in ICD recipi­
ents should be treated medically with either beta-blockers or 
amiodarone. In patients with CCS who develop ventricular fibrillation 
or polymorphic ventricular tachycardia, assessment for myocardial is­
chaemia should be performed without delay. In patients with CAD in 
whom sustained monomorphic ventricular tachycardia recurs while 
on amiodarone treatment, catheter ablation is recommended over 
the escalation of antiarrhythmic drugs.1207 Percutaneous treatment 
of secondary mitral regurgitation in patients with advanced HF may 
be considered to improve symptoms.526 Treatment of secondary tri­
cuspid regurgitation in advanced stages of disease was, until recently, 
supported by limited evidence.1208 Percutaneous tricuspid transcath­
eter edge-to-edge repair was found to reduce significantly severe tri­
cuspid regurgitation and was associated with improvements in QoL 
at 1 year.1209
7. Key messages
• Symptoms of myocardial ischaemia due to obstructive atherosclerot­
ic CAD overlap with those of CMD or vasospasm.
• Similar guideline-directed cardiovascular preventive therapy is re­
commended in women and men in spite of the sex differences in 
the clinical presentation.
• Inclusion of risk factors to classic pre-test likelihood models of ob­
structive atherosclerotic CAD improves the identification of patients 
with very low (≤5%) pre-test likelihood of obstructive CAD in whom 
deferral of diagnostic testing should be considered.
• CACS is a reliable ‘simple’ test to modify the pre-test likelihood of 
atherosclerotic obstructive CAD.
• First-line diagnostic testing of suspected CCS should be done by non- 
invasive anatomic or functional imaging.
• Selection of the initial non-invasive diagnostic test should be based on 
the pre-test likelihood of obstructive CAD, other patient character­
istics that influence the performance of non-invasive tests, and local 
expertise and availability.
• CCTA is preferred to rule out obstructive CAD and detect non- 
obstructive CAD.
• Functional imaging is preferred to correlate symptoms to myocardial 
ischaemia, estimate myocardial viability, and guide decisions on cor­
onary revascularization.
• PET is preferred for absolute MBF measurements, but CMR perfu­
sion studies may offer an alternative.
• Selective second-line cardiac imaging with functional testing in pa­
tients with abnormal CCTA and CCTA after abnormal functional 
testing may improve patient selection for ICA.
• ICA is recommended to diagnose obstructive CAD in individuals 
with a very high pre- or post-test likelihood of disease, severe symp­
toms refractory to GDMT, angina at a low level of exercise, and/or 
high event risk.
• When ICA is indicated, it is recommended to evaluate the functional 
severity of ‘intermediate’ stenoses by invasive functional testing (FFR, 
iFR) before revascularization.
• Computed FFR based on the 3D reconstruction of ICA is emerging as 
a valuable alternative to wire-based coronary pressure to evaluate 
the functional severity of ‘intermediate’ stenoses.
• The use of imaging guidance is now recommended when performing 
complex PCI.
• A single antiplatelet agent, aspirin or clopidogrel, is generally recom­
mended long term in CCS patients with obstructive atherosclerotic 
CAD.
• For high thrombotic-risk CCS patients, long-term therapy with two 
antithrombotic agents is reasonable, as long as bleeding risk is not 
high.
• For CCS patients with sinus rhythm, DAPT is recommended at the 
time of PCI and for 1 to 6 month(s), according to high or low bleeding 
risk, respectively.
• For CCS patients requiring OAC and undergoing PCI, OAC and 
DAPT (aspirin and clopidogrel) for 1 to 4 weeks, followed by 
OAC and clopidogrel for up to 6 months in patients not at high is­
chaemic risk and up to 12 months in patients at high ischaemic risk, 
followed by OAC alone should be considered.
• In CCS patients with functionally significant multivessel CAD, current 
evidence indicates benefit of myocardial revascularization over 
GDMT alone for symptom improvement, prevention of spontaneous 
MI, and reduction of cardiovascular mortality at long follow-up.
• Among CCS patients with normal LV function and no significant left 
main or proximal LAD lesions, current evidence indicates that myo­
cardial revascularization over GDMT alone does not prolong overall 
survival.
• Among CCS patients with reduced LV function and ischaemic cardio­
myopathy, current evidence indicates that surgical revascularization 
compared with GDMT alone prolongs overall survival at very long 
follow-up.
• Among patients with complex multivessel CAD without LMCAD, 
particularly in the presence of diabetes, who are clinically and ana­
tomically suitable for both revascularization modalities, current evi­
dence indicates longer overall survival after CABG than PCI.
• Among patients who are clinically and anatomically suitable for both 
revascularization modalities, a greater need for repeat revasculariza­
tion after PCI than surgery, independently of multivessel CAD ana­
tomical severity, has been consistently reported with current 
surgical and stent technology.
• Lifestyle and risk-factor modification combined with disease- 
modifying and antianginal medications are cornerstones in the man­
agement of CCS.
ESC Guidelines                                                                                                                                                                                          3497


<!-- PAGE 84 -->

### Page 84

• Shared decision-making between patients and healthcare profes­
sionals, based on patient-centred care, is paramount in defining the 
appropriate therapeutic pathway for CCS patients. Patient education 
is key to improve risk-factor control in the long term.
• The relatively high prevalence of ANOCA/INOCA and its associated 
MACE rate warrants improvement in the diagnosis and treatment of 
affected patients.
• Persistently symptomatic patients with suspected ANOCA/INOCA 
who do not respond to GDMT should undergo invasive coronary 
functional testing to determine underlying endotypes.
• Characterization of endotypes is important to guide appropriate 
medical therapy for ANOCA/INOCA patients.
• Research on effective methods to support specific healthy lifestyle 
behaviours, and sustain medication and healthy lifestyle adherence 
over time, is needed.
• More research is needed on improving the implementation of health- 
promoting policies and practices in the workplace setting.
8. Gaps in evidence
• It remains unclear if screening for subclinical obstructive CAD in the 
general population is useful.1106,1210 Further large-scale studies are 
needed to investigate the prognostic benefit of screening and treating 
asymptomatic CCS in the general population, preferably involving dif­
ferent geographical regions. Optimal screening options remain to be 
determined for specific groups at high risk (e.g. asymptomatic indivi­
duals with diagnosed diabetes for longer than 10 years).
• Most studies assessing diagnostic strategies in individuals with symp­
toms suspected of CCS were performed in populations with a mod­
erate (>15%–50%) pre-test clinical likelihood of obstructive CAD. 
Further studies are needed to determine the optimal and most cost- 
effective diagnostic strategy in individuals with a low (>5%–15%) pre- 
test clinical likelihood of obstructive CAD.
• The current diagnosis of ANOCA/INOCA and its different endo­
types is mainly determined by invasive coronary functional testing.36
Further research is needed to refine and assess non-invasive diagnos­
tic imaging modalities for CMD. Currently available and new 
non-invasive imaging modalities should be calibrated against invasive 
testing, allowing the use of their measurements interchangeably.
• The role of antithrombotic therapy in CCS patients with ANOCA/ 
INOCA remains to be established.
• Because of how evidence has accrued over time, there is no clear evi­
dence about the existence of first- and second-line antianginal ther­
apy. It is unclear whether long-acting nitrates, ranolazine, nicorandil, 
ivabradine, trimetazidine, or any of their combinations improve an­
ginal symptoms more than beta-blockers or CCBs.
• The optimal type and duration of DAPT is still uncertain in some sub­
sets of patients (e.g. patients with prior revascularization who might 
benefit from shorter or longer DAPT strategies).
• The long-term benefit of beta-blocker therapy in post-MI patients 
without reduced EF remains to be elucidated.
• In view of the reported positive impact of low-dose colchicine in pa­
tients with CCS in reducing MI, stroke, and revascularization, future 
studies should identify whether certain patient subgroups (e.g. those 
with elevated biomarker levels) might derive even greater clinical 
benefit from this treatment.
• A post hoc analysis of ISCHEMIA detected a graded association 
between the severity of obstructive CAD assessed by CCTA 
and all-cause mortality and acute MI during follow-up.317 There 
is a need for randomized data comparing contemporary medical 
treatment against early revascularization plus medical therapy in 
subsets of patients with an increased risk for death or MI as de­
termined by the post hoc analysis. Moreover, because the benefit 
of an invasive strategy with respect to cardiac mortality was 
shown in a meta-analysis of chronologically heterogeneous trials, 
including several conducted more than two decades ago, the im­
pact of early revascularization plus GDMT vs. contemporary 
GDMT on all-cause and cardiac mortality in patients with CCS 
should ideally be tested in a well-designed, adequately powered 
randomized trial.
• Some meta-analyses have reported a reduction in cardiac mortality 
without a reduction in all-cause mortality. There is a need to clarify 
the impact of revascularization in CCS patients on cardiovascular 
and non-cardiovascular mortality.
• Complete revascularization of multivessel CAD by PCI can be 
achieved as a single procedure (index PCI) or as staged PCI. In the 
setting of CCS, the value of staged PCI and the optimal interval be­
tween interventions needs to be evaluated.
• Whether CABG surgery and PCI are comparable among patients 
with ischaemic cardiomyopathy and HFrEF in the modern era of 
HF treatment needs to be evaluated.
• Various imaging techniques, such as low-dose DSE, CMR, and PET/ 
CT, can identify hibernating myocardium with the potential for func­
tional recovery after revascularization.1211 Further randomized trials 
with contemporary, well-defined modalities and strict adherence to 
protocol are needed to clarify the clinical benefits (if any) of viability 
testing.
• Residual ischaemia post-PCI, as determined by FFR/iFR, reflects re­
maining atherosclerotic lesions and/or suboptimal PCI results, but 
also persistent or worsening microvascular dysfunction. Whether 
post-PCI FFR/iFR is a ‘modifiable’ risk factor remains to be proved.
• Among patients suitable for off-pump CABG with complex multives­
sel CAD but no LMCAD, the impact of hybrid revascularization on 
outcomes, including peri-operative complications other than 
MACE, needs more extensive investigation. Data on the optimal 
time interval between MIDCAB-LIMA and PCI are lacking.
• Whether the decision process based on a multidisciplinary Heart 
Team leads to better outcomes than standard institutional practice 
remains to be investigated.
• The medical therapy of ANOCA/INOCA is largely empirical. 
Therefore, prospective randomized clinical trials are needed to de­
termine the efficacy of antianginal treatments in improving symptoms 
and outcomes for the different endotypes.
• Research on effective methods to support healthy lifestyle beha­
viours, and sustain medication and healthy lifestyle adherence over 
time, is needed. In addition, more research is needed on improving 
the implementation of health-promoting policies and practices in 
the workplace setting.
• There is a need for further evidence on the effectiveness of neuro­
modulation, spinal cord stimulation, therapeutic angiogenesis, and 
coronary sinus occlusion in patients who suffer from refractory 
angina, 
despite 
guideline-directed 
medical 
treatment 
and 
revascularization.


<!-- PAGE 85 -->

### Page 85

Table 10 ‘What to do’ and ‘What not to do’
Recommendations
Classa
Levelb
Recommendations for history taking, risk factor assessment, and resting electrocardiogram in individuals with suspected chronic 
coronary syndrome
In individuals reporting symptoms of suspected myocardial ischaemic origin, a detailed assessment of cardiovascular risk factors, medical 
history, and symptom characteristics (including onset, duration, type, location, triggers, relieving factors, time of day) is recommended.
I
C
If clinical or ECG assessment suggests ACS rather than CCS, immediate referral to the emergency department and/or repeated 
measurement of blood troponin, preferably using high-sensitivity or ultrasensitive assays, to rule out acute myocardial injury is 
recommended.
I
B
A resting 12-lead ECG is recommended in all individuals reporting chest pain (unless an obvious non-cardiac cause is identified), particularly 
during, or immediately after, an episode suggestive of myocardial ischaemia.
I
C
Using ST-segment deviations during supraventricular tachyarrhythmias, particularly during re-entrant atrioventricular tachycardias, per se, 
as reliable evidence of obstructive CAD, is not recommended.
III
B
Recommendations for basic biochemistry in the initial diagnostic management of individuals with suspected chronic coronary syndrome
The following blood tests are recommended in all individuals to refine risk stratification, diagnose comorbidities, and guide treatment:
• lipid profile including LDL-C;
I
A
• full blood count (including haemoglobin);
I
B
• creatinine with estimation of renal function;
I
B
• glycaemic status with HbA1c and/or fasting plasma glucose.
I
B
In patients with suspected CCS, it is recommended to assess thyroid function at least once.
I
B
Recommendations for estimating, adjusting and reclassifying the likelihood of obstructive atherosclerotic coronary artery disease in the 
initial diagnostic management of individuals with suspected chronic coronary syndrome
It is recommended to estimate the pre-test likelihood of obstructive epicardial CAD using the Risk Factor-weighted Clinical Likelihood 
model.
I
B
It is recommended to use additional clinical data (e.g. examination of peripheral arteries, resting ECG, resting echocardiography, presence of 
vascular calcifications on previously performed imaging tests) to adjust the estimate yielded by the Risk Factor-weighted Clinical Likelihood 
model.
I
C
Recommendations for resting transthoracic ultrasound and cardiac magnetic resonance imaging in the initial diagnostic management of 
individuals with suspected chronic coronary syndrome
A resting transthoracic echocardiogram is recommended: 
• to measure LVEF, volumes and diastolic function;
• identify regional wall motion abnormalities;
• identify non-coronary cardiac disease (e.g. hypertrophy, cardiomyopathy, valve disease, pericardial effusion);
• assess right ventricular function and estimate systolic pulmonary artery pressure;
to refine risk stratification and guide treatment.
I
B
Recommendations for the use of exercise ECG in the initial diagnostic management of individuals with suspected chronic coronary 
syndrome
Exercise ECG is recommended in selected patients for the assessment of exercise tolerance, symptoms, arrhythmias, BP response, and 
event risk.
I
C
Exercise ECG is not recommended for diagnostic purposes in patients with ≥0.1 mV ST-segment depression on resting ECG, left bundle 
branch block or who are being treated with digitalis.
III
C
In individuals with a low or moderate (>5–50%) pre-test likelihood of obstructive CAD, an exercise ECG is not recommended to rule out 
CAD if CCTA or functional imaging tests are available.
III
C
Recommendations for ambulatory ECG monitoring in the initial diagnostic management of individuals with suspected chronic coronary 
syndrome
Ambulatory ECG monitoring is recommended in subjects with chest pain and suspected arrhythmias.
I
C
Continued 
9. ‘What to do’ and ‘What not to do’ messages from the guidelines
Table 10 lists all Class I and Class III recommendations from the text alongside their level of evidence.
ESC Guidelines                                                                                                                                                                                          3499


<!-- PAGE 86 -->

### Page 86

Recommendations for non-invasive anatomical imaging tests in the initial diagnostic management of individuals with suspected chronic 
coronary syndrome—coronary computed tomography angiography, if available, and supported by local expertise
In individuals with suspected CCS and low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA is recommended to 
diagnose obstructive CAD and to estimate the risk of MACE.
I
A
CCTA is recommended in individuals with low or moderate (>5%–50%) pre-test likelihood to refine diagnosis if another non-invasive test is 
non-diagnostic.
I
B
CCTA is not recommended in patients with severe renal failure (eGFR <30 mL/min/1.73 m2), decompensated heart failure, extensive 
coronary calcification, fast irregular heart rate, severe obesity, inability to cooperate with breath-hold commands, or any other conditions 
that can make obtaining good imaging quality unlikely.
III
C
Recommendations for non-invasive tests in the initial diagnostic management of individuals with suspected chronic coronary syndrome 
—stress echocardiography, if available, and supported by local expertise
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, stress echocardiography is 
recommended to diagnose myocardial ischaemia and to estimate the risk of MACE.
I
B
During stress echocardiography, when two or more contiguous myocardial segments are not visualized, it is recommended to use 
commercially available intravenous ultrasound contrast agents (microbubbles) to improve diagnostic accuracy.
I
B
During stress echocardiography, myocardial perfusion using commercially available intravenous ultrasound contrast agents (microbubbles) 
is recommended to improve diagnostic accuracy and to refine risk stratification beyond wall motion.
I
B
Recommendations for non-invasive functional myocardial imaging tests in the initial diagnostic management of individuals with 
suspected chronic coronary syndrome—resting and stress single-photon emission computed tomography/positron emission 
tomography—cardiac magnetic resonance imaging, if available, and supported by local expertise
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, stress SPECT or, preferably, 
PET myocardial perfusion imaging is recommended to: 
• diagnose and quantify myocardial ischaemia and/or scar;
• estimate the risk of MACE;
• quantify myocardial blood flow (PET).
I
B
In patients selected for PET or SPECT myocardial perfusion imaging, it is recommended to measure CACS from unenhanced chest CT 
imaging (used for attenuation correction) to improve detection of both non-obstructive and obstructive CAD.
I
B
In individuals with suspected CCS and moderate or high (>15%–85%) pre-test likelihood of obstructive CAD, CMR perfusion imaging is 
recommended to diagnose and quantify myocardial ischaemia and/or scar and estimate the risk of MACE.
I
B
Recommendations for invasive coronary angiography in individuals with suspected obstructive coronary artery disease
When ICA is indicated, radial artery access is recommended as the preferred access site.
I
A
When ICA is indicated, it is recommended to have coronary pressure assessment available and to use it to evaluate the functional severity of 
intermediate non-left main stem stenoses prior to revascularization.
I
A
Invasive coronary angiography is recommended to diagnose CAD in individuals with a very high (>85%) clinical likelihood of disease, severe 
symptoms refractory to guideline-directed medical therapy, angina at a low level of exercise, and/or high event risk.
I
C
In individuals with de novo symptoms highly suggestive of obstructive CAD that occur at a low level of exercise, ICA with a view towards 
revascularization is recommended as first diagnostic test after clinical assessment by a cardiologist.
I
C
Recommendations for functional assessment of epicardial artery stenosis severity during invasive coronary angiography to guide 
revascularization
During ICA, selective assessment of functional severity of intermediate diameter stenoses is recommended to guide the decision to 
revascularize, using the following tools:
• FFR/iFR (significant ≤0.8 or ≤0.89, respectively);
I
A
• QFR (significant ≤0.8).
I
B
Systematic and routine wire-based coronary pressure assessment of all coronary vessels is not recommended.
III
A
Recommendations for selection of initial diagnostic tests in individuals with suspected chronic coronary syndrome
It is recommended to select the initial non-invasive diagnostic test based on pre-test likelihood of obstructive CAD, other patient 
characteristics that influence the performance of non-invasive tests, and local expertise and availability.
I
C
In symptomatic patients in whom the pre-test likelihood of obstructive CAD by clinical assessment is >5%, CCTA or non-invasive functional 
imaging for myocardial ischaemia is recommended as the initial diagnostic test.
I
B
To rule out obstructive CAD in individuals with low or moderate (>5%–50%) pre-test likelihood, CCTA is recommended as the preferred 
diagnostic modality.
I
B
CCTA is recommended in individuals with low or moderate (>5%–50%) pre-test likelihood if functional imaging for myocardial ischaemia is 
not diagnostic.
I
B
Continued


<!-- PAGE 87 -->

### Page 87

Functional imaging for myocardial ischaemia is recommended if CCTA has shown CAD of uncertain functional significance or is not 
diagnostic.
I
B
Invasive coronary angiography with the availability of invasive functional assessments is recommended to confirm or exclude the diagnosis of 
obstructive CAD or ANOCA/INOCA in individuals with an uncertain diagnosis on non-invasive testing.
I
B
Recommendations for definition of high risk of adverse events
An initial stratification of risk of adverse events is recommended based on basic clinical assessment (e.g. age, ECG, anginal threshold, 
diabetes, CKD, LVEF).
I
B
The use of one or more of the following test results is recommended to identify individuals at high risk of adverse events: 
• Exercise ECG: 
⚬Duke Treadmill Score < −10;
• stress SPECT or PET perfusion imaging: 
⚬Area of ischaemia ≥10% of the LV myocardium;
• Stress echocardiography: 
⚬≥3 of 16 segments with stress-induced hypokinesia or akinesia;
• stress CMR: 
⚬≥2 of 16 segments with stress perfusion defects or ≥3 dobutamine-induced dysfunctional segments;
• CCTA: 
⚬left main disease with ≥50% stenosis, three-vessel disease with ≥70 stenosis, or two-vessel disease with ≥70% stenosis, including the 
proximal LAD or one-vessel disease of the proximal LAD with ≥70% stenosis and FFR-CT ≤0.8.
I
B
In individuals at high risk of adverse events (regardless of symptoms), ICA—complemented by invasive functional measures (FFR/iFR) when 
appropriate—is recommended, with the aim of refining risk stratification and improving symptoms and cardiovascular outcomes by 
revascularization.
I
A
Recommendations for cardiovascular risk reduction, lifestyle changes, and exercise interventions in patients with established chronic 
coronary syndrome
An informed discussion on CVD risk and treatment benefits tailored to individual patient needs is recommended.
I
C
Multidisciplinary behavioural approaches to help patients achieve healthy lifestyles, in addition to appropriate pharmacological management, 
are recommended.
I
A
A multidisciplinary exercise-based programme to improve cardiovascular risk profile and reduce cardiovascular mortality is recommended.
I
A
Aerobic physical activity of at least 150–300 min per week of moderate intensity or 75–150 min per week of vigorous intensity and 
reduction in sedentary time are recommended.
I
B
Recommendations for antianginal drugs in patients with chronic coronary syndrome
It is recommended to tailor the selection of antianginal drugs to the patient’s characteristics, comorbidities, concomitant medications, 
treatment tolerability, and underlying pathophysiology of angina, also considering local drug availability and cost.
I
C
Short-acting nitrates are recommended for immediate relief of angina.
I
B
Initial treatment with beta-blockers and/or CCBs to control heart rate and symptoms is recommended for most patients with CCS.
I
B
Ivabradine is not recommended as add-on therapy in patients with CCS, LVEF >40%, and no clinical heart failure.
III
B
Combination of ivabradine with non-DHP-CCB or other strong CYP3A4 inhibitors is not recommended.
III
B
Nitrates are not recommended in patients with hypertrophic cardiomyopathy or in co-administration with phosphodiesterase inhibitors.
III
B
Recommendations for antithrombotic therapy in patients with chronic coronary syndrome
In CCS patients with a prior MI or remote PCI, aspirin 75–100 mg daily is recommended lifelong after an initial period of DAPT.
I
A
In CCS patients with a prior MI or remote PCI, clopidogrel 75 mg daily is recommended as a safe and effective alternative to aspirin 
monotherapy.
I
A
After CABG, aspirin 75–100 mg daily is recommended lifelong.
I
A
In patients without prior MI or revascularization but with evidence of significant obstructive CAD, aspirin 75–100 mg daily is recommended 
lifelong.
I
B
In CCS patients with no indication for oral anticoagulation, DAPT consisting of aspirin 75–100 mg and clopidogrel 75 mg daily for up to 6 
months is recommended as the default antithrombotic strategy after PCI-stenting.
I
A
In patients at high bleeding risk, but not at high ischaemic risk, it is recommended to discontinue DAPT 1–3 months after PCI and to 
continue with single antiplatelet therapy.
I
A
In CCS patients with a long-term indication for OAC, an AF therapeutic dose of VKA alone or, preferably, of DOAC alone (unless 
contraindicated) is recommended lifelong.
I
B
In patients with an indication for OAC who undergo PCI, initial low-dose aspirin once daily is recommended (loading dose when not on 
maintenance dose) in addition to OAC and clopidogrel.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3501


<!-- PAGE 88 -->

### Page 88

In patients who are eligible for OAC, DOAC (unless contraindicated) is recommended in preference to VKA.
I
A
After uncomplicated PCI in CCS patients with concomitant indication for OAC: 
• early cessation of aspirin (≤1 week);
• followed by continuation of OAC and clopidogrel: 
⚬up to 6 months in patients not at high ischaemic risk; or
⚬up to 12 months in patients at high ischaemic risk;
• followed by OAC alone;
is recommended.
I
A
The use of ticagrelor or prasugrel is generally not recommended as part of triple antithrombotic therapy with aspirin and an OAC.
III
C
It is recommended to initiate aspirin post-operatively as soon as there is no concern over bleeding.
I
B
A proton pump inhibitor is recommended in patients at increased risk of gastrointestinal bleeding for the duration of combined 
antithrombotic therapy (antiplatelet therapy and/or OAC).
I
A
Recommendations for lipid-lowering drugs in patients with chronic coronary syndrome
Lipid-lowering treatment with an LDL-C goal of <1.4 mmol/L (55 mg/dL) and a ≥50% reduction in LDL-C vs. baseline is recommended.
I
A
A high-intensity statin up to the highest tolerated dose to reach the LDL-C goals is recommended for all patients with CCS.
I
A
If a patient’s goal is not achieved with the maximum tolerated dose of statin, combination with ezetimibe is recommended.
I
B
For patients who are statin intolerant and do not achieve their goal on ezetimibe, combination with bempedoic acid is recommended.
I
B
For patients who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, combination with a PCSK9 inhibitor is 
recommended.
I
A
Recommendations for sodium–glucose cotransporter 2 inhibitors and/or glucagon-like peptide-1 receptor agonists in patients with 
chronic coronary syndrome
CCS patients with type 2 diabetes
SGLT2 inhibitors with proven CV benefit are recommended in patients with T2DM and CCS to reduce CV events, independent of baseline 
or target HbA1c and independent of concomitant glucose-lowering medication.
I
A
GLP-1 receptor agonists with proven CV benefit are recommended in patients with T2DM and CCS to reduce CV events, independent of 
baseline or target HbA1c and independent of concomitant glucose-lowering medication.
I
A
Recommendations for angiotensin-converting enzyme inhibitors in patients with chronic coronary syndrome
In CCS patients, ACE-Is (or ARBs) are recommended in the presence of specific comorbidities, such as hypertension, diabetes, or heart 
failure.
I
A
Recommendations for revascularization in patients with chronic coronary syndrome
It is recommended that patients scheduled for percutaneous or surgical revascularization receive complete information about the benefits, 
risks, therapeutic consequences, and alternatives to revascularization, as part of shared clinical decision-making.
I
C
For complex clinical cases, to define the optimal treatment strategy, in particular when CABG and PCI hold the same level of 
recommendation, a Heart Team discussion is recommended, including representatives from interventional cardiology, cardiac surgery, 
non-interventional cardiology, and other specialties if indicated, aimed at selecting the most appropriate treatment to improve patient 
outcomes and quality of life.
I
C
It is recommended to communicate the proposal of the Heart Team in a very balanced way and in a language that the patient can 
understand.
I
C
It is recommended that the decision for revascularization and its modality be patient-centred, considering patient preferences, health 
literacy, cultural circumstances, and social support.
I
C
It is recommended that the Heart Team (on site or with a partner institution) develop institutional protocols to implement the appropriate 
revascularization strategy in accordance with current guidelines.
I
C
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant left main stem stenosis to improve survival.
I
A
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant three-vessel disease to improve long-term survival and to reduce long-term cardiovascular mortality 
and the risk of spontaneous myocardial infarction.
I
A
In CCS patients with LVEF >35%, myocardial revascularization is recommended, in addition to guideline-directed medical therapy, for 
patients with functionally significant single- or two-vessel disease involving the proximal LAD, to reduce long-term cardiovascular mortality 
and the risk of spontaneous myocardial infarction.
I
B
In CCS patients with LVEF ≤35%, it is recommended to choose between revascularization or medical therapy alone, after careful evaluation, 
preferably by the Heart Team, of coronary anatomy, correlation between coronary artery disease and LV dysfunction, comorbidities, life 
expectancy, individual risk-to-benefit ratio, and patient perspectives.
I
C
Continued


<!-- PAGE 89 -->

### Page 89

In surgically eligible CCS patients with multivessel CAD and LVEF ≤35%, myocardial revascularization with CABG is recommended over 
medical therapy alone to improve long-term survival.
I
B
In CCS patients with persistent angina or anginal equivalent, despite guideline-directed medical treatment, myocardial revascularization of 
functionally significant obstructive CAD is recommended to improve symptoms.
I
A
In patients with complex CAD in whom revascularization is being considered, it is recommended to assess procedural risks and 
post-procedural outcomes to guide shared clinical decision-making.
I
C
Calculation of the STS score is recommended to estimate in-hospital morbidity and 30-day mortality after CABG.
I
B
In patients with multivessel obstructive CAD, calculation of the SYNTAX score is recommended to assess the anatomical complexity of 
disease.
I
B
Intracoronary imaging guidance by IVUS or OCT is recommended when performing PCI on anatomically complex lesions, in particular left 
main stem, true bifurcations, and long lesions.
I
A
Intracoronary pressure measurement (FFR or iFR) or computation (QFR) is recommended to guide lesion selection for intervention in 
patients with multivessel disease.
I
A
It is recommended that physicians select the most appropriate revascularization modality based on patient profile, coronary anatomy, 
procedural factors, LVEF, preferences, and outcome expectations.
I
C
Recommendations for mode of revascularization in patients with chronic coronary syndrome
Left main disease
In CCS patients at low surgical risk with significant left main coronary stenosis, CABG: 
• is recommended over medical therapy alone to improve survival
I
A
• is recommended as the overall preferred revascularization mode over PCI, given the lower risk of spontaneous myocardial infarction and 
repeat revascularization
I
A
In CCS patients with significant left main coronary stenosis of low complexity (SYNTAX score ≤22), in whom PCI can provide equivalent 
completeness of revascularization to that of CABG, PCI is recommended as an alternative to CABG, given its lower invasiveness and 
non-inferior survival.
I
A
Left main with multivessel disease
In CCS patients at low surgical risk with suitable anatomy, CABG is recommended over medical therapy alone to improve survival.
I
A
Multivessel disease and diabetes
In CCS patients with significant multivessel disease and diabetes, with insufficient response to guideline-directed medical therapy, CABG is 
recommended over medical therapy alone and over PCI to improve symptoms and outcomes.
I
A
Three-vessel disease, without diabetes
In CCS patients with significant three-vessel disease, preserved LVEF, no diabetes, and insufficient response to guideline-directed medical 
therapy, CABG is recommended over medical therapy alone to improve symptoms, survival, and other outcomes.
I
A
In CCS patients with preserved LVEF, no diabetes, insufficient response to guideline-directed medical therapy, and significant three-vessel 
disease of low-to-intermediate anatomic complexity in whom PCI can provide similar completeness of revascularization to that of CABG, 
PCI is recommended, given its lower invasiveness, and generally non-inferior survival.
I
A
Single- or double-vessel disease involving the proximal LAD
In CCS patients with significant single- or double-vessel disease involving the proximal LAD and insufficient response to guideline-directed 
medical therapy, CABG or PCI is recommended over medical therapy alone to improve symptoms and outcomes.
I
A
In CCS patients with complex significant single- or double-vessel disease involving the proximal LAD, less amenable to PCI, and insufficient 
response to guideline-directed medical therapy, CABG is recommended over PCI to improve symptoms and reduce revascularization rates.
I
B
Single- or double-vessel disease not involving the proximal LAD
In symptomatic CCS patients with single- or double-vessel disease not involving the proximal LAD and with insufficient response to 
guideline-directed medical therapy, PCI is recommended to improve symptoms.
I
B
Recommendations for management of chronic coronary syndrome patients with chronic heart failure
Managing CCS in heart failure patients
In HF patients with LVEF ≤35% in whom obstructive CAD is suspected, ICA is recommended with a view towards improving prognosis by 
CABG, taking into account the risk-to-benefit ratio of the procedures.
I
B
In HF patients with LVEF >35% and suspected CCS with low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA or 
functional imaging is recommended.
I
C
In HF patients with LVEF >35% and suspected CCS with very high (>85%) pre-test likelihood of obstructive CAD, ICA (with FFR, iFR, or 
QFR when needed) is recommended.
I
C
Continued 
ESC Guidelines                                                                                                                                                                                          3503


<!-- PAGE 90 -->

### Page 90

Managing heart failure in CCS patients
It is recommended that CCS patients with HF be enrolled in a multidisciplinary HF management programme to reduce the risk of HF 
hospitalization and to improve survival.
I
A
An ACE-I, an MRA, an SGLT2 inhibitor (dapagliflozin or empagliflozin), and, in stable conditions, a beta-blocker are recommended for CCS 
patients with HFrEF to reduce the risk of HF hospitalization and death.
I
A
An SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in patients with HF with mildly reduced ejection fraction (HFmrEF) or 
HFpEF to reduce the risk of HF hospitalization or cardiovascular death.
I
A
An ARB is recommended in symptomatic patients with CCS and HFrEF unable to tolerate an ACE-I or ARNI to reduce the risk of HF 
hospitalization and cardiovascular death.
I
B
Sacubitril/valsartan is recommended as a replacement for an ACE-I or ARB in CCS patients with HFrEF to reduce the risk of HF 
hospitalization and death.
I
B
Diuretics are recommended in CCS patients with HF and signs and/or symptoms of congestion to alleviate symptoms, improve exercise 
capacity, and reduce HF hospitalizations.
I
B
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with symptomatic HF (NYHA class II–III) of 
ischaemic aetiology (unless they have had an MI in the prior 40 days), and an LVEF ≤35% despite ≥3 months of optimized GDMT, provided 
they are expected to survive substantially longer than 1 year with good functional status.
I
A
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients who have recovered from a ventricular 
arrhythmia causing haemodynamic instability, and who are expected to survive for >1 year with good functional status, in the absence of 
reversible causes or unless the ventricular arrhythmia has occurred <48 h after an MI.
I
A
CRT is recommended for CCS patients with symptomatic HF, sinus rhythm, LVEF ≤35% despite GDMT, and a QRS duration ≥150 ms with 
an LBBB QRS morphology to improve symptoms and survival and to reduce morbidity.
I
A
CRT rather than right ventricular pacing is recommended for patients with HFrEF regardless of NYHA class or QRS width who have an 
indication for ventricular pacing for high-degree AV block in order to reduce morbidity. This includes patients with AF.
I
A
Recommendations for diagnosis and management of patients with angina with non-obstructive coronary arteries/ischaemia with 
non-obstructive coronary arteries
In persistently symptomatic patients despite medical treatment with suspected ANOCA/INOCA (i.e. anginal symptoms with normal 
coronary arteries or non-obstructive lesions at non-invasive imaging, or intermediate stenoses with normal FFR/iFR at coronary 
arteriography) and poor quality of life, invasive coronary functional testing is recommended to identify potentially treatable endotypes and 
to improve symptoms and quality of life, considering patient choices and preferences.
I
B
In individuals with suspected vasospastic angina, a resting 12-lead ECG recording during angina is recommended.
I
C
In patients with suspected vasospastic angina and repetitive episodes of rest angina associated with ST-segment changes that resolve with 
nitrates and/or calcium antagonists, invasive functional angiography is recommended to confirm the diagnosis and to determine the severity 
of underlying atherosclerotic disease.
I
C
For the treatment of isolated vasospastic angina: 
• calcium channel blockers are recommended to control symptoms and to prevent ischaemia and potentially fatal complications.
I
A
Recommendations for older, female, high bleeding risk, comorbid, and socially/geographically diverse patients
In older adults (≥75 years), particular attention to drug side effects, intolerance, drug–drug interactions, overdosing, and procedural 
complications is recommended.
I
C
In older, as in younger, individuals, diagnostic and revascularization decisions based on symptoms, extent of ischaemia, frailty, life expectancy, 
comorbidities, and patient preferences are recommended.
I
C
Similar guideline-directed cardiovascular preventive therapy is recommended in women and men.
I
C
Systemic post-menopausal hormone therapy is not recommended in women with CCS, given the lack of cardiovascular benefit and an 
increased risk of thrombo-embolic complications.
III
A
Bleeding risk assessment is recommended using the PRECISE-DAPT score, the qualitative ARC-HBR tool or other, validated method.
I
B
Attention to interaction between antiretroviral treatment and statins is recommended in patients with HIV.
I
B
Continued targeted efforts are recommended: 
• to increase delivery of safe and effective cardiac care to all CCS patients, especially those of lower socioeconomic classes; and
• to enhance inclusion in future clinical trials of geographical, social, or other groups that are currently underrepresented.
I
C
Recommendations for screening for coronary artery disease in asymptomatic individuals
Opportunistic screening of healthy individuals for cardiovascular risk factors and to estimate the risk of future cardiovascular events using 
scoring systems, e.g. SCORE2 and SCORE-OP, is recommended to detect individuals at high risk and guide treatment decisions.
I
C
Continued


<!-- PAGE 91 -->

### Page 91

### 10 Evidence tables

Evidence tables are available at European Heart Journal online.
11. Data availability statement
No new data were generated or analysed in support of this research.
12. Author information
Author/task force Member Affiliations: Konstantinos 
C. Koskinas, Department of Cardiology, Bern University Hospital— 
INSELSPITAL, University of Bern, Bern, Switzerland; Xavier 
Rossello, Cardiology Department Hospital Universitari Son Espases, 
Palma de Mallorca, Spain, Health Research Institute of the Balearic 
Islands (IdISBa), Universitat de les Illes Balears (UIB), Palma de 
Mallorca, Spain, and Clinical Research Department, Centro Nacional 
de 
Investigaciones 
Cardiovasculares 
(CNIC), 
Madrid, 
Spain; 
Marianna Adamo, Department of Medical and Surgical Specialties, 
Radiological Sciences and Public Health, Institute of Cardiology, ASST 
Spedali Civili di Brescia and University of Brescia, Brescia, Italy; 
James Ainslie, ESC Patient Forum, Sophia Antipolis, France; 
Adrian Paul Banning, Oxford Heart Centre, Oxford University 
Hospitals, Oxford, United Kingdom; Andrzej Budaj, Department 
of Cardiology, Centre of Postgraduate Medical Education, Warsaw, 
Poland; Ronny R. Buechel, Department of Nuclear Medicine, 
Cardiac Imaging, University and University Hospital Zurich, Zurich, 
Switzerland; Giovanni Alfonso Chiariello, Department of 
Cardiovascular 
Sciences, 
Fondazione 
Policlinico 
Universitario 
Agostino Gemelli IRCCS, Rome, Italy, and Università Cattolica del 
Sacro Cuore, Rome, Italy; Alaide Chieffo, Vita Salute San Raffaele 
University, Milan, Italy, and Interventional Cardiology Unit, IRCCS San 
Raffaele Scientific Institute, Milan, Italy; Ruxandra Maria 
Christodorescu, Department V Internal Medicine, University of 
Medicine and Pharmacy V Babes, Timisoara, Romania, and Research 
Recommendations for adherence to medical therapy and lifestyle changes
Mobile health interventions (e.g. using text messages, apps, wearable devices) are recommended to improve patient adherence to healthy 
lifestyles and medical therapy.
I
A
Behavioural interventions are recommended to improve adherence.
I
B
Simplifying medication regimens (e.g. using fixed-dose drug combinations) is recommended to increase patient adherence to medications.
I
B
Multiprofessional and family involvement is recommended to promote adherence, in addition to patient education and involvement.
I
C
Recommendations for diagnosis of disease progression in patients with established chronic coronary syndrome
Regardless of symptoms, periodic visits (e.g. annual) to a general practitioner or cardiovascular healthcare professional are recommended to 
evaluate cardiovascular risk factor control and to assess changes in risk status, disease status, and comorbidities that may require lifestyle, 
medical, or procedural interventions.
I
C
Reassessment of CAD status is recommended in patients with deteriorating LV systolic function that cannot be attributed to a reversible 
cause (e.g. longstanding tachycardia or myocarditis).
I
C
Risk stratification is recommended in patients with new or worsening symptoms, preferably using stress imaging.
I
C
In patients with symptoms refractory to medical treatment or at high risk of adverse events, invasive coronary angiography (with FFR/iFR 
when necessary) is recommended for risk stratification and for possible revascularization aimed at improving symptoms and prognosis.
I
C
Recommendations for treatment of revascularization failure
DES is recommended over drug-coated balloons for treatment of in-DES restenosis.
I
A
LIMA is indicated as the conduit of choice for redo CABG in patients in whom the LIMA was not used previously.
I
B
Recommendations for recurrent or refractory angina/ischaemia
In patients with refractory angina leading to poor quality of life and with documented or suspected ANOCA/INOCA, invasive coronary 
function testing is recommended to define ANOCA/INOCA endotypes and appropriate treatment, considering patient choices and 
preferences.
I
B
© ESC 2024
ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial fibrillation; ANOCA, angina with non-obstructive coronary arteries; ARB, angiotensin receptor 
blocker; ARC-HBR, Academic Research Consortium for High Bleeding; ARNI, angiotensin receptor neprilysin inhibitor; AV, atrioventricular; BP, blood pressure; CABG, coronary artery 
bypass grafting; CACS, coronary artery calcium score; CAD, coronary artery disease; CCB, calcium channel blocker; CCS, chronic coronary syndrome; CCTA, coronary computed 
tomography angiography; CKD, chronic kidney disease; CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; CT, computed tomography; CV, cardiovascular; 
CVD, cardiovascular disease; CYP3A4, cytochrome P450 3A4; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DHP, dihydropyridine; DOAC, direct oral anticoagulant; ECG, 
electrocardiogram; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; FFR-CT, coronary computed tomography angiography-derived fractional flow reserve; 
GDMT, guideline-directed medical therapy; GLP-1, glucagon-like peptide-1; HbA1c, glycated haemoglobin; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, 
heart failure with reduced ejection fraction; HIV, human immunodeficiency virus; ICA, invasive coronary angiography; ICD, implantable cardioverter defibrillator; iFR, instantaneous 
wave-free ratio; INOCA, ischaemia with non-obstructive coronary arteries; IVUS, intravascular ultrasound; LAD, left anterior descending; LBBB, left bundle branch block; LDL-C, 
low-density lipoprotein cholesterol; LIMA, left internal mammary artery; LV, left ventricular; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; MI, 
myocardial infarction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; OAC, oral anticoagulant; OCT, optical coherence tomography; PCI, 
percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 9; PET, positron emission tomography; PRECISE-DAPT, PREdicting bleeding Complications In 
patients undergoing Stent implantation and subsEquent Dual AntiPlatelet Therapy; QFR, quantitative flow ratio; SCORE2, Systematic Coronary Risk Estimation 2; SCORE-OP, 
Systematic Coronary Risk Estimation 2–Older Persons; SGLT2, sodium–glucose cotransporter 2; SPECT, single-photon emission computed tomography; STS, Society of Thoracic 
Surgeons; SYNTAX, SYNergy Between PCI with TAXUS and Cardiac Surgery; T2DM, type 2 diabetes mellitus; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3505


<!-- PAGE 92 -->

### Page 92

Center, Institute of Cardiovascular Diseases, Timisoara, Romania; 
Christi Deaton, Public Health and Primary Care, Cambridge 
University School of Clinical Medicine, Cambridge, United Kingdom; 
Torsten 
Doenst, 
Department 
of 
cardiothoracic 
surgery, 
Friedrich-Schiller-University Jena, university hospital, Jena, Germany; 
Hywel W. Jones, ESC Patient Forum, Sophia Antipolis, France; Vijay 
Kunadian, Translational and Clinical Research Institute, Faculty of 
Medical Sciences, Newcastle University and Cardiothoracic Centre, 
Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation 
Trust, Newcastle upon Tyne, United Kingdom; Julinda Mehilli, 
Medizinische Klinik I, Landshut-Achdorf Hospital, Landshut, Germany, 
and 
Klinikum 
der 
Universität 
München 
Ludwig-Maximilians 
University, Munich, Germany; Milan Milojevic, Department of 
Cardiac 
Surgery 
and 
Cardiovascular 
Research, 
Dedinje 
Cardiovascular Institute, Belgrade, Serbia; Jan J. Piek, Heart Center, 
Department of Clinical and Experimental Cardiology, Amsterdam 
Cardiovascular 
Sciences, 
Amsterdam 
UMC, 
University 
of 
Amsterdam, Amsterdam, Netherlands; Francesca Pugliese, 
Centre for Advanced Cardiovascular Imaging, The William Harvey 
Research Institute, Queen Mary University of London, London, 
United Kingdom, Barts Health NHS Trust, London, United Kingdom, 
and Heart Vascular and Thoracic Institute, Cleveland Clinic London, 
London, United Kingdom; Andrea Rubboli, Department of 
Emergency, Internal Medicine, and Cardiology, Division of Cardiology, 
S. Maria delle Croci Hospital, Ravenna, Italy; Anne Grete Semb, 
Preventive cardio-rheuma clinic, Diakonhjemmet Hospital, Oslo, 
Norway, and REMEDY Centre Diakonhjemmet Hospital, Oslo, 
Norway; Roxy Senior, Cardiology Royal Brompton Hospital and 
Imperial College London, London, United Kingdom, and Cardiology, 
Northwick Park Hospital, Harrow, United Kingdom; Jurrien M. ten 
Berg, Cardiology, St Antonius Hospital, Nieuwegein, Netherlands, 
and Cardiology, Maastricht University Medical Centre, Maastricht, 
Netherlands; Eric van Belle, Cardiology, Institut Cour Poumon— 
CHU de Lille, Lille, France, and Equipe 2, INSERM U 1011, Lille, 
France; Emeline M. Van Craenenbroeck, Cardiology department, 
Antwerp University Hospital, Edegem, Belgium, and GENCOR, 
University of Antwerp, Antwerp, Belgium; Rafael Vidal-Perez, 
Cardiology, 
Cardiac 
Imaging 
Unit, 
Complexo 
Hospitalario 
Universitario de A Coruña (CHUAC), A Coruña, Spain, and Centro 
de 
Investigación 
Biomédica 
en 
Red 
de 
Enfermedades 
Cardiovasculares (CIBERCV), Madrid, Spain; and Simon Winther, 
Department of cardiology, Gødstrup hospital, Herning, Denmark, 
and Institute of clinical medicine, Aarhus university, Aarhus, Denmark.
13. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document 
Reviewers: 
Michael 
Borger 
(CPG 
Review 
Co-ordinator) (Germany); Ingibjörg J. Gudmundsdóttir (CPG Review 
Co-ordinator) (Iceland); Juhani Knuuti (CPG Review Co-ordinator) 
(Finland); Ingo Ahrens (Germany); Michael Böhm (Germany); Davide 
Capodanno (Italy); Evald Høj Christiansen (Denmark); Jean-Philippe 
Collet¶ (France); Kenneth Dickstein (Norway); Christian Eek 
(Norway); Volkmar Falk (Germany); Peter A. Henriksen (United 
Kingdom); Borja Ibanez (Spain); Stefan James (Sweden); Sasko Kedev 
(Macedonia); Lars Køber (Denmark); Martha Kyriakou (Cyprus); 
Emma F. Magavern (United Kingdom); Angela McInerney (Ireland); 
John William McEvoy (United Kingdom); Caius Ovidiu Mersha 
(Romania); Borislava Mihaylova (United Kingdom); Richard Mindham 
(United Kingdom); Lis Neubeck (United Kingdom); Franz-Josef 
Neumann (Germany); Jens Cosedis Nielsen (Denmark); Pasquale 
Paolisso (Italy); Valeria Paradies (Netherlands); Agnes A. Pasquet 
(Belgium); Massimo Piepoli (Italy); Eva Prescott (Denmark); Amina 
Rakisheva (Kazakhstan); Bianca Rocca (Italy); Marc Ruel (Canada); 
Sigrid Sandner (Austria); Antti Saraste (Finland); Karolina Szummer 
(Sweden); Ilonca Vaartjes (Netherlands); William Wijns (Ireland); 
Stephan Windecker (Switzerland); Adam Witkowsky (Poland); Marija 
Zdrakovic (Serbia); and Katja Zeppenfeld (Netherlands).
¶Professor Jean-Philippe Collet sadly passed away during the development 
of these guidelines. Professor Collet’s contribution to these guidelines was, as 
always, highly valued.
ESC National Cardiac Societies actively involved in the review 
process of the 2024 ESC Guidelines on the management of chronic 
coronary syndromes:
Albania: Albanian Society of Cardiology, Naltin Shuka; Algeria: 
Algerian Society of Cardiology, Mohamed Abed Bouraghda; 
Armenia: 
Armenian 
Cardiologists 
Association, 
Hamlet 
G. Hayrapetyan; Austria: Austrian Society of Cardiology, Sebastian 
J. Reinstadler; Azerbaijan: Azerbaijan Society of Cardiology, Ogtay 
Musayev; Belgium: Belgian Society of Cardiology, Michel De Pauw; 
Bosnia and Herzegovina: Association of Cardiologists of Bosnia 
and Herzegovina, Zumreta Kušljugić; Bulgaria: Bulgarian Society of 
Cardiology, Valeri Gelev; Croatia: Croatian Cardiac Society, Bosko 
Skoric; Cyprus: Cyprus Society of Cardiology, Maria Karakyriou; 
Czechia: Czech Society of Cardiology, Tomas Kovarnik; Denmark: 
Danish Society of Cardiology, Lene H. Nielsen; Egypt: Egyptian 
Society of Cardiology, Islam Sh. Abdel-Aziz; Estonia: Estonian 
Society of Cardiology, Tiia Ainla; Finland: Finnish Cardiac Society, 
Pekka Porela; France: French Society of Cardiology, Hakim 
Benamer; Georgia: Georgian Society of Cardiology, Kakha Nadaraia; 
Germany: German Cardiac Society, Gert Richardt; Greece: 
Hellenic Society of Cardiology, Michail I. Papafaklis; Hungary: 
Hungarian Society of Cardiology, Dávid Becker; Iceland: Icelandic 
Society of Cardiology, Ingibjörg J. Gudmundsdóttir; Israel: Israel 
Heart Society, Arik Wolak; Italy: Italian Federation of Cardiology, 
Carmine Riccio; Kazakhstan: Association of Cardiologists of 
Kazakhstan, Bekbolat Kulzhanovich Zholdin; Kosovo (Republic 
of): Kosovo Society of Cardiology, Shpend Elezi; Kyrgyzstan: 
Kyrgyz Society of Cardiology, Saamay Abilova; Latvia: Latvian 
Society of Cardiology, Iveta Mintale; Lebanon: Lebanese Society of 
Cardiology, Bachir Allam; Lithuania: Lithuanian Society of 
Cardiology, Jolita Badarienė; Luxembourg: Luxembourg Society 
of Cardiology, Bruno Pereira; Malta: Maltese Cardiac Society, Philip 
Dingli; Moldova (Republic of): Moldavian Society of Cardiology, 
Valeriu Revenco; Montenegro: Montenegro Society of Cardiology, 
Nebojsa Bulatovic; Morocco: Moroccan Society of Cardiology, El 
Ghali Mohamed Benouna; Netherlands: Netherlands Society of 
Cardiology, Admir Dedic; North Macedonia: National Society of 
Cardiology of North Macedonia, Irena Mitevska; Norway: 
Norwegian Society of Cardiology, Kristin Angel; Poland: Polish 
Cardiac Society, Krzysztof Bryniarski; Portugal: Portuguese Society 
of Cardiology, André Miguel Coimbra Luz; Romania: Romanian 
Society of Cardiology, Bogdan Alexandru Popescu; San Marino: San 
Marino Society of Cardiology, Luca Bertelli; Serbia: Cardiology 
Society of Serbia, Branko Dušan Beleslin; Slovakia: Slovak Society of 
Cardiology, Martin Hudec; Slovenia: Slovenian Society of 
Cardiology, Zlatko Fras; Spain: Spanish Society of Cardiology, 
Román Freixa-Pamias; Sweden: Swedish Society of Cardiology,


<!-- PAGE 93 -->

### Page 93

Anna Holm; Switzerland: Swiss Society of Cardiology, Raban Jeger; 
Syrian Arab Republic: Syrian Cardiovascular Association, Mhd 
Yassin Bani Marjeh; Tunisia: Tunisian Society of Cardiology and 
Cardiovascular Surgery, Rania Hammami; Türkiye: Turkish Society 
of Cardiology, Vedat Aytekin; Ukraine: Ukrainian Association of 
Cardiology, Elena G. Nesukay; United Kingdom: British 
Cardiovascular Society, Neil Swanson; and Uzbekistan: Association 
of Cardiologists of Uzbekistan, Aleksandr Borisovich Shek.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), Katja 
Zeppenfeld (Netherlands), and Alexia Rossi§ (Italy).
§Contributor either stepped down or was engaged in only a part of the 
review process.
